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Summary
The understanding of gene regulation during varicella-zoster virus (VZV) infection is still 
rudimentary, although insight can be gained from the more extensively studied system of 
the genetically related herpes simplex virus type 1 (HSV-1). Upon infection, HSV-1 
expresses three main classes of genes in a coordinately regulated temporal cascade; the 
immediate-early (IE), early (E) and late (L) genes. The product of the HSV-1 IE3 gene, 
Vmwl75, is considered to be the major regulatory protein of HSV-1 because functional 
Vmwl75 is an absolute requirement for transactivation of E and L gene expression and 
for the down-regulation of its own IE3 promoter. The polypeptide encoded by VZV gene 
62 (VZV 140k) is the sequence homologue of HSV-1 Vmwl75. Transient transfection 
experiments have demonstrated that VZV 140k is a potent and promiscuous 
transactivator of gene expression, and that it can also negatively autoregulate its own 
gene 62 promoter. In addition, VZV 140k can complement HSV-1 viruses lacking 
functional Vmwl75. Therefore, by analogy to its HSV-1 counterpart, VZV 140k is likely 
to play a critical role in the regulation of VZV gene expression. The research described in 
this Thesis aimed to investigate the properties and activities of the DNA binding domain 
of the VZV 140k protein, in order to gain a better understanding of the mechanisms of 
140k-mediated gene regulation during infection.
The primary sequences of VZV 140k and HSV-1 Vmwl75 have been divided into five 
co-linear regions on the basis of the extent of their predicted amino acid identity. The 
region 2 sequences are particularly highly conserved between the two proteins and the
regulatory functions of Vmwl75 require the integrity of region 2. Furthermore,
■
sequences spanning HSV-1 Vmwl75 region 2 constitute a physically separable, stable 
DNA binding domain. Many of the experiments in this study stemmed from the initial 
demonstration that the corresponding region of the VZV 140k protein also yields a 
sequence-specific DNA binding domain when expressed as a non-fusion polypeptide in 
bacteria.
The bacterially expressed VZV 140k DNA binding domain specifically recognised 
multiple DNA sequences in the vicinity of its target promoters; the 140k binding sites 
identified within its own VZV gene 62 promoter may have a role in the negative 
autoregulatory function of the 140k protein. Several of the 140k recognition sites showed 
sequence similarity to the Vmwl75 consensus binding sequence, although gel retardation 
assays with a systematically mutagenised binding site found the VZV 140k DNA binding
Summary
domain peptide to be less sequence-specific than the corresponding domain of HSV-1 
Vmwl75. These and further differences that have been identified between the DNA 
binding activities of the VZV 140k and HSV-1 Vmwl75 DNA binding domains may 
explain the previously reported variations between the regulatory functions of 140k and 
Vmwl75.
The minimal region of the VZV 140k protein required for sequence-specific DNA 
binding has been defined by a deletion analysis to within 162 residues, essentially 
comprising the highly conserved region 2. However, additional sequences from the 
C-terminal end of region 1 were necessary for the full DNA binding interaction, as 
determined by DNase I footprinting analysis. As such, the DNA binding domain of VZV 
140k is larger than those reported for other transcriptional regulators (which are often less 
than 80 amino acids) and therefore it may constitute a novel type of DNA binding 
structure. A short sequence that exhibits intriguing homology to the conserved DNA 
recognition helix of the homeodomain DNA binding motif is found at the centre of the 
VZV 140k DNA binding domain. The alterations to the DNA binding interaction that 
resulted from the substitution of single amino acids within this region indicate its 
probable involvement in the DNA recognition by VZV 140k. Of particular note, mutation 
of a single lysine residue drastically reduced the DNA binding activity and destroyed the 
transactivation function of VZV 140k; this result emphasises the importance of DNA 
binding for VZV 140k-mediated gene regulation.
The highly purified VZV 140k DNA binding domain was a stable dimer in solution, as 
demonstrated by gel filtration, glycerol gradient centrifugation and cross-linking 
techniques. The fact that the VZV 140k DNA binding domain binds to DNA as a dimer 
was indicated by gel retardation assays that showed novel protein-DNA complexes of 
intermediate mobility following in vitro co-translation of pairs of VZV 140k peptides of 
differing sizes. In addition, the VZV 140k and HSV-1 Vmwl75 DNA binding domain 
peptides readily heterodimerised on co-translation, which indicated that these two related 
domains have similar modes of dimerisation. In vitro co-translation of a wide range of 
truncation and insertion mutation versions of the VZV 140k and HSV-1 Vmwl75 DNA 
binding domains, followed by analysis of their dimerisation by co-immunoprecipitation 
and their DNA binding ability by gel retardation, has indicated that the structural 
requirements for dimerisation are lower than for the DNA binding interaction.
Finally, construction of a hybrid Vmwl75 protein with the VZV 140k DNA binding 
domain replacing that of HSV-1 Vmwl75 has allowed the relatedness of the two 
domains to be assessed directly. The hybrid protein was functional in tissue culture 
transient transfection assays and furthermore, supported viral growth when expressed
vi
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from a recombinant HSV-1 genome. The details of the regulatory activities of the hybrid 
protein in the transient assays implied that the characteristic DNA binding activities of 
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The product of varicella-zoster virus gene 62 (VZV 140k) is likely to be the major 
transcriptional regulatory protein of VZV, by homology to its counterpart HSV-1 
protein, Vmwl75. The research presented in this Thesis concerns the properties and 
functions of the DNA binding domain of the VZV 140k polypeptide. This introduction 
aims to overview briefly the biology and molecular biology of VZV and to review the 
current state of knowledge of gene regulation among the Alphaherpesvirinae, with 
particular emphasis on the HSV-1 prototype system and the fundamental role played by 
the Vmwl75 protein. Since regulation of gene expression by viral immediate-early 
polypeptides requires interactions with the host cell transcriptional machinery, the later 
Sections of this Introduction will discuss relevant aspects of eukaryotic gene expression, 
with particular emphasis on the mechanisms whereby regulatory proteins influence 
RNA polymerase n  transcription.
1A The biology of VZV
1A.1 Definition, morphology and classification of the herpesviruses
Members of the family Herpesviridae are characterised by the inclusion of a linear 
double-stranded DNA genome in an enveloped virion particle of 120-300nm in diameter 
(reviewed by Roizman and Furlong, 1974; Rixon, 1993). The herpesvirus virion (Fig. 
1A.1) comprises four distinct layers as follows: the core contains the viral DNA 
(Epstein, 1962) and lies within the icosadeltahedral capsid. The capsid is 100-110nm in 
diameter and comprises 162 capsomeres (150 hexameric and 12 pentameric) (Wildy et 
a l, 1960). Surrounding the nucleocapsid is an amorphous proteinaceous tegument 
(Roizman and Furlong, 1974). The outer envelope consists of a host cell derived 
trilaminar membrane with viral glycoprotein spikes on the surface (Wildy et al., 1960; 
Wildy and Watson, 1962; Spear and Roizman, 1972).
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Figure 1A.1 The morphology of the herpesviruses. Schematic representation of the 
herpesvirion seen through a cross-section of the envelope (c), with glycoprotein spikes (d) of varying 
lengths projecting from its surface (Stannard et a l, 1987). The sides of the capsid (a) show twofold 
symmetry and the hexameric capsomeres are illustrated; the viral DNA is located within the capsid. The 
tegument (b) is located between the envelope and the nucleocapsid.
To date nearly 100 herpesviruses have been characterised, with diverse animal hosts and 
biologies. In common, all replicate in the nucleus, are able to remain latent in then- 
natural hosts, and production of progeny virus is accompanied by destruction of the 
infected cell. Seven herpesviruses have been isolated from humans: herpes simplex virus 
1 and 2 (HSV-1 and HSV-2), human cytomegalovirus (HCMV), varicella-zoster virus 
(VZV), Epstein-Barr virus (EBV) and human herpesvirus 6 and 7 (HHV-6 and HHV-7). 
These human herpesviruses are distributed in three subfamilies of the Herpesviridae: 
Alpha-, Beta-, and Gammaherpesvirinae, divided on the basis of their biological 
properties (Matthews, 1982; Roizman, 1982). Members of the Alphaherpesvirinae have 
a relatively short reproductive cycle (typically less than 24hr in tissue culture) and 
primarily establish latent infections in the sensory ganglia. This subfamily includes 
HSV-1, HSV-2, VZV, pseudorabies virus (PRV) and equine herpesvirus 1 (EHV-1) (the 
latter two are infections of swine and horses respectively). The Betaherpesvirinae 
members have a restricted host range in tissue culture and long reproductive cycles. 
Infection spreads slowly in tissue culture and results in enlargement of infected cells 
(cytomegalia). The virus can be maintained in the latent form in various tissues and 
members include HCMV, HHV-6 and HHV-7. The Gammaherpesvirinae, whose
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members include EBV, are generally restricted to either B or T lymphocytes in tissue 
culture, and latent infections are frequently established in lymphoid tissues.
Classification of herpesviruses on the basis of DNA sequence homology, similarities in 
genome arrangement and immunological relatedness of viral gene products tends to 
reflect phylogenic relationships more truly than the biological system of classification 
(Roizman et al., 1981). An example of this was seen with Marek’s disease virus (MDV), 
which had originally been biologically classified as belonging to the 
Gammaherpesvirinae, but has now been grouped with the Alphaherpesvirinae on the 
basis of limited sequence analysis (Buckmaster et al, 1988). Additionally, the complete 
genome sequence of the channel catfish virus (CCV), which had previously been 
regarded as a member of the Alphaherpesvirinae, showed no clear relationship to any of 
the other herpesviruses analysed and should be assigned to a separate taxonomic group 
(Davison, 1992). It will be important to take into account all the available data, 
especially sequence data, when classifying herpesviruses in future (Roizman et al, 
1992).
1 A.2 Biology and pathology of VZV infections
Varicella-zoster virus is an unusual herpesvirus in causing two common distinct clinical 
syndromes: chickenpox (varicella) upon primary infection, and shingles (herpes zoster) 
upon reactivation of latent virus. Chickenpox is a highly contagious but commonly mild 
exanthem, usually ubiquitous in children. Shingles is a less common endemic local 
vesicular condition, often extremely painful, which usually affects older patients. 
Although neither disease is life-threatening, both have possible serious consequences in 
immunocompromised individuals. The pathology of each disease will be discussed in 
more detail.
1A.2.1 History
The first report of chickenpox is attributed to a ninth century Persian physician, Rhazes, 
and was described as a pustular skin disease that conferred no protection against 
smallpox. The term 'varicella' is a variation on the word variola meaning smallpox - a 
more severe disease that was often confused with chickenpox until Heberden clinically 
distinguished them in the late 18th century (Gordon, 1962). In 1892, Bokay suggested 
that chickenpox in children could be related to herpes zoster exposure and Lipschutz 
first described in 1921, that the histology of vesicular lesions present in chickenpox and 
in zoster appeared similar (Jako and Jako, 1986). Following the first isolation of VZV in 
tissue culture in 1953 (Weller, 1953), Weller and co-workers finally demonstrated the
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identity between viruses isolated from varicella and zoster patients in 1958, leading 
them to suggest the name 'varicella-zoster virus' (Weller et al., 1958; Weller and Witton, 
1958).
1A.2.2 Varicella
VZV  entry is usually through the mucosa of the upper respiratory tract and oropharynx. 
Viral replication begins at the site of primary inoculation and after 4-5 days, primary 
viremia is established during which virus disseminates via the bloodstream and 
lymphatic system. Subsequently, virus taken up by cells of the reticuloendothelial 
system undergoes multiple cycles of replication. The host's immune response initially 
limits viral replication, but is soon overwhelmed and a more extensive secondary 
viremia develops. High titres of virus are released into the bloodstream, followed by 
infection of capillary endothelial cells and subsequent viral spread to epithelial cells of 
the endodermis and certain mucosal surfaces. Intra- and extracellular edema develop in 
the epidermis, producing a characteristic fluid filled vesicle containing cell-free VZV 
that may be shed to the environment. The viremic phase is terminated by specific 
humoral and cellular responses (CMI), approximately 3 days after the appearance of 
lesions (Asano etal., 1985; Arvin et al., 1986).
Complications of varicella result from increased viral spread and failure to limit 
replication. Varicella pneumonia is the most common serious complication in adults, 
neonates and the immunocompromised. Neurological conditions, encephalitis for 
example, develop in approximately 0.3% of varicella cases with a 5-15% rate of 
mortality (Guess et al., 1986).
1A.2.3 Herpes zoster
VZV  is thought to pass from varicella cutaneous lesions to the corresponding sensory 
ganglia via the nerve fibers, where it remains quiescent until reactivation as herpes 
zoster. The observation that reactivation is often precipitated by conditions associated 
with immunosuppression led Hope-Simpson (1965) to suggest that deterioration of host 
defences below the level of containment allows reactivated VZV to replicate in the 
sensory ganglia. By this model (Fig. 1A.2), most such reactivations (or reversions) are 
contained by circulating antibody or CMI, but occasionally the host defences fail to 
contain viral multiplication, leading to necrosis and intense inflammation of the ganglia 
and often also neuralgia. Infectious virus spreads down the sensory nerve and infects the 
skin, producing characteristic dermatomal zoster vesicles that gird the trunk or other 
parts of the body (zoster is derived from the Greek word for 'girdle').
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A common complication of herpes zoster is post-herpetic neuralgia (pain lasting more 
than 1 month). Additionally, spread of infection to adjacent areas of the nervous system 
can result in paralysis or palsy and in rare cases persistent CNS infection can lead to 
encephalitis. As with varicella, herpes zoster tends to be more severe with 
immunocompromised patients and the severity of the condition is related to the status of 












Figure 1A.2 Hope-Simpson's model of herpes zoster pathogenesis. The two arrows at the 
bottom indicate time of exposure to VZV; and black boxes represent clinically apparent disease; the 
dashed horizontal line indicates the critical level of host resistance required to contain VZV replication 
and reversion. Increased viral replication is marked by a corresponding increase in antibody production 
(increased level of host resistance); this neutralises the virus and is followed by a drop in host resistance in 
the case of successful reversions. Clinical disease occurs when the antibody level falls below the critical 
level. The Figure is an adaptation from Hope-Simpson (1965).
1A.2.4 Treatment and prevention
Three anti-viral compounds have proved efficacious for treatment of varicella, although 
specific therapy is often unnecessary in immunocompetent children; these are interferon, 
vidarabine (adenosine arabinoside) and acyclovir (an acyclic guanosine derivative) 
(reviewed by Whitley, 1992). The latter two are anti-VZV nucleoside analogues that 
specifically terminate DNA replication mediated by the viral DNA polymerase. These 
antivirals have also been reported to modestly alleviate acute herpes zoster if 
administered early in the course of the disease.
Preventive measures from varicella are not usually taken because infection generally 
provides lifelong immunity, although administration of VZIG prophylaxis (a high-titre 
VZV antibody preparation) greatly reduces the severity of varicella in high risk patients
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exposed to VZV. A live attenuated VZV vaccine (Oka strain) has been produced and 
used extensively in Japan. This affords a high degree of protection against varicella and 
is not associated with an increased incidence of zoster (Gershon et a l, 1992). Since 
chickenpox in adulthood would have more serious consequences than in childhood, the 
main concern regarding the attenuated vaccine has been the duration of immunity and 
this will only be resolved by longer follow-up studies of vaccinated individuals. Indeed, 
population studies have found the Oka strain capable of reactivating and causing herpes 
zoster, albeit at a lower apparent frequency than following normal varicella infection 
(Hardy etal., 1991).
1A.3 VZV latency
The distinct clinical and epidemiological characteristics of HSV-1 and VZV latency 
(reviewed by Meier and Straus, 1992) suggest that each virus has evolved a unique 
strategy to ensure the establishment, maintenance and reactivation of latency. Therefore 
it is not surprising that significant differences have been identified between the sites and 
patterns of viral gene expression during latent VZV and HSV-1 infections. The 
trigeminal ganglia neuronal cells are the site of HSV-1 latency. Although early studies 
additionally found the neuronal cells to be the site of latent VZV infection (reviewed by 
Cohrs et al., 1992), the most extensive in situ hybridisation analysis performed to date 
found VZV latent transcripts to be specifically localised to the satellite cells 
immediately surrounding the neuron (Croen et al., 1988). In contrast, both neuronal and 
non-neuronal cells support lytic VZV infections, during which all regions of the VZV 
genome are expressed in both types of cell (Nagishama et al., 1975; Croen et al., 1988).
In situ hybridisation analysis using RNA probes representing almost the entire VZV 
genome, identified transcription from at least three distinct and widely separated regions 
of the genome during latency (Croen et al., 1988). The genes selectively expressed 
during VZV latency include some, but not all of the putative immediate-early genes 
(including gene 62) and certain early genes (Meier et al., 1993) (Section 1B.4.1). The 
latent VZV transcripts are polyadenylated and appear to represent the same gene 
products that are transcribed during lytic infection. Thus VZV latency is characterised 
by a broad pattern of latency-associated transcription. This is in marked contrast to the 
situation with HSV-1 latency where two or three co-linear transcripts, termed the 
'latency associated transcripts' (or LATs), are detected in latently infected cells at greatly 
enhanced levels compared to during lytic infection (reviewed by Stevens, 1989). The 
HSV-1 LATs are spliced and include open reading frames which span a portion of the 
IE1 gene in the opposite polarity (see Fig. 1B.1), although it is not clear if a protein
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product is made in vivo. There have been no reports of VZV transcripts equivalent to the 
HSV-1 LATs, but if VZV latent specific transcripts exist they are unlikely to be 
analogous to the LATs because there is no true VZV counterpart of the HSV-1 IE1 ORF 
and also no splicing has been detected in the corresponding region of the VZV genome. 
However, the role played by the HSV-1 LATs during latent infection is far from clear.
During latency the HSV genome is extrachromosomal, circular and organised into an 
array of nucleosomes that resemble cellular chromatin (Fraser et al., 1990; Deshmane 
and Fraser, 1989). It would be interesting to ascertain whether this is also the case for 
the VZV genome during latency, and in particular, whether the transcriptionally active 
regions are nucleosome bound.
1A.4 VZV growth in vitro and animal models
VZV has been propagated in a variety of primary cell lines, usually of human or simian 
origin, although continuous cell lines such as Vero or human melanoma cells have also 
been employed with equal success. However, even cultured cells derived from the 
natural host are considered to be only partially permissive for VZV growth as they do 
not readily support the production of cell-free infectious virus (Weller and Witton, 
1958). Because of the highly cell associated nature of VZV, infected cells are routinely 
used as an inoculum; however this presents difficulties for tissue culture experiments 
requiring quantitative controlled infections. Highly optimised conditions for isolating 
cell-free virus produce yields at best one order of magnitude higher than the initial 
inoculum, and infection with the cell-free virus is very inefficient compared to using 
infected cells as the inoculum (Schmidt and Lennette, 1976). The various alternative 
explanations for the high particle/infectivity ratio of VZV replicated in vitro include the 
hypothesis that VZV particles are inactivated following targeting to lysosomal 
compartments during egress of the virus from the cell (Gershon et a l, 1973). The 
investigation of all aspects of VZV biology and structure have been significantly 
impaired by the inability to isolate stable, high titre stocks of cell-free virus. 
Consequently VZV growth in tissue culture is very poorly characterised.
The lack of a good animal model for infection has also hampered the understanding of 
VZV pathogenesis. The guinea-pig and common marmoset may be infected 
experimentally with VZV (Myers et al., 1980; Provost et al., 1987), but neither animal 
provides a good model for vesicular disease or latency. Simian varicella virus (SVV) 
infection of non-human primates is probably a closer model to the human varicella 
disease (Dueland et al, 1992).
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1A.5 The VZV Genome
The VZV DNA molecule is one of the smallest herpesvirus genomes at approximately 
80 x 106 Daltons in size (Dumas et al., 1980) and has a G+C content of 46%, which is 
rather less than that of most herpesviruses (Ludwig et al., 1972). Restriction 
endonuclease mapping has demonstrated that the linear duplex genome comprises two 
covalently linked segments, L (long) and S (short). The VZV DNA exists predominantly 
in two equally abundant isomeric forms, as the short segment is capable of inversion 
with respect to the long segment (Dumas et al., 1981) (right panel, Fig. 1A.3). The 
unique sequences of the long and short segments (U l and Us) are flanked by distinct 
inverted repeats R l and Rs, and the location of each repeat is defined by I (internal) or T 
(terminal) (left panel, Fig. 1A.3) (Ecker and Hyman, 1982; Straus et al., 1982; Gilden et 
al., 1982; Davison, 1984). More recently it has been found that the L segment inverts 
with respect to the S sequence approximately 5% of the time (Kinchington et al., 1985; 
Hayakawa and Hyman, 1987). The viral DNA therefore exists as four genome isomers, 
two major and two minor (right panel, Fig. 1 A.3).
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Figure 1A.3 Comparison of VZV and HSV-1 genomes, and the VZV genome isomers. 
The left panel shows schematics of the VZV (125kbp) and HSV-1 (152kbp) genomes and a scale in kbp is 
shown above. Inverted repeats (TRL/IRL and TRS/IRS) are shown as rectangles. The right panel shows 
the different isomers of the VZV genome; the two predominant forms contain the long segment in a single 
orientation, while the short segment is detected in an equimolar ratio in either of the two possible 
orientations, as indicated by the arrows. A small percentage of the VZV DNA molecules exist either in a 
circular form or with the long segment inverted.
An unpaired nucleotide is found at the 3' end of each VZV DNA strand and the genome 
is thought to circularise after viral entry and replicate by a rolling circle mechanism 
(Davison, 1984). In support of this hypothesis, circular VZV genomes have been 
visualised by electron microscopy (Straus et al., 1981; Kinchington et al., 1985). 
Additionally, five regions of reiterated VZV sequences (Rl to R5) were identified
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initially by restriction mapping, and the number of repeats within each reiteration varies 
between VZV strains (see Fig. 1A.4). The role of the reiterations is unknown, but they 
have proved useful in investigating epidemiology of VZV infections, and genome 
variability of VZV isolates as determined by restriction endonuclease mapping (Straus 
et a l, 1983; Hayakawa et a l 1986; Hondo et al, 1987; Kinoshita et al, 1988; Hondo 
and Yogo, 1988).
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Figure 1A.4 The VZV gene arrangement. Heavy horizontal lines represent the unique regions 
of the genome and open rectangles depict the inverted repeats flanking the unique regions, as indicated in 
Figure 1A.3. ATG-initiated ORFs predicted to encode proteins are shown as arrows against the 
appropriate DNA strand, with the given nomenclature. The open reading frames were identified by 
Davison and Scott (1986), with the exceptions of ORF 9A (Barnett et al., 1992) and gene 33.5 which 
encodes a truncated form of the ORF33 product (lacking the N-terminal portion) (Telford et a l, 1992). 
The location of the intron between ORFs 42 and 45 is indicated. Light vertical lines show positions of 
potential polyadenylation sites in the appropriate strand and the locations of sequence reiterations (R l to 
R5) are depicted by black boxes. The Figure was adapted from Davison and Scott (1986).
Davison and Scott (1986) have sequenced the entire genome of the Dumas strain of 
VZV. The total genome contained 124,884bp; Ul is 104836bp; TRl and IRl 88.5bp 
each; Us 5232bp; and TRs and IRs 7319.5bp each. They originally identified a total of 
71 ATG initiated ORFs, but subsequently a further two ORFs have been proposed (Fig. 
1A.4). However, the gene assignment process is potentially fallible because it is based
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primarily on interpretation of DNA sequences; it remains to be determined whether all 
the ORFs are utilised and it is possible that more will be identified in the future. Of the 
73 VZV transcription units, 66 are present in single copy and three are located within 
the genomic repeats and are therefore diploid. ORFs 42 and 45 are probably expressed 
as a spliced transcript, as indicated in Figure 1A.4. The VZV genes are arranged 
compactly on both DNA strands but do not overlap extensively (Fig. 1 A.4).
The entire HSV-1 genome has also been sequenced (McGeoch et al, 1988) and to date 
76 HSV-1 transcription units have been identified. The sequences of the VZV and 
HSV-1 genomes display extensive conservation both in genome organisation and in 
their encoded genes. An obvious difference between the HSV-1 and VZV genome 
arrangements is the virtual elimination of the VZV long repeat segments (Fig. 1A.3). 
Together with some shortening of the Us, this accounts for the smaller size of the VZV 
genome; these alterations are responsible for differences between the gene 
representation and layout in these regions of the VZV and HSV-1 genomes (see legend 
to Table 1A). A further interesting difference is the absence from the VZV genome of 
the terminally redundant sequences ('a' sequences) that are found at the HSV-1 genome 
ends and the IR l/IR s junction (McGeoch et al., 1988). Additionally, the genome 
sequence of another alphaherpesvirus, EHV-1, has recently been determined and 
includes 80 predicted ORFs (76 of which are single copy) in an arrangement closely 
co-linear with those of VZV and HSV-1 (Telford et al., 1992).
1A.6 VZV gene products
Initial attempts to identify VZV-specific polypeptides and analyse their functions were 
complicated by the difficulties associated with purification of VZV virions. The functions 
of the HSV-1 gene products have been investigated more extensively, and knowledge of 
the VZV genome sequence has allowed comparison of the predicted amino acid sequences 
of VZV ORFs with those of characterised HSV-1 proteins (McGeoch etal., 1986; Davison 
and Scott, 1986; McGeoch etal., 1988). Independent information as to the likely functions 
of the predicted products of certain VZV genes has also been gained from either sequence 
comparisons with non-herpesvirus proteins or from experimental work (reviewed by 
Davison, 1991). Thus, tentative functions, based mainly on the sequence comparisons, 
have been ascribed to many of the VZV genes (Table 1A). The VZV genome sequence 
predicts five membrane glycoproteins (gpI-gpV; Davison et al., 1986) each having an 
HSV-1 counterpart (Table 1A) (Davison and Scott, 1986); each prediction has been shown 
to be correct experimentally (see Section 1 A.7.2).
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4 UL54/IE2 (Vmw63) Regulator of gene expression e
5 UL53 (gK) Possible membrane protein
6 UL52 Component of DNA helicase-primase complex e
7 UL51
8 UL50 Deoxyuridine triphosphatase ne
9 UL49 Tegument protein
9A UL49A Possible membrane protein
10 UL48 (Vmw65) Tegument protein - transactivator of IE genes e
11 UL47 Tegument protein ne
12 UL46 ne
13 Thymidylate synthetase
14 UL44(gC) Membrane glycoprotein (gpV) - role in cell entry ne
15 UL43 Probable integral membrane protein ne
16 UL42 Associated with DNA polymerase e
17 UL41 Host shutoff virion protein ne
18 UL40 Ribonucleotide reductase small subunit e/ne
19 UL39 Ribonucleotide reductase large subunit e/ne
20 UL38 Capsid protein e
21 UL37 Possible DNA binding function
22 UL36 Tegument protein e
23 UL35 Capsid protein
24 UL34 Possible virion protein
25 UL33 Role in capsid maturation/DNA packaging e
26 UL32
27 UL31
28 UL30 DNA polymerase e
29 UL29 Single-stranded DNA binding protein e
30 UL28 Role in capsid maturation/DNA packaging e
31 UL27 (gB) Membrane glycoprotein (gpll) - role in cell entry e
32
33 UL26 Protease, acts in virion maturation e
33.5 UL26.5 Capsid protein, processed by UL26 in HSV-1
34 SUL25 Virion protein e
35 UL24 ne
36 UL23 Thymidine kinase ne
37 UL22 (gH) Membrane glycoprotein (gpIII) - role in cell entry e
38 UL21
39 UL20 Integral membrane protein - role in virion egress e/ne
40 UL19 Major capsid protein e
41 UL18 Capsid protein e
42+45 UL17
43 IJL16 ne
44 UL15, exons 1 and 2
46 UL14
47 UL13 Tegument protein, probable protein kinase ne
48 UL12 DNase - role in maturation/packaging DNA e
49 UL11 Myristylated tegument protein - role in envelopment
and transport of virions ne
50 UL10 Probable integral membrane protein ne
51 UL9 ORI-binding protein e
52 UL8 Component of DNA helicase-primase complex e
53 UL7
54 UL6 Role in virion morphogenesis e
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VZV Gene HSV-1 counterpart Assigned function of VZV product Status of HSV-1 product
59 UL2 Uracil-DNA glycosylase ne
60 ULl(gL)
61 RL2 or IEO (Vmwl 10) Transcriptional regulator ne
62/71 RSI or IE3 (Vmwl75) Transcriptional regulator e
63/70 US1 or IE4 (Vmw68) Transcriptional regulator e/ne
64/69 US 10 Virion protein ne
65 US9 Tegument protein ne
66 US3 Protein kinase ne
67 US7 (gl) Membrane glycoprotein (gpIV) ne
68 US8 (gE) Membrane glycoprotein (gpl) ne
Table 1A Functions of the VZV proteins. The first two columns give the nomenclature of the 73 
VZV genes and the corresponding HSV-1 genes, as determined by sequence comparisons (the identity of 
HSV-1 glycoprotein and transcriptional regulator gene products are given in brackets in the second 
column). The third column gives the likely functions of VZV gene products (data taken from Davison, 
1991; Ostrove, 1990; McGeoch et al., 1993). The references to appropriate DNA sequence data on which 
the assignment of VZV gene functions are based are given in Davison and Scott (1986) and functional 
characterisations of VZV gene products are reviewed by Davison (1991). The final column indicates 
(where determined) whether the HSV-1 counterpart proteins are essential (e) or non-essential (ne) for all 
viral growth, ‘e/ne’ specifies gene products that are essential for HSV-1 infection of animal models but 
are dispensable for viral growth in tissue culture. VZV has five genes (genes 1, 2, 13, 32 and 57) that have 
no HSV-1 counterparts. Likewise, three HSV-1 genes in the long segment (UL45, UL56, y34.5) have no 
VZV counterparts. The complement of genes and also the gene order in the short segments differs to a 
greater extent between VZV and HSV-1 than the essentially co-linear long segments; 7 HSV-1 Us genes 
have no VZV counterparts (Davison and McGeoch, 1986).
The VZV genome also encodes homologues of four of the five HSV-1 IE proteins (VZV 
ORFs 4, 61, 62 and 63) and these are likely to play roles in regulation of VZV gene 
expression of similar importance to their HSV-1 counterparts (Sections IB.3.4 and 
1B.4.2). Like HSV-1, VZV specifies a large number of enzymes involved in DNA 
synthesis and this is a characteristic of herpesviruses not shared with other animal 
nuclear DNA viruses (see Section 1 A.8).
Interestingly, VZV is unique for an alphaherpesvirus in its possession of a gene 
encoding a thymidylate synthetase enzyme (TS). VZV gene 13 was predicted to encode 
a TS enzyme by its homology to non-herpesvirus TS enzymes (Davison and Scott,
1986) and the ability of the VZV TS to complement E. coli TS" strains verified its 
identity as a functional TS enzyme (Thompson et al., 1987). Similarly, the protein 
kinases encoded by VZV genes 47 and 66 were identified as such by their sequence 
homology to known serine-threonine protein kinases (McGeoch and Davison, 1986; 
Smith and Smith, 1989). The thymidylate kinase (tk) enzyme (sometimes termed 
deoxypyrimidine kinase - dPyK) encoded by VZV gene 36, is probably the best 
characterised VZV gene product. A full decade before the tk gene was mapped (Sawyer 
et a l, 1986), it was recognised that VZV infection results in the induction of a tk activity 
(Dobenson et al., 1976; Ogino et al., 1977). Despite being sequence homologues, the 
VZV and HSV-1 tk enzymes have different enzymatic properties (Cheng et al., 1979).
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Thus the elucidation of the VZV sequence significantly increased the knowledge of the 
potential functions of VZV proteins, and the availability of clones spanning the entire 
VZV genome makes possible the expression and subsequent analyses of isolated VZV 
gene products, circumventing the problems associated with growing VZV in tissue 
culture. Thus the availability of the VZV and HSV-1 genome sequences provides a very 
favourable starting point for those studying VZV gene products, and it is likely that 
many interesting differences between the functional details of the VZV and HSV-1 
homologue proteins will be discovered, as illustrated by the characterisation of the VZV 
tk enzyme.
1 A.7 Identification and mapping of VZV transcripts 
1 A.7.1 VZV transcript analysis
Concurrent with the derivation of the VZV genome sequence, the overall transcription 
pattern of the genome was investigated. Northern blotting experiments identified the 
genomic positions that corresponded to 58 discrete VZV-specific RNA transcripts from 
total RNA extracts of VZV infected cells (Ostrove et al., 1985). A further 20 abundant 
VZV transcripts were subsequently identified and the direction of transcription was 
discerned for each RNA species using ssRNA probes (Reinhold et al., 1988). 
Cytoplasmic polyadenylated VZV transcripts have also been mapped (Maguire and 
Hyman, 1986). These studies indicated that the size and map locations of many of the 
VZV transcripts were consistent with the open reading frames identified within the 
genome sequence (Davison and Scott, 1986). In addition, the size and locations of VZV 
transcripts showed generalised analogy to those of the HSV genome and indicated that 
transcription in the VZV system grossly parallels transcription in HSV-1 infected cells.
Although much information can be gained from sequence analysis, verification of the 
actual situation requires experimental data; for example detailed transcript analysis has 
shown that predictions based on sequence data alone are not always correct. Analysis of 
the 5' end of the VZV thymidine kinase (tk) transcript has demonstrated that 
transcription is initiated from a specific start site that is upstream of several other 
putative transcriptional start sites for VZV gene 36. Additionally, the 3’ end of the tk 
transcript extends beyond several predicted poly(A) sites by over 400bp (Davison and 
Scott, 1986). Coupled with the examination of sequences upstream and downstream of 
other VZV ORFs, this data led Davison and Scott (1986) to speculate that there may be 
considerable variation between the transcriptional and translational control of the VZV 
and HSV-1 genes. Regarding the VZV 140k protein, a 4.3kb transcript encoding 140k is 
expressed in cell lines stably transformed with gene 62 (Felser et al., 1988) and 140k
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was confirmed as the product of gene 62 using a 140k-specific monoclonal antibody 
(Forghani et al., 1990). The 5’ end of the gene 62 transcript has been defined by primer 
extension and SI nuclease analyses (McKee et al., 1990). In addition, the 5' and 3' ends 
of the transcripts of gpIV (gene 67) and gpV (gene 14) (Ling et al., 1992; 91) and the 5' 
end of IE gene 61 (Nagpal and Ostrove, 1991; Stevenson et al., 1992) have been 
mapped.
1 A.7.2 Mapping o f genes encoding specific VZV polypeptides
Several groups have endeavoured to identify and map the transcripts encoding specific
proteins of functional interest, in particular, much attention has been given to mapping 
the VZV glycoprotein-encoding genes. Ellis et al. (1985) identified the DNA encoding 
gpl (the major structural glycoprotein) by screening a bacterial expression vector library 
containing VZV DNA fragments for gpl antigens using monoclonal antibodies, 
followed by the mapping of the gpl transcript to VZV gene 68. In vitro transcription of 
selected mRNA species, followed by immunoprecipitation with an anti-gpll antibody 
was used to identify the gpll translation product and hence map the gpll transcript to 
gene 31 (Keller et al., 1986). Yet another approach was used to identify the gene 
encoding the gpIII glycoprotein: the gpIII protein was purified and derivation of the N- 
terminal sequence allowed identification of its corresponding gene (gene 37) by 
hybridisation with degenerate nucleotides based upon the protein sequence (Keller et al.,
1987). VZV gene 67 has been identified as encoding the gpIV family of glycoproteins 
(Davison et al., 1985). Finally, sequence analysis predicted gene 14 to encode 
glycoprotein gpV, and has since been shown to be the case by functional
characterisation of the VZV gene 14 products (Kinchington etal., 1990).
Various non-structural VZV gene products have additionally been investigated. The 
transcript specifying the VZV thymidine kinase (tk) enzyme was mapped by transfecting 
plasmids carrying VZV fragments into mouse cells which lacked functional cellular tk 
enzyme (tk~), followed by screening for tk+ transformants. The VZV transcripts from the 
tk+ cells mapped to VZV gene 36 (Sawyer et al., 1986). There are several further 
examples where genes specifying particular polypeptides have been determined 
experimentally, however the wealth of information that can be obtained from the VZV 
and HS V-1 genome sequences suggests that a simpler and more informative approach in 
many cases might be to identify the VZV gene with the putative properties of interest by 
sequence analysis, followed by characterisation of the translation products of the cloned 
gene. The was the approach used in the mapping of VZV gene 62, encoding 140k.
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1A.8 The VZV replicative cycle
Very little is known about the VZV life cycle at the molecular level, but it is unlikely to 
differ greatly from that of the HSV-1 prototype system (for a review, see Grose and Ng, 
1992). In particular, the biochemical processes of viral DNA replication are unlikely to 
differ markedly between VZV and HSV-1 because each of the seven HSV-1 genes that 
are essential for HSV-1 DNA replication (Wu etal., 1988) have VZV sequence 
homologues (VZV ORFs 6, 16, 28, 29, 51, 52 and 55) (see Table 1A) (Davison and 
Scott, 1986). For example, the VZV DNA polymerase (ORF 28) shares more than 50% 
amino acid sequence identity with its HSV-1 counterpart (Becker, 1988). A VZV origin 
of replication (ORI) has been identified within each copy of the genome short repeat, in 
a position analogous to that occupied by one of the HSV-1 replication origins (ORIs) 
(Stow and Davison, 1986). Like the HSV-1 ORIs, the VZV ORI contains an almost 
perfect 45bp palindrome, with central alternating tracts of A and T residues. The VZV 
genome appears not to include an origin of replication in the equivalent position to the 
HSV-1 ORIl, although it is highly possible that one may be located elsewhere in the 
long unique segment of the VZV genome (Davison and Scott, 1986).
1A.9 Reconstruction of the VZV genome from sets of cosmids: a method 
for introduction of site-specific mutations
The poor growth properties of VZV in vitro have greatly hindered application of the 
genetic techniques that were the key to the identification of functions of many HSV-1 
gene products (i.e. production and analysis of ts and null mutants) (reviewed in Roizman 
and Sears, 1993). Successful genetically engineered alteration of a VZV gene (in the 
viral context) has only been reported at the thymidine kinase gene locus, by 
recombining a plasmid carrying the altered gene into the VZV genome (Lowe et al., 
1987; Shiraki etal., 1991). Drawbacks of this approach include the incorporation of a 
foreign marker required for recombinant selection, difficulties in obtaining VZV DNA 
for transfection, and in obtaining cell-free virus to plaque purify VZV mutants from wild 
type virus.
However, Van Zijl et al. (1988) have described a method for generating recombinant 
pseudorabies virus using a set of overlapping cosmid DNAs, and this has recently been 
applied successfully to the production of a VZV genome including a site-specific 
mutation (Cohen and Seidel, 1993). These experiments used four cosmids carrying
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overlapping fragments of VZV DNA that together spanned the entire VZV genome and 
a specific mutation was introduced into one of the cosmids in the thymidylate synthetase 
ORF, followed by transfection of all the cosmids into tissue culture cells. The VZV 
genomes containing the specific mutation were produced by recombination events and a 
plasmid expressing the VZV 140k transactivator was also co-transfected with the 
overlapping cosmids to improve the infectivity of the viral DNA. This overlapping 
cosmid approach has also been successfully employed for regenerating the HSV-1 
genome (Cunningham and Davison, 1993). However, the implications of this 
technology are especially important to the analysis of VZV gene functions, which has 
long been hampered by the difficulties discussed in the previous paragraph. As such the 
introduction of defined mutations into specific VZV genes using overlapping cosmids 
holds much promise for the future of VZV research.
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IB Gene regulation in the Alphaherpesvirinae
The details of VZV gene regulation are only beginning to emerge and will be discussed 
later (Section 1B.4). However, the high degree of similarity between the VZV and 
HSV-1 genome arrangements and the predicted sequences of their gene products, 
strongly suggests that these two alphaherpesviruses are likely to employ similar 
transcriptional programmes. Therefore it is valuable to discuss the more extensively 
analysed situation regarding HSV-1 gene expression.
1B.1 Temporal regulation of HSV-1 gene expression - an outline
The transcription of viral DNA is by the unmodified host RNA polymerase II (Costanzo 
et al., 1977; Ben-Zeev and Becker, 1977) and presumably utilises the host-cell basal 
transcription machinery (described in Section ID. 1.2). The HSV-1 polypeptides have 
been divided into three broad, coordinately regulated, sequentially produced groups of 
polypeptides, on the basis of their kinetics of synthesis and also their sensitivity to 
metabolic inhibitors during tissue culture infections (Honess and Roizman, 1974). The 
precise details of the period of synthesis of these groups of polypeptides varies with 
virus strain and host cell type and therefore makes detailed temporal description 
difficult.
The transcripts of the first group 
of HSV-1 polypeptides to be synthesised on infection, termed the immediate-early (IE) 
or alpha polypeptides (a), are expressed in the absence of de novo viral protein 
synthesis. The IE polypeptides are detected as early as lhr post-infection (pi), although 
synthesis peaks between 2 and 4hr pi. At least some of the IE proteins continue to 
accumulate throughout infection (Ackermann e ta l , 1984; Everett and Orr, 1991). A 
component of the HSV-1 virion particle is partly responsible for the induction of IE 
gene expression (Section IB.2.2). As will be discussed later (Section IB.3.4), all the 
HSV-1 IE polypeptides (with one exception) have been found to contribute to the 
regulation of synthesis of subsequent polypeptide groups.
The second group, the early (E) or beta polypeptides ((3), are detected very soon after 
infection and are synthesised at high rates for most of the infectious cycle, but are less 
abundant at the later stages of infection. The E polypeptides are produced in advance of
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viral DNA replication but have an absolute requirement for the presence of functional IE 
proteins for their synthesis (Honess and Roizman, 1975). The majority of polypeptides 
involved in viral nucleic acid metabolism are within the early group.
The remaining HSV-1 polypeptides fall into the late (L) or gamma (y) group. These can 
be detected as early as 2hr pi, but they are produced maximally only after DNA 
replication has produced a large copy number of replicated templates. Normal 
production of late gene products requires the presence of the viral IE polypeptides and 
active viral DNA replication (which is itself a function of the E gene products) for 
maximum efficiency (Preston, 1979a; Watson and Clements, 1980; Ward and Stevens, 
1975; Conley et al., 1981). The late group of polypeptides includes many of the 
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Figure 1B.1 HSV-1 gene products which regulate transcription. The positions of the genes 
encoding the five HSV-1 IE proteins and the IE /ra/u-inducing protein, Vmw65, are shown on a map of 
the HSV-1 genome, below are given the gene names and corresponding products. The IE4 and IE5 genes 
are transcribed from a common promoter situated within the short repeat region of the genome. The 
positions of the LAT transcription units (Section 1A.3), antisense to a portion of the IEl gene, are also 
indicated. The role of each of the transcriptional regulatory gene products in the control of HSV-1 gene 
expression is depicted in the lower part of the Figure, Vmw68 may have a role in activation of late gene 
expression but the role of Vmwl2 is unknown (Sections 1B.2.2 and IB.3.4). Early gene products, 
particularly those required for DNA replication, are necessary for late gene expression. The Figure is an 
adaptation of an original diagram by R. D. Everett.
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In general there is a close correlation between the time of appearance of individual 
mRNA transcripts and the kinetic class of the proteins encoded by them, indicating that 
the major regulatory processes occur at the transcriptional level (Clements e ta l , 1977; 
Jones and Roizman, 1979; Holland et al, 1980; Zhang and Wagner, 1987; Smith and 
Sandri-Goldin, 1988). However, the situation is not as straightforward as the strict 
synchronous IE, E and L groupings. A distinct subclass of late genes termed 'leaky' late 
(or Yi), are expressed prior to viral DNA synthesis, but require the onset of viral DNA 
replication for maximal expression; the remaining late genes have a stricter requirement 
for DNA replication and are termed 'true' late (7 2 ) (Powell et a l, 1975; Pedersden et al, 
1981). In reality, genes expressed later in infection appear to form more of a continuum 
with respect to their time of expression and dependence on viral DNA replication 
(reviewed by Wagner, 1985). Detailed analysis of the synthesis and accumulation of 
specific mRNA transcripts indicated that post-transcriptional events also play a part in 
controlling HSV-1 gene expression (Harris-Hamilton and Bachenheimer, 1985; 
Weinheimer and McKnight, 1987). Figure 1B.1 shows a summary of the factors 
involved in regulating HSV-1 gene expression, and their roles in controlling the 
temporal cascade.
IB.2 Regulation of HSV-1 immediate-early (IE) genes
1 .B.2.1 Cis-acting sequences involved in regulation of IE gene expression 
The HSV-1 genome encodes five IE genes located at the positions indicated in Figure
1B.1. The functions of the HSV-1 IE gene products are discussed in more detail later 
(Section IB.3.4). Once it had been demonstrated that the IE3 promoter region conferred 
its IE status (Post et a l, 1981), the detailed genetic dissection of the HSV-1 IE 
promoters soon followed. The promoters of HSV-1 IE genes, like many cellular 
promoters, were found to contain two separable regions involved in gene expression; 
(i) a minimal promoter region including a 'TATA box' that is sufficient for directing 
basal transcription (see Section ID. 1.3) and (ii) upstream regulatory sequences which 
include multiple ds-acting sites for host and virus encoded regulatory proteins (Mackem 
and Roizman, 1982a; b; Cordingley et al, 1983; Preston et a l, 1984; Kristie and 
Roizman, 1984; Bzik and Preston, 1986) (Fig. 1B.3). At least in the case of the IE3 
promoter, the far upstream promoter region functions as an enhancer (Lang et al, 1984; 
Preston and Tannahill, 1984).
Upstream promoter elements for common cellular sequence-specific factors have been 
identified that are likely to contribute to the high constitutive activity of these IE 
promoters. The hexanucleotide sequence GGGCGG is present in multiple copies in the
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HSV-1 IE promoters and some of these have transpired to be GC boxes' that bind and 
respond to rrans-activation by the cellular sequence-specific factor Spl in vitro (Jones 
and Tjian, 1985). Cw-acting binding sites for other ubiquitous cellular transactivators 
such as the CCAAT-box binding proteins (CBP) are also found in IE distal promoter 
regions and contribute to the efficiency of gene expression (Spector et al, 1990).
An important element for conferring IE inducibility is present in at least one copy in all 
the HSV-1 IE promoters and includes the sequence TAATGARAT (R = purine). 
Functional analyses have found this element to be essential for the response to a 
component of the HSV-1 virion, later identified as the protein Vmw65 (aTIF or VP 16) 
(Mackem and Roizman, 1982b; Campbell et al, 1984; Preston et al, 1984; Kristie and 
Roizman, 1984; Gaffney e ta l, 1985; Bzik and Preston, 1986). Overlapping the majority 
of TAATGARAT sequences is a consensus octamer motif that has been shown to bind 
the ubiquitous cellular octamer-binding transcription factor Oct-1 (NFIII, a-H l, OTF-1 
or TRF) (Pruijn et al, 1986; Kristie and Roizman, 1987; Gerster and Roeder, 1988; 
O’Hare and Goding, 1988). The interplay between Vmw65 and Oct-1 and their roles in 
IE-specific promoter induction will be discussed in the following Section.
In addition, GA rich elements (GA-RE) are present in the upstream regions of at least 
four HSV-1 IE genes and these elements are necessary for the fully efficient 
Vmw65-mediated activity of TAATGARAT (Bzik and Preston, 1986; Triezenberg et 
a l, 1988). Characterisation of the cellular GA-RE binding protein (GABP) identified 
two distinct subunits; one subunit shows sequence similarity to a family of 
transcriptional regulatory proteins while the other is related to a protein implicated in 
signal transduction (LaMarco e ta l, 1991). It appears from DNA binding analyses that 
GABP cooperates with Oct-1 to enhance formation of a multi-protein complex on 
selective TAATGARAT sites (Bailey and Thompson, 1992); this complex mediates IE 
promoter induction (see below). It is interesting to speculate from the sequence 
homologies to the GABP subunits, that the stimulatory effect of GABP may be coupled 
to external stimuli or cellular events.
Finally, the IEl and IE3 promoters also contain consensus binding sites (see Section
1C. 1.3) for the HSV-1 immediate-early protein Vmwl75 (Kristie and Roizman, 1986b; 
Muller, 1987). The significance of these binding sites for the activity of the HSV-1 IE 
promoters will be discussed later (Section IB.2.3).
1B.2.2 Transactivation o f HSV-1 IE promoters by the immediate-early complex (IEC) 
A virion component, Vmw65 (more widely known as VP16) has been shown to 
trans-induce IE gene expression selectively (Post et a l, 1981; Campbell et a l, 1984;
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Dalrymple et al., 1985; Pellet et a l, 1985). This function is important for the efficiency 
of lytic viral growth but it is not essential; an HSV-1 mutant defective only in the IE 
transactivation function of Vmw65 replicates poorly in vitro, has an elevated 
particle:pfu ratios and is avirulent in vivo (Ace et al., 1989). Vmw65 is unusual in 
having two distinct functions, as it is also an essential structural component of the virion 
tegument (Batterson and Roizman, 1983; Weinheimer etal., 1992).
The mechanism by which Vmw65 induces HSV-1 IE gene expression through the IE 
responsive element (TAATGARAT) has been studied intensively in recent years, not 
least because Vmw65 alone is unable to bind stably to the TAATGARAT element 
(Marsden et al., 1987). As mentioned in the previous Section, a cellular protein (Oct-1) 
binds to a site overlapping the TAATGARAT motif. Oct-1 itself has little effect on IE 
promoter activity but acts to recruit Vmw65 to the ‘immediate-early complex’ (IEC) that 
forms over the TAATGARAT element (McKnight et al., 1987; Preston et al., 1988; 
Gerster and Roeder, 1988; O’Hare and Goding, 1988; O’Hare et al., 1988; Stern et al., 
1989; apRhys et al., 1989). Oct-1 is a member of the POU protein subclass of 
homeodomain proteins and as such has a bipartite DNA binding interface (see Section 
1E.2.3). Truncation analysis of Oct-1 discerned that the homeodomain portion contacts 
the TAAT sequence while the POU-specific domain contacts the ATGC sequence 5’ to 
the TAATGARAT site (Verrijzer etal., 1990; 1992) (see Fig. IB.2).
Importantly, in vitro experiments using purified components have found that Vmw65 
and Oct-1 are not sufficient to reconstitute the IEC and that an additional cellular 
component is required (Gerster and Roeder, 1988; Kristie etal., 1989; Xiao and Capone, 
1990; Kristie and Sharp, 1990; Katan et al., 1990; Stern and Herr, 1991). The 
association of this auxiliary protein, known as HCF (Cl, CFF or VCAF), with Vmw65 
is thought to 'prime' the association of Vmw65 with Oct-1 over the TAATGARAT 
motif. Since mutations in the GAR AT portion of the TAATGARAT sequence also 
prevent IEC formation (O’Hare et al., 1988), it is likely that the Vmw65-HCF 
heterocomplex recognises the GARAT sequence, once recruited by Oct-1 (Fig. IB.2). 
Wilson et al. (1993) have recently shown that HCF comprises multiple subunits derived 
from a single polypeptide species by processing events. Their isolation of the cDNA 
clone encoding the HCF polypeptides should enable functional analysis of the complete 
IEC in reconstituted systems. The regions of the Oct-1 and Vmw65 proteins involved in 
IEC formation have been mapped by various mutational analyses. The details of these 
findings have been reviewed recently by O’Hare (1993) and will not be considered 
further here.
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Figure 1B.2 A model for IEC formation and transcriptional activation by Vmw65. This 
schematic diagram depicts interactions that have been experimentally observed between the various 
protein components of the IEC and the basal transcription machinery. Following release of the viral DNA 
from the capsid, the octamer sites of the IE promoters become occupied by Oct-1. Independently, Vmw65 
complexes to HCF, and this heterocomplex then recognises Oct-1 in the context of the flanking GARAT 
signal (specific to octamer motifs of IE genes) to form the immediate-early complex (IEC). The Vmw65 
acidic activation region is now positioned to activate transcription by promoting assembly of the 
transcription complex at the TATA box, through interactions with the basal transcription factors TFIIB 
and TFIID (comprising TBP and the TAFs, see Section ID. 1.4). The Drosophila TAFs are shown but are 
thought to have human homologues, the remaining TAFs and other basal factors have been omitted for 
simplicity. There is no experimental data to suggest how proteins bound over the upstream TAATGARAT 
element and those bound at the proximal regions of the promoter are brought together to allow Vmw65 to 
interact with the basal factors, although looping or condensation of DNA in nucleoprotein complexes are 
both possibilities. The Figure is a compilation of figures by O’Hare (1993) and Goodrich et al. (1993).
Of particular relevance to the transcriptional regulatory activity of Vmw65 are its two 
extremely potent transcriptional activation domains, which reside within its highly 
acidic C-terminus. Each Vmw65 activation domain can function independently when 
fused to heterologous portions of proteins that bind directly to DNA (Sadowski et al., 
1988; Cousens et al., 1989; Goodrich etal., 1993). Investigations using 'GAL4-VP16' 
chimeras (containing the activation domain(s) of Vmw65 fused to the yeast GAL4 DNA 
binding domain) have been highly productive in elucidating the details of the Vmw65 
transactivation mechanism. In vitro protein-protein interaction assays with GAL4-VP16 
revealed that both of the Vmw65 activation domains contribute interfaces for the 
interaction with the basal transcription factor TFIIB, whereas the furthest C-terminal 
domain additionally contacts a specific TAF component of the basal factor TFIID (Lin 
et al., 1991; Goodrich et al., 1993) (see Section 1D.1.4). Furthermore, the interaction
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with TFIIB has been shown to be essential for GAL4-VP16-mediated activation of gene 
expression in vitro (Roberts et al., 1993). VP 16 has also been reported to interact with 
the TATA binding protein (TBP) component of TFIID (Stringer et a l, 1990; Ingles et 
al., 1991), but with a lower affinity than the VP16-TFIIB interaction (Lin and Green, 
1991). Once recruited to the promoter, the interaction between Vmw65 and the basal 
transcription machinery may result in a conformational change in the 
TFIID-TFIIB-promoter complex, thus promoting assembly of the remaining basal 
factors into a functional transcription complex on the IE promoters (Hahn, 1993a) (Fig. 
IB.2). In support of this, a HeLa cell in vitro transcription system revealed that Vmw65 
and the Oct-1 POU domain facilitate the assembly of the preinitiation transcription 
complex on target promoters (Arnosti et al., 1993). The involvement of several cellular 
factors in the process of recruiting Vmw65 to the promoter (in the IEC) may serve to 
couple IE induction to an appropriate cell type or state.
1B.2.3 Repression o f HSV-1 IE promoters by Vmwl75
The finding that HSV-1 viruses with ts mutants in Vmwl75 over-express the IE gene 
products at the NPT was interpreted as indicating that Vmwl75 is continuously required 
for the rrans-repression of all HSV-1 IE genes (Preston, 1979a; Dixon and Schaffer, 
1980; Watson and Clements, 1980). Transient transfection assays have been employed 
extensively to analyse the basis of this apparent repression of IE gene expression, using 
various combinations of plasmid-borne copies of HSV-1 regulatory proteins and IE 
promoters (reviewed by Everett, 1987a). Due to the nature of these assays the results 
obtained varied according to the particular system employed (Everett, 1988b), however 
the general consensus was that Vmwl75 clearly repressed both constitutive and 
Vmw65-activated IE3 promoter activity, and also reduced activation of the IEl 
promoter (DeLuca and Schaffer, 1985; O’Hare and Hayward, 1985b; Gelman and 
Silverstein, 1986; Resnick et al., 1989). It was soon noted that both of these IE 
promoters included a ‘strong’ Vmwl75 binding site fitting the Vmwl75 consensus 
sequence that had been derived for several Vmwl75 binding sites (Muller, 1987; Kristie 
and Roizman, 1986b) (see Section 1C. 1.3). The Vmwl75 binding site within the IE3 
promoter spans the mRNA start site and has been implicated in the ability of Vmwl75 
to repress transcription from its own promoter (Muller 1987; DeLuca and Schaffer, 
1988; Roberts et al., 1988), whereas the IEl promoter site was located further upstream 
(Kristie and Roizman, 1986b). The IE3 and IEl sites are 2.6 and 3.5 helical turns away 
from their TATA boxes respectively, albeit on opposite sides of the TATA box, and the 
footprinting analyses of Didonato and Muller (1989) found that binding of Vmwl75 to 
either the IEl or the IE3 promoter binding site resulted in perturbations at the TATA 
box (less marked at the IEl TATA box). They suggested that Vmwl75 binding to the 
IEl and the IE3 site may have deleterious effects on the DNA binding interactions or the
23
Chapter IB: Alphaherpesvirus gene regulation
activity of the basal transcription machinery at the TATA box, leading to promoter 
repression. It appeared that the distance between the Vmwl75 binding site and TATA 
box and also their stereo-specific alignment was important for determining whether 
Vmwl75 binding results in promoter repression or transactivation, because removing 
the IE3 binding site to a greater distance apparently disrupted normal regulation and 
abolished the hypersensitivity at the TATA box. The naturally occurring Vmwl75 
consensus binding site in the HSV-1 gD promoter (a promoter that is activated by 
Vmwl75) is located 8 helical turns upstream of the TATA box and Vmwl75 binding to 
this site does not result in hypersensitivity at the TATA box (DiDonato and Muller, 
1989). A further report indicates that the proximity of the Vmwl75 binding site to the 
mRNA start site is likely to be a vital element in determining promoter repression (Koop 
etal., 1993).
Mutation of the Vmwl75 binding sites within the IE3 and IEl promoters has 
demonstrated a direct functional correlation between Vmwl75 binding and promoter 
repression in transient transfection assays (Roberts et a l, 1988; Resnick et a l, 1989). 
Further support of the importance of Vmwl75 DNA binding for promoter repression 
comes from the observation that all mutations of the Vmwl75 protein that result in loss 
of DNA binding activity also destroyed its repression phenotype (with one exception, 
Paterson e ta l,  1990). Interestingly, mutation of the Vmwl75 binding site in the IEl 
promoter in the context of the viral genome had no apparent effect on Vmwl 10 
polypeptide levels (Everett and Orr, 1991). In contrast, mutation of the Vmwl75 
binding site at the mRNA start site of the IE3 promoter linked to the tk gene in a 
recombinant viral genome, resulted in a 15 fold increase in tk expression (Michael and 
Roizman, 1993). Two additional non-consensus Vmwl75 binding sites (Section 1C. 1.3) 
in the upstream region of the IE3 promoter (Kristie and Roizman, 1986a; Michael and 
Roizman, 1989) additionally appeared to contribute to the down-regulation of the IE3 
promoter in the viral context (Michael and Roizman, 1993). Thus the evidence suggests 
that during normal HSV-1 infection only the IE3 promoter is repressed effectively by 
Vmwl75. The over-expression of the other IE mRNAs and their corresponding 
polypeptides observed in the absence of functional Vmwl75 (above) might simply 
result from increased availability of limiting basal transcription factors, which might 
otherwise be recruited to the E and L promoters. Indeed, during normal infection, only 
IE3 gene expression appeared to be down-regulated at the level of transcription and 
significant amounts of the other IE transcripts persisted until late in infection 
(Weinheimer and McKnight, 1987; Harris-Hamilton and Bachenheimer, 1985). It can be 
envisaged that high levels of the Vmwl75 transcriptional activator protein may have 
deleterious effects on the later stages of the viral replication cycle and this negative
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autoregulatory mechanism presumably provides a homeostatic mechanism to prevent 
this occurring.
The existence of a temperature-sensitive HSV-1 virus that produces a Vmwl75 protein 
capable of binding to the IE3 consensus binding site, yet fails to down-regulate IE3 gene 
expression (Paterson et al., 1990) indicates that the autoregulatory function of Vmwl75 
is likely to require interactions with other proteins in addition to DNA binding. Recent 
insight into the mechanism by which Vmwl75 autoregulates its own expression has 
been provided by DeLuca and co-workers. They demonstrated that Vmwl75, and the 
basal transcription factors TFIID (or TBP) and TFIIB (see Section ID. 1.2) can 
simultaneously co-occupy their respective binding sites within the IE3 promoter region, 
and furthermore the three proteins appeared to bind in a cooperative manner (Smith et 
a l, 1993). By using a reconstituted in vitro transcription analysis of the IE3 promoter, 
backed up by analysis of viral mutants, Gu et al. (1993) demonstrated that 
Vmwl75-mediated repression only occurs in the presence of the cellular transcriptional 
regulatory protein Spl and this repression required functional Vmwl75 and Spl binding 
sites. Taken together these data indicate that the down-regulation of IE3 gene expression 
is not a consequence of disruption of the basal transcription machinery, but instead is 
caused by a reduction in Spl-mediated induction (which is an important factor in the 
high constitutive level of IE promoter activity; Bzik and Preston, 1986). Additionally, 
the TAFs were implicated in repression of the IE3 promoter, as the TATA binding 
protein (TBP; TFIID but lacking the TAFs, see Section ID. 1.4) was not interchangeable 
with TFIID for repression in vitro. Thus Vmwl75 may repress the IE3 promoter by 
interfering with the interactions of Spl or its co-activator/TAF with the basal 
transcription machinery (Gu etal., 1993).
IB.3 Activation of HSV-1 early (E) and late (L) gene expression
1B.3.1 Cis-acting sequences involved in regulation o f E gene expression 
The finding that transcriptional induction of early promoters requires the presence of 
functional viral IE gene products (Section 1B.1) stimulated the analysis of cis-acting 
signals mediating virus induced gene expression. The promoter regulatory regions of 
two members of the HSV-1 E class of genes, namely glycoprotein D (gD) and 
thymidine kinase (tk), have been extensively investigated.
In the earliest analysis of any HSV-1 promoter, McKnight et al. (1981) measured the 
expression from tk promoter deletion mutant derivatives microinjected into xenopus 
oocytes and they later extended their findings using the now classical ‘linker-scanning’
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(LS) analysis (McKnight and Kingsbury, 1982). These experiments defined the minimal 
tk promoter as approximately 110 nucleotides extending upstream of the mRNA start 
site and identified the necessity of the TATA box for efficiency and fidelity of 
transcriptional initiation. A CCAAT motif and two GC boxes were identified as distal 
regulatory elements influencing tk promoter activity in oocytes. The GC boxes and 
CCAAT boxes were later shown to bind the well characterised cellular transactivator 
proteins Spl and CCAAT binding protein (CBP) respectively (Jones etal., 1985; 
Graves et al., 1986). Transient transfection analysis of the LS mutants followed by 
HSV-1 infection of tissue culture cells, failed to identify any additional promoter 
sequences specifically required for viral induction of tk gene expression (Eisenberg et 
al., 1985; ElKareh et al., 1985) (confirming the earlier results with the gD promoter 
described below), and this was also found to be the case in the viral context (Coen et al.,
1986).
Far-upstream Distal Proximal










Figure IB.3 Important sequence elements required for activity of the HSV-1 
promoters. Schematic representations of promoters from each of the three temporal classes of HSV-1 
genes. The top line indicates a scale in nucleotides starting from the mRNA start sites (indicated by the 
arrows at +1 nucleotides) as a guide to the locations of the various promoter elements. The majority of 
promoters in all three classes contain a typical TATA box, but vary in the upstream region between 
classes. The IE and E promoters include distal elements which bind a variety of host regulatory factors, 
such as GC boxes (which bind Spl) and CCAAT boxes (which bind CBP) and G-rich sequences found in 
certain promoters bind the YY1 factor. The far-upstream regions of the IE promoters additionally include 
at least one TAATGARAT element, which is required for Vmw65-mediated induction of IE gene 
expression (Sections 1B.2.1 and IB.2.2). Late genes require no specific upstream binding sites for 
regulatory proteins but have a requirement for replication of the viral template, sequences in the vicinity 
of the mRNA start site / leader appear to contribute to temporal expression of late promoters (Section 
IB.3.2).
Using a similar approach, Everett transfected plasmids carrying fragments of the gD 
promoter linked to an assayable marker gene into tissue culture cells followed by HSV-1 
infection, and discerned that sequences located within 83bp of the mRNA start site were 
sufficient for fully efficient viral-mediated induction of transcription from the gD 
promoter by the HSV-1 IE products (Everett, 1983). A subsequent deletion and insertion
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mutational analysis identified the importance of the gD TATA box and found that 
induction of the gD promoter both in trans (by viral IE proteins) and in cis (by the SV40 
enhancer) was governed by the TATA box and two distal G-rich elements in each case 
(Everett, 1984a). The distal-most G-rich element was the more important of the two for 
gD promoter activity (Everett, 1984a), and this sequence has recently been shown to be 
the recognition site for the cellular factor YY1 (Seto et al, 1991; Chen et al., 1992; 
Mills et al, 1994). No virus-specific regulatory elements were identified in the gD 
promoter, implying that Jra^-induction by viral factors is mediated through the same 
sequences that are recognised by the uninfected cellular transcriptional apparatus 
(summarised in Fig. IB.3). Furthermore the HSV-1 early promoters appear to most 
closely resemble inducible cellular RNA pol II promoters, as illustrated by the 
regulation of cellular globin genes in the viral context with early kinetics (Smiley et al, 
1987; Smiley and Duncan, 1992). The mechanism used for down-regulation of early 
gene expression at later times in infection remains to be determined.
1B.3.2 Cis-acting sequences involved in regulation o f L gene expression 
Efficient expression of HSV-1 late gene products requires replication of the viral 
template and functional IE and E gene products (Section 1B.1). Early investigations of 
sequence requirements for activation of the US 11 and gC true late gene promoters 
(either plasmid-borne or in the viral context) demonstrated that sequences spanning the 
TATA box/mRNA start were sufficient for true late gene regulation when linked to a 
functional origin of replication (the replication enzymes were supplied by HSV-1 
infection) (Johnson and Everett, 1986a; b; Homa et al., 1986; Shapira et al., 1987). 
Furthermore, a 15bp fragment spanning the TATA box of the gC promoter could 
mediate gene expression with late kinetics (Homa et al., 1988). It appeared therefore, 
that although replication is a strong requirement for induction of the true late promoters, 
no specific upstream recognition elements for virus specific or cellular transactivators 
are required. However, recognition sites for the cellular factor YY1 have recently been 
identified in the upstream promoter regions of several leaky late genes (UL19, UL37 
and gB genes); deletion of this element in the UL19 promoter reduced gene induction by 
HSV- 1  gene products approximately 9 fold, as measured by transient transfection assays 
(Seto etal., 1991; Chen eta l, 1992; Mills etal., 1994).
What factors then determine expression of these genes with late kinetics? Evidence from 
several studies suggested that true L gene regulation is defined by possession of a 
specific type of TATA box (Johnson and Everett, 1986b; Homa etal., 1988; Flanagan et 
al., 1991a), although conflicting evidence exists, for example substitution of the TATA 
box from the gC (late) promoter into the tk (early) locus had no effect on temporal 
expression of tk (Imbalzano and DeLuca, 1992). Further studies have found that
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sequences downstream of the TATA box, around the mRNA start site / leader, 
contribute to L promoter activity and may even account for the requirement for 
replication (Blair et al.f 1987; Mavromara-Nazos and Roizman, 1989; Kibler et al., 
1991; Steffy and Weir, 1991). There are various possible means by which these 'leader' 
sequences could confer L gene regulation: they may bind a specific tra/w-acting factor 
necessary for L gene expression, or they may bind a negative factor that is dislodged by 
replication of the template. In support of the latter, the experiments of 
Mavromara-Nazos and Roizman (1987) suggested that DNA replication alleviates a 
negative constraint that is unique to late genes in the viral context. Alternatively, the late 
leader sequences may form a secondary structure (such as a stem-loop structure) that has 
a repressive effect on gene expression until it is disrupted by replication. The precise 
role played by these leader sequences awaits clarification. However, if any 
leader-binding factors are involved, they must have fairly degenerate DNA binding 
specificities as no putative c/s-acting sequence is common to the leader region of HSV-1 
late genes. An interesting possibility is that non-specific DNA binding proteins may 
mediate repression of late HSV-1 gene expression, such as the histone proteins of 
chromatin (Section ID.2.4). However, the similarities with the cellular 
chromatin-mediated mechanism of reducing the basal level of gene expression will be 
limited, as only a small fraction of the HSV-1 DNA from lytically infected cells was 
found to be in a nucleosome-like arrangement (Leinbach and Summers, 1980; 
Muggeridge and Fraser, 1986; Seal et al, 1988).
1B.3.3 What is the role played by Vmwl75 in the activation o fE  and Lpromoters? 
From the analysis of ts mutant viruses, it was apparent that Vmwl75 stimulates HSV-1 
E and L gene expression (Section IB.3.4) and therefore the discovery that Vmwl75 
exhibited sequence-specific DNA binding properties (Section 1C. 1.3) led to the search 
for Vmwl75 binding sites within its target promoters. A consensus Vmwl75 binding 
site within the distal region of the HSV-1 gD promoter and two further non-consensus 
Vmwl75 sites (one upstream and one downstream of the mRNA start site) have been 
identified (Faber and Wilcox, 1986b; Tedder et al., 1989). While these sites were not 
specifically identified in the mutational analysis of the gD promoter (Everett, 1984a; 
Section IB.3.1), they contributed to activation by Vmwl75 in vitro (Tedder et al., 
1989). Multimerisation of the consensus site increased Vmwl75-mediated 
transactivation in transient assays (Tedder and Pizer, 1988). However, removal of all 
three binding sites from the viral genome had little or no apparent effect on gD 
expression during HSV-1 infection (Smiley et al., 1992). Similarly the tk promoter 
includes several non-consensus Vmwl75 binding sites (Kristie and Roizman, 1986a; 
Imbalzano et al., 1990) but a virus carrying a version of Vmwl75 unable to bind 
specifically to the tk promoter binding sites in vitro did not show reduced levels of tk
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gene expression during viral infection (Imbalzano et al., 1990). There exists only one 
report of a direct involvement of a Vmwl75 binding site in the transactivation of a viral 
promoter, but the implications of this analysis are complicated by the location of this 
particular site in the leader of a true late gene (Romanelli et al, 1992).
Whether or not the interaction of Vmwl75 with its binding sites transpires to be a 
requirement for promoter activation (discussed in Section 1C. 1.7), it is clear that the 
TATA box is singly the most important promoter element for fra/w-induction of E and L 
genes by Vmwl75. The precise sequence of the TATA box can affect the efficiency of 
promoter transactivation (Everett, 1988b). Additionally, HSV-1 rra/w-inducing proteins 
can activate many cellular genes carried on plasmids, or integrated into the cellular or 
viral genome (Everett and Dunlop, 1984; Everett, 1985; Smiley et al, 1987; Panning 
and Smiley, 1989), yet they failed to activate the TATA-less rodent aprt gene placed in 
the viral context (Tackney et a l, 1984). These data suggest that the cellular factor that 
binds the TATA box (TFIID) is a critical target of Vmwl75-mediated promoter 
activation. In support of this, Imbalzano and DeLuca (1992) found that 
Vmwl75-mediated induction of chimeric promoters was greater when the promoter 
included a TATA box with a weak affinity for TBP (the TATA binding protein, a 
component of TFIID; see Section 1D.1.4) (i.e. the tk TATA box), as compared to the 
induction of a construct containing a TATA box having a stronger affinity for TBP (the 
gC TATA box). This was interpreted as indicating that Vmwl75 promotes or stabilises 
the interaction of TBP with the promoter. Further evidence in support of the functional 
involvement between Vmwl75 and TFIID came from results indicating that the PRV 
IE180 protein (the Vmwl75 homologue) activates transcription in vitro by facilitating 
the rate of TFIID binding to the TATA box (Abmayr et a l, 1988; Section 1C.3.1). 
Moreover, physical interactions between HSV-1 Vmwl75 and the TBP component of 
TFIID have recently been demonstrated and the data indicated that TBP and Vmwl75 
bind to DNA in a cooperative manner (Smith et al, 1993).
IB.3.4 HSV-1 gene products regulating the activity o f HSV-1 E and L gene 
expression
The HSV-1 IE gene products are required for the induction of E and L gene 
transcription (Section 1B.1), and this Section outlines the involvement of each of the IE 
polypeptides in the induction process (reviewed more comprehensively by Everett, 
1987a). The findings of transient assays are notoriously variable (Everett, 1988b) and 
will only be discussed here if particularly relevant. Figure IB.3 shows the genomic 
location of each of the five HSV-1 IE genes. The IEl and IE3 genes are encoded within 
the genomic repeats and are therefore diploid. Although HSV-1 primary transcripts are 
rarely spliced, three of the IE polypeptides are translated from spliced mRNAs (Wagner,
29
Chapter IB: Alphaherpesvirus gene regulation
1985). Four of the five IE proteins are phosphorylated and localise to the nucleus where 
they associate with chromatin (Pereira et al., 1977; Hay and Hay, 1980; Fenwick et al, 
1980; Ackermann et al.y 1984); the exception is Vmwl2 which is non-phosphorylated 
and cytoplasmic (Marsden et a l, 1982). In addition, Vmwl2 is the only HSV-1 IE 
protein lacking a VZV homologue (Section 1B.4.2).
Vmwl75 (ICP4): Viruses with ts lesions or large deletions in the IE3 gene have 
demonstrated that Vmwl75 is an essential polypeptide that is required for the transition 
from IE to later classes of gene expression (Marsden et al., 1976; Courtney et al., 1976; 
Watson and Clements, 1978; Preston, 1979a; Dixon and Schaffer, 1980; Preston, 1981; 
DeLuca et a l, 1985), and furthermore is continuously required for expression of the 
later temporal classes of genes (Preston, 1979b; Watson and Clements, 1980). The 
properties and functions of Vmwl75 are further discussed in Section 1C.1, but suffice to 
say here that Vmwl75 is considered to be the major transcriptional regulator of HSV-1.
VmwllO (ICPO): Vmwl 10 is not essential for virus growth in tissue culture, but 
insertion or deletion inactivation of VmwllO leads to a cell type, cell cycle and 
multiplicity-dependent defect in viral gene expression (Stow and Stow, 1986; Sacks and 
Schaffer, 1987; Everett, 1989; Cai and Schaffer, 1991). HSV-1 infections in vivo 
may be at low multiplicity, therefore these defects of the Vmwl 10 deficient viruses 
observed at low moi suggest that VmwllO may be required early in infection to 
up-regulate gene expression to a level that allows establishment of lytic infection. 
Additionally, viruses lacking VmwllO failed to stimulate reactivation of latent viral 
genomes in an in vitro latency system (Russell et al., 1987) and addition of Vmwl 10 is 
sufficient to reactivate latent HSV-2 from the same system (Harris et a l, 1989). The 
possible involvement of Vmwl 10 in establishment of lytic infection and reactivation of 
latent virus is an area of much investigation in the HSV field.
Transient transfection experiments have found VmwllO to be a promiscuous 
transactivator of all classes of viral genes both by itself and in synergy with Vmwl75 
(Everett, 1984b; O’Hare and Hayward, 1985a; b; Quinlan and Knipe, 1985; Gelman and 
Silverstein, 1985; 1986) (see Section 1C.1.6). The mechanism of VmwllO-mediated 
activation of gene expression is not well understood, but is likely to be mediated by 
protein-protein interactions as no sequence-specific VmwllO DNA binding activity has 
been detected (Everett et al., 1991b).
The functionally important regions of VmwllO have been mapped using various 
mutagenic approaches (reviewed by Everett et al., 1991c). An essential cysteine-rich 
sequence near the N-terminus forms a C3 HC4  zinc-finger, as demonstrated by
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expression, purification and NMR spectroscopy of the equivalent domain of the EHV-1 
gene 63 protein (Everett et al., 1993a; Barlow et al., 1994). Unlike the previously 
characterised types of zinc-binding domains (Section 1E.4), the C3HC4  motif does not 
appear to be involved in sequence-specific DNA binding but is more likely to mediate 
interactions with other polypeptides. This specific type of zinc-finger is found in a large 
family of proteins involved in a wide range of nuclear processes (Freemont et al., 1991; 
Freemont, 1993). As yet, the precise function of none of these related domains has been 
determined. However, the zinc-binding domain of VmwllO is essential for its roles in 
gene activation in transfection assays, in the onset of virus infection, and in reactivation 
of latent virus in vitro (Everett, 1988a; 1989; Harris et al., 1989).
An additional region important for the transactivation function of VmwllO, as 
determined by transient assays, has been mapped to the C-terminus of the protein. This 
region forms a strong and specific interaction with a cellular 135kD protein found in all 
the cell types analysed (Meredith et al., 1994); further characterisation of this protein is 
likely to shed light on the role played by VmwllO during infection. VmwllO localises 
to, and subsequently causes redistribution of discrete nuclear domains during infection 
(Maul et al., 1993), and the pattern of VmwllO localisation is altered by deletion of 
either the zinc-finger or the C-terminal domain (Maul and Everett, 1994). It can be 
speculated that the transactivation functions of VmwllO may occur as a result of 
modification of nuclear processes, probably mediated by protein-protein interactions 
formed by both its zinc-finger and C-terminal domain.
Vmw63 (ICP27): Studies with viruses containing ts lesions or a deletion in Vmw63 
have demonstrated the essential role played by Vmw63 in HSV-1 growth. These viruses 
overproduce certain IE and E gene products, yet fail to induce late gene expression 
(Sacks et al., 1985; McCarthy et al., 1989; Rice and Knipe, 1990). Evidence from 
transfection studies supported these findings, demonstrating that Vmw63, in the 
presence of Vmwl75 and VmwllO, can repress some E promoters and enhance 
activation of some L promoters (Everett, 1986; Rice and Knipe, 1988; Sekulovich et al., 
1988; Su and Knipe, 1989). The multi-functional nature of Vmw63 is borne out by the 
identification of both repressor and activator domains near the C-terminal end of the 
protein (Hardwicke etal., 1989; Rice etal., 1989; McMahan and Schaffer, 1990).
The mechanisms by which Vmw63 performs its regulatory roles are poorly understood. 
Comparisons of the accumulation of specific transcripts and their protein products 
during infection with a Vmw63 ts virus, indicated that Vmw63 probably functions 
post-transcriptionally (Smith et al., 1992b). McLauchlan et al. (1992) reported that 
functional Vmw63 is required for the ‘late polyadenylation factor’ activity, which
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selectively increases the usage of a virus late gene poly(A) site in preference to that of 
an IE site during in vitro polyadenylation and also in the viral context (McLauchlan et 
al. , 1989). Although this effect was not shown to discriminate clearly between poly(A) 
sites of different temporal classes, it is possible that Vmw63 may contribute to the 
temporal regulation of HSV-1 gene expression by influencing the processing of 
pre-mRNA transcripts selectively. In addition, Sandri-Goldin and Mendoza (1992) 
demonstrated that the level of host-cell pre-mRNA splicing was reduced following 
transfection of Vmw63; this may be a consequence of Vmw63-mediated redistribution 
of the small nuclear ribonucleoprotein (snRNP) complexes that are involved in splicing 
events (Phelan et al., 1993). Of the spliced HSV-1 transcripts, all but two are expressed 
from IE genes, whereas most cellular pre-mRNAs must be spliced. Therefore this 
redistribution of snRNP complexes at later times in infection may serve to inactivate 
snRNPs and reduce the relative efficiency of host-cell gene expression in favour of viral 
transcription.
Vmw68 (ICP22): Viruses with a deletion of the IE4 gene were viable in tissue culture 
(Post and Roizman, 1981) indicating that Vmw6 8  is non-essential. However one such 
deletion virus grew poorly on certain cell types, under-expressed at least one L gene and 
was avirulent in mice (Sears etal., 1985).
Vmwl2 (ICP47): The non-essential nature of the Vmwl2 polypeptide is inferred from 
the ability of deletion mutants lacking the IE5 gene to grow efficiently in tissue culture 
(Longnecker and Roizman, 1986; Mavromara-Nazos et al., 1986a). No function has 
been assigned to Vmwl2 but its cytoplasmic location alone indicates that it is unlikely 
to be involved in transcriptional regulation.
Other viral products involved in the regulation of early and late genes: The major 
DNA binding protein (UL29) has been implicated in a general negative regulation of 
gene transcription and may play a role in maintaining the highly ordered cascade of 
HSV- 1  gene expression, by an as yet unknown mechanism (Godowski and Knipe, 1983; 
1985; 1986).
IB .4 Regulation of VZV gene expression 
1B.4. 1 VZV protein synthesis in a temporal manner
Analysis of the kinetics of VZV protein synthesis by the classic metabolic-inhibitor 
experiments used to define HSV-1 genes (Section IB. 1) has been complicated by the 
difficulty in achieving efficient, or synchronous VZV infections of tissue culture cells
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(Section 1A.4). However, cycloheximide reversal experiments have identified at least 
four VZV immediate-early gene products (Lopetegui et al., 1985; Shiraki and Hyman,
1987); phosphoproteins with sizes around 185kD and 43kD, and also a protein around 
34kD were common to both studies. These experiments detect IE proteins produced in 
tissue culture infections by initially inhibiting de novo protein synthesis by 
cycloheximide, which allows accumulation of IE mRNA, followed by translation of the 
IE mRNAs after washing out the cycloheximide. Further transcription is inhibited by the 
addition of actinomycin D. The analysis of the kinetics of VZV protein synthesis has 
proved difficult, but relatively successful infections were obtained when monolayers 
were overlayed with VZV infected cells (showing 100% cpe), at a ratio of 4 uninfected 
cells per infected cell. Radiolabelling enabled the protein species which are synthesised 
at various times post infection (pi) to be analysed (Ruyechan et al., 1991). The first viral 
polypeptides detected by this approach appeared at lOhr pi and had disappeared by 45hr 
pi. At 21hr pi a second set of polypeptides appeared, and these had largely disappeared 
by 52hr pi. A final set of polypeptides appeared between 21 and 28hr pi and were 
synthesised until late in infection. These data indicate that VZV does encode 
polypeptides whose expression can be divided into three broad temporal classes in a 
manner analogous to the HSV-1 cascade. In addition, the polypeptide synthesis pattern 
of another alphaherpesvirus, EHV-1, follows a coordinately regulated and sequentially 
ordered immediate-early / early / late cascade, as determined by use of metabolic 
inhibitors in tissue culture infections, although it should be noted that in contrast to the 
situation with HSV-1 or VZV, EHV-1 expresses a single IE transcript (Caughman et al., 
1985; Gray et al., 1987a; b; for a review, see Harty et al., 1991).
1B.4.2 The VZV IE gene products
The VZV genome is held to encode four immediate-early peptides. The 185kD protein 
identified in the cycloheximide several experiments (above) is likely to correspond to 
the gene 62 product (Felser et al., 1988), and the 45kD protein probably corresponds to 
ORF63 (D. Stevenson, personal communication). However the sizes of the gene 61 
product (heterologous phosphoprotein of 62-65kD) (Stevenson et al., 1992) and the 
gene 4 product (51.5kD) do not correlate with any of the remaining VZV proteins 
produced during cycloheximide reversal. The similar genome locations and homology 
between the predicted sequences of the HSV-1 and VZV IE proteins strongly suggested 
that these proteins would be functionally equivalent (Davison and Scott, 1986). That 
VZV encoded transcriptional activators was demonstrated experimentally when VZV 
infection of transfected cells induced gene expression from plasmid-borne HSV-1 gD or 
rabbit p-globin promoters (Everett and Dunlop, 1984). Further transfection experiments 
demonstrated that a DNA fragment spanning VZV ORF 62 was sufficient for 
transactivation of HSV-1, VZV and cellular promoters (Everett, 1984b; 1985; Inchauspe
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et al., 1989). Subsequently the involvement of all four putative VZV IE products in 
transcriptional regulation has been tested, mainly in transient transfection assays due to 
the difficulties that would be associated with propagation of site-specific mutated VZV 
in tissue culture; these transient assays have characteristically yielded some 
inconsistencies between different systems. In the following analyses, the tk (early) and 
gpl and gpn (late) (Vafai etal., 1984) promoters were invariably used as representatives 
for the putative temporal classes of VZV genes. Although each VZV IE protein has an 
HSV-1 sequence homologue, interesting differences in the details of the functions of the 
VZV proteins, as compared to their HSV-1 counterparts (Section 1B.3.4), are becoming 
apparent.
140k (ORF62): The product of VZV gene 62 has a predicted molecular weight of 
140,000D, and is therefore referred to as 140k (Davison and Scott, 1985). VZV 140k is 
the sequence homologue and functional counterpart of the product of HSV-1 gene IE3, 
Vmwl75 (Section 1C.2.1). Transient transfection assays have been used to demonstrate 
that VZV 140k is a potent transactivator of all classes of VZV promoters and also 
heterologous promoters at the transcriptional level (Everett, 1984b; Inchauspe et al., 
1989; Cabirac etal., 1990; Inchauspe and Ostrove, 1989; Perera etal., 1992a; b; Section
1C.2.3). Like its HSV-1 counterpart protein (Section IB.2.3), VZV 140k negatively 
autoregulates its own expression in transient transfection assays, although this appears 
to occur in a cell type dependent manner (Disney et al., 1990; Perera et al., 1992b). The 
high abundance of VZV 140k within the virion tegument (Kinchington etal., 1992) may 
have implications for VZV gene regulation ; following release from the tegument, 
140k may activate the other IE promoters in advance of de novo viral protein synthesis, 
playing a role analogous to HSV-1 Vmw65 (Section IB.2.2). The functions and 
properties of VZV 140k are discussed in detail in Section 1C.2.
ORF61: The VZV gene 61 product shows limited sequence homology to HSV-1 
VmwllO (encoded by the HSV-1 IE1 gene) but in contrast to IE1, gene 61 is only 
represented once in the viral genome. The ORF61 protein has recently been 
characterised as a nuclear, phosphorylated heterogeneous species of 62-65 kD 
(Stevenson etal., 1992). Even though sequence similarities between HSV-1 VmwllO 
and VZV ORF61 are confined to the N-terminus, to sequences spanning the VmwllO 
zinc-finger (Section IB.3.4), a stable cell line expressing ORF61 is able to complement 
a VmwllO deletion mutant HSV-1 virus (Moriuchi et al., 1992). Transient assays have 
demonstrated VZV ORF61 to be a potent trans-repressor or activator of ORF4 and 
ORF62 mediated activation, depending on the cell type used (Nagpal and Ostrove, 
1991; Perera etal., 1992a). In some experiments, the ORF61 trans-repressor effect was 
specific to VZV promoters and occurred at the transcriptional level (Nagpal and
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Ostrove, 1991), while in another report ORF61 was found to be a promiscuous 
transactivator in the absence of other viral gene products (Moriuchi et al., 1993b). These 
differences are likely to be a consequence of the variations between the details of the 
experimental systems used. Interestingly, ORF61 expressing cell lines complemented an 
HSV-1 virus (in 1814) that lacks the IE trans-inducing function of Vmw65 (Section 
IB.2.2); VZV DNA transfected into these cell lines had enhanced infectivity 
(approximately 10 fold) (Moriuchi et al., 1993b). The evidence so far suggests that VZV 
ORF61 may be important for up-regulating VZV gene expression at an early stage in the 
viral life cycle.
ORF4: The product of VZV gene 4 is the sequence homologue of HSV-1 Vmw63 (the 
HSV-1 IE2 gene product). However, VZV gene 4 only partially complements an HSV-1 
virus with a ts lesion in Vmw63 when supplied by co-infection with VZV or from a 
transformed cell line (Felser et al., 1987; Moriuchi et al., 1994). Furthermore, the cell 
line expressing VZV ORF4 fails to complement an HSV-1 virus carrying a Vmw63 
deletion mutation (Moriuchi et al, 1994). VZV ORF4 was found by transient 
transfection analysis to activate expression of a variety of VZV and cellular genes both 
alone and in synergy with VZV 140k. This transactivation by ORF4 shows a degree of 
selectivity, as only IE gene 62 and a selection of putative early VZV genes were 
activated, while the inducibility of VZV late genes was not consistent between analyses 
(Inchauspe etal., 1989; Inchauspe and Ostrove, 1989; Perera etal., 1992a; Defechereux 
et al., 1993; Moriuchi et al., 1994). The regulatory functions of ORF4 appeared to 
influence both transcriptional and post-transcriptional events, as the increase in reporter 
mRNA levels following transfection of a plasmid expressing gene 4 could not alone 
account for the high levels of reporter enzyme activity (Defechereux et al., 1993). 
Therefore, in common both VZV ORF4 and its HSV-1 counterpart appear to influence 
pre-mRNA processing, but the two proteins show numerous other functional differences 
and this presumably accounts for the weak complementation seen in the experiments 
described above.
ORF63: The product of VZV gene 63 shows partial sequence homology to HSV-1 
Vmw6 8  (encoded by HSV-1 gene IE4), although VZV gene 63 is diploid in contrast to 
HSV-1 IE4 (Table 1A). As is the case with HSV-1 Vmw6 8 , the functions of the VZV 
protein are poorly understood. To date, there exists a single published transient 
transfection study of ORF63 function; this reports that VZV ORF63 inhibits expression 
of VZV gene 62, activates early but has no effect on putative late VZV promoters 
(Jackers et al., 1992). A study of the functional interplay between ORF63 and the other 
VZV IE proteins is required before speculation as to its likely role in infection.
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IB.4.3 Transactivation o f the VZV IE promoters
Because transcription of VZV gene 62 can be induced following HSV-1 infection of cell 
lines including an integrated copy of VZV gene 62, it was suggested that the HSV-1 
Vmw65 virion trans-inducing factor might also activate the VZV IE promoters in these 
experiments (Felser et al., 1988). Subsequently, a plasmid-borne copy of HSV-1 
Vmw65 was found to strongly transactivate the gene 62 promoter in transient assays, 
and a deletion analysis of the gene 62 promoter defined the Vmw65-responsive element 
to lie within residues -410 to -131 of the mRNA start site. Interestingly, the sequence 
AAATGAAAT (centred at -254bp) within this region is strikingly similar to the 
TAATGARAT site that mediates viral induction of the HSV-1 IE promoters (McKee et 
al., 1990) (Fig. 1B.4; Section 1B.2.1).
San
CACACCGTCGACGTGCATTTGATTAACTAGATGCCGGATGGGTGGAAACAACCCGTGTTA -3  5 6
octamer (TATA)
TATAAGATGTTTTGCATGTGAGACAACCCCAATTGTGTTTATGTATATTATATATCGTCT -2 9 6
(mRNA) Dral octamer/TG
GTAGACACACGATGATTGGTTGTTATTTAAACATATGTAAATGAAATTCACATGTCTGGT -2  3 6
Rsal
ATCCCTTGTTATGATGTTGTAAGGTATGCGGAAATAGACACCGGGCGTACATCGCCAACC -1 7  6
Xhol
AGCGGTCTCTCCTTAAACGCATACTATGGTCCATGAACTTCCCGCCTCGAGTCTCGTCCA -1 1 6
ATCACTACATCGTCTTATCATTAAGAATATTTACACGGTGACGACACGGGGAGGAAATAT - 5  6 





Figure 1B.4 The VZV gene 62 promoter. Nucleotides are numbered from the mRNA start site at 
+1 that was identified by transcript analysis (McKee et al., 1990) and a TATA box homology is found at 
positions -25 to -30. Octamer and TAATGARAT-like motifs (TG) are found within a 13bp sequence 
centred over -255 (another octamer motif in inverse orientation is present between nucleotides -346 to 
-339). The first ATG codon of the gene 62 ORE is shown in bold. The mRNA start site previously 
proposed on the basis of sequence analysis alone is indicated at -287 nucleotides and the corresponding 
TATA box homology at nucleotides -301 to -312 is also indicated (Felser et al., 1988). Putative cis-acting 
sequences for common cellular transcriptional regulator proteins (i.e. Spl and CBP) have been predicted 
in the upstream regulatory region for each proposed mRNA start site, but are not shown. Also shown in 
bold, are the hexamer homologies to the ATCGTC 5’motif of the HSV-1 Vmwl75 consensus binding site 
(see Section 1C.2.3). Restriction sites used in preparation of radiolabelled DNA fragments derived from 
the gene 62 promoter (Fig. 3A.6) are also given.
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Again by analogy to the HSV-1 situation, sequences similar to the octamer element have 
been found in the gene 62 promoter (Davison and Scott, 1986), and one of particular 
interest overlaps the gene 62 AAATGAAAT sequence (Fig. 1B.4). DNase I footprinting 
analysis has shown that in the presence of a cellular extract, HSV-1 proteins were able 
to specifically bind over the AAATGAAAT element (McKee et al, 1990). It was 
possible therefore, that VZV utilises a mechanism similar to that seen in the HSV-1 
system (Section IB.2.2), for induction of its IE promoters.
The VZV genome does indeed encode a sequence homologue of HSV-1 Vmw65, VZV 
ORF10 and like its HSV-1 counterpart it is also incorporated into the virion tegument 
(Dalrymple et a l, 1985; Kinchington e ta l, 1992). However, VZV ORF 10 is 80 amino 
acids shorter than Vmw65, lacking sequences similar to the Vmw65 C-terminal acidic 
transcriptional activation region (Section IB.2.2). The absence of the C-terminal 
sequences from the VZV protein may account for the failure of ORF 10 to direct 
formation of the IEC complex (Section IB.2.2) on the gene 62 AAATGAAAT element, 
and also the failure of VZV ORF 10 to transactivate the VZV gene 62 promoter in 
transient assays (McKee et a l, 1990). In contradiction to these earlier findings, 
Moriuchi et a l (1993a) have observed VZV ORFlO-mediated activation of the VZV 
gene 62 promoter and also the promoters of HSV-1 genes IE1 and IE3 in transient 
assays, albeit at a lower level than Vmw65-mediated transactivation. Additionally an 
HSV-1 mutant lacking functional Vmw65 (virus ml814) was complemented on a stable 
cell line expressing ORF 10. This cell line enhanced the infectivity of HSV-1 virions 
(Moriuchi et al, 1993a), a situation very similar to that seen with cell lines expressing 
VZV ORF61 in the previous Section.
No obvious TAATGARAT sequence homologies have been found within the other 
VZV IE promoters, and it has been postulated that the VZV transcriptional programme 
might be more similar to that of EHV-1, with its single IE protein, than to the HSV-1 
programme (Stevenson et al, 1992). It is possible that VZV ORF 10 functions to 
up-regulate expression of the gene 62 promoter during infection in a similar manner to 
HSV- 1  Vmw65, mediated by an activation domain not conserved with its HSV- 1  
counterpart. The gene 62 product, 140k (either synthesised de novo or released from the 
virion tegument) could then transactivate the remaining IE promoters and initiate the 
temporal cascade of VZV gene expression.
Similarly EHV-1 gene 12 encodes a sequence counterpart of HSV-1 Vmw65. The 
upstream region of the EHV IE promoter includes a TAATGARAT element and is 
transactivated by the EHV-1 ORF 12 protein (Purewal et a l, 1992). Even though the 
EHV- 1  ORF 12 protein includes some of the C-terminal sequences not present in VZV
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ORF 10, they lack the acidic character of the C-terminal transcriptional activation region 
of HSV-1 Vmw65. PRV however, apparently does not encode a Vmw65 homologue 
(Hampl et al., 1984) although the promoter of the sole PRV IE gene (Cheung, 1989; 
Vlcek et al., 1989) contains a TAATGARAT element and can be trans-induced by 
HSV-1 Vmw65 (Campbell and Preston, 1987). This raises the question of the function 
of the TAATGARAT element in the PRV promoter. It has been suggested that the IE 
promoter ds-acting sequences themselves (such as the TAATGARAT element) are 
sufficient to confer the IE kinetics of gene expression in the absence of Vmw65 (Ace et 
al., 1989), since HSV-1 IE proteins were still highly expressed following infection with 
virus m l814 during cycloheximide reversal experiments (virus ml814 lacks functional 
Vmw65). In the case of PRV, it may be that binding of host factors to the 
TAATGARAT element is sufficient to induce IE promoter activity in the cell types 
infected during natural infection, although there is no evidence to indicate the existence 
of a cellular counterpart of HSV-1 Vmw65. It is interesting that the TAATGARAT 
element is conserved in the promoters of the major IE genes of each of these 
alphaherpesviruses, yet the sequence and even the possession of the viral rra/w-inducing 
factor is variable. This indicates that the mechanisms used for induction of IE gene 
expression are likely to differ between the alphaherpesviruses and may contribute to the 
differences in their biologies.
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1C The major transcriptional regulatory proteins of the 
Alphaherpesvirinae
All the alphaherpesviruses analysed so far have been found to encode a sequence 
homologue of the VZV 140k transcriptional regulatory protein. Of these, the HSV-1 
counterpart protein, Vmwl75, has been most extensively analysed and therefore the 
majority of this Section will discuss the properties of HSV-1 Vmwl75. By analogy, 
VZV 140k and the other alphaherpesvirus homologue proteins are likely to possess 
similar properties to HSV-1 Vmwl75. As will be discussed in the later parts of the 
Section, this is transpiring to be the case.
1C.1 HSV-1 Vmw 175
The sequence-specific DNA binding protein Vmw 175 is essential for the expression of 
early and late HSV-1 genes (Section IB.3.4) and for the down-regulation of its own 
promoter (Section 1B.2.3), and is therefore held to be the major transcriptional regulator 
of HSV-1. Vmwl75 is encoded by the diploid IE3 gene, one copy of which is present in 
each of the short repeat regions of the HSV-1 genome (Fig. 1B.1) (Rixon et al., 1982). 
HSV-1 Vmwl75 was first identified as a viral polypeptide by Honess and Roizman 
(1973) and was subsequently shown to be a large phosphorylated, nuclear-localised 
protein, that exists as a homodimer in solution (Pereira et al., 1977; Metzler and Wilcox,
1985). Migration on SDS-PAGE shows Vmw 175 to be a heterogeneous species (see 
below) with apparent molecular weights of around 175kD on SDS-PAGE (Pereira et al., 
1977), although the predicted molecular weight of the 1298 amino acid product of the 
IE3 ORF is 133kD (McGeoch etal., 1986). Vmwl75 is present in approximately 100 
copies in the tegument of each virus particle (Yao and Courtney, 1989), an amount 
which is significantly lower than the corresponding VZV 140k protein (Kinchington et 
al., 1992). However, a recent report states that Vmwl75 is predominantly located in 
non-infectious particles that lack a nucleocapsid, rather than in the infectious virions 
(McLauchlan and Rixon, 1992; Szilagyi and Cunningham, 1991).
1C. 1.1 Post-translational modifications
Vmwl75 is present in three phosphorylated forms in infected cells, having slightly 
differing mobilities on SDS-PAGE gels (Pereira et al., 1977). The phosphates are
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located on serine and threonine residues and can cycle on and off during infection 
(Wilcox et al., 1980; Faber and Wilcox, 1986a). A serine-rich tract located between 
Vmwl75 residues 176 and 206 is thought to be the major site of phosphorylation; this 
serine-rich tract is also found in the other members of this alphaherpesvirus family of 
proteins. Other parts of the protein are additionally phosphorylated during infection 
(Faber and Wilcox, 1986a; DeLuca and Schaffer, 1988), and this is likely to account for 
the viability of an HSV-1 virus lacking the serine-rich sequences (Paterson and Everett, 
1990). The extent of phosphorylation of the Vmw 175 protein appears to differentially 
affect its DNA binding activity, as discussed in Section 1C. 1.3.
As Vmw 175 includes several consensus GTP-binding elements and can be adenylated 
and guanylated in isolated nuclei, it has been suggested that Vmw 17 5 may belong to a 
class of GTP-binding proteins which function in transcriptional transactivation (Blaho 
and Roizman, 1991). Additionally, Vmwl75 can be poly(ADP-ribosyl)ated in isolated 
nuclei, and an antibody specific for poly(ADP-ribose) was used to indicate that all the 
forms of Vmw 175 isolated from infected tissue culture cells are poly(ADP-ribosyl)ated 
(Preston and Notarianni, 1983; Blaho etal., 1992). The functional relevance of these 
modifications of Vmwl75, if any, are not clear.
1C. 1.2 Nuclear localisation
HSV-1 Vmw 175 is transported to the nucleus after synthesis where it becomes 
associated with chromatin (Courtney and Benyesh-Melnick, 1974; Cabral et al, 1980; 
Hay and Hay, 1980). The nuclear localisation of several other viral proteins, notably 
VmwllO, is impaired during infection with certain ts viruses which encode Vmw 175 
proteins that remain in the cytoplasm, indicating that Vmwl75 may facilitate transport 
of these viral proteins to the nucleus (Knipe and Smith, 1986). The Vmwl75 nuclear 
localisation signal has been mapped to between residues 682 and 774; this region 
includes a short basic sequence (PREGRKRKSP) that is related to the SV40 large T 
antigen and adenovirus Ela nuclear localisation signals (DeLuca and Schaffer, 1987; 
Paterson and Everett, 1988a; Kalderon et al, 1984; Krippl et a l, 1985). The nuclear 
distribution of Vmw 175 alters during the course of infection. At early times Vmw 175 is 
diffusely located throughout the nucleus, but following the onset of viral replication, 
Vmw 175 redistributes to discrete ’replication compartments' which also contain the 
major DNA binding protein, the viral DNA polymerase and viral DNA (Quinlan et al., 
1984; Randall and Dinwoodie, 1986; Knipe et al., 1987); these replication 
compartments are likely to be the sites of transcription of viral genes expressed later in 
infection.
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1C. 1.3 DNA binding
HSV-1 Vmw 175 in crude cell extracts was found to bind to non-specific DNA-cellulose 
columns (Powell and Purifoy, 1976; Hay and Hay, 1980), although an early purification 
of Vmwl75 resulted in loss of DNA binding activity and the suggestion that Vmwl75 
bound DNA via a host polypeptide (Freeman and Powell, 1982). Affinity purified 
Vmw 175 has subsequently been found to bind DNA directly, in a sequence-specific 
manner (Kattar-Cooley and Wilcox, 1989), and the intrinsic DNA binding ability of 
Vmwl75 was also indicated by south-western blotting experiments (Michael et al.,
1988). An equilibrium dissociation constant of the Vmwl75-DNA complex was 
reported to be approximately 1.1 nM (at 4°C in the presence of lOOmM NaCl using 
affinity purified Vmw 175 on a consensus binding site) (Kattar-Cooley and Wilcox,
1989); this value is in the same range as those of the SV40 T antigen and the E. coli 
trytophan (trp) repressor (Muller eta l, 1987; Klig etal., 1987).
Vmw 175 is the only HSV-1 immediate-early protein that possesses sequence-specific 
DNA binding activity and various techniques including filter binding, gel retardation, 
Exonuclease III digestion and nuclease and chemical footprinting analyses have been 
employed to investigate its DNA targets. Specific sequences in the HSV-1 IE1, IE3 and 
gD promoters, and two sites within the tet gene of pBR322 were among the first 
Vmw 175 binding sites to be identified (Beard et al, 1986; Faber and Wilcox, 1986b; 
88; Kristie and Roizman, 1986a; b; Muller, 1987). These binding sites displayed a 
degree of sequence similarity and Faber and Wilcox (1986b) put forward the consensus 
sequence ATCGTCnnnnYCGRC (n = any, Y = pyrimidine, R = purine) based on 
comparisons of three of these sites. Although highly conserved, the 5' ATCGTC motif is 
not sufficient for DNA recognition by Vmwl75 (Roberts et al., 1988); methylation 
interference footprinting analyses and mutations within the consensus sites have 
demonstrated the importance of both the 5' and 3' motifs of the sequence for DNA 
recognition by Vmwl75 (Muller, 1987; Roberts et a l, 1988; Michael and Roizman, 
1989; Pizer et al., 1991; Everett et al., 1991a). The consensus ATCGTnnnnnYSG was 
derived from the findings of an extensive mutational analysis that quantified the effect 
of single substitutions throughout the region spanning the HSV-1 IE3 consensus binding 
site (Everett etal., 1991a); this experimentally defined consensus sequence closely 
corresponds to the original consensus of Faber and Wilcox (1986b). Importantly, this 
mutagenesis found no single base to be essential for DNA recognition by Vmw 175 and 
the DNA binding specificity of Vmw 175 appeared to be fairly relaxed (Everett et al, 
1991a).
However, the majority of Vmwl75-responsive promoters lack such consensus binding 
sites. Sequences recognised by Vmw 175 that do not obviously fit the consensus have
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been described in HSV-1 IE, early and late promoter regions and the Vmw 175 
interaction with these 'non-consensus' Vmw 175 binding sites may be of a lower affinity 
(Michael et al., 1988; Tedder et al., 1989; Michael and Roizman, 1989; Imbalzano et 
al., 1990; DiDonato et al., 1991; Flanagan et al., 1991a). The findings of missing 
contact analyses led DiDonato et al., (1991) to suggest that all Vmwl75 binding sites 
might be related and they proposed a more degenerate version of the Vmw 175 binding 
consensus that could describe both the consensus and non-consensus sites. This is 
consistent with the findings of the mutational analysis of the IE3 binding site (above) 
which indicated that the inherent DNA binding activity of Vmw 175 is of a fairly low 
specificity. In addition, a statistical matrix was compiled from their binding site data and 
was used to derive a matrix mean model that described the probability of any one base 
occurring at each position of a Vmw 175 binding site; this was found to be an accurate 
predictor of known Vmwl75 binding sites (DiDonato et al., 1991). Analysis of the 
HSV-1 genome with this matrix mean model demonstrated that potential Vmw 175 
binding sites occur frequently throughout the entire genome, in both coding and non­
coding regions of genes from all three temporal classes.
The interaction of Vmwl75 with non-consensus sites in HSV-1 E and L promoter 
regions has been found to require the presence of cellular or infected-cell factors, 
indicating that additional proteins may be involved in the recognition of these sequences 
by Vmwl75 (Papavassiliou and Silverstein, 1990a; Flanagan et al., 1991a; 
Papavassiliou et al., 1991). The complexes formed appeared to be less stable with 
infected cell extracts than with non-infected cell extracts (Papavassiliou and Silverstein, 
1990b). Also the extent of phosphorylation of Vmw 175 differentially affected its ability 
to bind sequences within the different temporal classes of promoters (Papavassiliou et 
al., 1991; Michael et al., 1988). It is possible that the phosphorylation state of Vmw 175 
determines the interaction with these additional factors and hence acts to differentially 
control binding site recognition and promoter activity. It is interesting that the 
bacterially expressed isolated Vmwl75 DNA binding domain (which is not 
phosphorylated) is capable of interacting with both consensus and non-consensus 
binding sites (Wu and Wilcox, 1990); it may be that the phosphorylation of sites 
elsewhere regulates the DNA binding activity of the intact Vmw 175 protein.
In addition, the binding of Vmw 175 to DNA is facilitated by the basal transcription 
factors TFIID and TFIIB (Smith et al., 1993) (Section 1D.1.2), and Vmwl75 amino 
acids between 142 and 210 are required for the cooperative interactions of Vmwl75, 
TFIID (or TBP) and TFIIB to form the tripartite complex on the DNA. Interestingly, 
this region spans the serine-rich tract (Section 1C. 1.1) that may serve as a transcriptional 
activation region (Shepard et al., 1989; Section 1C. 1.9). Finally, the DNA binding
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interaction of Vmw 175 induces a significant DNA bend at its occupied binding sites in 
the HSV-1 gD and IE3 promoters in vitro (Everett et al., 1992). The functional 
relevance of this distortion to the DNA conformation is unknown, but it is a feature of 
the DNA binding interaction of many sequence-specific DNA binding proteins. The 
portions of the Vmw 175 protein involved in DNA binding have been defined, as 
discussed later (Sections 1C. 1.9 and 1C. 1.10).
1C. 1.4 Dimerisation
The native Vmwl75 protein has been purified as a homodimer which has physical 
parameters to indicate that it is a highly elongated molecule (Metzler and Wilcox, 1985). 
Lower abundance tetrameric forms of Vmwl75 have additionally been observed, but it 
is not known whether these represent a distinct population present during infection, or 
merely a consequence of dimer aggregation during the concentration steps of the 
purification procedure (Kattar-Cooley and Wilcox, 1989). That Vmw 175 binds to DNA 
as a dimer was indicated by the production of heterodimer bands upon gel retardation 
analysis of pairs of differently sized Vmw 175 partial polypeptides; one of each pair was 
expressed from the viral genome and the other from a transfected plasmid or 
transformed cell line (Shepard and DeLuca, 1989; Shepard et al., 1990; Shepard and 
DeLuca, 1991a). In accordance, Michael and Roizman (1989) reported that two 
molecules of Vmwl75 bind to each Vmwl75 binding site, as indicated by the two 
sequential supershifts of the Vmwl75-DNA complex observed upon addition of a Fab 
fragment of a Vmw 175 MAb to a gel retardation experiment. It is noteworthy that the 
Vmwl75 consensus binding site ATCGTCnnnnYCGRC (see above) is unusual for a 
target site of a dimeric DNA binding protein (Section IE), in that it does not show any 
sequence symmetry or palindromic nature. Section 3D. 10 discusses the alternative ways 
in which the Vmw 175 dimer could interact with its non-palindromic binding site.
Further evidence of the dimeric nature of the Vmw 175 protein during infection was 
demonstrated by the ability of selected pairs of functionally impaired Vmw 175 proteins 
to complement each other by forming a functional heterodimer molecule (Shepard and 
DeLuca, 1989; Shepard and DeLuca, 1991a). In one pair of partial Vmwl75 peptides of 
particular note, a peptide lacking sequences necessary for DNA binding (deleted for 
residues 185 to 309) could supply in trans the sequences required for the transactivation 
function that were lacking from a truncated Vmwl75 protein, comprising residues 1-774 
(Shepard and DeLuca, 1989). In another case, heterodimerisation with a truncated 
peptide (X25) inhibited the regulatory functions of wild type Vmw 175 in a trans- 
dominant manner, apparently by altering the conformation of the wild type polypeptide 
(Shepard et al., 1990). Furthermore, expression of the X25 peptide in transgenic mice 
conferred a significant antiviral effect in vivo (Smith and DeLuca, 1992).
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Regarding the sequences mediating dimerisation, one report proposed that the 
N-terminal 90 residues were involved in dimerisation of Vmw 175 (DeLuca and 
Schaffer, 1989) although these sequences are inessential for the functions of Vmwl75 
(DeLuca and Schaffer, 1987; 1988). The dimeric nature of the isolated Vmw 175 DNA 
binding domain indicated that sequences between residues 275 and 523 are required for 
dimerisation (Everett et al., 1991a) (Section 1C. 1.10). The specific sequences mediating 
dimerisation have not been further refined, although several mutations have been 
reported within this region that do not affect dimerisation: insertion mutations at 
residues 320 and 338 do not disrupt heterodimer formation with a truncated Vmwl75 
peptide (Shepard and DeLuca, 1991a), and Vmwl75 DNA binding domain peptides 
including single amino acid substitutions within the highly conserved tract of amino 
acids between residues 445 and 487 (see Section 1C. 1.9) can still be purified as dimers 
(Allen and Everett, 1994). The sequences within the DNA binding domain that are 
required for dimerisation have been investigated extensively in this study (Section 3D).
1C. 1.5 Temperature-sensitive mutants o f Vmwl75
The pivotal role played by Vmw 175 in the HSV-1 transcriptional programme was 
demonstrated by the analysis of HSV-1 viruses with temperature-sensitive (ts) lesions of 
Vmwl75 (Section IB.3.4). Various ts lesions in Vmwl75 have been described and these 
fall into two classes, and the mapping of the lesion sites indicated that Vmw 175 may 
comprise distinct functional domains. The more stringent class of ts mutants 
over-expressed IE gene products and exhibited no early or late gene expression at the 
NPT (Courtney et al., 1976; Marsden et al., 1976; Watson and Clements, 1978; Preston, 
1979a; Dixon and Schaffer, 1980). These studies highlighted the crucial role of 
Vmw 175 during infection. Later temperature shift experiments demonstrated a 
continuous requirement for Vmw 175 for E and L gene expression (Watson and 
Clements, 1980). Where mapped, these mutations have been found to lie within the 
N-terminal portion of Vmw 175. For example, the tsK mutation is caused by a single 
alanine to valine substitution at residue 475 within the DNA binding domain of 
Vmwl75 (Preston, 1979a; Preston, 1981; Davison et al., 1984) (Fig. 1C.3). The tsK 
protein fails to bind DNA at the NPT in vitro, suggesting that DNA binding is a 
requirement for the regulatory functions of Vmw 175 (Paterson et al., 1990). The second 
class of Vmw 175 ts viruses are capable of low levels of early gene expression, undergo 
limited DNA replication but fail to express late polypeptides. The lesions of these 
partially active mutants map to the C-terminal third of Vmw 175, suggesting that a 
distinct function required for late gene expression may require the integrity of this part 
of Vmwl75 (DeLuca et al., 1984; Paterson et al., 1990). It has been shown that 
plasmids expressing ts Vmw 175 polypeptides were also ts in their ability to activate 
transcription in transfection assays and in their DNA binding abilities (DeLuca and
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Schaffer, 1985; Paterson et al., 1990). This is important, as it supports the functional 
relevance of the findings of transient transfection analyses (below).
1C. 1.6 Transactivation
Following the genetic analyses with the ts mutants, the regulatory functions of Vmw 175 
were investigated exhaustively by various different experimental approaches. An 
extension of the ts virus studies indicated that Vmw 175 activated gene expression in 
trans from transfected plasmids bearing early promoter-reporter constructs (Everett, 
1983; O'Hare and Hayward, 1984). Other early studies utilised transformed cell lines 
expressing either Vmw 175 or the target promoter or sometimes both, to investigate the 
effects of Vmwl75 on expression of HSV-1 E and L genes (Dennis and Smiley, 1984; 
Silver and Roizman, 1985; Persson et al., 1985; Arskenasis et al., 1988). The findings of 
these experiments were highly variable and the ill-defined nature of the stably 
transformed cell lines cast doubt on their relevance. However, the cell lines expressing 
Vmw 175 have been invaluable in the construction and propagation of viruses with 
engineered mutations within the IE3 ORF (Section 1C. 1.9) and have additionally been 
used to demonstrate that Vmw 175 can complement an Ela-deficient mutant adenovirus 
(Tremblay e ta l, 1985).
The approach of transiently co-transfecting tissue culture cells with plasmids carrying 
cloned effector and reporter constructs was considered more reliable and has been 
employed widely. The ability of the Vmwl75 product of the cloned IE3 gene to 
transactivate plasmid-borne reporter genes was first described by Everett (1984b). 
Numerous studies measuring accumulation of mRNA or assaying reporter activity have 
since demonstrated the ability of Vmw 175 to transactivate several HSV-1 early and late 
promoters (Quinlan and Knipe, 1985; O'Hare and Hayward, 1985a; b; Gelman and 
Silverstein, 1985; 1986). Transactivation by Vmwl75 is at the level of transcriptional 
initiation, as indicated by in vitro nuclear run-off assays and in vitro transcription 
experiments (Godowski and Knipe, 1986; Beard etal., 1986; Pizer etal., 1986).
In addition, Vmw 175 has been reported to activate gene expression synergistically with 
the HSV-1 IE1 gene product, VmwllO; that is, the effect of Vmwl75 and VmwllO 
together was greater than their combined individual effects (Everett, 1984b; Quinlan and 
Knipe, 1985). It should be noted that the activities of Vmwl75, VmwllO and the 
combined activities of the two proteins were not always consistent between different 
transient transfection studies and this was probably a reflection of differences in the 
cell-types used and experimental detail (Everett, 1988b). Even though Vmwl 10 has also 
been reported to be a promiscuous transactivator in transient assays (Section 1B.3.4), it 
is clear that VmwllO cannot functionally substitute for Vmwl75, as viruses lacking
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functional Vmwl75 do not grow on normal cell lines (DeLuca et al., 1985; Russell et 
al., 1987; DeLuca and Schaffer, 1988; Paterson and Everett, 1990). The synergistic 
phenotype could be explained by Vmwl75 and VmwllO influencing two different 
rate-limiting steps in the transcription process and the data is consistent with the 
regulatory function of VmwllO acting at a later stage to Vmw 175. However, the 
functional relevance of the synergy observed between Vmwl75 and VmwllO in 
transfection assays is unclear, as viruses which lack a functional IE1 gene activate viral 
gene expression as efficiently as wild type virus (at high moi) (Everett, 1989).
Experiments have shown that HSV-1 Vmw 175 is able to activate a variety of cellular 
promoters located in unnatural contexts (Section IB.3.3). Perhaps of greater relevance to 
the situation during infection, it has been found that various endogenous cellular genes 
are induced by HSV-1 infection in a Vmw 175-dependent manner, as determined by 
differential RNA analysis (Kemp and Latchman, 1988), although the transcription of 
most cellular genes is shut-off upon infection (reviewed by Fenwick, 1984). The identity 
of these trans-induced cellular proteins or the significance of their increased gene 
expression is not known.
1C. 1.7 Is DNA binding a requirement for transactivation by Vmw 175?
Whether the DNA binding function of HSV-1 Vmw 175 is essential for transactivation 
of its target promoters has yet to be firmly established. In favour of the requirement for 
DNA binding is the highly conserved nature of the DNA binding domain between 
Vmwl75 and the other Alphaherpesvirinae family members (Fig. 1C.3). Furthermore, 
virtually all mutations within the defined Vmwl75 DNA binding domain that disrupt 
the ability of Vmw 175 to bind to DNA, also disrupt the transactivation function, the tsK 
mutation being the classical example (Preston, 1979a; Paterson et al., 1990) (Section 
1C.1.5). The single exception to this was provided by a pseudorevertant Vmwl75 
polypeptide (ril2) that exhibited an impaired DNA binding activity in vitro but was able 
to support viral growth in tissue culture (Shepard and DeLuca, 1991b). The existence of 
the single ril2  mutation is sufficient to question the requirement for DNA binding, 
although it appears possible that the DNA binding experiments of DeLuca and 
colleagues did not reflect the situation during infection, because in our hands the 
isolated DNA binding domain of the Vmw 175 ril2 protein has a normal DNA binding 
phenotype at room temperature (Allen, 1993).
Certain mutations in the C-terminal third of HSV-1 Vmwl75, outside the DNA binding 
domain, also influence the DNA binding activity of Vmwl75 (see Section 1C. 1.9). Four 
Vmwl75 proteins with temperature sensitive lesions in this portion of the protein fail to 
bind DNA, yet activate certain early genes during infection at the NPT (Paterson et al.,
j
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1990). It is possible that the interaction of these ts proteins with additional viral or 
cellular factors (such as TFIIB and TFIID, see below) may enable sufficient DNA 
binding for the activation of early gene expression, and as such the results of DNA 
binding assays in vitro may not be an accurate reflection of the situation within the cell.
As discussed in Sections 1B.3.1, 1B.3.2 and IB.3.3, sites that uniquely specify induction 
by Vmw 175 have not been identified as requirements for HSV-1 promoter activity 
during infection, even though multimerisation of the Vmw 175 binding sites in the gD 
promoter increased promoter activation by Vmw 175 during transient transfection assays 
(Tedder and Pizer, 1988) and their presence contributed to activation in vitro (Tedder et 
al., 1989). Given that the highly degenerate nature of Vmw 175 binding is likely to result 
in the presence of Vmw 175 binding sites scattered throughout the HSV-1 genome 
(Section 1C. 1.3), the data is consistent with the idea that the removal of specific 
Vmw 175 binding sites will be functionally compensated for by other Vmw 175 binding 
sites nearby.
The alternative argument might be that Vmw 175 binding to DNA is not required for the 
transactivation of early and late viral promoters, but instead is mediated by modification 
of the activities of the basal transcription machinery. The interaction with basal 
transcription factors is indeed likely to be an important part of the transactivation 
mechanism because Vmw 175 forms a tripartite complex with the basal transcription 
factors TFIIB and TFIID (or TBP) on promoters in vitro, in a cooperative manner. 
However, the interaction of Vmw 175 with the basal transcription factors still requires 
the presence of a Vmwl75 binding site (Smith et al., 1993) and if Vmwl75 is acting as 
a nucleating agent by binding DNA and stabilising the DNA association of the proteins 
that it contacts, then its DNA binding function would be predicted to play a critical role 
in transactivation. It is interesting that mutant Vmw 175 proteins that are unable to form 
a tripartite complex in a cooperative manner, are only one-half to one-third as active as 
wild type Vmwl75 in transient assays (Smith et al., 1993). This indicates that in 
addition to stimulating TFIID/TFIIB recruitment to the promoter, transactivation by 
Vmw 175 also involves other mechanisms or interactions with other proteins, perhaps 
mediated by sequences in the C-terminal third of the protein that appear to be important 
for the transactivation function but not for the interaction with the basal factors (see Fig. 
1C.2).
The available data suggest that DNA binding is required for Vmwl75-mediated 
transactivation of early and late HSV-1 promoters. It can be imagined from the large 
size of the Vmw 175 protein and the wide sequence variation in its target binding sites, 
that Vmw 175 utilises multiple mechanisms and interactions with various cellular
47
Chapter 1C: The 140k family of proteins
proteins to mediate transactivation of its wide range of target promoters. Further details 
of these possible interactions and the transactivation mechanism are likely to be 
discerned in the near future using the reconstituted in vitro transcription system of 
DeLuca and colleagues (Gu et al., 1993). A model for the transactivation mechanism of 
the alphaherpesvirus major regulatory proteins is proposed in Section 4B.
1C. 1.8 Structure
The predicted amino acid sequence of Vmw 175 shares an overall identity of 29% with 
its VZV 140k counterpart, and the two proteins have been divided up into five regions 
on the basis of the extent of amino acid conservation between them (McGeoch et al.,
1986) (Fig. 1C.1 and Table 1C). This pattern of amino acid conservation between VZV 
140k and HSV-1 Vmw 175 is additionally found in other members of this family of 








I30-50% homology over 80% homology
Figure 1C.1 Structure of the HSV-1 Vmwl75 and the VZV 140k proteins. The scale 
demarks the regions 1 to 5 that were defined on the basis of amino acid similarity between the VZV 140k 
and HSV-1 Vmw 175 proteins (McGeoch et al., 1986). Protein sequences are indicated by blocks, where 
the shading represents the corresponding amino acid identity between the two sequences, as discussed in 
the text. The heavy horizontal lines are inserted to allow alignment of sequences, and do not themselves 
represent protein sequences. The letter S indicates the position of the conserved serine-rich tract (Section 
1C. 1.1) and the letter N indicates the putative nuclear localisation signal (Section 1C. 1.2).
Region 1 is poorly conserved between the HSV-1 Vmw 175 and VZV 140k proteins in 
size and amino acid composition, except for the conservation of a tract of serine residues 
(Section 1C. 1.1; marked 'S' in Fig. 1C. 1) and limited sequence similarity at the 
N-terminus. Region 2 shares 46% identity between the two proteins. Towards the 
C-terminus of region 2 is a stretch of residues that are more than 80% conserved and the 
HSV-1 tsK mutation maps within this highly conserved area (Section 1C. 1.5; Fig. 1C.3). 
The conservation of region 3 sequences is restricted to the nuclear localisation signal
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(marked 'N' in Fig. 1C.1) and region 3 of Vmwl75 is 214 residues longer than its VZV 
counterpart (Table 1C). Region 4 is highly conserved (56% identity) between HSV-1 
Vmwl75 and VZV 140k and includes stretches of near identity between the two 
proteins. Several ts lesions have been mapped to these highly conserved regions 
(Preston, 1981; Paterson et al., 1990). Region 5 is largely non-conserved in sequence 
and size.
The mapping of HSV-1 Vmwl75 ts lesions to regions 2 and 4 (Section 1C.1.5), together 
with the high degree of conservation between VZV 140k and HSV-1 Vmw 175 within 
these regions, indicated that regions 2 and 4 were likely to be functionally important; 
this was borne-out by the mutational analyses described in the following Section.
size:
size:
region 1 region 2 region 3 region 4 region 5
1-314 315-489 490-796 797-1224 1225-1298
314 175 307 428 74
1-467 468-641 642-734 735-1148 1149-1310
467 174 93 414 162
Table 1C Details of the protein regions of HSV-1 Vmw 175 and VZV 140k. The amino 
acid coordinates for the five regions of the HSV-1 Vmw 175 and VZV 140k proteins are given in the top 
row for each protein, below are given the number of residues included in each region.
1C. 1.9 Mutational analysis
Mutational analysis has proved a powerful method with which to study the structure, 
function and properties of HSV-1 Vmwl75. The regions of Vmwl75 involved in 
transactivation, transcriptional repression and DNA binding have been investigated in 
several laboratories. Deletion, insertion and truncation mutations have been constructed 
in plasmid-borne copies of the IE3 gene and the activities of the resulting mutant 
Vmw 175 proteins analysed in transient transfection assays (Mavromara-Nazos et al., 
1986b; DeLuca and Schaffer, 1987; Paterson and Everett, 1988a; b; Shepard et al.,
1989). Additionally, some of these mutations have been recombined into the normal IE3 
gene loci of the viral genome (DeLuca and Schaffer, 1988; Shepard et al., 1989; 
Paterson and Everett, 1990; Allen and Everett, 1994). Cell lines expressing integrated 
copies of the IE3 gene (DeLuca et a l, 1985; Davison and Stow, 1985) were used for 
propagation of many of these viruses and their parent null mutations. The results of 
these mutational analyses are summarised below, sub-divided into the five regions of the 
Vmw 175 coding region for clarity:
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Region 1 (codons 1-314) Residues 1-90 are dispensable for the regulatory functions of 
Vmw 175 in transient assays and for virus growth in tissue culture (DeLuca and 
Schaffer, 1987; 1988). The region between codons 162 and 229, including the serine 
rich tract, is also inessential during infection (Paterson and Everett, 1990). A viable 
virus which includes a spontaneous deletion of Vmw 175 codons 209 to 236 verifies the 
inessential nature of sequences in this region (Schroder etal., 1985). However, deletions 
of the serine-rich sequences from a polypeptide already lacking the C-terminal third of 
Vmw 175 eliminates the transactivation function in transient assays and indicates that the 
serine-rich tract and the C-terminal domain partially complement each other for 
transactivation (Shepard etal., 1989). The serine-rich sequences have been predicted to
ir
form a loop structure, whose negative charge may serve as a transcriptional activation 
region (Shepard et al., 1989). The majority of insertion mutations within region 1 have 
little effect on the functions of Vmw 175, although the C-terminal 60 or so amino acids 
of region 1 are functionally important, as discussed below (Paterson and Everett, 1988a; 
b; Shepard etal., 1989). * (when phosphorylated)
Region 2 (codons 315-489) The debilitating effects of insertion mutations (insertion of 
4 or 2 amino acids) made within the C-terminus of region 1 and throughout the whole of 
region 2 demonstrated the critical nature of these sequences for the autoregulation and 
transactivation functions of Vmw 175 in transient assays and DNA binding in vitro, and 
additionally for Vmwl75 functions during virus growth (Paterson and Everett, 1988a; b; 
Shepard et al., 1989; Allen and Everett, 1994b). These sequences of Vmwl75 actually 
comprise a separable DNA binding domain, as discussed in Section 1C. 1.10. The 
insertion mutational analyses indicated that the very highly conserved sequences 
between amino acids 445 and 487 were critical for DNA binding and it has been 
proposed from secondary structure predictions that this region of Vmw 175 may contain 
a helix-turn-helix (HTH) DNA binding motif (Shepard et al., 1989) (Section IE.2). 
Residues 445-457 are predicted to form an a-helix, a predicted (5-turn follows 
(458-464) and then comes another a-helical domain (briefly interrupted by a proline 
residue at amino acid 476; see Fig. 1C.3) (Allen and Everett, 1994); however neither of 
these a-helical regions of Vmw 175 exhibit the amphipathic residue distribution that is 
characteristic of the helices within the classical HTH motif (Section 1E.2). A thorough 
single amino acid substitution analysis of this putative HTH region in the isolated 
Vmwl75 DNA binding domain has defined several point mutations that result in a 
temperature-sensitive DNA binding phenotype, and those at Vmw 175 residues 456 and 
459 and a double substitution of residues 463/464 prevented DNA binding (see Fig. 
1C.3); Vmw 175 proteins including these substitutions were unable to support virus 
growth, indicating the correlation between DNA binding as measured in vitro, and the
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ability of the protein to support the viral lytic cycle in tissue culture (Allen and Everett, 
1994 ).
An insertion mutation at Vmw 175 residue 338 selectively reduced the DNA binding 
activity to a consensus binding site and eliminated binding to a non-consensus binding 
site, suggesting that sequences at the N-terminus of region 2 may be involved indirectly 
in DNA binding (Shepard et al., 1989). Therefore sequences at the C-terminus of region 
2 and also sequences spanning the boundary of regions 1 and 2, are implicated in the 
DNA binding function of Vmw 175. An insertion between these two segments, at 
residue 368, produced a Vmw 175 polypeptide that was wild type for DNA binding 
(Shepard et al., 1989); however this is in contrast to the mutations in this central portion 
of region 2 that eliminated DNA binding in the analysis of Paterson and Everett 
(1988b). It seems that this is a complex situation, with insertion mutations throughout 
the region causing disruption of DNA binding function. However, the effects of the 
insertions may be indirect, as conformational distortions are inevitable.
Region 3 (codons 490-796) The majority of mutations within region 3 have very minor 
effects on the functions of Vmw 175, although some significantly reduce DNA binding 
presumably through steric effects (Paterson et al., 1988a; b). However sequences within 
region 3 do have an important role to play, as truncated peptides including residues 
1-590 possessed no regulatory activity while a peptide 1-774 was functional (DeLuca 
and Schaffer, 1987; 1988). This may be a consequence of removal of the nuclear 
localisation signal that maps to this region (Section 1C. 1.2).
Region 4 (codons 797-1224) and Region 5 (codons 1225-1298) Despite being the most 
highly conserved protein region between HSV-1 Vmwl75 and VZV 140k, the 
functional role of region 4 remains unclear. Interestingly, Vmwl75 polypeptides 
including residues 1-825 or 1-1060 had impaired regulatory activities 
(Mavromara-Nazos, 1986; DeLuca and Schaffer, 1987; 1988), while a shorter 
polypeptide including residues 1-774 was fully functional for normal autoregulation and 
E gene activation (DeLuca and Schaffer, 1987; 1988). Additionally, several very minor 
insertions or ts mutations within regions 4 and the N-terminal portion of region 5 
severely disrupted the DNA binding and regulatory activities of Vmw 175 (Paterson and 
Everett, 1988a; b; Paterson et al., 1990). The fact that minor mutations had a much 
greater effect than deletion of the complete region suggests that although the C-terminal 
sequences are not essential for the functions of Vmw 175, they do play a role, as yet 
unknown, in regulating the activities of Vmw 175. The precise structure adopted by 
these regions may be important for Vmw 175 activity as the mutations within region 4 
that disrupted the regulatory activities of Vmw 175 also appeared to affect the
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conformation of the mutant Vmwl75 polypeptides (Paterson and Everett, 1988b; 
Paterson et al., 1990). However, when the 1-774 residue Vmwl75 polypeptide was 
recombined back into the viral genome, it was found that DNA replication and late gene 
expression were inefficient; thus the C-terminal regions are implicated in facilitating 
Vmwl75 function at later times in infection (DeLuca and Schaffer, 1988).
HSV-1 
V m w l75
region 1
0 100 200 300 400 500 600 700 800 900 1000 1100 1200 1300aa












late regulatory activities 
transactivation
Figure 1C.2 The important functional regions of HSV-1 Vmw 175. The scale at the top 
indicates the protein regions 1 to 5 that correspond to the representation of HSV-1 Vmw 175 shown below, 
the intensity of shading of the portions of the protein indicate the degree of amino acid homology to VZV 
140k (as defined in Fig. 1C.1). The lower scale indicates amino acid residues in the 1298 residue protein, 
and at the bottom are shown the functional domains of Vmw 175 as defined by the mutational analyses of 
DeLuca and Schaffer (1988); Paterson and Everett (1988a; b), Shepard et al. (1989). The light shading in 
the region required for DNA binding indicates sequences that appeared to be indirectly involved in DNA 
recognition, while the dark shading indicates those sequences that appeared to be more directly involved. 
The sequences within region 1 are also required for the formation of a tripartite complex with the basal 
transcription factors TFIID/TFIIB in a cooperative manner (Smith et al, 1993).
In summary, it is apparent from these mutagenic analyses that the regions that are most 
highly conserved between HSV-1 Vmw 175 and VZV 140k (regions 2 and 4) are the 
most important for the functions of Vmwl75 (see Fig. 1C.2). The integrity of sequences 
spanning region 2 is critical for the DNA binding, transactivation, and repression 
functions of Vmw 175, and these sequences are actually sufficient for DNA binding 
(Section 1C. 1.10). Also, the structural requirements for the negative autoregulation 
function appear to be lower than those for transactivation, as demonstrated by a 
Vmw 175 partial peptide that spanned the DNA binding domain and retained 
autoregulatory activities in transient transfection assays (Shepard et al., 1989). 
Transactivation of early promoter constructs additionally required either sequences 
spanning the serine-rich tract in region 1, or the C-terminal sequences in regions 4 and 5 
(Shepard et al., 1989). The evidence suggests that both the C-terminal region and the 
serine-rich tract of Vmw 175 contribute to transactivation during infection, perhaps by 
contacting distinct cellular transcription factors.
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1C.1.10 The isolated Vmwl75 DNA binding domain
The mutational analyses of the intact Vmwl75 protein (above) illustrated the 
importance of the C-terminus of region 1 and the whole of region 2 for DNA binding 
and this was borne-out by the ability of peptides including only these sequences to bind 
to DNA. Wu and Wilcox (1990) expressed in E. coli residues 262 to 490 of Vmwl75, 
fused with a portion of trpE sequence; this fusion peptide bound to both consensus and 
non-consensus Vmw 175 binding sites in a sequence-specific manner. A truncation 
analysis of the Vmw 175 DNA binding domain using trpE fusion-peptides found 
sequences between residues 262 and 274 to be important for high affinity binding, while 
sequences between 275 to 305 and also residues 465 to 490 were essential for DNA 
binding (Wu and Wilcox, 1990). A further truncation analysis with non-fusion 
bacterially expressed Vmw 175 peptides, defined residues 275-523 (peptide II OX) as 
encoding a sequence-specific DNA binding domain, although perhaps with a slightly 
relaxed DNA binding specificity as compared to a peptide comprising residues 253-523 
(peptide I9X) (Pizer et al., 1991; Everett et al., 1991a). Also, the I10X peptide binds 
DNA in gel retardation experiments yet fails to yield DNase I footprints (R. D. Everett, 
personal communication and this Thesis, Fig. 3B.7), thus the Vmw 175 sequences 
between 253 and 275 probably play an indirect role in DNA binding, as suggested by 
Wu and Wilcox (above). It is interesting that, in addition to the conserved region 2 
sequences, the Vmw 175 DNA binding domain also includes the less highly conserved 
C-terminus of region 1 (see Fig. 1C.3). The less conserved nature of these region 1 
sequences is perhaps consistent with the findings of mutagenic and truncation analyses 
which have suggested that these region 1 sequences are likely to stabilise the structure of 
the domain, rather than being directly involved in sequence-specific DNA binding 
(Shepard et al., 1989; Wu and Wilcox, 1990). At around the same time it was shown 
that proteolysis of full length Vmw 175 could release a similar DNA binding peptide, 
having N- and C-terminal boundaries between residues 229 and 292, and 495 and 518 
respectively. This indicates that the DNA binding sequences of Vmw 175 comprise a 
stable and physically separable domain (Everett etal., 1990).
The finding that the I9X Vmw 175 DNA binding domain had a DNA binding specificity 
very similar to that of the intact Vmw 175 protein (Everett et al., 1991a) was of great 
importance, because it indicated that the DNA binding properties of the isolated DNA 
binding domain are likely to reflect the situation with the intact protein, without the 
complicating influences of the putative regulatory sequences found within the 
C-terminus of the Vmw 175 protein. The convenience of the bacterial system for 
expressing large amounts of the DNA binding domain peptides has made this a very 
favourable approach for the analysis of the DNA binding activity of this family of 
proteins, and has been the basis for several recent studies.
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Figure 1C.3 The sequences of the alphaherpesvirus
the DNA binding domain. The amino a d d : ^ ^ “ unterparts (McGeoch et a l,  1986; 
of HSV-1 Vmwl75 and its VZV, SVV, PR^» EHV » nj iogo- Grundy et al., 1989; Schwyzer et
Davison and Scott, 1985; Clarke et al., 1993; Cheung, , •> PileUp programme, although region 1
al, 1993 and Anderson el al, 1992). The alignment was a’ids present in five
sequences are shown without gaps as n^ ' N e  tomo’ Pd , eIlt in M  seven sequences are shown in
or more of the seven proteins are given below the alignment ano u t- ces shown in ^ ld  in the HSV-1
bold; many of the remaining residues are sejm-consery ^  disrupt the DNA binding activity of the
Vmwl75 sequence are the «K  mu.at.on ( r e s t d u m u t a t i o n )  (Section 1C.1.9). In Ute VZV 
Vmwl75 DNA binding domain (residues 456,459 disrupted the DNA binding and regulatory
140k sequence, substitution of the residue shown in bo ( . u o y . i  Vmwl75 helix-tum-helix DNA
functions of 140k (Section 3E). The residues that com pn* the putauveHSV v m w i/o  ne
binding motif (Section 1C. 1.9) are indicated by the letters h (helix) and t (turn) (Allen and Everett, 1994,.
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These have included the purification of the Vmw 175 DNA binding domain to 
homogeneity and subsequent demonstration of its dimeric nature in solution (Everett et 
al, 1991a), and mutagenesis of the putative helix-turn-helix motif of Vmw 175 (Section 
1C. 1.9) (Allen and Everett, 1994). The high yields of DNA binding domain peptides 
that can be produced by this approach will hopefully facilitate the production of crystals 
suitable for elucidation of the structure of the DNA binding domain.
1C.2 VZV 140k
The 1310 residue IE protein encoded by VZV gene 62 has a predicted molecular weight 
of 139,989D and is referred to here as VZV 140k (alternative names: IE 175, ORF62, 
pl40), although it has a mobility on SDS PAGE closer to 175,000 (Davison and Scott, 
1985; Felser et al, 1988). As discussed previously (Section 1C. 1.8), the predicted amino 
acid sequence of VZV 140k shows extensive homology to the HSV-1 Vmw 175 
sequence and the level of conservation of regions 2 and 4 is particularly high between 
the two proteins (McGeoch et a l, 1986; Fig. 1C.1). The two copies of the gene 
encoding VZV 140k occupy equivalent genomic positions to those of the HSV-1 IE3 
genes (Fig. 1A.4) (Davison and Scott, 1986). VZV 140k is a phosphoprotein and can be 
phosphorylated in vitro by the VZV serine protein kinase associated with VZV ORF47 
(Ng et al, 1994). 140k is present in abundance in the virus tegument (Kinchington et 
al, 1992) and this is consistent with it being a major VZV antigen in the human immune 
response (Arvin et a l, 1991). Furthermore, VZV 140k has potential value as a vaccine 
component as guinea pigs immunised with a vector expressing VZV gene 62 are 
protected against subsequent VZV challenge (Sabella e ta l, 1993).
1C.2.1 VZV 140k, afunctional counterpart o f HSV-1 Vmwl75 
The functional similarity of VZV 140k to its HSV-1 sequence homologue was 
demonstrated by the ability of either a plasmid-borne copy of VZV gene 62 or a cell line 
stably transformed with gene 62, to complement growth of HSV-1 viruses with deletion 
or ts lesions within the HSV-1 IE3 gene (Felser et al, 1987; 1988). In addition, an 
HSV-1 virus containing copies of VZV gene 62 in place of the HSV-1 IE3 genes (virus 
HSV-140) is viable in tissue culture (Disney and Everett, 1990). Characterisation of the 
HSV-140 virus found that VZV 140k can perform many, but not all of the functions of 
HSV-1 Vmw 175 in tissue culture infections; the HSV-140 virus failed to give obvious 
plaques on normal cell lines and produced reduced amounts of certain late polypeptides 
at high moi, and at low moi the polypeptide expression from HSV-140 was very 
inefficient. These data indicate that the VZV 140k and HSV-1 Vmw 175 proteins differ 
in functional detail.
55
Chapter 1C: The 140k family of proteins
1C.2.2 The 140k DNA binding domain
VZV 140k sequences equivalent to those comprising the HSV-1 Vmw 175 DNA binding 
domain (Section 1C. 1.10) have been expressed in E. coli fused to 323 codons of the 
bacterial trpE gene. This fusion peptide, FP617, included 140k residues 417 to 647 that 
span the N-terminus of region 1 and the whole of region 2 (Wu and Wilcox, 1991) (Fig. 
3A.1). The FP617 peptide exhibited sequence-specific DNA binding activity, although 
with a lower apparent DNA binding affinity than the equivalent domains of the 
corresponding HSV-1 and PRV proteins. The FP617 peptide bound various sequences 
in the PRV IE, HSV-1 IE3 and VZV gene 62 promoters (Wu and Wilcox, 1991), as well 
as binding the Vmwl75 consensus binding site that lies within the HSV-1 gD promoter 
(Betz and Wydoski, 1993). Also a chimeric trpE fusion DNA binding domain which 
included the C-terminus of the VZV 140k domain (residues 507 to 647) linked to the 
N-terminus of the HSV-1 Vmw 175 domain, possessed the same DNA binding 
specificity as the FP617 140k domain. This result suggested that the C-terminal portion 
of region 2 determines the DNA binding specificity, but unfortunately the 
complementary domain swap peptide (the N-terminus of the 140k domain fused to the 
C-terminus of the Vmwl75 domain) was non-informative (Wu and Wilcox, 1991). 
Similarity between the VZV 140k and HSV-1 Vmw 175 DNA binding domains has been 
further indicated by the identification of a common antigenic epitope spanning the 
boundary of regions 1 and 2 of these proteins (Everett et al., 1993c).
1C.2.3 Regulatory functions o f VZV 140k
Transactivation: Transient transfection assays have demonstrated that VZV 140k can 
activate VZV promoters from all three putative kinetic classes including IE (ORF4 and 
ORF61) (Perera et al., 1992a), E (tk) and L (gpl, gpIV, gpV) (Inchauspe et al., 1989; 
Perera etal., 1992a; Nagpal and Ostrove, 1991). VZV 140k also activates heterologous 
viral and cellular promoters: these include HSV-1 tk (Inchauspe and Ostrove, 1989; 
Cabirac etal., 1990) HSV-1 gD (Everett, 1984b; Disney, 1990) SV40, c-myc and the 
HIV LTR (Inchauspe and Ostrove, 1989). That VZV 140k is a more promiscuous 
transactivator than HSV-1 Vmw 175 was indicated by the inability of HSV-1 Vmw 175 
to activate the VZV tk promoter or the enhancer-less SV40 promoter (Inchauspe and 
Ostrove, 1989; Sekulovich etal., 1988).
In addition, VZV 140k is also a more potent transactivator than HSV-1 Vmw 175 
(Cabirac etal., 1990; Disney, 1990). Recently a potent transcriptional activation domain 
has been mapped to the N-terminal sequences of VZV 140k between residues 9 and 86, 
by testing the ability of fragments of VZV 140k fused to the yeast GAL4 DNA binding 
domain to activate a reporter construct in transient transfection experiments (Cohen et 
al., 1993; Perera et al., 1993). A 140k protein with these putative activation sequences
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deleted was non-functional and interfered with the regulatory function of the full-length 
protein, perhaps through competition for a cellular transcription factor or promoter 
binding site (Perera er al., 1993). The 140k activation domain has been reported to be of 
a comparable strength (Cohen et al., 1993), or about 6-fold less potent (Perera et al., 
1993), than the powerful HSV-1 Vmw65 transcriptional activation region. As is the case 
with many eukaryotic regulatory factors (Section ID.2.2), the VZV 140k activation 
sequences have an acidic nature. As yet no transcriptional activation domain has been 
reported for the HSV-1 Vmwl75 protein, although it will not be equivalent to that of 
VZV 140k as the N-terminal 90 residues of Vmwl75 are non-essential (DeLuca and 
Schaffer, 1987; 1988).
Like its HSV-1 counterpart protein (Section 1C. 1.6), VZV 140k can activate gene 
expression in synergy with other viral IE gene products. Synergistic activation with 
VZV ORF4 has been observed in several studies whereas synergy with VZV ORF61 
depended on the cell type used (Inchauspe et al., 1989; Perera et al., 1992a). One study 
found that VZV 140k could also activate gene expression in synergy with the HSV-1 
VmwllO protein, the partial sequence homologue of VZV ORF61 (Cabirac et al., 
1990); but again this activity depended on the particular system employed (Disney,
1990). It appears that the transactivation function of VZV 140k is mediated by 
sequence-specific DNA binding, as multiplication of the HSV-1 gD Vmwl75 consensus 
binding site increased the efficiency of VZV 140k-mediated transactivation from the gD 
promoter in transient transfection experiments (Betz and Wydoski, 1993) (the FP617 
fusion DNA binding domain peptide binds to this site in vitro).
Negative autoregulation: Treatment of cell lines expressing VZV 140k with 
cycloheximide increased accumulation of VZV gene 62 mRNA and indicated that VZV 
140k, like its HSV-1 counterpart (Section IB.2.3), may negatively autoregulate its own 
expression (Felser et al., 1988). This was shown to be the case in transient transfection 
experiments in Vero and BHK cells (Disney et al, 1990). However, contradictory 
results were obtained using T lymphocytes and neural cell lines, in which VZV 140k 
positively stimulated its own expression (Perera et al., 1992b). Both studies were in 
agreement on the fact that VZV 140k slightly activated the HSV-1 IE3 promoter rather 
than down-regulating it, and this was supported by the over-expression ot the VZV 140k 
protein observed during infection with a virus that includes the VZV ORF62 under the 
control of the HSV-1 IE3 promoter sequences (virus HSV-140; Disney and Everett,
1990). The fact that HSV-1 Vmwl75 down-regulates the VZV gene 62 promoter, 
whereas VZV 140k activates the HSV-1 IE3 promoter (Disney et al., 1990) indicates 
that even though HSV-1 Vmwl75 and VZV 140k appear functionally similar in many 
aspects, the two proteins are not interchangeable for autoregulation. Regarding the
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failure to observe either VZV 140k-mediated or HSV-1 Vmwl75-mediated 
down-regulation of the VZV gene 62 promoter in the T lymphocyte and neural cell lines 
(Perera et a l, 1992b), it should be noted that in these cell lines HSV-1 Vmwl75 also 
had no demonstrable affect on its cognate promoter even though it has been established 
that Vmwl75 down-regulates its own expression during infection (Section 1B.2.3).
DNase I footprinting analyses found that the VZV 140k DNA binding domain fusion 
peptide FP617 recognises a sequence in the immediate vicinity of the VZV gene 62 
mRNA start site defined by McKee et al. (1990) (Wu and Wilcox, 1991). This sequence 
includes a divergent form of the ATCGTC motif of the HSV-1 Vmwl75 consensus 
binding site and by analogy to the situation regarding the autoregulation function of 
HSV-1 Vmwl75 (Section IB.2.3), this interaction is implicated in the down-regulation 
of the gene 62 promoter by VZV 140k. They proposed that binding to a specific 
sequence of conserved nucleotides at or near the mRNA start site may be a common 
autoregulatory mechanism used by the major transcriptional regulatory proteins of the 
alphaherpesviruses (Wu and Wilcox, 1991).
However, Wu and Wilcox (1991) found the FP617 peptide to have an even stronger 
affinity for another sequence adjacent to the previously proposed mRNA start site 
further upstream (Felser et al.y 1988); this sequence also included an ATCGTC motif 
(see Fig. 1B.4). They suggested that 140k differentially influences gene 62 transcription 
by binding with different affinities to the two alternative transcription start sites and to 
support their hypothesis they cite an unpublished observation that longer gene 62 
mRNA transcripts have been detected that may have originated from the upstream start 
site. However, this would appear highly unlikely from the presence of translational start 
and stop codons located between this putative upstream mRNA start site and the ATG 
codon at the start of the major open reading frame.
I C . 3  P R V I E 1 8 0
Pseudorabies virus expresses a single IE RNA, which like its HSV and VZV 
counterparts is expressed from the inverted repeat sequences bounding Us, and encodes 
a 1446 residue polypeptide of 180kD (Ihara et a l, 1983). The predicted sequence of the 
product of the PRV IE gene, PRV IE 180, exhibits the similar pattern of sequence 
conservation seen between HSV-1 Vmwl75 and VZV 140k (Cheung, 1989; Vlcek et 
al, 1989) (Section 1C.1.8). Experiments using the tsG{ virus with a ts lesion in PRV 
IE 180, have indicated that only IE 180 RNA is transcribed at the NPT (Ben-Porat et a l, 
1982; Ihara et a l, 1983). Therefore the functional IE180 protein is required for
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expression of the later classes of PRV genes, also these experiments suggested that 
IE 180 represses its own expression, and as such the PRV transcriptional programme 
shows similarities to that of HSV-1 (Section 1B.1). The promiscuous transactivating 
phenotype of IE 180 has been demonstrated using transient expression experiments 
(Green etal., 1983; Imperiale et a l, 1983; Everett, 1984b) and Thali et al, (1990) have 
proposed that PRV IE 180 functions to activate gene expression from suboptimally 
activated RNA polymerase II promoters. Suboptimally activated promoters are those 
that are not already fully activated by multiple c/s-acting or enhancer elements, and 
those that are not bound in repressive chromatin structures; hence during infection the 
viral promoters are the most abundant targets for PRV IE180-mediated activation.
Experiments have shown that PRV IE 180 binds to multiple sequences within the 
adenovirus major late promoter (used in the in vitro transcriptional analyses described 
below) and the human hsp 70 promoter, and that DNA binding to these sequences is 
required for promoter transactivation in vitro (Cromlish et a l, 1989). The binding of 
PRV IE 180 to numerous sites within its target promoters is a feature conserved with the 
VZV 140k protein but not with the HSV-1 Vmwl75 protein (this Thesis, Sections 3A.6 
and 3A.8). The sequences involved in 'promoter targeting' were found to lie within the 
N-terminal half of IE180 (Martin et al., 1990b) and a fusion protein consisting of 
sequences spanning the conserved region 2 of IE 180 binds DNA in a sequence-specific 
manner (Wu and Wilcox, 1991). Its DNA targets included a site fitting the HSV-1 
Vmwl75 consensus binding sequence immediately adjacent to the PRV IE mRNA start 
site, and this may be involved in its autoregulatory function.
In addition, a potent transcriptional activation domain has been mapped to the 34 
N-terminal residues of PRV IE 180, by employing the same approach used to identify 
the activation sequences of VZV 140k (Section 1C.2.3) (Martin et al., 1990b). 
Importantly, a PRV IE 180 protein lacking these putative activation sequences is stable 
and fails to activate gene expression. Furthermore, it inhibited activation by the GAL4- 
IE 180(1-34) construct. Like the N-terminal VZV 140k activation domain (Section
1C.2.3), the PRV IE 180 N-terminal activation domain has an acidic nature but the 
sequences are not particularly well conserved with 140k or the other members of this 
family of proteins.
1C.3.1 The PRV IE  180 protein facilitates transcription by recruiting the basal 
transcription factor TFIID to the promoter
Although the role played by IE 180 during PRV infection has not been well 
characterised, biochemical analyses of the partially purified IE 180 protein using in vitro 
transcription systems have provided important insight into the likely mechanism of
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action of this family of alphaherpesvirus proteins. The finding that the transactivator 
proteins PRV IE 180, HSV-1 Vmwl75 and adenovirus Ela overlapped in function 
(Feldman et al., 1982; Tremblay et al., 1985) was the first indication that these 
promiscuous viral activators might function through the cellular basal transcription 
machinery. The ability of PRV IE 180 (but not the tsGi IE 180 protein) to activate 
transcription in a cell-free system indicated that it does not function by simply 
increasing the concentration of a transcription factor in vivo (Abmayr et al., 1985). In a 
follow up study, it was found that the effect of adding IE 180 to the in vitro transcription 
reaction was very similar to either (i) titration of non-specific factors from the promoter 
template by the addition of excess competitor DNA, or (ii) preincubation of the 
promoter template with the basal transcription factor TFIID (Abmayr et al., 1988). 
These data imply that non-specific proteins normally compete with TFIID for binding to 
the promoter, thus making binding of TFIID rate-limiting for transcription. PRV IE180 
enables TFIID to overcome this rate-limiting step, presumably by facilitating the 
TFIID-promoter interaction. These analyses are consistent with the more recently 
observed functional interplay between the HSV-1 Vmwl75 protein and TFIID (Smith et 
al., 1993; Gu etal., 1993).
Further experiments by Workman etal. (1988) employed an in vitro system where 
transcriptional preinitiation complex formation was in direct competition with 
nucleosome assembly over the target promoter region. Under these conditions, the 
presence of PRV IE 180 facilitated the TFIID-promoter interaction in preference to the 
assembly of nucleosomes. Although these findings obviously have great significance for 
the general mechanism of promoter activation from chromatin templates, their relevance 
to the situation during viral infection is not clear because at least for the HSV-1 and 
BHV-1 genomes, only a minor fraction of the lytic DNA appears to be bound in 
nucleosomes (Leinbach and Summers, 1980; Muggeridge and Fraser, 1986; Seal et al.,
1988).
1C.4 EHVIE1
The single IE transcript of equine herpesvirus 1 again maps to the short repeats of the 
genome (Gray etal., 1987a; b), and has a spliced leader sequence (Harty et al., 1989), a 
feature shared with its BHV-1 counterpart (Wirth et al., 1991). The largest open reading 
frame in this region has 1,487 codons and predicts a polypeptide of 155kD with the 
same pattern of amino acid conservation seen with the other alphaherpesvirus proteins 
(Grundy et al., 1989). However, four antigenically cross-reactive EHV-1 IE 
Polypeptides (ranging in size from 200 to 125kD) are translated from the single IE
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mRNA in vitro (Robertson et al., 1988) and are likely to arise from post-translational 
modifications of a larger protein precursor. The largest polypeptide, IE1, is the most 
abundant and is the major phosphorylated form of the protein. Cycloheximide blocking 
of IE mRNA translation has indicated the key role played by the IE gene products in 
regulating the expression of all other EHV-1 genes (Gray et al., 1987a). The regulatory 
properties of EHV-1 IE1 have been examined in transient transfection assays on various 
promoters (Smith et al., 1992a); IE1 activated early and late EHV promoters as well as 
the HSV-1 tk promoter, the SV40 promoter-enhancer region and the enhancer-less SV40 
promoter. In these assays, transactivation of the late EHV-1 promoters also required the 
presence of another EHV-1 gene product that shows sequence homology to HSV-1 
Vmw63 (Section IB.3.4). Like its VZV counterpart, EHV IE1 appears to be a more 
promiscuous activator than HSV-1 Vmwl75.
In addition, EHV-1 IE negatively autoregulated its own promoter in the transient assays 
and the ds-acting autoregulatory elements have been mapped to between -288 and +73 
of the IE gene (Smith et al., 1992a). By analogy to the apparent mechanism whereby 
HSV-1 Vmwl75 down-regulates its own production (Section IB.2.3), negative 
autoregulation of EHV-1 IE1 production is likely to be mediated through a sequence 
homologous to the Vmwl75 consensus binding site that is found overlapping the EHV- 
1 IE mRNA start site (Smith et al., 1992a). The negative regulatory function of EHV-1 
IE1 appeared to be more specific than that of its HSV-1 Vmwl75 counterpart, as it fails 
to down-regulate the HSV-1 IE3 promoter (Smith et al., 1992a). This is reminiscent of 
the findings of similar experiments with the VZV 140k protein (Disney et al., 1990). In 
fact, the evidence suggests that the VZV and EHV-1 protein counterparts are more 
closely related to each other than to the HSV-1 Vmwl75 protein, because as well as 
having similarly promiscuous transactivating phenotypes and similar specificities of 
transcriptional repression, the sequences of the conserved EHV-1 and VZV protein 
regions 2 and 4 show a higher level of homology than to HSV-1 Vmwl75. (Grundy et 
al., 1989). This is consistent with the proposed similar nature of the VZV and EHV-1 
transcriptional programmes, as discussed in Section 1B.4.3.
1C.5 Other alphaherpesvirus homologues of HSV-1 Vmwl75
The sequences of other members of this family of alphaherpesvirus regulatory proteins 
have recently been derived and the conservation of the predicted amino acid sequences 
of regions 2 and 4 in all these proteins further indicates the functional importance of 
these particular portions of sequence (see Fig. 1C.3 for a comparison of the sequences
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spanning region 2). In addition, all the proteins contain the serine-rich sequence and the 
basic putative nuclear localisation signal (Sections 1C. 1.1 and 1C. 1.2).
BHV-1 The sequence of the ICP4 protein of bovine herpesvirus type 1 is divided into 5 
regions, but it is unique in having the polyserine tract displaced to region 5, rather than 
being in region 1. Also BHV-1 ICP4 has two striking stretches of polyglutamic acid 
residues within region 3 that are not found in the other counterpart proteins but may 
have implications for its transactivation function (Section 1D.2.2). BHV-1 ICP4 shares 
functional similarities with other members of the family; it repressed its own promoter 
and activated other E and L herpesvirus promoters in transient transfection assays 
(Schwyzer etal., 1993).
SVV The simian varicella virus homologue of HSV-1 Vmwl75 has recently been 
sequenced and found to share 53% amino acid identity with VZV 140k but only 24% 
identity with HSV-1 Vmwl75 (Clarke et al., 1993). This is a reflection of the similar 
nature of the VZV and SVV diseases and also their genome structures (Gray et al., 
1992).
MDV Marek's disease virus induces T-cell lymphomas in susceptible chickens and is 
one of the more divergent alphaherpesviruses in both characteristics of the disease and 
DNA sequence, as is exemplified in the predicted sequence of the MDV ICP4 protein 
(Anderson etal., 1992).
The HSV-2 counterpart of HSV-1 Vmwl75 has a sequence very similar to that of the 
HSV-1 protein, and this is not too surprising from the high degree of overall homology 
between the two genome sequences (B. Barnett, personal communication). In 
agreement, the HSV-2 Vmwl75 protein is functionally interchangeable with HSV-1 
Vmwl75 during HSV-1 infection (Smith and Schaffer, 1987).
In summary, the sequence homologues of the major transcriptional regulatory protein of 
HSV-1, Vmwl75, show strong conservation of the functionally important regions 
(regions 2 and 4) and where analysed they possess similar regulatory functions. The 
thoroughly characterised nature of the HSV-1 Vmwl75 protein provides a basis for 
comparative studies with the other alphaherpesvirus counterparts, and interesting 
differences in the details of their functions have been identified. Particularly noteworthy 
are the analyses of the PRV IE 180 protein, which have yielded important information 
regarding the probable mechanism of action of the whole family of proteins, and have 
complemented and extended the mechanistic studies of HSV-1 Vmwl75. In addition, 
the information that can be gained from the sequences of these evolutionarily closely
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related proteins complements the functional studies on the individual proteins. The 
sequences of the more divergent members, such as MDV ICP4 (see Fig. 1C.3), have 
special value for indicating conserved portions of sequences that may mediate functions 
common to all the proteins, as well as identifying differences that may account for the 
properties specific to a particular protein.
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ID Eukaryotic RNA polymerase II transcription and its 
regulation
Our knowledge of the details of the transcription process has advanced extremely 
rapidly over the last decade and this Section will review only the initiation of 
transcription of inducible protein-coding genes by RNA polymerase II. Emphasis will 
be given to the human system, although the mechanism of transcriptional initiation is 
remarkably conserved in eukaryotes ranging from yeast to man. As viral transactivators 
appear to function through mechanisms analogous to those of cellular transcriptional 
activator proteins, the later Sections will discuss the mechanisms used by the host cell to 
regulate transcriptional initiation.
1D.1 Basal RNA polymerase II transcription
ID. 1.1 RNA polymerase II
Eukaryotic cells contain three RNA polymerases which are large multi-subunit 
complexes, and each is responsible for transcribing a distinct set of genes: RNA 
polymerase I (pol I) transcribes ribosomal RNA genes; pol II is the RNA polymerase of 
protein-coding genes; pol III transcribes 5S rRNA and tRNA genes (for a 
comprehensive review, see Young, 1991). RNA polymerase II isolated from HeLa cells 
contains 10 subunits ranging from 10 to 240kD. The function and subunit structure of 
RNA polymerase II has been well conserved among the eukaryotes and by analogy to 
the essential nature of the yeast pol II subunits, all the HeLa pol II subunits are likely to 
be functionally important. In addition, the two largest subunits of eukaryotic RNA 
polymerases show clear sequence homology to the P and p' subunits of the single RNA 
polymerase of E. coli (Allison et al., 1985). The structure of the yeast pol II enzyme, 
determined at 16 A resolution, provides a structural basis for functional analyses of the 
transcription process (Darst et al., 1991).
Of particular interest is the unusual C-terminal domain (CTD) of the largest subunit of 
RNA polymerase II which comprises multiple tandem repeats of the consensus 
heptapeptide YSPTSPS; the number of these repeats is important for viability in yeast 
(reviewed by Corden, 1990). The CTD can be extensively phosphorylated at the serine 
and threonine residues and pol II is consequently present in phosphorylated and 
non-phosphorylated forms within the cell; the catalytically active enzyme is
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phosphorylated (Cadena and Dahmus, 1987). The evidence so far supports a model 
where the non-phosphorylated form of pol II preferentially associates with the 
promoter-bound preinitiation complex, and the subsequent phosphorylation of the CTD 
potentiates the transition from transcriptional initiation to elongation (Fig. 1D.1) (Payne 
et al.f 1989; Laybourn and Dahmus, 1989; 1990; Lu et al., 1991). In agreement, a 
CTD-specific kinase is associated with the TFIIH component of the basal transcription 
machinery; this only phosphorylates the CTD when pol II is contained within a 
complete transcriptional preinitiation complex (Lu et al., 1992). A complementary 
CTD-phosphatase activity has been identified in HeLa cell extracts (Chesnut et al., 
1992), which may play a role in the recycling of RNA pol II between rounds of 
transcription. Affinity chromatography has demonstrated that the non-phosphorylated 
CTD of pol II (but not the phosphorylated form) binds to the basal transcription factor 
TBP (see next Section) (Usheva et al., 1992). In addition, the CTD has been reported to 
interact non-specifically with DNA in vitro (Suzuki, 1990); the possible functional 
implications of these interactions for the transition from transcriptional initiation to 
elongation are discussed further in Section ID. 1.3. Genetic analyses in yeast have 
indicated that the CTD of pol II also mediates the activity of selected transcriptional 
activators and repressors, and is therefore implicated in the regulation of transcriptional 
initiation (Allison and Ingles, 1989; Scafe et al., 1990; Peterson et al., 1991).
1D. 1.2 The basal transcription factors
In contrast to the prokaryotic RNA polymerase, the functional activities of the 
eukaryotic enzymes require multiple accessory proteins. Seven auxiliary factors are 
involved in the accurate initiation of transcription from class II promoters by RNA 
polymerase II; these are commonly known as the basal or general transcription factors 
and together with pol II they constitute the basal transcription machinery. These basal 
transcription factors, TFIIA, B, D, E, F, H and J, were isolated by fractionation of HeLa 
cell nuclear extracts and the composition and role played by each factor is given in 
Table ID (reviewed by Zawel and Reinberg, 1993). The cloning of the cDNAs encoding 
many of the HeLa basal factors has facilitated their functional analysis in vitro, and has 
enabled sequence comparisons with components of other transcription systems (Zawel 
and Reinberg, 1993). The basal factors are required for transcription from all class II 
promoters and are therefore favourable targets of cellular transcriptional regulatory 
proteins (see Section 1D.2.3). Furthermore, viral regulatory proteins, for example the 
HSV-1 proteins Vmwl75 and Vmw65 (VP 16), appear to influence the level of 
transcription of their target promoters through interactions with components of the basal 
transcription machinery (Sections 1B.3.3 and 1B.2.2). [Note that HSV-1 Vmw65 will be 
referred to as VP 16 for the remainder of Section ID, as this is the nomenclature 
appropriate to the transcription field].
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Several recent studies using in vitro reconstituted transcription systems have managed to 
reproduce transcription with only a subset of the basal factors: TBP, TFIID and pol II 
were sufficient to transcribe the IgH promoter when the template was negatively 
supercoiled, although transcription from the relaxed template required the full set of 
factors (Parvin and Sharp, 1993). This result inferred that the free energy of supercoiling 
functionally replaces the requirement for the remaining basal factors, by promoting 
formation of an open complex for transcriptional initiation (Section ID. 1.3). Another 
study found that transcription of certain promoters required only Drosophila TBP, 
TFIIB, pol II and the RAP30 subunit of TFIIF (Tyree et al., 1993). Transcription with 
these basal factor subsets is fairly inefficient (Drapkin et al., 1993), but this provides a 
favourable basis for the functional analysis of the remaining factors upon their addition 
to the reconstituted minimal in vitro transcription system.























38kD Initiates complex assembly by binding to the TATA box 
Interacts with the CTD of pol II and also many TAFs 
Contacts activators (i.e. VP16)
Unknown Stabilises the TFIID-DNA interaction
Removes repressors of basal transcription 
from the TFIID complex
33kD Contacts acidic activators (i.e. VP 16)
Binds to DA complex 
Accurately positions pol II
220kD Commonly referred to as RAP30/RAP74
Recruits pol II to the promoter 
Affects efficiency of transcriptional elongation
200kD Binds to DABpolF complex
230kD Binds to DABpolFE complex
Associated with CTD kinase
TFIIJ Unknown Unknown Binds to DABpolFEH complex
Table ID The polypeptide composition and known functions ot the HeLa basal 
transcription factors. The composition and native size are given for each of the RNA polymerase II 
basal transcription factors: TFIIA, B, F, E, H, J and the TBP component of TFIID (see Section ID. 1.4), 
* factors whose cDNA has been isolated.
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ID. 1.3 Ordered assembly o f the transcription complex and transcriptional initiation 
With the exception of 'housekeeping' genes which have poorly defined promoter 
elements, class II promoters contain at least one of two minimal promoter elements: the 
TATA box (typically located 30 bp upstream of the mRNA start site) and the initiator 
element (Inr) (which encompasses the mRNA start site) (see Fig. 1D.1, panel A). The 
TATA box and / or the Inr can support basal transcription in the absence of other 
promoter elements. As all the alphaherpesvirus promoters so far analysed contain a 
TATA box homology, transcriptional initiation from promoters lacking a TATA box 
will not be considered here. For a review of initiation from TATA-less promoters, see 
Zawel and Reinberg (1993).
DNA binding analyses indicated that the assembly of the basal transcription machinery 
over the minimal promoter elements proceeded in a highly ordered manner to form a 
stable transcriptional initiation complex (Van Dyke et al., 1988; Buratowski et al.,
1989). An updated version of the assembly scheme is described below and illustrated in 
Figure 1D.1 (reviewed by Conaway and Conaway, 1993). TFIID is the only basal 
transcription factor with sequence-specific DNA binding activity, and binding of TFIID 
to the TATA box constitutes the initial step in the formation of a 
transcription-competent complex (Fig. 1D.1, panel B) (Sawadogo and Roeder, 1985; 
Van Dyke et al., 1988). Thereafter, the remaining factors enter the complex via 
protein-protein interactions. As discussed in the next Section, TFIID is a multi-subunit 
complex composed of the TATA-binding protein (TBP) and TBP-associated factors 
(TAFs). In the next step of the assembly process, TFIIA binds to the TBP component of 
TFIID and stabilises the TFIID-DNA interaction. TFIIA can remain associated or leave 
at any subsequent step in the pathway, and the sole role of TFIIA may be to displace a 
repressor of basal transcription that binds to TFIID (see Section 1D.2.4). Next, TFIIB 
enters the complex to yield the TFIID/TFIIA/TFIIB or DAB complex (panel C). TFIIB 
is responsible for the precise positioning of pol II at the promoter, a fact cleverly 
demonstrated by swapping components between two yeast in vitro transcription systems 
(Li et al., 1994). The recruitment of TFIID to the promoter is known to be slow 
(Reinberg etal., 1987), and affinity purification of preinitiation complexes at various 
stages of assembly has indicated that the binding of TFIIB is also a rate-limiting step 
(Lin and Green, 1991). Thus, these two steps are likely targets for enhancement by 
transcriptional activators (Section 1D.2.3). This has been shown to be the case with the 
PRV homologue of VZV 140k (Section 1C.3.1). In the next stage of the assembly of the 
preinitiation complex, Pol II is escorted to the DAB complex by TFIIF, to yield the 
DABpolF complex (panel D) (Flores et al., 1991). Then follows the ordered association 
of TFIIE, TFIIH and TFIIJ to produce the complete preinitiation complex (panel E).
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Figure 1D.1 RNA polymerase II mediated transcriptional initiation. This schematic 
diagram presents a model for assembly of the transcriptional initiation complex and its conversion to an 
elongation complex, see text for a description of the stages A to F. The basal transcription factors are 
indicated by letters A B D, E, F, H and J. Only eight of the 52 repeats found in the C-terminal domain 
(CTD) of mammalian’ RNA pol II are shown (Corden et al., 1985). Nucleotide coordinates indicate the 
region of the promoter spanned by the complexes, as determined by footprinting analyses. The Figure is 
after Zawel and Reinberg (1992).
68
Chapter ID: RNA polymerase 11 transcription
It is also possible that a subset of the basal transcription factors may assemble with the 
polymerase in a holoenzyme prior to entering the preinitiation complex (inferred by Li 
et al.y 1994). The details of the process whereby the transcription complex is activated 
are far from clear, although the evidence indicates that ATP hydrolysis converts the 
preinitiation complex to an active conformation (reviewed by Conaway and Conaway, 
1993). ATP hydrolysis is also an apparently distinct requirement for melting the DNA 
duplex in order to yield an open complex for transcriptional initiation (Wang et al, 
1992b). Phosphorylation of the CTD of pol II may then enable the enzyme to clear the 
promoter region and initiate RNA synthesis (in the presence of rNTPs) (Fig. 1D.1, panel 
F). As discussed earlier (Section ID. 1.1), the non-phosphorylated CTD may be bound to 
the TBP component of TFIID in the preinitiation complex. Phosphorylation of the CTD 
might then dissociate the CTD-TBP association and allow pol II to disengage from the 
factors remaining at the promoter. This proposed mechanism is highly attractive because 
it would enable TFIID (and perhaps other factors such as TFIIB) to remain bound at the 
promoter, primed for re-initiation (Fig. 1D.1, panel F). This prediction has some 
experimental support (Van Dyke etal., 1988). Alternatively, phosphorylation of the 
CTD of pol II could facilitate the transition from transcriptional initiation to elongation 
by releasing the CTD-DNA interaction (Section ID. 1.1). The mapping of the 
interactions between the components of the basal transcription machinery is well 
underway (reviewed by Drapkin et al, 1993; Zawel and Reinberg, 1993).
1D. 1.3 The TFIID multi-protein complex
The TFIID component of the basal transcription machinery is important as it appears to 
be the target of not only numerous cellular regulatory proteins, but also the VZV 140k 
family of proteins. The native size of TFIID isolated from HeLa cells was found to be 
over lOOkD (Reinberg et al, 1987); however, the cloned activity corresponded to a 
38kD polypeptide (Kao et al, 1990; Peterson et al, 1990; Hoffman et al, 1990). This 
suggested that endogenous TFIID is a multi-protein complex which contains the 38kD 
protein, referred to as the TATA-binding protein (TBP), and associated factors. Some of 
these TBP-associated factors, or 'TAFs', could be dissociated from the TFIID complex 
under conditions of high ionic strength, but the remaining polypeptides remained tightly 
bound and required denaturing conditions for their removal (Pugh and Tjian, 1991). 
This raised the possibility that some TAFs are always associated with TBP while others 
transiently interact with the TFIID complex to regulate its function.
In vitro, both TBP and TFIID were found to be equally capable of mediating basal 
transcription. However, TFIID, but not TBP, could support transcription activated by a 
wide variety of sequence-specific activators including VP16, Spl and CTF. Based on 
these results it was postulated that native TFIID contains 'co-activators' which physically
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link transactivators to components of the basal transcription machinery (Pugh and Tjian, 
1990; Peterson e ta l, 1990; Dynlacht e ta l, 1991; White e ta l, 1991; Zhou e ta l, 1992). 
In agreement, at least some of the purified Drosophila TAFs function as co-activators in 
vitro (Dynlacht et a l, 1991). The co-activator function of these TAFs also exhibited 
functional specificity, as those that mediated activation by proline-rich activators were 
unable to mediate activation by acidic activators (Tanese et al, 1991) (see Section
1D.2.3).
Affinity purification of TFIID from HeLa cells has indicated the presence of numerous 
TAFs, and much recent effort has concentrated on their characterisation (Zhou et al, 
1992; 1993, and references therein) (see Fig. 1D.2). The largest human TAF, TAFn250, 
transpired to be identical to the cell cycle regulator CCG1; this indicated a link between 
cell cycle regulation and the basal transcription machinery (Ruppert et a l, 1993). A 
temperature sensitive version of TAFn250 provided the first direct evidence that TAFs 
mediate transcriptional activation in vivo (Wang and Tjian, 1994). Furthermore, the 
effects of this mutation on transcriptional activation were gene specific, supporting the 
functional specificity of the TAFs observed in vitro.
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Figure 1D.2 The Human TFIID complex. Diagrammatic representation of the TBP and TAF 
components of HeLa TFIID. Only those TAFs that have clearly been established to be a part of the HeLa 
TFIID complex are shown (Zhou et al., 1992, 1993). The 700kD holoTFIID shown here includes TAFs 
ranging from 28-250kD, and the TAFs are named according to their apparent size on SDS-PAGE (kD). 
The positions on the DNA and relative positions of the TAFs and TBP are shown on the basis of the 
available information from footprinting and far-western analyses (Zhou et al., 1993, and references 
therein). TBP is drawn schematically to indicate the lack of interaction of the non-conserved N-terminal 
portion with either DNA or TAFs.
Important advances have also been made in the analysis of the Drosophila TAFs, 
including the identification of the distinct TAF components of TFIID that interact with 
the activation domains of the transcriptional regulators Spl and VP 16 (Hoey et al, 
1993; Goodrich et al, 1993; Gill et a l, 1994) (Fig. 1B.2). These analyses are relevant to 
the human situation because of the high degree of sequence identity between at least 
some Drosophila and human TAFs. Within the TFIID complex, some of the interactions 
between TAFs are thought to hold the subunits together, while others may be subject to 
dynamic change induced by regulatory factors. Indeed, an inhibitory domain in one of
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the Drosophila TAFs controls the promoter binding activity of TFIID and may be 
regulated by other TAFs or regulatory factors (Kobubo et al.y 1994). Two of the seven 
cloned Drosophila TAFs showed significant sequence homology to histones H3 and H4 
and this raises intriguing functional implications; these particular TAFs may be involved 
in wrapping DNA into a nucleosome-like structure or displacing the H3/H4 components 
of chromatin to allow transcriptional initiation (Kobubo et al., 1994).
TBP has recently been found to be a requirement for transcription from promoters which 
lack a TATA box and also for transcription from class I and III promoters, processes 
which presumably require TBP to be associated in distinct multi-protein complexes 
(reviewed by Sharp, 1992; White and Jackson, 1992; Rigby, 1993). Indeed, multiple 
chromatographically separable TBP-containing complexes with different functional 
properties exist in HeLa cells (Timmers and Sharp, 1991; Timmers et al., 1992; Brou et 
al., 1993). Some of the TAFs were common to all these TFIID complexes, while others 
were unique (Brou et al, 1993). Therefore, it appears that the factors associated with 
TBP are responsible for modulating the response to transcriptional activators and also 
for determining promoter specificity. The TAF components of TBP increase the protein 
surface available to accommodate multiple protein-protein interactions with a diverse 
array of transcriptional regulators, and the association of different sets of TAFs with 
TBP would generate unique and specific interaction surfaces as targets for different 
activators.
As would be predicted from its fundamental role in the transcription process, the TATA 
binding protein, TBP, is highly conserved among all eukaryotes. The C-terminal domain 
of TBP is particularly well conserved, whereas the N-terminal domain is variable in 
length and sequence. The C-terminal 180 amino acid domain is sufficient to fulfil the 
majority of the functions and interactions mediated by TBP (for reviews, see Pugh and 
Tjian, 1992; Hernandez, 1993). In addition to its interactions with DNA, the TAFs, 
TFIIB and TFIIA, the TATA binding protein (TBP) also associates with transcriptional 
regulatory factors, co-activators and repressors of basal transcription (see Sections
ID.2.3 and ID.2.4). It seems highly surprising that a protein region the size of the 
C-terminal domain of TBP can participate in so many interactions, even given the fact 
that many are likely to be dynamic. A possible explanation has been provided by the 
recent 3-D structures (both in the presence and absence of DNA) of the plant 
Arahidopsis thaliana TBP and the conserved C-terminal domain of yeast TBP (Nikolov 
etal., 1992; Kim etal., 1993a; Chasman etal., 1993; Kim etal., 1993b). These show 
that the C-terminal domain of TBP adopts a novel protein fold for DNA binding, which 
gives the protein a saddle-like shape straddling the DNA and presents a large convex 
surface available for interactions with other proteins (Fig. 1D.3) (see Section 1E.5.2).
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Figure 1D.3 Transcription factors that interact with the convex outer surface of TBP. 
The crystal structures of the C-terminal domain of TBP demonstrate that it forms a molecular saddle over 
the DNA, as shown here in cross-section. Many different types of factors have been shown to bind TBP as 
discussed in the text (also see Struhl, 1994) and the binding site for TFIIA on TBP’s surface has been 
well-defined (Lee et al, 1992).
1D.2 Regulation of RNA polymerase II transcription
1D.2.1 Promoter elements involved in transcriptional regulation
The activity of the basal transcription machinery is modulated by sequence-specific 
regulatory factors that bind to short consensus sequences usually located within lOObp 
of the minimal promoter region (proximal promoter elements), and to enhancer elements 
which are often several kbp further upstream (reviewed by Saltzman and Weinmann, 
1989). Where present, enhancers characteristically function independently of distance 
or orientation and comprise multiple elements for different transcriptional activators; 
some recognition elements are shared between enhancer and proximal promoter 
sequences.
Cis-acting promoter elements function either separately or in various combinations, to 
confer responses to a wide range of signals by influencing the activity of the basal 
transcription machinery (see Section 1D.2.3). Some of the regulatory factors bound by 
these elements are ubiquitous and contribute to the constitutive activity of the promoter 
(for example Spl and CBP), while other elements bind factors which are tissue specific 
or are regulated by specific stimuli (for example heat shock, or steroids). The particular 
complement and arrangement of the cis-acting elements within a promoter defines its 
specific pattern of gene expression (reviewed by Saltzman and Weinmann, 1989). How 
enhancers work is not known, although they clearly promote the formation of stable
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transcription complexes (Mattaj etal., 1985; Weintraub, 1988). A popular proposed 
mechanism for enhancer action is that direct contact occurs between sequence-specific 
factors bound at proximal promoter elements and the enhancer, by looping-out the 
intervening DNA (Ptashne, 1986). This hypothesis has been tested using the HSV-1 tk 
promoter, which is normally stimulated by Spl associating with its two proximal 
elements; however, insertion of six Spl sites 1.8kb upstream greatly stimulated 
transcription, and direct interaction between the two sets of Spl sites has been visualised 
by electron microscopy (Courey et al., 1989; Mastrangelo et al., 1991; Su et al., 1991). 
This type of looping between enhancer and proximal elements also occurs with 
heterologous DNA binding proteins (Li etal., 1991). It should be noted that these 
experiments examined factors bound to naked DNA and that the packaging of DNA into 
nucleosomes in vivo may help bring the proximal and enhancer elements into proximity, 
thus allowing contacts between regulatory factors to be made. Such interactions might 
be either direct or indirect through non-DNA binding mediator proteins.
1D.2.2 Domain structure o f transcriptional activators
An important discovery for the study of the regulation of gene expression was that 
transcriptional activator proteins are modular in structure, having a DNA binding 
domain that confers specificity and a separate and functionally independent activation 
domain(s) that enhances the activity of the basal transcription machinery (reviewed by 
Ptashne, 1988; Frankel and Kim, 1991). As such, these domains can be interchanged 
using molecular genetics to create chimeric proteins with novel activities. It is 
interesting that certain viral activator proteins rely on host cell proteins to supply the 
DNA binding domain in trans, as is the case with VP16 (Section IB.2.2) and adenovirus 
Ela (Liu and Green, 1990). Transcriptional activation regions have been roughly 
classified on the basis of their primary sequence: acidic (found in proteins such as VP16 
and yeast GCN4, GAL4), proline-rich (i.e.CTF), and glutamine-rich (i.e. Spl ) 
(reviewed by Mitchell and Tjian, 1989). In contrast to the wealth of knowledge 
concerning the different types of DNA binding domains (Section IE), the structure and 
details of the molecular interactions of the transcriptional activation regions remain 
more of a mystery.
Acidic activation regions have been most extensively analysed. They appear to have no 
sequences or structures in common except for a net negative charge; the sequence 
requirements of specific acidic activation regions have been investigated by mutational 
analyses (reviewed by Hahn, 1993b). One study found that the net negative charge of 
the VP16 activation region contributed to, but was not sufficient for transcriptional 
activation. Instead, it appeared that bulky hydrophobic residues were more important, 
and one particular phenylalanine residue was critical, for the VP16 activation lunction
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(Cress and Triezenberg, 1991). No essential residues were identified in the GAL4 acidic 
activation region (Gill and Ptashne, 1987) and even elimination of all of the negative 
charges caused only a modest reduction in GAL4 activator function (Leuther et al.f 
1993). Contrary to earlier belief, acidic activation regions fail to adopt an a-helical 
structure, as indicated by circular dichroism spectroscopy (Van Hoy et al., 1993). The 
fact that the GCN4 acidic activation domain could be extensively deleted without 
reducing its activity in vivo strongly suggested that tertiary structure is unimportant for 
the activation function (Hope et al, 1988). Therefore, the interaction of acidic activators 
with their target(s) is unlikely to depend upon precise rigid, structural complementarity 
and this is consistent with the observation that certain acidic activation domains can 
function in all the eukaryotic systems tested from yeast to humans regardless of their 
origin. Possible mechanisms whereby the activation domains stimulate transcription will 
be considered below.
1D.2.3 Mechanisms o f transcriptional activation
All transcriptional activation domains presumably stimulate the activity of the basal 
transcription machinery through either direct or indirect interactions. The majority of 
studies on the mechanism of transcriptional activation have employed the acidic 
activation region of HSV-1 VP16, due to its potency (Sadowski et a l, 1988). As 
discussed in Section IB.2.2, the VP16 activation region forms direct and specific 
contacts with the basal transcription factor TFIIB and a TAF component of the TFIID 
complex in vitro; VP16-TBP interactions have also been reported. The TFIIB-VP16 
interaction has been shown to be vital for VP16-mediated transcriptional activation in 
vitro (Roberts et al, 1993). In support of the relevance of the TFED-VP16 interaction, 
the transcriptional activity of mutant VP 16 activation domain derivatives correlated with 
their affinity for TFIID, as measured by in vitro binding assays (Ingles et al, 1991). The 
basal factors TFIIB and TFIID have also been found to be the targets of other activation 
regions. A synthetic acidic activation region increased the efficiency of TFIIB binding 
to the TFIID-promoter complex in vitro (Lin and Green, 1991) and viral activators 
bearing non-acidic activation regions, such as E la and EBV Zta, have also been found 
to contact TFIID and apparently stabilise its association with DNA (Lee et a l, 1991; 
Lieberman and Berk, 1991).
An obvious interpretation of these data is that these transcriptional activation regions 
recruit TFIID and / or TFIIB to the promoter during preinitiation complex formation, 
thus stimulating transcription by overcoming a rate-limiting step. However, there are 
several other equally plausible explanations. It has been suggested that the basal 
transcription factors frequently assemble into non-productive complexes in the absence 
of an activator; this was based on the observation that a very small fraction of promoters
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act as transcription templates during in vitro transcription experiments, even though 
footprinting analyses detect complexes on the majority of templates (Herschlag and 
Johnson, 1993). Transcriptional activators may favour assembly of productive 
transcription complexes, and there is evidence to support this (Wang e ta l, 1992a). The 
binding of an activator to TFIID and / or TFIIB may block the assembly pathway for 
non-productive complexes, perhaps by inducing conformational changes in the basal 
factors. Alternatively, non-productive complexes may be a consequence of inhibitory 
factors binding to the basal transcription factors. In this scenario, the activator might 
compete with the repressor for binding sites on the basal transcription factor. In support 
of this mechanism, several activators have been observed to stimulate transcription by 
displacing repressors of basal transcription from TBP (see next Section). It is possible 
that similar types of transcriptional repressors also bind to other components of the basal 
transcription machinery, such as TFIIB. Therefore, by preventing negative factor 
binding by direct competition, activators would stimulate the rate of transcriptional 
initiation.
In addition to their apparent importance for the function of acidic activation domains, 
the TAF co-activator components of TFIID are also an essential requirement for 
activation mediated by the activators Spl and CTF in vitro (Section ID. 1.4). This 
suggests that the mechanisms of transcriptional activation by the glutamine- and 
proline-rich activation domains may also involve contacts with the TAFs during the 
initiation process in vivo. Activators bearing different classes of activation domains 
presumably contact distinct targets, and the fact that the activation domains of Spl and 
VP16 specifically interact with different TAFs in vitro supports this (Section ID. 1.3). 
That TBP can be associated with distinct factors or sets of factors which specifically 
mediate the activity of one or several different activation domains (Brou et al, 1993), 
may explain the results of 'squelching' experiments which suggest that distinct 
transcriptional co-activators can be titrated by acidic and non-acidic activation domains 
(Martin et al, 1990a; Tasset et al, 1990). These squelching experiments test the ability 
of activators to interfere with each other by competing for the same targets.
Experiments in yeast also indicated that basal factors are not sufficient to promote 
transcriptional stimulation by the acidic activation domains of VP 16 and GCN4, and 
that auxiliary factors, termed mediators or adaptors, are required (Berger et a l, 1990; 
Kelleher et a l, 1990; Flanagan et al, 1991b). These mediators may represent a class of 
transcription factors distinct from the TAFs of higher eukaryotes, as yeast TBP is not 
part of a stable multi-subunit complex in the same way as the TFIID of higher 
eukaryotes (Schmidt eta l, 1989). These yeast mediators may either connect activator 
proteins to the basal transcription machinery in a manner analogous to the TAFs, or they
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may facilitate the interaction of activators with chromatin proteins to bring about 
antirepression of chromatin-bound templates (see Section 1D.2.4). Furthermore, the 
results of squelching experiments in yeast have suggested that not all acidic activators 
target the same mediator, indicating that there are several different classes of acidic 
activators that function through distinct pathways (Berger et al., 1992).
Another interesting observation is that transcriptional activator proteins bound to the 
same promoter can stimulate gene expression cooperatively or synergistically, with 
activator proteins bearing the same class or different classes of activation domains. This 
enhanced activity may be through their stimulation of different rate-limiting steps in the 
transcriptional initiation process or through multiple favourable contacts with the basal 
transcription machinery. The suggestion that certain activators contact several basal 
factors (as seen with VP 16) may explain the greatly enhanced transcriptional stimulation 
which results from certain combinations of activators.
1D.2.4 Transcriptional antirepression
Many of the functional studies of activation domains described in the previous Section 
used reconstituted in vitro transcription systems in which the magnitude of 
activator-mediated transcription observed did not approach the physiological levels of 
activation. It was apparent that additional factors repressed the basal level of gene 
expression in vivo, but were absent from these purified in vitro systems. The presence of 
general repression mechanisms within the cell would act to lower the resting level of 
gene expression, and therefore enable a much greater response to transcriptional 
activators. Thus activators could function by counteracting transcriptional repression 
('antirepression') as well as stimulating the inherent basal transcription process ('true 
activation'). Two distinct types of generalised repression mechanisms have been 
identified that have wide ranging implications for transcriptional regulation, as 
described below.
A large body of data from genetic and biochemical experiments indicates that chromatin 
structure plays an important role in the regulation of gene expression, and in vitro 
systems have demonstrated that pre-assembly of nucleosomes and / or histone H1 onto 
DNA templates drastically inhibits transcriptional initiation, presumably by sterically 
blocking the assembly of the transcription complexes (reviewed by Workman and 
Buchman, 1993; Croston and Kadonaga, 1993). Thus, activators must function at least 
in part to counteract chromatin-mediated repression. This was observed in vitro when 
Spl or GAL4-VP16 was bound to a naked DNA template, prior to chromatin assembly 
and transcriptional analysis (Croston et al., 1992; Kamakaka et al., 1993). However, 
these experiments would only reflect the situation immediately following DNA
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replication in vivo (i.e. when the DNA may be transiently naked), but in the majority of 
cases the rapid induction of gene expression observed in vivo would require the activator 
to bind and transactivate a promoter that is already assembled into chromatin. Therefore, 
a major question in the regulation of gene expression is how do the transcription factors 
gain access to the DNA bound in nucleosomes? Chromatin disruption is known to 
accompany transcriptional activation in vivo (reviewed by Croston and Kadonaga, 
1993); significantly these alterations include the depletion of histone HI, an observation 
which supports the identification of HI as a general repressor in vitro (Croston et al., 
1991). Activators may be responsible for directing this reconfiguration of the chromatin 
to allow the basal factors access to the promoter and to assemble into the transcriptional 
initiation complex. Recent in vitro experiments with reconstituted chromatin 
assembly-transcription systems have demonstrated that this is the case, but additional 
proteins are required to facilitate this activator-mediated chromatin reconfiguration and 
antirepression process (Tsukiyama et al., 1994; J. T. Kadonaga, personal 
communication).
The other general repression mechanism that has been identified involves the binding of 
small proteins to the basal transcription factor TFIID; these include the HeLa cell 
proteins Drl and Dr2, and the yeast proteins NCI, NC2 and ADI (Meisterernst and 
Roeder, 1991; Meisterernst et al., 1991; Inostroza et al., 1992; Zawel and Reinberg, 
1993; Auble and Hahn, 1993). The Drl repressor functions in two ways: (i) it binds to 
TFIID and precludes further assembly of the preinitiation complex (i.e. the binding of 
TFIIA and TFIIB) and (ii) it disrupts preinitiation complexes such as DABpolF (see Fig.
ID. 1). In addition, the Drl-TFIID complexes can be disrupted by the viral 
transactivators Ela and SV40 (Zawel and Reinberg, 1993). Another inhibitory factor 
NCI (that may be a counterpart of Dr2), binds to TFIID and down-regulates the basal 
promoter activity (Meisterernst et al., 1991). Both NCI and Dr2 are displaced when 
excess TFIIA is added, or by the presence of an acidic activator (Zawel and Reinberg,
1993). The yeast repressor ADI can also be displaced by TFIIA, but in contrast to the 
other inhibitory factors, ADI binding to TFIID dissociates the TFIID-DNA interaction 
(Auble and Hahn, 1993).
In addition to these general mechanisms that are used to repress basal transcription, 
other repressors affect transcription by recognising specific DNA sequences in selected 
promoters and then reducing the activity of the basal transcription machinery or 
blocking the stimulatory effects of activators (reviewed by Levine and Manley, 1989; 
Renkawitz, 1990). Passive repressors compete with activators or basal transcription 
factors for occupancy of promoter elements; for example the autoregulation function of 
SV40 large T antigen is due to its binding to a site overlapping the minimal elements of
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its own promoter (Tjian, 1981). Active repressors either disrupt the function of specific 
activators, or the basal transcription machinery, through protein-protein interactions. For 
example, Drosophila engrailed represses transcription from its proximal promoter 
elements via a repression domain that is functionally transferable to other DNA binding 
domains, in a manner analogous to activation domains (Jaynes and O’Farrell, 1991). 
Because some transcriptional repression domains, for example the Drosophila 
even-skipped domain (Han and Manley, 1993), can function on minimal promoters 
comprising only a TATA box, it is likely that at least some repression domains modify 
the activities of the basal machinery directly, or indirectly through co-repressors (as has 
been suggested by squelching experiments). Interestingly, many repressors can also act 
as activators in different situations, and they have distinct repression and activation 
domains that are presumably subject to differential regulation. Additionally, differential 
splicing can produce related activators and repressors from the same gene (reviewed by 
Foulkes and Sassone-Corsi, 1992).
In summary, the initiation of transcription is a complex multi-step process, and as such 
provides numerous stages for the regulation of transcription. Repression and activation 
mechanisms both play crucial roles in determining the activity of the basal transcription 
machinery. The level of transcription of a eukaryotic gene at any one time is likely to be 
determined by the concerted actions of several activators and repressors bound to 
multiple promoter elements. The TFIID complexes present large and varied surfaces for 
specific protein-protein interactions with these regulatory factors to allow specific 
effects on the activity of the basal machinery.
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IE. 1 Overview of DNA binding strategies
Sequence-specific DNA binding proteins possess a discrete DNA binding domain that is 
folded in a way that presents a protruding surface, a flexibly extended structure, or both 
in order to contact the DNA bases of the target binding site. These domains are usually 
stabilised by a hydrophobic core and are usually physically separable from the rest of 
the protein. Many DNA binding proteins bind to DNA as symmetrical dimers and their 
DNA binding domains often include a specific type of dimerisation motif closely 
associated with the DNA binding motif. On the basis of sequence conservation of these 
motifs, DNA binding domains are classed into structural families that employ distinct 
modes of DNA recognition. However, there are examples of DNA binding domains that 
show very little sequence homology yet adopt similar structures, as seen with the variant 
HTH motifs (see Section IE.2.3).
The DNA recognition element is often an a-helix which fits snugly into the major 
groove, although DNA binding strategies for several proteins using P-sheets for DNA 
recognition have also been elucidated (Section IE.5). The different classes of DNA 
binding domains characteristically contact bases in either the major or minor, or both 
grooves of DNA. In addition, multiple hydrogen bonds with the DNA phosphate 
backbone are critical for correctly positioning the recognition element, and also for 
fixing the DNA in a specific conformation to allow the optimal protein-DNA interaction 
(discussed further by Luisi, 1994). The salient features of each class of DNA binding 
domain, as elucidated by nuclear magnetic resonance and X-ray crystallographic 
analyses, will be discussed in the following Sections (for reviews, see Harrison, 1991; 
Pabo and Sauer, 1992; Burley, 1994).
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1E.2 The helix-tum-helix (HTH) DNA binding motif 
1E.2.1 The prokaryotic HTH motif
The helix-turn-helix (HTH) was the first DNA recognition motif to be characterised 
structurally and it has been found in the majority of analysed bacterial and 
bacteriophage transcriptional regulatory proteins (for reviews, see Brennan and 
Matthews, 1989; Harrison and Aggarwal, 1990). The HTH motif is defined as a 20 
residue segment comprising two a-helices separated by a four residue turn; the helices 
lie at 120° to each other. The second amphipathic helix is the DNA recognition element 
that lies in the major groove of DNA and contacts the bases. Additional residues outside 
the HTH motif are often important for DNA recognition, as is the case with the X 
repressor-DNA complex where a flexible N-terminal arm makes critical contacts in the 
major groove (Jordan and Pabo, 1990). The HTH motif cannot fold or function by itself, 
but is found in diverse structural environments as part of a larger DNA binding domain. 
The prokaryotic HTH proteins bind to DNA as dimers and each monomer recognises a 
symmetrical half-site.
1E.2.2 Homeodomains
As discussed in Section 3E.1, the homeodomain is a conserved 60 residue DNA binding 
domain, found in a large number of eukaryotic transcription factors that play important 
roles in development (reviewed by Kornberg, 1993; Wright, 1994). The homeodomain 
is structurally related to the HTH motif and consists of three a-helices and an N- 
terminal arm; however, the prokaryotic and homeodomain HTH units dock against the 
DNA in significantly different ways (Kissinger et al., 1990). The DNA co-crystal 
structures for homeodomains from yeast MATa2 and Drosophila Antennapedia and 
engrailed, demonstrate that the homeodomain binds to DNA as a monomer by inserting 
the long third a-helix into the major groove of the DNA and its N-terminal arm into the 
adjacent minor groove (Otting et al., 1990; Kissinger et al., 1990; Wolberger et al, 
1991).
1E.2.3 POU domains and variant eukaryotic HTH motifs
Certain subfamilies of homeodomain proteins have an additional DNA binding motif, 
flanking the homeodomain, that is required for high affinity and sequence-specific DNA 
binding (Scott etal., 1989; Laughon, 1991). A well characterised example of this is 
provided by the divergent homeodomain of the POU proteins, referred to as the 
POU-specific domain (see Section 3E.7) (reviewed by Verrijzer and van der Vliet, 1993; 
Wright, 1994). The POU-specific domain lies on the N-terminal side of the 
homeodomain and was first identified in the Pit-1, Oct-1, Oct-2, and Unc-86 proteins
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(hence the name POU) (Herr et a l, 1988). The structures of the Oct-1 POU-specific 
domain show it to comprise four a-helices arranged in a manner surprisingly similar to 
the HTH-containing DNA binding domains of the bacteriophage X and 434 repressors 
(Assa-Munt et a l, 1993; Dekker et al, 1993). Recent additional structures of variant 
HTH motifs have been reported: the third tandem repeat of the proto-oncogene c-Myb, 
the HNF-3y /fork head DNA binding motif, the globular domain of histone H5, rat 
LFB1/HNF1 and the yeast heat shock transcription factor (HSF), and all show extended 
versions of the HTH motif with the inserted amino acids accommodated in the turn 
region (Ogata et al, 1992; Clark et al, 1993; Ramakrishnan et al, 1993; Ceska et al, 
1993; Harrison et al, 1994). The DNA binding domain of HSF includes a four-stranded 
antiparallel (3-sheet capping the HTH motif, while the DNA binding domains of HNF-3y 
and GH5 include loops flanking the HTH which make additional contacts with the 
minor groove (for a review of this 'winged-helix' motif see Brennan, 1993). The 
LFB1/HNF1 protein is unusual for this type of domain, because it binds to DNA as a 
dimer.
1E.3 Basic-leucine zipper (bZIP) and basic-helix-loop-helix (bHLH) DNA 
binding domains
The bZIP and bHLH DNA binding domains are found in proteins with important roles 
in differentiation and development, and have been grouped together here because they 
share many similar features (for reviews, see Baxevanis and Vinson, 1993; Ellenberger,
1994). Transcription factors within each family can associate as homodimers or 
heterodimers with distinct DNA binding and transcriptional properties. The bZIP and 
bHLH domains both comprise a C-terminal amphipathic a-helix which mediates 
dimerisation (the HLH or ZIP region, see below), and a basic N-terminal DNA binding 
region. The basic regions of the bHLH and bZIP proteins are unstructured in solution 
but become a-helical upon insertion into the major grove for recognition of the DNA 
target sequence (see below) (Weiss et al, 1990; Anthony-Cahill et al, 1992). The 
leucine zipper and helix-loop-helix dimerisation segments contribute to DNA binding 
specificity by appropriately positioning the basic region helices and determining which 
subunits form stable dimers.
1E.3.1 The bZIP domain
The bZIP domain usually comprises 60-80 residues and is found in a wide variety of 
transcription factors (Hope and Struhl, 1987; Landschulz et al, 1988). The DNA 
co-crystal structures of the bZIP domain of yeast GCN4 (Ellenberger et a l, 1992; Konig 
and Richmond, 1993) show that the bZIP dimer is composed of two smoothly curving
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oc-helices, associated in a coiled coil at their C-terminal ends (the leucine zipper). The 
helices diverge at their N-terminal ends and extend through the major groove of DNA 
where the basic regions contact the DNA bases and phosphate backbone. Dimerisation 
is mediated by the leucine zipper: an apolar residue (usually leucine) is found at every 
4th position of each heptad repeat within the C-terminal 30-40 residues of the 
amphipathic helix, and the hydrophobic faces of a helix from each monomer pack 
together in a two-stranded parallel coiled coil with the leucines interdigitating (O'Shea et 
al., 1991; reviewed by Alber, 1992).
1E.3.2 The bHLH domain
Like the leucine zipper proteins, the activity of the bHLH proteins (Murre et al., 1989) 
is modulated by heterodimer formation. The bHLH motif bears resemblance to the bZIP 
motif: the structures of homodimer-DNA complexes for the oncoprotein Max and the 
transcription factor USF demonstrate that the HLH is a parallel four-helix bundle with 
an extended strand (the loop) connecting helices 1 and 2; a pair of protruding basic 
region helices contact the DNA in a similar manner to the basic region helices of the 
bZIP motif (Ferre-D'Amare et al., 1993; 1994). Dimerisation is mediated by coiled coil 
interactions between the amphipathic C-terminal helix of each HLH monomer. Some 
bHLH proteins, including Max, have an additional zipper segment C-terminal to the 
HLH that adds extra stability and specificity to the dimer interaction.
1E.4 Zinc-binding domains
Zinc-binding domains are found in proteins involved in very diverse aspects of 
eukaryotic gene regulation and contain zinc as a structural element; they are classified 
according to the mode of zinc coordination, secondary structure elements, and 
modularity (reviewed by Kaptein, 1992; Schmiedeskamp and Klevit, 1994).
1 E.4.1 Cys2ffis2  zinc fingers
The original 'zinc finger' is an approximately 30-residue module with one zinc ion 
coordinated by two cysteines and two histidines, TFIIIA being the classical example. 
(Miller et al., 1985). The modules are usually present in at least three copies and bind 
adjacent triplets of bases in the major groove of DNA. Numerous structural studies have 
shown that each module is a peptide loop containing a two strand P-hairpin and a single 
a-helix (ocPP motif); this fold is stabilised by the coordination of the zinc ion via the 
side-chains of two cysteine and histidine amino acids.
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1E.4.2 Steroid /  nuclear receptor DNA binding domains
Typified by the glucocorticoid and oestrogen receptors, these DNA binding domains 
contain about 70 residues and have two loop-helix modules, each with four cysteines 
coordinating a zinc ion. The two Cys4 modules coalesce to form a single globular 
domain with the two a-helices packed against each other at nearly right angles 
(reviewed by Freedman and Luisi, 1993). The a-helix of the N-terminal module 
contacts bases of the target site within the major groove of DNA, whereas the helix of 
the C-terminal module presents a dimerisation interface for coiled coil interactions. 
Proteins containing this type of domain bind to palindromic recognition elements as 
dimers (Mader et al., 1989).
1E.4.3 Others zinc-binding domains
Another class of zinc motif, containing two zinc ions coordinated by six cysteine 
residues, has been found only in yeasts. The X-ray structure of the GAL4 DNA binding 
domain-DNA complex revealed the globular nature of this a-helical domain, in which 
two of the cysteines are shared between the zincs (Marmorstein et al., 1992). GAL4 
binds to DNA as a dimer, with each monomer inserting its metal-binding domain into 
the major groove on opposite faces of the DNA; dimerisation is mediated by formation 
of a coiled coil between a-helical regions of each domain. Other recent structures 
demonstrate the striking diversity of zinc-containing DNA binding domains: the TFIIS 
elongation factor contains a novel Cys4 domain comprising a compact three-stranded 
antiparallel p-sheet, and can bind polynucleic acids in a sequence independent manner 
(Qian et al., 1993). The GAGA-1-DNA complex illustrated a novel Cys4 a /p  motif 
which makes both major and minor groove base contacts (Omichinski et al., 1993).
IE.5 DNA binding domains with P-sheet recognition elements or scaffolds
1E.5.1 Prokaryotic ribbon-helix-helix proteins
The met repressor of E. coli and the arc repressor of phage P22 are members of a family 
of proteins that use a p-ribbon recognition motif to probe the major groove of DNA 
(Breg etal., 1990; Somers and Phillips, 1992; reviewed by Raumann et al., 1994). 
Dimers of these proteins have a core with four a-helices, and a single antiparallel 
P-ribbon (formed from a segment of each monomer) protrudes from the core and lies in 
the major groove of DNA. Another similar family of proteins with P-sheet recognition 
motifs includes the prokaryotic HU DNA-packaging protein and the E. coli integration 
host factor (IHF). The HU dimer also has a core of four a-helices, but it has a separate 
P-ribbon projecting from each monomer (Tanaka et al., 1984); at least for the IHF
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protein, the two p-ribbons are believed to contact the minor groove (Yang and Nash, 
1989).
1E.5.2 Novel eukaryotic DNA binding motifs
The TATA binding protein (TBP) plays a fundamental role in all eukaryotic 
transcription (see Section ID. 1.4) and its structure demonstrates a novel mode of DNA 
recognition (reviewed by Klug, 1993; Struhl, 1994). The conserved C-terminal domain 
of TBP folds into a symmetrical ten-stranded, antiparallel p-sheet, which provides a 
large concave surface (referred to as the 'molecular saddle') to follow the minor groove 
of DNA. Strikingly, the DNA is kinked in two places under the 'saddle' of TBP to give a 
severe DNA bend (about 100° overall) towards the major groove; this results in an 
opening and shallowing of the minor groove which complements the concave surface of 
TBP (Kim etal., 1993a; b).
The X-ray structure of the dimeric DNA binding domain of the papilloma virus E2 
transactivator has revealed an unusual protein scaffold comprising a barrel-like 
structure formed by eight antiparallel P-strands (the p-barrel) (Hedge et al., 1992). A 
long a-helix connects p-strands 1 and 2 of each half-barrel and serves as the DNA 
recognition helix; the DNA bends smoothly around the P-barrel allowing the a-helix of 
each monomer to penetrate the major groove and interact with the bases of its target site.
The HMG box occurs in a variety of chromosomal proteins and transcription factors, 
several of which are known to interact with the minor groove of DNA. The three 
a-helices of the DNA binding domain of HMG-1 adopt a novel 'arrow-head' structure 
(Weir etal., 1993).
In summary, several common themes have emerged from the structures of DNA binding 
domains and the strategies used for DNA recognition, yet there is also significant 
diversity within each family of DNA binding domains. No doubt more novel DNA 
binding domain structures will be determined in the future which may explain the mode 
of binding of domains, such as the VZV 140k DNA binding domain, that do not 
obviously conform to the established families.
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IF The aims of the research presented in this Thesis
The initial aims of this study were to investigate the DNA binding properties of a 
bacterially expressed fragment of the VZV 140k ORF encompassing its DNA binding 
domain and to define its limits. Purification of the domain would allow the analysis of its 
biochemical properties. By analogy to the situation with the HSV-1 Vmwl75 DNA 
binding domain, it seemed likely that the VZV 140k domain would be dimeric. 
Therefore, truncation and insertion mutant DNA binding domains (expressed in E. coli or 
in vitro) could be constructed and assayed by a wide range of techniques with the aim of 
identifying sequences mediating dimerisation. Combined with DNA binding analyses of 
the mutant domains, these experiments would aim to define the sequences that were 
responsible for DNA binding and dimerisation interactions.
The subsequent intention was to compare the characteristics of the VZV 140k DNA 
binding domain with those of its HSV-1 Vmwl75 counterpart, in order to investigate the 
basis for the differences in the regulatory properties of the 140k and Vmwl75 proteins. 
Construction of a hybrid protein with the VZV 140k DNA binding domain in the 
background of the HSV-1 Vmwl75 protein, and characterisation of its regulatory 
properties in transient transfection assays, would enable the functional relevance of 
possible differences between the DNA binding properties of the 140k and Vmwl75 
DNA binding domains to be assessed. Recombining the hybrid ORF back into the 
HSV-1 genome would indicate whether the DNA binding domains of 140k and HSV-1 
Vmwl75 were functionally interchangeable in the viral context.
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2A Materials 
2A.1 Enzymes
Restriction enzymes, proteinase K and calf intestinal phosphatase were supplied by 
Boehringer Mannheim. RNase A, bovine pancreas DNase I, lysozyme and thrombin were 
obtained from Sigma. RQ1 placental RNasin ribonuclease inhibitor was supplied by 
Promega. T4 polynucleotide kinase and T4 DNA polymerase were from New England 
Biolabs, T4 DNA ligase was supplied by Gibco. Taq DNA polymerase was obtained 
from Cetus. Klenow fragment DNA polymerase was purified in house by Miss M. 
Watson from recombinant E. coli cells.
2A.2 Radiochemicals
With the exception of 14C chloramphenicol (ImM) which was supplied by Dupont, 
radiochemicals were supplied by Amersham at the following specific activities:
oc32P-dNTPs 3,000Ci/mmol (lOpCi/pl)
14C chloramphenicol 50.13mCi/mmol (O.lpCi/fil)
35S L-methionine approximately 800Ci/mmol (15pCi/pl)
3H Leucine 140Ci/mmol (5pCi/|il)
14C-labelled high molecular weight protein markers
10-50|iCi/mg protein
2A.3 Synthetic oligonucleotides
The M13 universal sequencing primer was obtained from New England Biolabs. All other 
synthetic oligonucleotides used in this study were either produced in house using a
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Biosearch model 8600 DNA synthesiser by Dr J. McLauchlan, or on a Cruachem PS250 
automated synthesiser by Mr F. R. VanDeursen and Miss S. Fitzpatrick.
2A.4 Plasmids and bacteriophage
The well characterised universal cloning vectors pUC9, pUC19, pACYC184 and 
M Bmp 18 were used in this study, but are not described here. The other plasmids utilised 
are described briefly below, and were kindly provided by the acknowledged authors 
(coordinates given are relative to the transcription start site (+1) of the gene in question):
p585.4 (C. M. Preston, unpublished) is a derivative of the pET-8c T7 expression vector 
(Studier et al., 1990) with minor alterations including removal of the original HindUl site 
and creation of a novel unique Hindlll site between the Ncol and BamHl sites. 
pUCIE3 (R. D. Everett, unpublished) includes HSV-1 IE3 gene sequences spanning the 
IE3 consensus binding site, on an Aval-BamHl fragment (-18 to +27), cloned into vector 
pUC19.
pBEND2 (Zweib et al., 1989) includes unique Xbal and Sail restriction sites flanked by 
direct 236bp repeats bearing 17 duplicated restriction sites, in a pBR322 background. 
pGEX2TN3 (R. D. Everett, unpublished) was derived from the commercial vector 
pGEX2T (Pharmacia) by inserting a DNA fragment (carrying Ncol, EcoRl and HindiII 
sites) between the BamHl and EcoRI sites downstream of the GST coding sequence (this 
cloning removed the original BamHl and EcoRl sites).
pT7I9X (Pizer et al., 1991) includes sequences encoding HSV-1 Vmwl75 amino acid 
residues 252 to 523, on an EcoRl-BamHl fragment (+752 to +1566) of plasmid pI9 
(Paterson and Everett, 1988a), cloned into plasmid p585.4.
pT7I10X (Pizer et al., 1991) includes sequences encoding HSV-1 Vmwl75 amino acid 
residues 275 to 523, on an EcoRl-BamHl fragment (+823 to +1566) of plasmid pi 10 
(Paterson and Everett, 1988a), cloned into vector p585.4.
pJIlOX (R. D. Everett, unpublished) includes the identical HSV-1 Vmwl75 sequences 
carried by plasmid pT7I10X, cloned into vector p585T7a (Section 3A.2). 
pT7I10il2X-i20X series of plasmids (R. D. Everett, unpublished) derivatives of 
PT7I10X, with single 12bp insertions in the IE3 gene sequences that have been described 
previously (Paterson and Everett, 1988a).
pT7110 (Everett et al., 1991b) contains the entire HSV-1 IE1 cDNA cloned on an Ncol 
Hpal fragment cloned into the Ncol-HindlH sites of plasmid p585.4.
P140 (McKee et al., 1990) contains VZV gene 71 (gene 62) coding regions and its 
promoter-leader sequences (-1146 to the genomic terminus), on a Clal-Pstl fragment of 
plasmid pVZVSstf (Davison and Scott, 1983) cloned into vector pUC9.
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pC33 (or pV17) (Disney, 1990) a version of pl40 containing a 12bp linker insertion at 
nucleotide +1253, disrupting amino acid Ser 418.
pC34 (or pV18) (Disney et al., 1990) a version of pl40 containing a 12bp linker 
insertion at nucleotide +1418, disrupting amino acid Ser 472.
pVZVteK (R. D. Everett, unpublished), carries a version of VZV gene 62 with 
alterations to the coding sequence which result in the substitution Ala 628 Val, equivalent 
to the HSV-1 Vmwl75 tsK mutation (Ala 475 Val).
pl40BT (McKee et a i, 1990), a derivative of pl40, with a unique BglII site inserted at 
position +57.
pl40SV (Disney et al., 1990) carries VZV gene 62 sequences from nucleotide +57, 
under the control of the SV40 early promoter-enhancer regions.
pl75 (Everett, 1987b) contains HSV-1 IE3 gene sequences from +27 (on a BamHl-Sstl
fragment) under the control of the SV40 early promoter-enhancer regions.
pI8 (Paterson and Everett, 1988a) a derivative of plasmid p i75 created by insertion of a
12bp EcoRl linker at nucleotide position 684 of the HSV-1 IE3 gene.
pI9 (Paterson and Everett, 1988a) a derivative of plasmid pl75 created by insertion of a
12bp EcoRl linker at nucleotide position 752 of the HSV-1 IE3 gene.
pLI10/ll (Allen and Everett, 1994) a derivative of plasmid pi 10 (Paterson and Everett,
1988a) created by removal of the second BamHl site in region 3 of the HSV-1 IE3 coding
sequence, by oligonucleotide-directed mutagenesis.
p i l l  (Everett, 1987b) contains the entire HSV-1 IE1 coding region and promoter 
sequences cloned on a Sstl-Hpal fragment into vector pUC9.
pMCl (Campbell et al., 1984) includes the complete HSV-1 gene UL48, encoding 
Vmw65, cloned into vector pUC9.
pSVEB (Paterson and Everett, 1988a) contains the SV40 early promoter-enhancer 
regions (not linked to any coding sequences) cloned into vector pBR322. 
pgDCAT (Everett, 1986) contains the promoter of the HSV-1 gD gene (-392 to +11) on 
a Sstl-Hindlll fragment fused to the CAT gene in vector pBWL2 (Gaffney et al., 1985). 
pIE3CAT (Stow et al., 1986) includes the HSV-1 IE3 promoter (-331 to +27), on a 
Hindlll-BamHl fragment fused to the CAT gene in a vector derived from plasmid pBLW2 
(Gaffney et al., 1985).
P140CAT (McKee et al., 1990) includes the VZV gene 62 promoter-leader sequences 
from -1146 to +57 on a Clal-BglII fragment of plasmid pl40BT fused to the CAT gene in 
vector pCAT, derived from plasmid pBLW2 (Gaffney et al., 1985). 
pSVECAT (R. D. Everett, unpublished) includes the SV40 early promoter-enhancer 
sequences linked to the CAT gene in a vector derived from plasmid pBLW2 (Gaffney et 
al, 1985).
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ptkCAT (Everett, 1986) contains the promoter sequences of the HSV-1 tk gene on a 
BamHl-BgBl fragment (approximately -650 to +53) linked to the CAT gene in a vector 
derived from plasmid pBLW2 (Gaffney et al, 1985).
p IE lC A T  (Everett and Orr, 1991) contains the HSV-1 IE1 gene promoter on a 
Sstl-Ncol fragment linked to the CAT gene in the vector pCAT, derived from plasmid 
pBLW2 (Gaffney et al., 1985).
M13IE3EB series of plasmids (Everett et a l, 1991a), each includes a single 
nucleotide substitution in the IE3 consensus binding site on the EcoRl-BamHl cap site 
fragment (-108 to +27) of the HSV-1 IE3 gene, cloned into M Bmp 18.
2A.5 Bacterial strains
E. coli strain DH5a (V'/endAl hsdR17 O vm ^) supE44 thi-1 recAl gyrA (Nalr) relAl 
A(lacZYA-argF)U169 ((j)80dlacA(lacZ)M 15) was the usual host for construction, 
maintenance and propagation of recombinant plasmids. E. coli strain JM101 (F’ traD36 
lacI(tA(lacZ)M15proA+B+/supE thi A (lac-proAB) (Messing, 1979) or strain TGI (K12 
A (lac-pro) supE thi hsdD5/F'traD36 proA+B+ lactt lac ZAM15) were used for growth 
and maintenance of M13 bacteriophage. E. coli strain BL21 (DE3) pLysS (F~ ompT r B 
n rB) (Studier et al., 1990) was used for the expression experiments; bacteriophage DE3 
encodes an inducible T7 RNA polymerase and plasmid pLysS encodes T7 lysozyme and 
carries a chloramphenicol resistance marker. E. coli strain BL21 (DE3), lacking the 
pACYC184 based pLysS plasmid, was used for the in vivo co-translation experiments 
described in Section 3D.3.1.
2A.6 Bacterial culture media
The following bacterial culture media were used:
L-broth: lOg NaCl, lOg Bactopeptone, 5g yeast extract per litre.
LB agar: L-Broth plus 1.5% (w/v) agar.
2YT broth: 5g NaCl, 16g Bactopeptone, lOg yeast extract per litre.
H top agar: 8g NaCl, lOg Bactotryptone, 8g agar per litre.
SOC broth: lOmM NaCl, 2.5mM KC1,2% Bactotryptone, 0.5% yeast extract.
Bacterial culture media for growth and maintenance of pUC or pBR322 based plasmids 
was supplemented with ampicillin at lOOjitg/ml, media for growing pACYC184 based 
plasmids was supplemented with chloramphenicol at 25pg/ml. Bacterial media for E. coli 
strain BL21 (DE3) pLysS was additionally supplemented with chloramphenicol at 
25|ig/ml to maintain the pLysS plasmid.
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2A.7 Cells and tissue culture media
WS HeLa cells (obtained from Dr W. Schaffner, Zurich) were grown in Dulbecco's 
Modified Eagle's Medium (DMEM) (Gibco) supplemented with lOOunits/ml penicillin, 
100|ag/ml streptomycin, 2.5% foetal calf serum (Gibco) and 2.5% newborn calf serum 
(Gibco).
BHK-21 C-13 cells, a fibroblastic cell line derived from baby hamster kidneys 
(MacPherson and Stoker, 1962), were grown in Glasgow Modified Eagle's Medium 
(GMEM) (Gibco) with 10% newborn calf serum supplemented with 100 unit/ml 
penicillin, 100|Ltg/ml streptomycin and 10% tryptose phosphate broth.
Vero cells (obtained from the ATCC via Flow Laboratories) were grown in GMEM 
(Gibco) with 10% foetal calf serum supplemented with lOOunits/ml penicillin, 100(ig/ml 
streptomycin and 10% tryptose phosphate broth.
2A.8 Viruses
Virus D30EBA was deriv -  ed from the HSV-1 Glasgow strain 17 syn+, which forms 
non-syncytial plaques on BHK cells (Brown et al., 1973). D30EBA (Paterson and 
Everett, 1990) has a large deletion created within both copies of the IE3 gene which 
removes codons 83 to 1236.
2A.9 Antisera
The following monoclonal antibodies (MAbs) were obtained from Dr A. Cross of this 
Institute:
MAb 10,084 (Everett et al., 1993c) was raised against the purified bacterially expressed 
HSV-1 Vmwl75 DNA binding domain peptide, I9X, and recognises an epitope between 
residues 310 and 329 of HSV-1 Vmwl75. MAb 10,084 cross-reacts with an epitope 
spanning residues 462 and 472 of VZV 140k.
MAbs 11,060 and 10,503 (Everett et a l, 1993b) were raised against the purified 
Baculovirus expressed HSV-1 VmwllO polypeptide. MAb 11,060 recognises an epitope 
within the 105 N-terminal residues of VmwllO. MAb 10,503 recognises an epitope 
within the 140 C-terminal residues of Vmwl 10.
Normal mouse serum was produced from non-immunised mice.
Rabbit polyclonal antisera 108 and 109 were raised against the purified bacterially 
expressed VZV 140k DNA binding domain peptide, VT2 (Section 3C.5).
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Protein A horse radish peroxidase (HRP) conjugate, anti-mouse IgG whole molecule 
peroxidase conjugate, sheep anti-mouse (SaM) and fluorescein isothiocyanate (FITC) 
conjugated sheep anti-rabbit immunoglobulin were purchased from Sigma.
2A.10 Solutions
Blue juice (10 X agarose gel loading buffer): 1 X TBE, 1% SDS, 50% Glycerol,
1 mg/ml bromophenol blue.
Coomassie stain:
20 X dNTPs:
Fix (protein gel fixative): 
Formamide dyes mix:
Giemsa stain:
Glycine SDS PAGE buffers:
50:50:7, Methanol:dH20:acetic acid, 0.2% R250 
Coomassie brilliant blue.
ImM dATP, dCTP, dGTP, dTTP.
4:1:27, Acetic acid:ethanol:dH20.
lOmM EDTA, 1 mg/ml xylene cyanol FF, 1 mg/ml 
bromophenol blue in formamide.
1.5% Giemsa in glycerol, heated to 50°C for 2hr and 
diluted with an equal volume of methanol.
3 X Boiling mix: 1ml SGB, 1ml 20% SDS, 500^1 BME, 1ml glycerol,
lmg/ml bromophenol blue.
RGB (resolving gel buffer): 181.5g Tris, 4g SDS, 11 dFhO, pH 8.9 (HC1).




5 X Kinase buffer: 
5 X Ligase buffer:
3.16g Tris, 2.0g glycine, 0.5g SDS, 11 dH20.
280mM NaCl, 50mM HEPES, 1.5mM Na2HP04, pH to 
7.12 with NaOH.
0.05M Tris.HCl (pH 7.5), 0.3M NaCh, ImM EDTA, 
0.2% NP40, pH to 7.5.
350mM Tris.HCl (pH 7.5), 50mM MgCl2, 25mM DTT.
250mM Tris.HCl (pH 7.6), 50mM MgCl2, 5mM DTT, 
5mM ATP, 25% (w/v) PEG 8000.
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M buffer (1 X):
5 X non-SDS loading buffer:
PBSA:
PBSc:







Towbin (blotting buffer): 
Trypsin:
Tricine SDS PAGE buffers:
3 X Boiling mix:
Gel buffer:
Lower tank buffer: 
Upper tank buffer:
lOmM Tris.HCl, lOmM MgCl2, 50mM NaCl, ImM 
DTE, pH 7.5.
lOmM Tris.HCl (pH8.0), ImM EDTA, lOmM BME, 
0.1% CHAPS, 50% glycerol and 0.25mg/ml 
bromophenol blue.
170mM NaCl, 3.4mM KC1, lOmM HP04, 1.8mM 
KH2P04, pH 7.2.
PBSA plus CaCl22H20  and MgCl26H20  at lg/1.
lOOmM Tris-HCl, lOOmM MgCl2, pH 8.5.
8% Sucrose, 5% triton X-100, 50mM EDTA (pH 8.0), 
50mM Tris (pH 8.0).
90mM Tris.HCl (pH 8.0), 90mM boric acid, ImM 
EDTA.
25mM Tris.HCl (pH 7.5), 137mM NaCl, 5mM KC1, 
0.7mM CaCl2, 0.5mM MgCl2, 0.6mM Na2HP04, pH to 
7.4 with HC1.
lOmM Tris.HCl, ImM EDTA, pH 8.0.
150mM NaCl, 40mM Tris.HCl, ImM EDTA, pH 7.5.
ImM Tris.HCl, 0.5mM EDTA, pH 7.5.
25mM Tris.HCl, 192mM glycine, 20% (v/v) methanol, 
pH 8.3.
0.25% (w/v) trypsin dissolved in Tris.saline.
150mM Tris, 12% SDS, 36% Glycerol, 6% BME, 
lmg/ml bromophenol blue, pH 6.8.
3.0M Tris, 0.3% SDS, pH 8.45.
200mM Tris, pH 8.9.
0.1M Tris, 0.1M tricine, 0.1% SDS.
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TTBS: TBS + 0.05% TWEEN-20.
Versene: 0.6mM EDTA in PBSA, 0.002% (w/v) phenol red.
2A. 11 Chemicals and reagents
Unless specifically stated below, all chemicals and reagents were obtained from BDH 
Chemicals UK or Sigma Chemical Co. and were at least of analytical grade. The sources 
of the reagents and materials given in the Methods Sections are not repeated here.
Ammonium hydroxide (Fisons).
Ammonium persulphate, Bio-Rad protein assay reagent, Coomassie brilliant blue, gelatin, 
TEMED and tricine (Bio-Rad).
Ampicillin (Beecham Research).
Boric acid, butan-l-ol, butan-2-ol, chloroform, ethanol, glacial acetic acid, glycerol, 
hydrochloric acid, isopropanol and methanol (Prolabo).
Caesium chloride (Melford Laboratories Ltd.).
Diethylether (Rathbum).
Ecoscint A (National Diagnostics).
En3hance (Dupont).
Formamide, formaldehyde and piperidine (Fluka).
Formic acid (May and Baker Ltd.).
Glutaraldehyde (Agar Scientific Ltd.).
polydl.polydC and 7-deaza-dGTP, dNTPs and ddNTPs (Pharmacia).
Protease inhibitors; leupeptin, aprotinin and bestatin (Boeringer Mannheim).
2B DNA manipulation and cloning procedures 
2B.1 Large scale plasmid DNA preparation
Single E. coli colonies, from agar plates selecting for a plasmid-borne resistance marker, 
were inoculated into 10ml of 2YT broth (plus appropriate antibiotics, see Section 2A.6), 
and shaken overnight at 37°C. The overnight culture was inoculated into 350ml of L-broth 
(plus antibiotics) and shaken for 20hr at 37 °C.
Plasmid DNA or RF M l3 DNA was prepared by the 'maxi-boiling' technique as 
described by Holmes and Quigley (1981), and supercoiled plasmid DNA was purified on
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caesium chloride / ethidium bromide gradients. Bacterial cultures were centrifuged at 
5 krpm for 6 min at 4°C (Sorvall GS3 rotor) and the pellet resuspended in 20ml of STET 
buffer. 2ml of a fresh lOmg/ml solution of lysozyme in STET was added and the 
suspension was brought to the boil and placed in a boiling water bath for 45sec. The 
lysate was cleared by centrifugation at 18krpm for 45min at 4°C (Sorvall SS34 rotor). 
DNA was precipitated from the supernatant with an equal volume of isopropanol and 
pelleted by centrifugation at 3krmp for lOmin at RT (Beckman CPR centrifuge). After 
draining, the pellets were resuspended in 5.5ml TE and the total volume determined 
(Xml). X+0.7g of CsCl was added to the DNA solution to give a final density of around 
1.6g/ml, and 200pl of lOmg/ml EtBr was added to give a final concentration of around 
0.25mg/ml. After several hours at 4°C, the solution was cleared by centrifugation at 
3krpm for lOmin at 4°C. The supernatant was transferred to a sealable centrifuge tube 
(Dupont 03945 tubes) and spun at 40krpm (Beckman TV865 vertical rotor) for <16hr at 
14°C. After removal of the upper chromosomal DNA band from the gradient, the lower 
supercoiled plasmid band was collected (using syringes fitted with wide-bore needles 
through the side of the tube).
EtBr was removed from the plasmid DNA solution by at least two extractions in 
butan-l-ol (TE saturated) followed by dialysis against TE for 3hr at RT. Next, the 
solution was treated with 100|Lig/ml RNase A for lhr at 65°C, followed by a lhr 
incubation with 100pg/ml proteinase K and 0.1% SDS at 37°C. The DNA was then 
purified by extractions with phenol (saturated in TE) and chloroform, then by ethanol 
precipitation. The DNA pellet was resuspended in 400|ll1 0.3M NaAc and ethanol 
precipitated again. The lyophilised pellet was washed with 80% ethanol, resuspended in 
TE and stored at 4°C. DNA concentration was determined by measuring the absorbance at 
260nm, assuming 1A2 6o= 50pg/ml.
A more rapid procedure for large scale preparation of plasmid DNA, by alkali lysis of 
bacteria and polyethylene glycol precipitation of DNA, was occasionally used following 
the method of Ausubel et al. (1993a).
2B.2 Miniprep plasmid DNA preparation
Plasmid DNA or RF M13 DNA was prepared on a small scale as follows: single colonies 
of transformed bacteria were picked and inoculated into 3ml aliquots of L-broth containing 
antibiotics as appropriate (Section 2A.6), cultures were grown overnight at 37°C with 
shaking. The bacterial cells from 1.5ml of culture were pelleted for 30sec (benchtop 
microcentrifuge) and resuspended in 200pl STET. To this was added 5pl of a fresh 
10mg/ml solution of lysozyme in STET and the tube immediately placed in a boiling water
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bath for 45sec. The suspension was centrifuged for lOmin and the pellet removed. The 
supernatant was transferred to a fresh tube and 0.9vol isopropanol added to precipitate the 
DNA. After centrifugation for lOmin, the plasmid DNA pellet was washed with 80% 
ethanol, lyophilised, resuspended in 20|xl TE and stored at -20°C. Prior to sequencing 
(Section 2B.12), miniprep DNA was treated with RNase A to 20pg/ml for 20min at 37°C, 
followed by phenol, chloroform extractions and ethanol precipitation.
2B.3 Restriction enzyme digestion of DNA
Digests with appropriate restriction enzymes were generally carried out in 20fil volumes 
containing 1 unit enzyme per 0.5pg DNA per lhr at the appropriate temperature, using the 
commercial buffers specified and supplied by the manufacturer. In general, the Boeringer 
Mannheim A, B, L, M, H buffer system was used. Usually, 0.5|ig plasmid DNA was 
digested for diagnostic analysis on agarose gels, whereas 2-1 Opg plasmid DNA was 
digested for preparative isolations of DNA fragments. Restriction digest analysis of 
miniprep DNA preparations used 5pl of DNA, digested in a 20pl reaction volume 
including 50fig/ml RNase A.
2B.4 Electrophoretic separation and purification of DNA fragments 
2B.4.1 Non-denaturing agarose gels
DNA fragments (over 200bp) produced by restriction enzyme digests and PCR reactions 
were resolved by non-denaturing agarose gel electrophoresis. Samples in 0.1 vol Blue 
juice were loaded onto horizontal slab gels of 0.5-1.5% (w/v) agarose in 1 X TBE, and 
electrophoresed in 1 X TBE at up to 12V/cm. Appropriate DNA fragment size markers 
(i.e. Hpall digested pBR322, Hindlll digested phage ADNA or HaeIII digested phage 
0X174 DNA) were also ran on the gel. After the dye front had migrated the required 
distance, the gel was stained in lpg/ml EtBr for lOmin, rinsed thoroughly in H2 O and 
photographed with short-wave uv transillumination (long-wave for preparative gels) using 
a Polaroid instant camera or photographed onto heat-sensitive paper using The Imager 
(Appligene).
2B.4.2 DNA purification from  agarose gels by silica matrix adsorbtion 
( 'gene cleaning')
A commercial kit, GENECLEANII (BIO 101 Inc., La Jolla, CA) was used for recovery 
of DNA from agarose blocks which had been excised from agarose gels during 
visualisation under long-wave uv transillumination. The kit contains a silica matrix that 
binds DNA in the presence of high concentrations of sodium iodide (Vogelstein and
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Gillespie, 1979). Blocks containing the required DNA fragments were mixed with 4.5vol 
of saturated Nal and 0.5vol TBE modifier and incubated for 5min at 55°C until the 
agarose had disolved. Silica matrix was added (5p,l for up to 5p,g of DNA) and the 
mixture incubated for 5min at RT. Following a 5sec centrifugation, the pellet was washed 
3 times using 'NEW' wash (a Tris-buffered mixture of NaCl, ethanol and water). The 
DNA was eluted from the silica matrix by resuspending the pellet in 20pd TE and 
incubating for 2min at 55°C. After a 30sec centrifugation, the 'genecleaned' DNA solution 
was collected and stored at -20°C. The GENECLEANII procedure was also applied to 
situations where electrophoresis was not required, for example, to purify DNA away from 
enzymes, nucleotides or unwanted buffer components. In these later cases, 3vol of Nal 
was used and the TBE modifier omitted.
2B.4.3 Non-denaturing polyacrylamide gels
DNA fragments (40-400bp) were resolved on 5-8% polyacrylamide (a+b:b; 20:1, where 
a = acrylamide and b = NN'-methylenebisacrylamide) vertical gels run in 1 X TBE. The 
gels (1.5mm thick) contained 1 X TBE and were polymerised by addition of 0.00 lvol 
TEMED and 0.0lvol 10% APS. Samples in 0.2vol 5 X non-SDS loading buffer were 
loaded and electrophoresed at up to 16V/cm. The position of 3 2 P-radiolabelled DNA 
fragment bands were identified by brief autoradiography (for approximately 5min), 
otherwise EtBr staining was used (Section 2B.4.1).
2B.4.4 Denaturing polyacrylamide gels
Denaturing polyacrylamide (a+b:b; 20:1) vertical gels were used to resolve the products of 
DNA sequencing reactions (Section 2B.12), DNase I footprinting reactions (Section 
2D.4) and also to purify oligonucleotides (Section 2B.7). The gels contained 1 X TBE, 
8 M urea, and were polymerised by addition of O.OOlvol TEMED and O.Olvol 10% APS. 
The 8 % or 12% gels used for sequencing and DNase I footprinting analyses were 
0.35mm thick X 35cm long; samples in formamide dyes mix were denatured by boiling 
for 2min prior to loading and electrophoresis in 1 X TBE at 40W for 2-5hr. The 16% gels 
used for purifying synthetic oligonucleotides were 1.5mm thick, 25cm long and were ran 
in 1 X TBE at 250V for 5hr.
2B.4.5 DNA purification from polyacrylamide gels by elution
DNA fragments that had been resolved on non-denaturing polyacrylamide gels and also 
oligonucleotides ran on denaturing polyacrylamide gels were purified by passive elution 
from gel slices. Gel slices containing the relevant DNA fragments (excised during 
visualisation by long-wave uv transillumination or after detection by autoradiography) 
were fragmented, and the DNA eluted into 500ftl TE by shaking overnight at 37°C. The 
suspension was filtered through siliconised glass wool and the DNA was ethanol 
precipitated from the filtrate, lyophilised, resuspended in TE and stored at -20°C.
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2B.5 End repair and DNA ligation
Before ligating DNA fragments together, it was occasionally necessary to enzymatically 
modify the ends of the fragments to allow the ligation reaction to proceed. After any of the 
end repair procedures described below, enzymes were heat inactivated by incubation for 
lOmin at 65°C and the DNA isolated by 'genecleaning' (Section 2B.4.2), before further 
restriction enzyme digests and prior to setting up ligation reactions.
2B.5.1 Filling-in o f 5* overhangs
To enable blunt end ligation, 5’ overhangs were filled in to produce DNA fragments with 
flush ends. After heat inactivation of the restriction enzyme, the buffer conditions were 
adjusted to resemble those of M buffer (by dilution or salt addition) and this DNA solution 
was incubated with lp.1 20 X dNTPs and 2u Klenow fragment for 30min at 37°C. To 
obtain DNA fragments with a single blunt end, the end-filling reaction was included prior 
to digestion with the second restriction enzyme.
2B.5.2 Removal o f 3 ' overhangs
T4 DNA polymerase is more efficient than the Klenow fragment at digesting back the 3’ 
overhangs formed by some restriction enzymes, to yield flush fragment ends for blunt end 
ligations. After heat inactivation of the restriction enzyme, 8 u T4 polymerase was added to 
the DNA solution and incubated for 30min at 37°C.
2B.5.3 Phosphate removal from  5' ends
The 5’ phosphate was removed from DNA fragments in order to prevent re-ligation of 
vector fragments with complementary sticky ends that were produced by digestion with a 
single restriction enzyme. After heat inactivation of the restriction enzyme, the digested 
vector DNA was incubated with lu calf intestinal alkaline phosphatase for 30min at 37°C 
in a buffer giving final concentrations of 1 mol/1 diethanolamine, 10mmol/l 4-nitrophenyl 
phosphate, 0.5mmol/l MgCl2, pH 9.8.
2B.5.4 Phosphate addition to 5 ' ends
It was necessary to add phosphate to the 5’ ends of synthetic oligonucleotides or PCR 
products, to facilitate their ligation into plasmid vectors. Kinasing reactions included lOu 
T4 polynucleotide kinase, 2pl lOmM ATP and 5 X Kinase buffer, and were incubated for 
30min at 37°C.
2B.5.5 Ligation reactions
DNA fragments and cut vector DNA (in a molar ratio of 10:1), which had been previously 
digested with the appropriate restriction enzyme(s), end-repaired if necessary, isolated and 
purified from agarose gels (Sections 2B.4.1 and 2B.4.2), were ligated together in
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10-20pl reactions containing 2u T4 DNA ligase and 5 X ligase buffer for 4-16hr at RT. 
After the incubation period, the ligase enzyme was heat inactivated at 65°C for lOmin, 
followed by purification of the DNA by phenol and chloroform extractions or 
'genecleaning' (Section 2B.4.2), prior to transformation of half the ligation mix into 
competent E. coli cells as described below.
2B.6 Preparation and transformation of competent bacteria for plasmid 
growth and maintenance
A 1ml overnight culture of E. coli strain DH5a, inoculated from a single fresh colony, 
was diluted into 100ml of L-broth and shaken for about 3hr at 37°C until the culture 
OD6 3 0  reached about 0.3. The culture was cooled on ice for 20min prior to harvesting the 
bacteria by centrifugation at 5krpm for lOmin at 4°C. The pellet was resuspended in 25ml 
cold 0.1M MgCl2and immediately re-pelleted at 5krpm for lOmin at 4°C. Resuspension 
in 5ml cold 0.1M CaCl2 and incubation on ice for 45min, was followed by centrifugation 
at 5krpm for lOmin at 4°C. The cells were resuspended in 5ml cold 0.1M MOPS, 50mM 
CaCl2 , 20% glycerol. After 20min on ice, cells were aliquoted into 100-500|il amounts, 
flash frozen, and stored at -70°C.
About lOng plasmid DNA, or half a ligation reaction, was incubated with lOOjil of 
competent bacterial cells for 30min on ice, followed by a 45sec 42°C heat shock. The 
transformation reaction was incubated on ice for a further 2min before addition of 0.5ml 
SOC broth supplemented with MgCl2, MgS(> 4  and glucose, each to 20mM. The 
transformation mix was shaken for lhr at 37°C, before plating cells onto LB agar 
containing the appropriate antibiotics (Section 2A.6) for selection of transformants. Plates 
were incubated at 37 °C overnight to allow single colonies to form.
2B.7 Purification of synthetic oligonucleotides
Synthetic oligonucleotides were produced by the phosphoramidite method and supplied 
on 200pl synthesis columns. Oligonucleotides were eluted by pushing 1.5ml ammonium 
hydroxide through the column, 200pl at a time with 20min incubations at RT between 
each fresh addition. The ammonium hydroxide solution was collected from the bottom of 
the column. After the final incubation period, the ammonium solution was pushed back 
and forth through the column several times (using syringes fitted to both ends of the 
column). The oligonucleotide-ammonium solution was incubated for 5hr at 55°C to 
remove the base protecting groups, followed by lyophilisation. The DNA pellet was 
dissolved in 200pl TE, boiled for 2min in an equal vol of formamide, and electrophoresed 
on a 16% polyacrylamide gel containing 8 M urea (Section 2B.4.4). Oligonucleotide bands
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were visualised under uv light, as dark shadows against a fluorescing TLC plate. 
Oligonucleotides were eluted and precipitated from slices of the gel as described 
previously (Section 2B.4.5), resuspended in lOOpl TE and stored at -20°C. The 
concentration of the oligonucleotide solution was determined by spectrophotometry 
(OD26o1*0 = 50fig/ml).
2B.8 Polymerase chain reaction (PCR) amplification of DNA
Conditions used for the PCR amplification of sequences encoding the VZV 140k DNA 
binding domain were determined empirically and were as follows: PCR reactions were 
performed in 25pl reaction volumes containing lOng plasmid DNA template, 16pmoles of 
each primer (described in Fig. 3F.1), 50mM KC1, 20mM Tris.HCl (pH 8.4), 15mM 
MgCl2, 800pM dNTPs and 2u of Taq thermostable DNA polymerase. Reactions were 
overlaid with 50pl mineral oil and cycled for 25 rounds of PCR in a Perkin-Elmer DNA 
Thermal cycler 460. PCR cycling parameters were as follows: (a) template duplex melting 
at 94°C for 3min for the first cycle, subsequent cycles had a 30sec incubation at 94°C to 
melt the primer-template duplex; (b) primer annealing for 30sec at 60°C for 3 cycles, 58°C 
for 3 cycles, 56°C for 3 cycles and the remaining cycles at 55°C; (c) primer elongation at 
72°C for 1.5min. After 25 cycles, the remaining DNA ends were elongated by incubation 
at 72°C for 7min, before cooling to 0°C. PCR products were analysed by agarose gel 
electrophoresis (Section 2B.4.1), then purified by 'genecleaning' (Section 2B.4.2) prior 
to subsequent cloning steps (Section 3F.2).
2B.9 Preparation of single-stranded template M l3 DNA
Small scale preparations of single-stranded template M13 DNA were required for 
oligonucleotide-directed mutagenesis reactions (Section 2B.10), for sequencing of M13 
vectors (Section 2B.12), and for preparation of 'prime cut' probes (Section 2D. 1.2). A 
single colony of M13 host bacterium strain JM101 (strain TGI was used for all 
procedures related to the oligonucleotide-directed mutagenesis) was inoculated into 10ml 
2YT broth and shaken overnight at 37°C. 200pl of the overnight culture was diluted into 
100ml 2YT broth, this was then dispensed into universals in 3ml amounts. Single plaques 
harbouring bacteriophage M13 were picked from fresh transformation plates, inoculated 
into universals, and shaken for 3hr at 37°C. Approximately 1.5ml of each bacterial culture 
was centrifuged for 30sec at RT, rotated through 180° and re-spun. Next 800pl of the 
supernatant was removed to a fresh tube containing 200pl 20% PEG / 2.5M NaCl, mixed 
and incubated for 30min at RT. The bacteriophage precipitate was spun down for 5min 
and resuspended in lOOpl TE. The bacteriophage DNA was purified by phenol and
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chloroform extractions, then IOjlxI 4M NaAc was added to the solution prior to an ethanol 
precipitation. The pellet was washed with 80% ethanol, lyophilised, resuspended in 20pJ 
0.2 X TE, and stored at -20°C.
2B.10 Oligonucleotide-directed mutagenesis of M13 vectors
Specific amino acid substitutions were introduced into the VZV 140k sequence using the 
Oligonucleotide-Directed In Vitro Mutagenesis System Version 2 (Amersham), which is 
based on the protocol of Eckstein and co-workers (Sayers et a l, 1988). The target 
sequence for mutagenesis had previously been cloned into RF M13mpl8 and 
single-stranded template DNA prepared (Section 2B.9). To check that the mutagenic 
oligonucleotide anneals with the intended sequence of the template DNA, the 
oligonucleotide was used as a primer in a sequencing reaction before being used to direct 
mutagenesis. The manufacturer's mutagenesis protocol was followed and a control 
mutagenesis reaction was performed in parallel, using the mutant oligonucleotide and 
template supplied with the system. An outline of the stages in the oligonucleotide-directed 
mutagenesis system is given in Figure 2B. Briefly, the mutagenesis was as follows:
First of all, 4pmoles of phosphorylated oligonucleotide (Section 2B.5.4) was annealed to 
5pg of template M13 DNA, by placing in a 70°C water bath for 3min, followed by 
incubation for 30min at 37°C. To this was added 3u Klenow fragment, 3u T4 ligase and a 
nucleotide mix including an analogue of dCTP to allow primer extension and ligation of 
the mutant DNA strand, during an incubation period of 16hr at 15°C. After this time, 
single-stranded (non-mutant) DNA was removed using centrifugal filter units. The 
heteroduplex RF DNA molecules were ethanol precipitated from the filtrate and the 
non-mutant strand was nicked with the enzyme Neil (Section 2B.3); the nucleotide 
analogue protects Neil sites in the mutant DNA strand from cleavage. Selective 
degradation of the nicked non-mutant DNA strand was achieved by incubation with 50u 
Exonuclease III for 15min at 37°C, followed by heat inactivation of the enzymes. 
Incubation with 1.25u DNA polymerase I, nucleotides and 1.5u T4 ligase for 3hr at 15°C 
ensured synthesis of closed circular homoduplex mutant RF M13 DNA. Finally, lvol 4M 
ammonium acetate (pH 5.4) was added to facilitate ethanol precipitation, and the 
precipitated DNA pellet was washed with 80% ethanol, lyophilised and resuspended in 
100|il TE. 20pl of the mutagenesis reaction products were transformed into competent 
TGI bacterial cells, plated out and screened for mutants (Section 2B.11).
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Figure 2B Plan of the strategy used by the Amersham oligonucleotide-directed in vitro 
mutagenesis system. The arrow head indicates the position of a specific mutation in the synthetic 
oligonucleotide. The mutation is initially introduced into a single strand of the bacteriophage DNA, and 
then copied into the complementary DNA strand to produce a homoduplex mutant bacteriophage, as 
described in the text.
2B.11 Preparation and transformation of competent bacteria for 
bacteriophage growth and maintenance
A single colony of JM101 or TGI cells was inoculated into 10ml 2YT broth and shaken 
overnight at 37°C. Next, 1ml of the overnight culture was diluted into 100ml 2YT broth, 
and shaken for around 3hr until OD630 of 0.3 was reached. Competent JM101 cells were 
prepared using the procedure previously described in Section 2B.6. TGI cells were 
pelleted at 3krpm for 5min at 4°C, resuspended in 0.5vol pre-chilled 50mM CaCl2 and left 
on ice for 20min. Cells were pelleted again at 3krpm for 2min at 4°C, before resuspending 
in O.lvol cold 50mM CaCl2, and competent cells were stored on ice until required.
Four hours before transformation of competent cells with bacteriophage DNA, a 10ml 
culture of JM101 or TGI cells was set up in 2YT broth, using an overnight culture
101
Chapter 2: Materials and Methods
inoculum, and shaken at 37 C. Around lng of RF M13 DNA or 20 j l l 1 of mutagenesis 
reaction product (Section 2B.10) was added to 300|il of competent cells and incubated for 
40min on ice. The transformation reaction was heat-shocked at 42°C for 45sec, stored on 
ice for a further 5min, then plated out as follows: the transformation reaction was 
transferred to a pre-warmed bijoux (37°C), 200fil of log phase E. coli cells from the 4hr 
culture and 3ml H top agar (that had been melted and kept at 45°C) were added, mixed by 
rolling, and poured onto pre-warmed (37°C) agar plates. Once set, the plates were 
inverted and incubated overnight at 37 °C to allow formation of individual plaques on the 
E. coli lawn. For selection of insertions or mutations introduced into the lacz gene, 2% 
X-gal in dimethylformamide and lOOmM IPTG were added to the H top agar to allow 
blue / white (wild type / disrupted) colour selection of progeny plaques.
2B.12 Dideoxy sequencing of DNA
The dideoxynucleotide chain termination sequencing method (Sanger et al., 1977) was 
used to determine the DNA sequence of denatured plasmid DNA templates or 
single-stranded M13 DNA templates, in the regions spanning cloning junctions or 
encompassing oligonucleotide-directed mutations. Firstly, 2|ig of duplex plasmid DNA 
was denatured by mixing with 2|il of fresh 2M NaOH in a lOjil reaction volume followed 
by incubation for lOmin at RT. After this time, 3pl of 3M NaAc (pH 4.5) and 7(ll1 of 
dH20 were added, followed by 60pd of ethanol, incubation on dry ice for lOmin and 
centrifugation for lOmin. The pellet of denatured DNA was washed with 80% ethanol, 
lyophilised and resuspended in lOpd dH20.
To anneal the sequencing primer to the DNA template: 8pl of denatured plasmid DNA or 
single stranded bacteriophage M13 template (2|ig) (Section 2B.9) was mixed with ljil of 
5ng/|il oligonucleotide primer and 1|ll1 10 X seq buffer and incubated for 20min at 37°C. 
2u Klenow fragment buffered in 10 X seq was added to the annealed DNA/primer 
reaction. Each annealing reaction was divided into four wells of a 96 well reaction plate 
(Nunclon), for the four chain termination reactions. 2p,l of a termination mix (comprising 
12|il of a sequencing mix containing one ddNTP + dNTPs (see below), plus 0.57p,M 
dATP and 5|iCi a 32 P-dATP in a final volume of 14jil) was added to the relevant well and 
mixed by centrifugation at lkrpm for lOsec. The plate was incubated for 15min at 37 C to 
allow primed DNA synthesis until terminated by the incorporation of a ddNTP. Next, 2jil 
of a ’chase' mix containing all 4 dNTPs, each at 0.25mM, was added to the wells, mixed 
as before and incubated for 30min at 37°C; this elongates non-terminated chains into 
higher molecular weight DNA. 2pl of formamide dyes mix was added to each well, and 
the plate boiled for 2min immediately prior to loading samples into the spaces formed 
between the teeth of a sharks-tooth comb. Electrophoretic separation used 8% denaturing
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polyacrylamide gels as described previously (Section 2B.4.4). The dried gel was exposed 
to Kodak X-omat S film overnight.
Nucleotide components of sequencing mixes
Sequencing solutions:
dA-O dT-O dC-O dG-O
5mM dTTP 20 (pi) 1 20 20
5mM dCTP 20 20 1 20
5m M 7-deaza dGTP 20 20 20 1
10 X TE seq 50 50 50 50
dH20 540 370 370 370
(TE seq: lOmM Tris.HCl (pH 8.0), O.lmM EDTA)
Sequencing mixes:
dN-O mix ddNTP dH20
T seq 500 (pi) 500 (600pM ddTTP) 0
C seq 500 105 (140pM ddCTP) 395
G seq 500 155 (200pM ddGTP) 345
A seq 500 250 (140pM ddATP) 250
2C Expression and purification of DNA binding domain 
peptides
2C.1 Preparation and transformation of competent bacteria for protein 
expression
A single fresh colony of E. coli strain BL21 (DE3) pLysS was inoculated into 10ml 2YT 
broth (supplemented with chloramphenicol, see Section 2A.6) and shaken at 37°C for 
around 3hr until the OD630 reached about 0.3. Cells were pelleted at 3krpm for 5min at 
4°C, resuspended in 2.5ml ice cold 0.1M MgCl2 and re-centrifuged at 3krpm for 5min at 
4°C. The pellet was resuspended in 300pl ice cold 0.1M CaCl2 and stored on ice until 
used. Approximately lOng of plasmid DNA was transformed into lOOpl competent 
bacteria as described previously (Section 2B.6) and plated onto agar containing antibiotics 
as appropriate (Section 2A.6).
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2C.2 Bacterial expression and partial purification of DNA binding 
domain peptides
Several BL21 (DE3) pLysS colonies, freshly transformed with a T7 expression plasmid, 
were inoculated into 10ml 2YT broth (supplemented with appropriate antibiotics, Section 
2 A.6 ) and shaken overnight at 37°C. lOOpl of the overnight culture was diluted into 
100ml 2YT broth (plus antibiotics as above), and shaken at 37 °C until the OD6 3 0  was 
about 0.5. IPTG was added to O.lmM and peptide expression induced at 26°C, for a 
further 2hr. Bacteria were harvested by centrifugation at 5krpm for 5min at 4°C (Sorvall 
GS3 rotor) and resuspended in O.lvol resuspension buffer (50mM HEPES (pH 7.2), 
lOOmM NaCl, 6 mM CHAPS, ImM PMSF and O.lmM DTT). After freeze-thawing, the 
bacteria were lysed by sonication for 4 X lOsec at 80-90W (using a Dawe soniprobe; 
Type 7532A). The solution was incubated with DNase I to 24jig/ml; RNase A to 
100pg/ml and MgCl2 to 6 mM for 30min on ice. NaCl was added to 1M, followed by 
incubation for lOmin on ice. Polymin-P was added to 0.2% and the mixture incubated for 
a further lOmin. The resulting suspension was centrifuged at 15krpm for 15min at 4°C 
(Sorvall SS34 rotor). The supernatant was adjusted to 35% ammonium sulphate (by 
dropwise addition of a saturated solution) and incubated on ice for 40min. The 
precipitated proteins were collected by centrifugation at lOkrmp for lOmin at 4°C and 
dissolved in 300pl resuspension buffer. The extract was clarified by centrifugation at 
lOkrpm for 5 min at 4°C and the partially purified soluble peptides were stored at -70°C. 
Samples taken throughout the purification procedure were analysed by SDS PAGE as 
described below.
2C.3 SDS polyacrylamide gel electrophoresis (SDS PAGE) of proteins
Denatured proteins were resolved by electrophoresis through polyacrylamide minigels 
containing SDS (Laemmli, 1970) using the Bio-Rad miniprotean II apparatus and the 
glycine buffer system. Polyacrylamide resolving gels (a+b:b; 40:1; final acrylamide 
concentration between 10% and 16% as appropriate) contained 0.25 X RGB; 0.0lvol 
10% APS and 0.00lvol TEMED were added to polymerise the gel. Butan-2 -ol was 
layered over the resolving gel mix to give a smooth interface. Once set, the butanol was 
removed and the gel rinsed, prior to overlaying the stacking gel (5% polyacrylamide, 0.25 
X SGB, O.Olvol 10% APS and O.OOlvol TEMED). Samples and molecular weight 
markers (Sigma) (as required), were boiled for 2min in appropriate amounts of 3 X SDS 
boiling mix before loading and electrophoresis in tank buffer at >200V until the dye front 
reached the bottom of the gel. The tricine buffer system was used to give better resolution 
of low molecular weight proteins. Tricine polyacrylamide (a+b:b, 35:2) gels use a single
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gel buffer for resolving and stacking gels, but the tricine system has separate tank buffers 
for lower and upper tank chambers.
Following electrophoresis, gels were either stained with Coomassie stain for 5min 
followed by destaining in methanol:acetic acid:water, (50:7:50), before photographing the 
gel on heat-sensitive paper using The Imager (Appligene). Alternatively, to locate 
radiolabelled proteins, gels were washed for lOmin in Fix, followed by a lOmin wash in 
En3hance, rinsed in H20, dried under vacuum and placed in contact with Kodak X-omat 
S film for autoradiography (fluorography for 3H) or placed against a phosphor screen 
(Molecular Dynamics) for Phosphorlmager scanning analysis.
2C.4 Western blotting analysis of proteins 
2C.4.1 Electroblotting to nitrocellulose
Proteins resolved on SDS PAGE minigels were transferred to nitrocellulose by the 
method of Towbin e ta l (1979). The western blotting gel sandwich described below was 
prepared under Towbin buffer, and all components of the sandwich had been pre-soaked 
in this buffer. The minigel was placed on a square of Whatman 3MM paper, and a sheet 
of nitrocellulose paper (Schleicher and Schuell Inc.), cut to size, was placed on top of the 
gel, ensuring that no air bubbles were trapped between the layers. Another square of 
Whatman paper was placed on top and the sandwich arranged in the Bio-Rad mini 
transblot cell according to the manufacturer’s instructions. Proteins were electroblotted to 
nitrocellulose at 0.28A for 3hr.
2C.4.2 Immunodetection
Nitrocellulose membranes were blocked in 200ml 3% gelatin in TTBS by shaking gently 
for 30min at 37°C. This was repeated with a fresh 200ml 3% gelatin in TTBS. The 
membrane was washed twice in 200ml TTBS for 5min before adding the first antibody. 
Polyclonal antiserum (rabbit) or specific monoclonal antibody (mouse) was diluted as 
appropriate (1:1000 to 1:10,000) in 1% gelatin in TTBS, and the membrane was 
incubated with 20ml of this first antibody dilution overnight at RT, with constant 
agitation. The membrane was washed 6 times with 100ml TTBS for 5min each, before 
adding the second antibody. Protein A horse radish peroxidase (HRP) conjugate or 
anti-mouse IgG whole molecule peroxidase conjugate (as appropriate) was diluted 1:1000 
in 1% gelatin in TBS; the membrane was incubated with 10ml of this second antibody 
dilution for lhr at RT, with agitation. After washing twice with 200ml TTBS, proteins 
were either detected using colour reagents or enhanced chemiluminescence (ECL). For 
colour detection of proteins, 60mg HRP colour development reagent (Bio-Rad) was 
mixed with 20ml ice cold methanol. To this was added a solution of 60|il H20 2 (30%
105
Chapter 2: Materials and Methods
stock) in 100ml TBS. The membrane was washed twice with 200ml TBS, prior to 
incubation with the colour detection solution in the dark until protein bands appeared 
(about lOmin). ECL detection of proteins used ECL western blotting detection reagents 
(Amersham). 1ml of each of the two ECL reagents were combined and poured onto the 
drained membrane, and after lmin the membrane was placed between two sheets of saran 
wrap and briefly exposed to Kodak X-omat S film.
2C.5 FPLC purification of VZV 140k DNA binding domain peptides
Partially purified extracts of VZV 140k DNA binding domain peptides were prepared 
from 11 bacterial cultures (scaled up from Section 2C.2) and purified by FPLC column 
chromatography. Purification used three preparative column steps; two sequential ion 
exchange chromatography steps, followed by a gel filtration step. The following FPLC 
buffer was used for all column elutions at the salt concentrations specified in Section 
3C.2: 50mM HEPES (pH 7.5), ImM PMSF, O.lmM DTT, 0.01% CHAPS. PMSF and 
DTT were added immediately before use and all buffers were filtered through 22pm filters 
(Milllipore) and de-gassed before use. Columns were equilibrated with at least 5 column 
volumes of elution buffer prior to loading samples. Aliquots of column fractions were 
analysed by SDS PAGE (Section 2C.3) to identify peptide-containing fractions for 
subsequent chromatography steps.
2C.5.1 Mono Q anion exchange column
The first step in the FPLC purification procedure used a 20ml Mono Q anion exchange 
column (HR 16/10, Pharmacia) equilibrated in 0.1M NaCl FPLC buffer. 1ml of a pre­
cleared partially purified peptide extract (from 330ml bacterial culture), diluted to 5ml in 
0.1M NaCl FPLC buffer, was loaded onto the Mono Q column and eluted with a linear 
0.1 to 1.0M NaCl gradient.
2C.5.2 Mono S cation exchange column
Pooled Mono Q flow-through fractions were diluted to 0.05M NaCl if necessary (Section 
3C.2.4) or loaded directly onto an equilibrated 20ml Mono S cation exchange column 
(HR 16/10, Pharmacia) and a linear A to B NaCl gradient eluted the 140k peptides (where 
A is low salt and B is high salt FPLC buffer, as specified in Section 3C.2). The gradient 
was temporarily levelled off as appropriate, to obtain maximum separation of the VZV 
140k peptides from bacterial contaminant proteins. Peak fractions were concentrated using 
Centricon 10 centrifugation filtration units (Amersham).
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2C.5.3 Superose 12 gel filtration column
The peptide sample from the concentrated Mono S peak fractions (in a volume of 250pl) 
was loaded onto a Superose 12 column (Pharmacia) equilibrated and eluted in an FPLC 
buffer of the NaCl concentration at which the 140k peptide eluted from the Mono S 
column. Peak fractions were pooled and concentrated by centrifugation filtration to yield 
>90% homogeneous peptide solutions, as determined by SDS PAGE analysis. Purified 
peptides were stored at -70°C.
2C.6 Purification of bacterially expressed GST-fusion peptides
Portions of the VZV 140k ORF fused to the glutathione-S-transferase (GST) gene of the 
parasitic helminth Schistosoma japonicum were bacterially expressed and purified 
following the method of Ausubel etal. (1993b). pGEX-fusion vectors were transformed 
into competent DH5a bacteria as previously described (Section 2B.6). 11 cultures of 
transformed bacteria were grown in 2YT broth (plus antibiotics, see Section 2A.6) at 
37°C until the OD6 3 0  reached about 0.4. Peptide expression was induced for a further 2hr 
at 37°C by addition of IPTG and bacteria harvested (as described in Section 2C.2). The 
pellet was resuspended in 10ml PBS A and placed at -20°C. The thawed cells were lysed 
by incubation with lOOpl 40mg/ml lysozyme and 1ml 5% Na-deoxycholate for 40min on 
ice. Triton X-100 was added to a final concentration of 1%, after a further 5min the 
solution was centrifuged at 20krpm for lOmin at 4°C (Sorvall SS34 rotor). 1ml of a 50% 
slurry of glutathione agarose beads was incubated with the supernatant for about lhr at 
RT. The beads were spun down briefly and washed twice with 20ml 1% Triton X-100 in 
PBSA. The beads were then washed in 20ml 'wash' buffer (50mM Tris.HCl (pH 7.5), 
150mM NaCl). After a final wash in 20ml 'thrombin cleavage’ buffer (2.5mM CaCl2 in 
'wash' buffer) the beads were resuspended in 1 ml 'thrombin cleavage' buffer containing 
16|il of 0.4pg/ml thrombin (1% (w/w) fusion protein). Thrombin cleaved the fusion 
peptides at the thrombin cleavage site, C-terminal to the GST sequences, during a lhr 
incubation at RT. The beads were spun out to yield a supernatant containing the purified 
VZV 140k peptide that was released by the thrombin cleavage. Samples were taken 
throughout this procedure for SDS PAGE analysis.
2C.7 In vitro transcription-translation in rabbit reticulocyte lysates
DNA binding domain peptides were expressed in vitro using the TnT T7 Coupled 
Reticulocyte Lysate System (Promega), in the presence of 3 5 S-methionine (or 
3H-leucine), following the manufacturer's instructions. Briefly, T7 expression plasmids 
(0.001-l(ig) were transcribed by T7 RNA polymerase and translated by components of
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the lysate for 90min at 31°C, in 50|il reaction mixes containing the following: 25|il TNT 
rabbit reticulocyte lysate, 2|il TNT reaction buffer, lql TnT T7 RNA polymerase, lpl 
ImM amino acid mix minus methionine (or minus leucine), 40|iCi 35S-methionine (or 
25qCi 3H-leucine) and 40u RQ1 RNasin ribonuclease inhibitor. Low plasmid amounts 
were used (about 0.00 lpg) when extracts were prepared for DNA binding analyses, to 
prevent the plasmid DNA from sequestering the DNA binding peptides. The amount of 
each plasmid required to produce equivalent peptide yields was determined empirically for 
co-translation experiments, due to variations in the efficiency of expression from different 
T7 expression constructs. For co-immunoprecipitation experiments, l|ig of each plasmid 
DNA was included in a 50|il translation reaction. The translation products (l-5pl) were 
analysed by SDS PAGE followed by autoradiography (Section 2C.3), before use in gel 
retardation (Section 2D.2) or co-immunoprecipitation analyses (Section 2E.4).
2D DNA binding analyses 
2D.1 Radiolabelling of DNA
2D. 1.1 End-labelling o f DNA fragments and synthetic oligonucleotides 
End-labelled DNA probes were produced by filling-in the overhangs produced by 
restriction enzyme digestion or by annealing overlapping oligonucleotides, in the presence 
of a radiolabelled dNTP. To construct radiolabelled restriction fragments, the plasmid was 
cut with the first restriction enzyme (Section 2B.3), followed by heat inactivation of the 
enzyme for lOmin at 65°C. Then 20|iCi of a suitable a 32 P-dNTP (choice depending on 
the template nucleotides), l|il of ImM of the remaining three dNTPs and 2u Klenow 
fragment were added and buffer conditions adjusted to those of buffer M (by dilution or 
addition of salt). After incubation for 30min at 37°C, l|il 20 X dNTPs was added and 
incubation continued for a further lOmin. Heat inactivation of the Klenow fragment was 
followed by digestion with the appropriate second restriction enzyme. Labelling of both 
restriction fragment ends was achieved by cutting with both enzymes prior to the labelling 
reaction. To radiolabel complementary overlapping oligonucleotides, equal amounts of 
each single stranded oligonucleotide were annealed together for 5min at 80°C and slowly 
cooled to RT. The labelling reaction contained 20ng duplex oligonucleotide and was 
otherwise exactly as above. Radiolabelled DNA probes were purified on either 5% 
(100-400bp) or 8% (20-100bp) non-denaturing polyacrylamide gels (Section 2B.4.3) and 
eluted as described previously (Section 2B.4.5).
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2D. 1.2 Preparation of ‘prime cut’ radiolabelled DNA fragments
DNA fragment probes with equivalent specific activities were prepared by the 'prime cut' 
method (Biggin et al., 1984), for comparative gel retardation analyses using DNA 
fragments with point mutations in the HSV-1IE3 consensus binding site (Section 3A.9). 
Single-stranded template DNAs (3|il) (Section 2B.9) from the M13IE3EB series of 
bacteriophage (including the mutagenised IE3 binding site), were annealed with 2 j l l 1 M13 
universal primer in the presence of l|il 10 X seq buffer, for 90min at 60°C. 5pl of a label 
mix (2 t^l 32P dATP, 4jil 0.5mM three remaining dNTPs, l|il 11.8|iM ATP, 2p,l 10 X seq 
buffer, 4u Klenow fragment, 3pl dH20) was dispensed into each tube and incubated for 
30min at RT. After this time, l|il of 20 X dNTPs was added and incubated for a further 
lOmin. Heat inactivation of the enzyme was followed by restriction enzyme digests of the 
duplex bacteriophage and the resulting 'prime cut' radiolabelled DNA fragments were 
resolved on 5% non-denaturing polyacrylamide gels (Section 2B.4.3) and the required 
fragment isolated as described previously (Section 2B.4.5). Radioactivity concentrations 
of probes were equalised by Cerenkov counting and making suitable dilutions in TE. 
'Prime cut' probes used for any series of experiments were prepared using the same label 
mix, and a wild type probe was prepared in each series of probe preparations, to allow 
standardisation of the DNA binding results.
2D.2 Gel retardation assays
The abilities of peptides to bind specifically to radiolabelled DNA molecules was assayed 
by gel retardation. Optimal binding conditions were determined empirically, depending on 
the particular type of assay, and were as follows:
Appropriate amounts of bacterially expressed DNA binding domain peptides or HeLa 
nuclear extracts were mixed with buffer giving final concentrations of lOmM Tris.HCl 
(pH8.0), ImM EDTA, lOOmM NaCl, 0.1% NP40, 50|ig/ml BSA. Non-specific 
competitor (lp,g polydl.polydC or 0.5}ig pUC9) was also included. The mixture was 
incubated for 20min on ice with lng of end-labelled DNA fragment probe or freshly made 
'prime cut' probe. In vitro translated extracts were incubated in buffer containing lOmM 
Tris.HCl (pH8.0), ImM EDTA, lOOmM NaCl, 0.2% CHAPS, lOOmM DTT.
For analyses of the stability of protein-DNA complexes, lqg of unlabelled oligonucleotide 
specific competitor was added to incubation reactions for increasing lengths of time before 
electrophoresis. For analyses of the specificity of DNA binding, the protein was incubated 
with increasing amounts of unlabelled specific competitor for 20min, prior to incubation 
with the radiolabelled probe.
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After incubation, 0.2vol of 5 X non-SDS loading buffer was added and the samples 
applied to non-denaturing 4% polyacrylamide gels (a+b:b; 30:1) (1.5mm wide X 20cm 
long) containing 0.5 X TBE (diluted from 10 X TBE stock), O.Olvol 10% APS and 
0.00lvol TEMED. Gels were electrophoresed in 0.5 X TBE at 150V for about 3hr at 4°C. 
When required, 35cm gels were used to increase the resolution of complexes. After 
electrophoresis, gels were soaked in Fix for lOmin and dried down under vacuum. 
Complexed and unbound probe were detected by autoradiography of dried gels using 
Kodak X-omat S film and intensifying screens at -20°C for 1-14 days.
Where appropriate, the extent of binding was determined by scintillation counting 
(Beckman LS 5000CE) of dried gel slices (in 5ml ecoscint A) corresponding to the 
positions of free and bound probe, previously located by autoradiography. To allow for 
background values contributed by complexes with E. coli proteins, dried gel slices from 
control lanes were also cut out and counted. Control values were subtracted from the 
sample counts, to allow calculation of the percentage of total probe bound. For more 
recent experiments, quantification was by Phosphorlmager analysis of gels exposed to 
phosphor screens, using Image-Quant software (Molecular Dynamics).
2D.3 Pore exclusion electrophoresis
The sizes of protein-DNA complexes were estimated by electrophoresis through 
polyacrylamide gels of graded porosity, using the method of Andersson et al. (1972). 
Partially purified bacterially expressed peptides were incubated with radiolabelled DNA as 
described above. Samples were loaded onto linear 4% to 24% non-denaturing 
polyacrylamide gradient gels (a+b:b, 30:1) containing 0.5 X TBE, O.Olvol 10% APS and 
0.00lvol TEMED. An appropriate selection of protein standards of known molecular 
weights (Sigma) were run on the same gel. Gels were run in 0.5 X TBE at 150V at 4°C 
until the macromolecules had reached their equilibrium position in the polyacrylamide 
molecular sieve (after about 40hr). The migration distance of protein-DNA complexes, 
visualised by autoradiography, were compared to those of the Coomassie-stained protein 
standards, to give an estimate of the size of complexes.
2D.4 DNase I footprinting assay
Site specific protection of DNA fragments from partial DNase I digestion, by DNA 
binding domain peptides, was determined by modification of the method of Galas and 
Schmitz (1978). DNA binding reactions contained 4ng of target DNA fragment 
(radiolabelled at a single end) and suitable amounts of partially purified bacterially 
expressed peptides in buffer giving final concentrations of lOmM Tris.HCl (pH 7.5),
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ImM EDTA, lOmM BME, 0.1% CHAPS and lOOmM NaCl. After a 20min incubation at 
RT, MgCl2 to lOmM and CaCl2 to 2mM were added. Then 0.0625u of DNase I was 
added to the protein-DNA solution, and after 60sec at RT, digestion was halted by 
addition of 20pg proteinase K in lOOjil of a buffer containing 1% SDS, 100|Lig/ml tRNA, 
200mM NaCl, 20mM EDTA, and incubating at 50°C for 20min. The DNA fragments 
were purified by phenol and chloroform extractions, ethanol precipitation and 
resuspended in formamide dyes mix. A G+A Maxam and Gilbert chemical sequencing 
reaction (Maxam and Gilbert, 1980) was run on the same gel as the footprinting reactions, 
to provide a sequencing ladder for orientation of the footprint. The G+A reaction was as 
follows: 4ng of the lyophilised DNA probe fragment was resuspended in 2% 
diphenylamine, ImM EDTA, 66% formic acid and incubated for 5min at RT. The mix 
was diluted in 45|il d ^ O  and extracted three times with 400pl diethylether, and then 
lyophilised. The DNA pellet was resuspended in 100|il of freshly diluted 1M piperidine 
and incubated at 90°C for 20min to cleave modified purine bases. The products were 
purified by two ethanol precipitations before resuspension in formamide dyes mix. 
Samples were applied to 8% (probes <100bp) or 12% (probes >100bp) denaturing 
polyacrylamide sequencing gels and electrophoresed as described previously (Section 
2B.4.4). The dried gel was exposed to Kodak X-omat S film for 1-14 days with an 
intensifying screen at -20°C.
2E Physical analyses of DNA binding domain peptides
2E.1 Glutaraldehyde cross-linking
The ability of DNA binding domain peptides to form multimers was analysed by 
incubation with glutaraldehyde, which irreversibly and covalently cross-links a- and 
e-amino groups of lysine residues of proteins in close proximity (Peters and Richards, 
1977). Amounts of partially purified or FPLC purified peptides that yield clearly visible 
bands upon Coomassie-staining of SDS PAGE gels (approximately 4p,g), were incubated 
in a buffer containing 50mM HEPES (pH 7.5), 0.1M NaCl, ImM PMSF, either with or 
without 0.01% glutaraldehyde, for 30min at 31°C. Parallel incubations, including 4|ig of 
monomeric protein standard (bovine carbonic anhydrase; Sigma) were performed to 
indicate the background level of non-specific cross-linking by glutaraldehyde. The 
Products of the cross-linking were resolved by SDS PAGE (Section 2C.3) and visualised
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by Coomassie blue staining, or transferred to nitrocellulose and immunodetected (Section 
2C.4).
2E.2 Superdex 75 analytical gel filtration chromatography
The native molecular mass of DNA binding domain peptides in solution was determined 
using the high resolution FPLC Superdex 75 gel filtration column (Pharmacia). About 
50pg of partially purified, FPLC purified DNA binding domain peptide, or gel filtration 
protein standard (Sigma) was loaded in a volume of 200pl onto the Superdex 75 column 
equilibrated in a buffer containing 50mM HEPES (pH 7.5), 0.3M NaCl, ImM PMSF, 
O.lmM DTT, 0.01% CHAPS. The proteins were eluted from the column in this buffer 
and detected by the uv monitor (0D28o setting of 0.05) upon exit from the column. The 
identity of proteins in the peaks were verified by SDS PAGE analysis (Section 2C.3) of 
column fractions. The accurate retention volume of each protein peak was provided by 
evaluation of the stored peak data for each column run using the software in the FPLC 
equipment. The approximate molecular mass of a DNA binding domain peptide in 
solution was derived from a standard curve produced from the retention volumes of a 
range of protein standards (Fig. 3C.6).
2E.3 Glycerol gradient centrifugation sedimentation analysis
Sedimentation on 10-30% glycerol gradients was used to estimate the true molecular sizes 
of DNA binding domain peptides, as compared to protein standards. 5ml linear gradients 
of 10-30% glycerol in 50mM HEPES (pH 7.5), 0.5M NaCl were prepared in AH650 
tubes (Dupont). Air bubbles were carefully removed and the gradients allowed to settle for 
30min at RT. Approximately 10pg of FPLC purified peptide and appropriate protein 
standards were layered on top of the gradient in a lOOpl volume containing 50mM 
HEPES (pH7.5), 0.5M NaCl, 0.1% CHAPS and ImM PMSF. Gradients were 
centrifuged at 40krpm for 46hr at 14°C (Sorvall AH650 rotor), with low acceleration and 
deceleration. 200pl fractions were collected from the top of gradients and analysed by 
SDS PAGE (Section 2C.3).
2E.4 Co-immunoprecipitation of in vitro translated peptides
Interactions between DNA binding domain peptides in solution were detected by 
co-immunoprecipitation of peptides co-translated in vitro (Section 2C.7) with an epitope 
^gged peptide (see Fig. 3D. 10). Extracts from rabbit reticulocyte lysate translation 
reactions (50pl) were pre-cleared by incubation for 30min at 4°C with lOvol IP buffer
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containing 5|ll1 normal mouse serum, 12.5|il sheep anti-mouse Ig (SaM) and 60jil 50% 
slurry of protein A sepharose beads. After a 2min spin, 20|il of the pre-cleared 
supernatant was incubated for 2hr at 4°C with 2pl MAb, 5fxl (SaM) and 60p,l 50% slurry 
protein A sepharose in a volume made up to 400pl with IP buffer. Immune complexes 
were pelleted by centrifugation for 2min. The pellet was washed 3 times with IP buffer, 
and then washed with a buffer containing 0.6M LiCl, 0.1M Tris.HCl (pH 7.5), 1% 
BME. The pellet was finally washed in PBSA and resuspended in 20pl 1 X SDS boiling 
mix and boiled for 5min. The beads were pelleted and the supernatant applied to an SDS 
PAGE gel (Section 2C.3), with radiolabelled protein markers as appropriate. After 
electrophoresis, the proteins were electroblotted to nitrocellulose membranes (Section 
2C.4.1). Co-immunoprecipitated proteins were detected by autoradiography or 
phosphorimaging of the dried membranes. Inclusion of a cocktail of protease inhibitors 
throughout the immunoprecipitation procedure reduced proteolytic degradation (bestatin, 
leupeptin, aprotinin, PMSF, at concentrations recommended by the manufacturer).
2E.5 Urea denaturation - renaturation
Equal amounts (approximately 50|ig) of partially purified or FPLC purified bacterially 
expressed peptides were diluted to 400|il in buffer R; where R buffer contained 50mM 
HEPES (pH 7.5), 0.3M NaCl, 0.01% CHAPS, ImM PMSF, O.lmM DTT. Peptide 
dilutions containing either a single peptide or a mix of two peptides were denatured by 
dialysis overnight at 4°C against 400ml buffer R containing 8M urea (previously 
deionised with Amberlite resin). The dialysis sacks were transferred to 400ml buffer R for 
4hr at 4°C to renature the peptides. Samples (around I jlxI) of the peptide dilutions, both 
before and after this treatment, were analysed by gel retardation assay (Section 2D.2).
2F Tissue culture
2F.1 Growth of tissue culture cells
Eukaryotic cells for transfection experiments and virus work were grown in tissue culture 
disposable plasticware (Nunc, Sterilin Ltd.). BHK, Vero and WS HeLa cells were 
passaged in 175cm2 flasks in the relevant tissue culture media (described in Section 2A.7) 
and were grown at 37°C under 5% C 02 in a humidified incubator. Confluent monolayers
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were harvested in 10ml medium after a 20ml versene wash and brief trypsinisation with 
20ml trypsin:versene (1:4). Cells were resuspended by pipetting and used directly, 
although BHK and Vero cells remained viable for several days at 4°C.
2F.2 Calcium phosphate mediated transfection for CAT assay
WS HeLa, BHK or Vero cells were seeded at 1 X 106 cells per 50mm petri dish and were 
transfected by the calcium phosphate precipitation method 24hr later (Corsalo and 
Pearson, 1981). Transfections used 4pg of CAT reporter constructs, which carry a 
heterologous promoter-leader sequence fused to the chloramphenicol acetyltransferase 
(CAT) open reading frame. Varying amounts of effector plasmids (0-10pg) were used as 
appropriate and pUC9 was added to equalise the amount of DNA within experiments. All 
transfection buffers were freshly filtered using 0.2pm sterile Acrodiscs (Gelman 
Sciences). TEP buffer was added to the DNA to bring the volume to 140pl, followed by 
dropwise addition of 20pl 2M CaCl2 . The DNA solution was in turn added dropwise to 
160pl of 2 X HBS buffer. After standing for 30min at RT, the precipitate was sprinkled 
onto the cell monolayer. After 24hr at 37 °C the cells were washed and re-fed with fresh 
medium. 24hr later, cells were scraped into 3ml TEN, pelleted at 2krpm for 5min at 4°C, 
resuspended in 0.25M Tris, pH 7.8 and sonicated. The sonicates were cleared by a 2krpm 
spin for 5min, and stored at -20°C.
2F.3 Chloramphenicol acetyltransferase (CAT) assay
Activation of gene expression from CAT-reporter plasmids by transiently transfected 
effector plasmids, was assayed by determining the CAT enzyme activity in cell sonicates 
(Section 2F.2), using a method adapted from Gorman et al. (1982). Assay mixtures 
contained lpl of 50mM acetyl Co A, lpl of 14C-chloramphenicol, 13pl dH20  and 25pl of 
cell extract. Typically, 5pi cell sonicates from transactivation experiments were diluted to 
25pl in 0.25M Tris, pH 7.8, and assayed for 30min at 37°C. Sonicates from repression 
experiment were assayed undiluted for 4hr at 37°C. After incubation, the reactions were 
extracted with 200pl of ethyl acetate, lyophilised, resuspended in 20pl ethyl acetate and 
spotted onto 0.25mm Silica gel TLC plates (Camlab). Ascending chromatography was 
performed using 100ml of 19:1, chloroform:methanol tank buffer until the solvent front 
had reached the top of the plate. The dried TLC plate was placed against a phosphor 
screen. The percentage conversion to product was calculated by quantitating the 
radioactivity in the substrate and product spots using a Phosphorlmager scanner with 
Image-Quant software (Molecular Dynamics).
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2F.4 Determination of protein concentration of cell extracts
The total concentration of proteins in each cell extract used in the CAT assay was 
determined using the method of Bradford (1976). 195pl of a 1:4 dilution of protein assay 
reagent (Bio-Rad) was aliquoted into the wells of a flat bottomed microtitre plate (all 
dilutions were in 0.25M Tris, pH 7.8). To the 'sample' wells were added 5pl of a 1:9 
dilution of each extract, to the 'standard' wells were added 5pl of stock dilutions of BSA 
containing 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 or 1.4mg/ml BSA. 5pl of 0.25M Tris (pH 7.8) 
was added to the 'blank' well. After around 20min at RT, the absorbances at 610nm were 
measured using an Anthos Labtec HT2 plate reader, which subtracted the 'blank' reading, 
derived a standard curve from the BSA 'standard' readings and calculated the protein 
content of sample extracts. For each extract, the percentage conversion from substrate to 
product per microgram protein was derived by dividing the percentage conversion to 
product, calculated from the CAT assay (Section 2F.3), by the average protein 
concentration from duplicate protein determinations.
2F.5 Liposome mediated transfection (Lipofection)
BHK cells were seeded at 5 X 105 cells per 50mm petri dish and 24hrs later were 
transfected with plasmid DNA, using a liposome-mediated DNA transfection procedure 
based on the method of Feigner et al. (1987) as described below. Liposomes were kindly 
prepared by Mrs M. Elliott as follows: 4jig DDAB was added to 1ml DOPE (supplied as 
lOmg/ml in chloroform) and the chloroform evaporated using a N2 supply. The 
lyophilised pellet was resuspended in 10ml sterile d^O  and sonicated until clear, to yield 
liposomes ready for use. 6|ig plasmid DNA was made up to a volume of 170|il with a 
buffer containing 150mM NaCl, 20mM HEPES.NaOH pH 7.4. The DNA solution was 
mixed with 2ml Opti-MEM (low serum medium, Gibco), before addition of 30|il 
liposomes, mixing and standing for lOmin at RT. Meanwhile, the sub-confluent 
monolayers were washed once with Eagle’s medium (Gibco) (plus 
penicillin/streptomycin) (Section 2A.7) and drained thoroughly. The liposome-DNA mix 
was transferred to the monolayer and incubated at 37°C. After 4 hours, 2ml Eagle’s 
medium plus 5% calf serum (CS) (and penicillin/streptomycin as previously) was added 
to each plate and incubation continued for 24hr. Monolayers were washed, re-fed with 
BHK medium and incubated for a further 24hr before immunofluorescence analysis or 
viral infection (see below).
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2F.6 Immunofluorescent staining of VZV 140k in transfected cells
BHK cells prepared as described above were washed with PBSc and the monolayer fixed 
with 1.8% formaldehyde, 2% sucrose in PBSc for lOmin at RT. The monolayer was 
washed 3 times with PBSc, and permeabilised with 0.5% NP40, 10% sucrose, 1% CS in 
PBSc for 5min at 20°C. Cells were washed 3 times with PBSc plus 1% CS, and dried 
briefly at 37°C. Polyclonal antiserum 109 was diluted 1:500 in PBSc plus 1% CS, then 
one drop of this first antibody dilution was placed on a marked spot on the monolayer for 
lhr at RT (care was taken to prevent cells from drying out during incubations). The 
monolayer was washed 3 times with PBSc plus 1% CS, dried, then incubated for lhr in 
the dark at RT with lOpl of a 1:30 dilution of FITC-conjugated sheep anti-rabbit Ig in 
PBSc, placed on the same spot as before. The monolayer was washed 3 times with PBSc, 
and dried. 10|il of 90% glycerol in PBSc was placed on the spot, covered with a coverslip 
and the cells observed by uv fluorescence microscopy. Suitable fields of view were 
photographed using Kodak ASA400 black and white film.
2F.7 Production of recombinant virus
Lipofection (Section 2F.5) was used to introduce linearised plasmid DNA into BHK cells 
as the initial step in the production of recombinant HSV-1 based viruses. BHK cells were 
seeded at 4 X 105 per 35mm petri dish and grown for 24hr at 37°C. Transfection mixes 
included 2|ag of Pstl linearised plasmid DNA (previously 'genecleaned' and checked by 
agarose gel electrophoresis for complete linearisation), the total DNA in each transfection 
was made upto 3[ig with calf thymus (CT) DNA. A negative control plate was transfected 
with 3|ig CT DNA to indicate the background level of wild type HSV-1 in the D30EBA 
viral stock. After lipofection (using half the volumes given in Section 2F.5), cells were 
grown for 24hr at 37°C before infecting with virus. A D30EBA viral stock, (made as 
described below) was diluted 1:1000 in BHK medium, cell monolayers were drained and 
100(il of diluted virus sprinkled onto each plate. The plates were incubated at 37°C, with 
agitation every lOmin. After lhr the monolayers were re-fed with BHK medium and cells 
grown for a further 24hr, before washing and replacing fresh medium. Cells were grown 
for 2-3 days at 37°C until cpe became visible. Cells were harvested into the medium, 
sonicated for lOsec and stored at -70°C. These sonicates were used as viral stocks without 
further treatment.
2F.8 Titration of virus stocks
Virus stocks produced as described above were titrated by plaque assay. 10-fold serial 
dilutions of stocks were prepared in BHK serum. The growth medium was removed from
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confluent BHK monolayers (seeded at 1 X 106 cells per 35mm petri dishes 24hr 
previously). lOOpI of diluted virus was added to each dish and was adsorbed to the cells 
by incubation for lhr at 37°C (with gentle agitation every lOmin). The monolayers were 
overlaid with Eagle's medium (Gibco) plus 5% human serum (Flow) to prevent 
secondary plaque formation. After incubation for 3-5 days at 37 °C, cells were fixed with 
Cidex (Johnson and Johnson) for around 30min and stained with Giemsa stain for a 
further 30min. Plates were washed and plaques counted using a dissection microscope.
2G Computing
Computer analysis of DNA and protein sequences were performed on the MicroVAX II 
computer in this Institute using the software package form the University of Wisconsin 
Genetics Computer Group (GCG Inc., Madison, Wis.). For details refer to Genetics 
Computer Group (1991) Program Manual for the GCG Package, Version 7, April 1991, 
575 Science Drive, Madison, Wisconsin, USA 53711.
117
Chapter 3: Results
3A Expression and DNA binding characteristics of the VZV 
140k DNA binding domain
3A.1 Strategy
The majority of studies described in this thesis utilise peptide fragments that encompass 
the DNA binding domain of the product of VZV gene 62, 140k. The approach of 
analysing the DNA binding domain in isolation from other viral sequences was adopted 
because of the difficulties encountered in a previous attempt to detect sequence-specific 
DNA binding by the intact VZV 140k polypeptide (Disney, 1990). As discussed in the 
Introduction (Section 1C. 1.10), the bacterially expressed DNA binding domain of 
HSV-1 Vmwl75 is a stable separable domain that binds to DNA with a very similar 
affinity and specificity to the intact polypeptide. Therefore it is reasonable to assume 
that the binding properties of the VZV 140k DNA binding domain would reflect those 
of the full 140k polypeptide. The DNA binding domain of HSV-1 Vmwl75 comprises 
the highly conserved region 2 of the protein, although the C-terminal portion of the less 
highly conserved region 1 is additionally required for DNA binding (Figs. 1C.2 and 
1C.3). Due to the functional and sequence similarities between HSV-1 Vmwl75 and 
VZV 140k (see Section 1C.2.1 and Fig. 1C.1), it seemed likely that the DNA binding 
activity of 140k would reside in comparable regions of the protein to that of Vmwl75. 
Immediately prior to the commencement of these PhD studies, Wu and Wilcox 
communicated before publication (1991), that this was indeed the case. They expressed 
in E. coli, 140k codons 417 to 647, preceded by 323 codons derived from the bacterial 
trpE ORF. They found that this fusion peptide, FP617 (Fig. 3A.1), bound DNA in a 
sequence-specific manner (Wu and Wilcox, 1991; Section 1C.2.2). The experiments in 
this Section use the same regions of 140k (amino acid residues 417 to 647) expressed as 
a non-fusion polypeptide, VT2 (Fig. 3A.1), to eliminate the possible influence of a large 
stretch of heterologous E. coli coding region on the properties of the fusion protein. By
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homology to the HSV-1 Vmwl75 DNA binding domain (Wu and Wilcox, 1990; Pizer 
et al., 1991), the VT2 peptide includes sequences from the C-terminus of region 1 and 
the whole of region 2 of the 140k protein. The intention was to confirm and extend the 
findings of Wu and Wilcox (1991) using the non-fusion VZV 140k DNA binding 
domain.





(Wu & Wilcox) trpE 417 647
VT2
417 647
Figure 3A.1 Diagrammatic representations of VZV 140k and peptides encompassing 
its DNA binding domain. The 1310 amino acid VZV 140k protein (shown at the top) is divided into 
five regions based on the degree of amino acid similarity with HSV-1 Vmwl75 (see Section 1C. 1.8). The 
highly conserved regions 2 and 4 are shown shaded and the first and last amino acid coordinates of region 
2 are shown. Peptides FP617 and VT2 encompass the 140k DNA binding domain and include region 2. 
The FP617 peptide contains 140k residues 417 to 647 fused to codons 1-323 of the trpE gene of the E. 
coli tryptophan operon, represented by the black box (Wu and Wilcox, 1991). The non-fusion VT2 
peptide used in this study contains 140k residues 417 to 647.
During the course of the analyses described in this Section (3A), the DNA binding 
characteristics of the VZV 140k DNA binding domain were compared to those of the 
homologous domain of HSV-1 Vmwl75. The aim was to identify possible variations in 
DNA binding activities that could account for the functional differences reported 
between the 140k and Vmwl75 proteins in transient transfection assays (see Section 
1C.2.3). The T7 bacterial expression system of Studier et al (1990) was adopted for the 
expression of portions of the VZV gene 62 coding sequence, as this approach had 
proved highly effective for the expression of the Vmwl75 DNA binding domain (Pizer 
etal., 1991).
3A.2 Construction of the p585T7 series of T7 expression vectors
The p585T7 series of vectors were constructed to facilitate fusion of portions of the 
VZV gene 62 coding sequence to the T7 transcription-translation signals and to enable 
expression of inserts in the required reading frame.
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p585T7a 5 * - CC ATG GCT GAA TTC G - 3 1
3 ' - GG TAC CGA CTT AAG C - 5 '
Ncol EcoRI
p585T7b2 5 ' - CC ATG GCT AGA ATT CG - 3 1
3 ' - GG TAC CGA TCT TAA GC - 5 '
(Ncol) EcoRI 
p585T7c 5 ' -CC ATG AAT TCG - 3 1
3 ' -GG TAC TTA A G C - 5 1
Figure 3A.2 Construction of the p585T7 series of vectors. Only relevant restriction enzyme 
sites are shown. p585T7 vectors carry fragments of bacteriophage T7 DNA (indicated by shaded boxes) to 
direct expression in the direction indicated by the arrows; these include the (f>10 promoter, the slO  
translation initiation region for the gene 10 protein and the T0 transcription termination signal which were 
originally inserted into the BamHI site of pBR322 to make plasmid pET-8c (Studier et al., 1990). Plasmid 
p585.4 was previously derived from pET-8c by digestion with Hindlll, filling-in and re-ligation to remove 
the Hindlll site, a novel Nhel site was introduced in the process; also a new Hindlll site was introduced 
between the T7 promoter and terminator regions (these differences to pET-8c are shown in bold). P585T7 
vectors have the unique EcoRI site removed, a large Sphl-Pvull fragment removed and the pUC19 MCR 
inserted between the Ncol and Hindlll sites with the aid of Ncol-EcoRl adaptors (indicated by the black 
box) as described in the text. The reading frames of the three p585T7 vectors were determined by the 
version of adaptor inserted and are indicated at the bottom of the panel; adaptor derived sequences are 
shown in bold and the restriction enzyme target sequences are underlined.
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The p585T7 vectors were derived from plasmid pET-8c (Studier et al., 1990) via the 
intermediate vector p585.4 (Fig. 3A.2) as follows: the unique EcoRI site was removed 
from plasmid p585.4 by digestion with EcoRI, followed by filling-in of the 5' overhangs 
and re-ligation. The plasmid was then cut at the unique PvwII and SphI sites and the 5' 
overhangs filled-in, followed by re-ligation. This removed a large fragment of 
non-essential DNA (1504 nucleotides) and increased the number of unique restriction 
enzyme sites available for insertion of VZV gene 62 sequences into the multiple cloning 
region (MCR). The MCR of vector pUC19 was isolated on an EcoRI-Hindlll fragment 
and co-ligated into the Ncol-Hindlll digested p585.4 derivative vector along with 
Ncol-EcoRl adaptors. An 8 or 9bp Ncol-EcoRl adaptor was used to yield plasmid 
versions p585T7a and p585T7b2 respectively, enabling translation of inserts in two 
alternative reading frames (Fig. 3A.2). The p585T7c vector allowed expression in the 
third reading frame and was constructed by digesting plasmid p585T7a with Ncol and 
EcoRI, filling-in of 5' overhangs, followed by re-ligation of the vector. The EcoRI site 
was restored and the Ncol site removed during this procedure. For each of the p585T7 
vectors, translation of sequences inserted into the MCR was initiated on the ATG of the 
adaptor Ncol site. Translation termination codons are positioned downstream of the 
BamHI site of the T7 terminator; stop codons in the different reading frames are 
distributed over a 60bp sequence and this accounts for the variation in the numbers of 
vector-encoded amino acids at the C-terminus of the T7 expression products (Section 
3B.3).
3A.3 Construction of the VZV 140k DNA binding domain expression 
vectors p585T7aVT2 and p585T7aVT2X
VZV gene 62 sequences spanning the 140k DNA binding domain were inserted into the 
p585T7a expression vector as follows: an EcoRI site introduced by linker insertion into 
codon 418 of plasmid pV17, was utilised for isolation of an EcoRl-BstEll fragment 
carrying gene 62 codons 417 to 647. Plasmid pV17 was cut with BstEll and the 5' 
overhang filled-in, before a second restriction digest with EcoRI. The resulting 
ficoRI-fBsrEII) fragment was inserted between the adaptor EcoRI site and the MCR 
Smal site of vector p585T7a. The version of the Ncol-EcoRl adaptor in plasmid 
p585T7a maintained the correct 140k peptide reading frame. BamHI digestion, followed 
by re-ligation of the plasmid construct removed DNA sequences between the BamHI 
sites of the multiple cloning and T7 terminator regions. Plasmid p585T7aVT2 encoded a 
256 residue peptide, designated VT2 (Fig. 3A.3). Plasmid p585T7aVT2X was derived 
from p585T7aVT2 by blunt end insertion of a duplex self-complementary 18mer Xbal 
linker oligonucleotide into the filled-in BamHI site of plasmid p585T7aVT2. The linker
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oligonucleotide contained stop codons (underlined) in all three reading frames as 
follows: 5'-AATTAATCTAGATTAATT-3' (the X b a l  site is shown in bold). This 
process removed 16 vector-encoded residues from the C-terminal end of the expressed 
protein that were present in the VT2 polypeptide. The 240 residue expression product of 
plasmid p585T7aVT2X was designated VT2X. The p585T7aVT2X version of the 
plasmid was made in addition to p585T7aVT2, due to the finding that X' versions of the 
HSV-1 Vmwl75 DNA binding domain peptides were generally more stable than the 
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Figure 3A.3 Plasmid p585T7aVT2 and the VZV 140k DNA binding domain 
expression products VT2 and VT2X. Only selected restriction enzyme sites are marked on the 
p585T7aVT2 plasmid. The location of the T7 transcriptional initiation and termination signals are 
indicated by shaded boxes and arrows indicate the direction of expression. The black box represents the 
Ncol-EcoRl oligonucleotide adaptor. The striped box represents the VZV gene 62 coding region (codons 
417-647) on an EcoKl-BstEll fragment from plasmid pV17, inserted into the vector p585T7a as discussed 
in the text. Plasmid p585T7aVT2X differs from p585T7aVT2 by having an Xbal linker inserted into the 
BamHI site 3’ to the gene 62 coding sequences. Shown at the bottom are representations of the expression 
Products of plasmid p585T7aVT2, peptide VT2; and the product of p585T7aVT2X, peptide VT2X. VT2 
includes 4 N-terminal adaptor encoded residues (MAEF) followed by residues 417 to 647 of the 140k 
Protein (striped box) and 21 vector-encoded residues (white boxes represent vector-encoded residues). 
VT2X is identical to peptide VT2 apart from having only 5 C-terminal vector-encoded residues (GDQLI). 
The 256 residue VT2 peptide has a predicted size of 28.4kD and the 240 residue peptide VT2X has a 
Predicted size of26.7kD.
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3A.4 Bacterial expression and partial purification of the VZV 140k DNA 
binding domain
To determine whether VZV gene 62 codons 417 to 647 yield a stable domain when 
expressed as a non-fusion peptide, plasmid p585T7aVT2 was transformed into the BL21 
(pLysS) DE3 strain of E. coli, a culture grown and expression from the T7 promoter 
induced as described in Sections 2C.1 and 2C.2. Samples of the culture were taken after 
various induction times at 37°C for analysis by SDS PAGE (Fig. 3A.4). A novel peptide 
of the approximate predicted size was apparent in the VT2 tracks at the position marked 
by the arrow. The VT2 band became more prevalent as the duration of induction was 
increased, and after a 2hr induction period the VT2 peptide was clearly the most 
abundant protein in the bacterial lysate (track 4). Therefore VZV 140k residues 417 to 
647 are expressed to very high levels as a stable non-fusion peptide in bacterial cells.
VT2 control 
I II I
0.5 1 1.5 2 0.5 1 1.5 2hr MW
1 2 3 4 5 6 7 8 9
Figure 3A.4 Induction and expression of the VZV 140k DNA binding domain in E. 
coli. 10ml cultures of bacterial cells transformed with plasmid p585T7aVT2 or p585T7a were grown 
and expression from the T7 plasmids induced at 37°C (Sections 2C.1 and 2C.2). 1ml aliquots were 
removed after 0.5, 1, 1.5 and 2hr induction periods and cells were pelleted and resuspended in 20 j l i 1 1 X 
TE. After freeze-thaw, 5|il samples were analysed by 12.5% SDS PAGE. Tracks 1-4 contain extracts from 
cells transformed with plasmid p585T7aVT2 (VT2) and tracks 5-8 contain extracts from cells transformed 
with p585T7a (control). Track 9 contains low molecular weight markers: BSA, 66kD; albumin, 45kD; 
glyceraldehyde-3-phosphate dehydrogenase, 36kD; carbonic anhydrase, 29kD; trypsinogen, 24kD; trypsin 
inhibitor, 20.1kD; lactalbumin, 14.2kD. The position of peptide VT2 is marked by an arrow; the particular 
T7 expression construct used in this experiment expressed a VT2 peptide which included an extra 15 
vector-derived residues at the C-terminus of the peptide having a predicted size of 30.1kD (271 amino 
acids) rather than the expected size of 28.4kD (256 amino acids). The form of the p585T7aVT2 vector 
described in Section 3A.3 was used in subsequent experiments.
A 2hr induction period did not appear to be deleterious to the level of VT2 expression. 
Trial experiments found that induction at 26°C tended to produce a more stable peptide, 
whilst not greatly reducing the peptide yield (not shown). Therefore a 2hr induction 
Period at 26°C was used in all subsequent experiments. To determine whether the 140k
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DNA binding domain was soluble, partially purified extracts of the VT2 and VT2X 
peptides were prepared as described in Section 2C.2. Figure 3A.5 shows an SDS PAGE 
analysis of samples taken at stages throughout the purification procedure; clearly both 
the VT2 and VT2X peptides were highly soluble. In the following DNA binding 
analyses, peptides VT2 and VT2X can be considered to be interchangeable as they were 
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Figure 3A.5 Partial purification of the bacterially expressed VZV 140k DNA binding 
domain. Transformed E. coli were grown, expression from the T7 plasmids induced and crude extracts 
were prepared by ammonium sulphate precipitation (Section 2C.2); samples were analysed by 12.5% SDS 
PAGE. BL21 is an extract prepared from induced bacteria lacking an expression plasmid, VT2 and VT2X 
indicate extracts prepared from bacteria carrying plasmids p585T7aVT2 and p585T7aVT2X respectively. 
Tracks 1, 4 and 7 contain lysed bacteria after harvesting; tracks 2, 5 and 8 contain post polymin P 
precipitation supernatants. Tracks 3, 6 and 9 contain partially purified extracts after 35% ammonium 
sulphate precipitation and the amount of extract in these tracks corresponds to that produced from 5ml of 
induced bacterial culture. Track 10 contains low molecular weight standards: BSA, 66kD; albumin, 45kD; 
glyceraldehyde-3-phosphate dehydrogenase, 36kD; carbonic anhydrase, 29kD; trypsinogen, 24kD; trypsin 
inhibitor, 20.1kD; lactalbumin, 14.2kD. The positions of peptides VT2 (28.4kD) and VT2X (26.7kD) are 
marked by arrows.
3A.5 The VZV 140k DNA binding domain interacts with its own VZV 
gene 62 promoter in gel retardation assays
Initial investigations into the DNA binding activity of the 140k DNA binding domain 
peptides used probes derived from the VZV gene 62 promoter, as the autoregulation of 
the gene 62 promoter seen in transient transfection assays (Disney et al., 1990) was 
likely to involve sequence-specific binding, by analogy to the situation with the HSV-1 
Vmwl75 protein (Section 1B.2.3). Moreover, Wu and Wilcox (1991) had recently 
detected interactions between the gene 62 promoter and their 140k DNA binding 
domain fusion peptide (FP617, Fig. 3A.1).
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VZV Gene 62 promoter
-500
5' RE site 3' RE site 5' RE site
UP6 Sail (-410) Rsal (-188)
5UP6 Sail (-410) Oral (-270)
BT Xhol (-130) Bglll (+57)
5BT XhQl (-130) Taql (-51)
3BT Rsal (-23) A val(+43)
UP6oligo Aval (-311) BamHI (-283)
Figure 3A.6 The VZV gene 62 promoter fragment probes. The numbers on the scale 
correspond to nucleotide positions in the gene 62 promoter. The locations of the experimentally 
determined mRNA start site at +1 (McKee et al., 1990) and the previously proposed mRNA start site at 
-287 (Felser et al., 1988) are indicated by the arrows (see Fig. 1B.4). Below the scale are shown the 
relative positions of the probe fragments derived from the gene 62 promoter; the table gives the identity 
and position of restriction enzyme (RE) sites used for their isolation (see Fig. 1B.4). Underlined 
restriction sites indicate the radiolabelled end of each fragment probe (Section 2D. 1.1). Both ends of the 
UP6oligo were labelled. Fragment probes were isolated from plasmid pl40, apart from the BT fragment 
which was isolated from plasmid pl40BT which has a Bglll site artificially introduced at nucleotide +57. 
In the case of the UP6oligo probe, the numbers refer to gene 62 promoter sequences (shown in bold 
below) included in the probe. The UP6oligo probe comprises a pair of 35mer oligonucleotides synthesised 
to yield Aval and BamHI sticky ends flanking the gene 62 sequences when annealed together; a sequence 
homology to the 5' motif of the HSV-1 Vmwl75 consensus binding site is underlined:
5 ' - CCGAGATATTATATATCQTCTGTAGACACACGATG -  3 '
3 ' -  C TATAATATATAGC AGAC ATC TGTGTGC TAC C T AG -  5 '
DNA binding by the partially purified 140k DNA binding domain peptides was tested 
by gel retardation assay using the UP6  and BT probes, which span large stretches of 
gene 62 promoter sequences (Fig. 3A.6). The shorter probes (5UP6, 3BT and 5BT) were 
subsequently used to further analyse locations of specific sequences recognised by the 
140k peptide. All gel retardation assays included l|ig non-specific competitor 
(polydlipolydC) and typical results with the VT2 peptide are shown in Figure 3A.7. 
Each of the gene 62 fragment probes analysed gave a discrete protein-DNA complex
h r i i I r
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referred to as the primary complex (PC) with the 140k peptide extracts, but not with a 
control extract (see Fig. 3A.10, track 1). Therefore it can be assumed that this bacterially 
expressed portion of 140k is correctly folded and does not require additional 
post-translational modifications to enable sequence-specific DNA binding. Increasing 
the amount of VT2 peptide produced further retarded secondary (SC) and higher order 
complexes which presumably contained additional VT2 peptides. The higher order 
complexes could be due to either additional protein-DNA interactions at other binding 
sites or perhaps additional protein-protein interactions. DNase I footprinting on the BT 
probe (Fig. 3A.8) supports the former case, but it should be noted that higher order 
complexes also arose on the 5UP6 probe in gel retardation assay (Fig. 3A.7) even 
though only one binding site was apparent by DNase I footprinting in this region of the 
gene 62 promoter (Fig. 3A.8). It is possible that in addition to the sequence-specific 
binding activity of VT2, there exists transient or low-specificity VT2-DNA interactions 
that fail to be detected by DNase I footprinting analysis.
Figure 3A.7 Gel retardation analysis of the VZV gene 62 promoter region. Partially 
purified VT2 peptide was incubated with the indicated gene 62 fragment probes (described in Fig. 3A.6) 
and the products were resolved by native gel electrophoresis, as described in Section 2D.2. Tracks 14, 15 
and 19 contained no protein extract. The remaining tracks included a VT2 extract; tracks 1-13 contained a 
range of amounts from 0.05 to l.Opi; tracks 16 and 20 contained 0.5pl; 17 and 21 contained l.Opl and 18 
contained 2pl; the VT2 extract used had a VT2 concentration of approximately 0.2pg/pl as determined by 
comparison with BSA standards on SDS PAGE gels (not shown). The position of free probe is indicated 
by 'P', the primary complex by 'PC and the secondary complex by 'SC', higher order complexes remain
unlabelled.
VT2 VT2
probe 5UP6 3BT 5BT
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The specificity of the VT2-DNA binding interaction was tested by competition 
experiments (data not shown) (see Section 2D.2); the primary VT2-DNA complex was 
50% competed from the UP6 oligo and 5UP6 DNA targets by a 200-fold molar excess of 
unlabelled UP6 oligo, whereas the 5BT and 3BT probes, and also the IE3L probe (Fig. 
3A.11) required slightly higher amounts of competitor to achieve a similar degree of 
complex reduction. Approximately 4pg of polydlipolydC or 750ng of pUC9 competed 
off 50% of the VT2-DNA complexes. These results suggest that the 140k DNA binding 
domain recognises these different promoter sequences with similar moderate affinities.
3A.6 The VZV 140k DNA binding domain recognises multiple VZV gene 
62 promoter sequences in DNase I footprinting analysis
The specificity of the interaction between the 140k DNA binding domain peptide and 
the VZV gene 62 promoter fragments was investigated by DNase I footprinting. Typical 
results (Fig. 3A.8) indicated that VT2 bound to multiple sites within the gene 62 
promoter region, apparently with similar affinities, as no order of occupation of sites 
was observed upon titration of the VT2 extract (see right panel of Fig. 3A.8). Consistent 
with the findings of Wu and Wilcox (1991), the sequences protected by VT2 included 
sites (referred to as U and P4) in the immediate vicinities of both mRNA start sites 
proposed for the gene 62 promoter (see Section 1C.2.3, Fig. 1B.4). This suggests that 
the autoregulatory mechanism used by VZV 140k may be similar to that of HSV-1 
Vmwl7 5 , although the recognition of multiple sequences is particular to the 140k 
domain and indicates possible differences between their precise mechanisms. 
Characteristically, the sites of protection by VT2 from DNase I digestion were flanked 
by regions of DNase I hypersensitivity, and this was particularly apparent on the BT 
probe (Fig. 3A.8). Upon close analysis of the protected sequences it was lound that 
several of the sites contained sequences similar to the bipartite HSV-1 Vmwl75 binding 
consensus ATCGTCnnnnYCGRC (Faber and Wilcox, 1986b; Section 1C.1.3) (Fig. 
3A.9).
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Figure 3A.8 DNase I footprints on the VZV gene 62 promoter region. DNase I 
footprinting assays were performed with end-labelled UP6 and BT DNA fragments as described in 
Section 2D.4. Details of probes are given in Fig. 3A.6 and the gene 62 nucleotides included in each probe 
are indicated on the footprints, in each case the non-coding strand was radiolabelled. Arrows indicate the 
proposed transcriptional initiation sites at nucleotides -287 and +1 (see Fig. 1B.4). Brackets representing 
regions of protection from DNase I digestion are labelled U (-302 to -280), PI(-107 to -97), P2 (-81 to 
-74), P3 (-52 to -47), P4 (+6 to +18) and P5 (+27 to +46). In both panels: track 1 contained the relevant 
Maxam and Gilbert G+A sequencing reaction, track 2 contained no extract, track 3 and 4 contained 
partially purified bacterial extract carrying the p585T7a vector. Tracks labelled VT2 contained partially 
purified bacterial VT2 extract. Triangles represent progressively increasing amounts of extract. On the 
UP6 probe: 0.4, 1, 2, 5 and lOpl VT2 extract was included in tracks 5-9. On the BT probe: 0.05, 0.2, 0.5 
and lpl of extract was included in tracks 5-8. Amounts of control extract corresponded to the same range 
of amounts of the VT2 extract used in each experiment.
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Figure 3A.9 Sequence and location of VT2 binding sites in the VZV gene 62 promoter. 
Numbers on the top scale indicate nucleotide positions corresponding to the gene 62 promoter. The 
locations of both proposed mRNA start sites are shown by bent arrows. Expansions of the gene 62 
promoter sequences (coding strand) specifically protected from DNase I digestion by the 140k DNA 
binding domain peptide VT2 in Fig. 3A.8 are labelled U, PI to P5. Obvious homologies to the motif 
found in die 5' portion of the HSV-1 Vmwl75 binding consensus are underlined, the arrow indicates a 
motif in the opposite orientation on the non-coding strand. Shown in outline are the sequences in the 
vicinity of the proposed gene 62 mRNA start sites that are similar to the HSV-1 Vmwl75 consensus 
sequence; these sites were also recognised by Wu and Wilcox's FP617 fusion peptide (Wu and Wilcox, 
1991; Section 1C.2.2).
3A.7 Analysis of whether binding of the VZV 140k DNA binding domain 
to additional sites is cooperative
It was of interest to determine whether the higher order complexes seen in gel 
retardation analyses (Fig. 3A.7) and the protection of multiple binding sites in the 
DNase I footprinting (Fig. 3A.8) arose due to facilitated or cooperative binding of 140k 
DNA binding domain peptides. A wide range of VT2X peptide concentrations were 
incubated with the BT probe which has multiple binding sites for the 140k DNA binding 
domain (as discerned in Fig 3A.8), and the complexes were resolved by gel retardation 
assay. A Hills plot (top right panel, Fig. 3A.10) was derived from the information in the 
autoradiograph from one such experiment (top left panel, Fig. 3A. 10). The part ot the 
plot that reflects occupation of second, third and fourth binding sites (indicated by the 
best fit line in the graph at the top right panel of Fig. 3A.10) has a gradient of 
approximately 1 and indicates that the initial binding of additional VT2X peptides to the 
BT probe occurred in an independent or non-cooperative manner (see legend to Fig. 
3A.10).
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Figure 3A.10 Analysis into the nature of binding of additional VZV 140k DNA 
binding domain peptides. The top left hand panel shows a gel retardation analysis upon the BT 
probe (details given in Fig. 3A.6), tracks 2-15 included increasing amounts (0.001-lpl) of a partially 
purified VT2X peptide extract which had a VT2X concentration of 0.38pg/pl (determined by comparison 
with BSA standards on SDS PAGE gels). Track 1 contains a control extract from plasmid p585T7a 
transformed bacteria and track 16 contains no extract. The top right hand panel shows the corresponding 
Hills plot where Y is the fraction of binding sites occupied; die total number of binding sites in the BT 
probe was assumed to be 5 (from the 5 complexes apparent on longer exposure of the autoradiograph 
shown here and also from the DNase I footprinting assay in Figure 3A.8). This analysis was based on the 
assumption that the PC indicates one occupied binding site, SC indicates two occupied binding sites and 
so on. The fraction of binding sites occupied at each concentration of VT2X was calculated as follows: the 
scintillation count for an individual protein-DNA complex (see Section 2D.2) was multiplied by the 
number of sites occupied in that particular complex, the combined value for all complexes in a single 
track was then divided by 5 times the total value of scintillation counts of free and complexed probe. The 
best fit lines in both graphs were fitted by eye. A Hills plot gradient of more than one indicates 
cooperative binding and if the gradient is equal to one binding is non-cooperative. The lower panel shows 
4 Hills plot from a gel retardation analysis of VT2 binding to the 5UP6 probe (details in Fig. 3A.6), very 
similar to that shown on the left hand panel of Figure 3 A.7. Data was calculated on the assumption that 
the number of binding sites was 5 (from the 5 successive protein-DNA complexes formed in gel 
retardation analyses) on the 5UP6 probe. Re-calculation of the data for 4 or 6 binding sites produced very 
little alteration in the gradient of the plot shown here.
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However, the nature of binding is best measured where log Y/l-Y = 0, at this point the 
gradient increased to more than 1 , suggesting cooperativity of binding (top right hand 
panel, Fig. 3A.10). A corresponding analysis upon the 5UP6 promoter fragment (details 
in Fig. 3A.6) produced a Hills gradient of approximately 2 (lower panel, Fig. 3A.10). 
This particular region of the VZV gene 62 promoter included a single binding site 
apparent by DNase I footprinting analysis (Fig. 3A.8). Although further analyses are 
required, this initial data suggests that the loading of additional VT2 peptides beyond 
the initial occupation of specific binding sites is cooperative, and may correlate with the 
widening of regions of protection from DNase I digestion that occurred with higher 
peptide levels in the DNase I footprinting analyses (see below).
3 A . 8  I n t e r a c t i o n s  o f  t h e  V Z V  1 4 0 k  D N A  b i n d i n g  d o m a i n  w i t h  t h e  H S V - 1  
I E 3  a n d  g D  p r o m o t e r s
The interaction between the VZV 140k DNA binding domain and functional HSV-1 
Vmwl75 consensus binding sites was investigated, as several of the VT2 binding sites 
identified in the VZV gene 62 promoter showed sequence homology to the Vmwl75 
binding consensus (Fig. 3A.9). DNA fragment probes from the HSV-1 IE3 promoter 
and HSV-1 glycoprotein D (gD) early gene promoter were used in DNA binding 
analyses (details in Fig. 3A.11).
The HSV-1 IE3 probes included the Vmwl75 consensus binding site (Muller, 1987) 
spanning the mRNA start site. This binding site is involved in the autoregulation of the 
IE3 promoter (Section IB.2.3). In view of the observation that VZV 140k does not 
repress the IE3 promoter (Disney et a l, 1990), the relationship between VT2 and the 
IE3 binding site was analysed, initially by gel retardation assay. Incubation of the VT2 
or VT2X peptide with the IE3 probes gave specific protein-DNA complexes and 
additional multiple complexes arose on titration of peptide, as noted earlier with the 
VZV gene 62 promoter probes (Section 3A.5). Figure 3A.15, track 2 shows two such 
complexes on the IE3L probe, while track 3 shows a primary complex produced with an 
equivalent amount of the Vmwl75 DNA binding domain peptide, I9X. Therefore the 
140k DNA binding domain has an affinity for this region of the HSV-1 IE3 promoter 
similar to that of the Vmwl75 domain. The 140k DNA binding domain trpE fusion 
protein (FP617) has been reported to have a binding activity of roughly one-tenth that of 
the equivalent Vmwl75 fusion protein on HSV-1 IE3 and gD promoter fragment probes 
(Wu and Wilcox, 1991; Betz and Wydoski, 1993).
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Figure 3A.11 HSV-1 IE3 and gD promoter fragment probes. Schematics of the HSV-l 
DNA fragment probes used in this study. Numbers on the scales correspond to nucleotide positions in 
each promoter and the mRNA start sites are shown by bent arrows. The position and sequence of the IE3 
(Muller, 1987) and the gD (Faber and Wilcox, 1986b) consensus Vmwl75 binding sites are given. The 
thick lines represent sequences included in the IE3L, IE3S and gD probe fragments, the restriction sites 
used for their isolation are indicated; asterisks indicate the radiolabelled end of each fragment probe. IE3L 
and IE3S fragment probes were isolated from plasmids pIE3CAT or pUCIE3, the gD fragment probe was 
isolated from plasmid pgDCAT.
A high-resolution DNase I footprinting analysis on the HSV-1 IE3S fragment probe 
provided verification that the VZV 140k DNA binding domain specifically recognised 
the HSV-1 IE3 consensus site. The VT2 peptide protected, albeit faintly, both halves of 
this bipartite Vmwl75 consensus site from DNase I digestion (Fig. 3A.12). As seen 
previously on the VZV gene 62 promoter (Fig. 3A.8), DNase I hypersensitivity was 
induced at the edges of the protected sequences as the amount of VT2 extract present 
increased. The footprint produced at this site by the VZV 140k DNA binding domain, 
VT2 , differed in several respects to that produced by the corresponding domain of 
HSV-1 Vmwl75 (peptide I9X, for details see Section 1C. 1.10 and Fig. 3B.7). VT2 
induced greater DNase I hypersensitivity to the 5' side of the binding site but provided 
less complete protection within the binding site itself (Fig. 3A.12). In particular, VT2 
failed to protect the region between the 5' (ATCGTC) and 3’ (CGG) motifs. Therefore, 
even though both peptides recognised the same IE3 consensus site, the details of their 
structural interactions must differ.
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Figure 3A.12 DNase I footprinting analysis of the HSV-1 IE3 consensus binding site. 
DNase I footprinting reactions included the IE3S probe (Fig. 3A.11), but only nucleotides -15 to +15 are 
shown. The coding strand was the radiolabelled DNA strand. In both panels: track 1 contains the G+A 
Maxam and Gilbert sequencing reaction and track 2 contained no extract; the 'con' track included 5pl of 
an extract from bacteria containing plasmid p585T7a. On the left hand side: tracks 4-8 contain 0.4, 1, 2, 5 
and lOpl of a partially purified bacterial VT2 extract respectively. On the right hand side: tracks 3-5 
contain increasing amounts of partially purified I9X extract covering an equivalent range of peptide 
concentrations to the VT2X range used on the left. An expansion of the sequence of the IE3 Vmwl75 
consensus binding site is shown and the direction and position of transcriptional initiation is marked by 
the arrow. The I9X footprint was kindly provided by Dr R. D. Everett.
The gD promoter probe (Fig. 3A.11) included the Vmwl75 consensus binding site 
(gDII site) that is known to contribute to the stimulation of transcription by HSV-1 
Vmwl75 in vitro (Tedder etal., 1989). VZV 140k is a potent transactivator of the HSV- 
1 gD promoter in transient transfection assays (Disney, 1990) and the 140k DNA 
binding domain recognised the gD fragment probe in gel retardation assays (see Fig. 
3E.6). Analysis of the specificity of the interaction between the VT2 peptide and the gD 
promoter identified multiple sequences weakly protected from DNase I digestion, that 
were flanked by DNase I hypersensitivity sites (Fig. 3A.13). This was reminiscent of the 
pattern observed on the VZV gene 62 promoter (Fig. 3A. 8 ) and suggests that binding to 
multiple sites is unlikely to be a feature specific to the negative autoregulatory function 
of VZV 140k. The sites protected by VT2 included the gDII Vmwl75 consensus 
sequence and at least four other sequences not recognised by Vmwl75; these additional 
binding sites were centred around gD nucleotides -125, -85, -55 and -45 (Fig. 3A.13). 
DNase I footprinting with the highest amount of VT2 (Fig. 3A.13, track 5) resulted in a 
generalised widening of the protected sequences, perhaps due to lower specificity 
interactions. This effect was previously seen, although to a lesser extent, on the VZV 
gene 62 promoter probe BT (right hand panel of Fig. 3A.8, track 8 ) and also on the UP6
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probe (Fig. 3B.6, track 8 ). The interaction of the 140k DNA binding domain trpE fusion 
peptide (FP617) with the HSV-1 gDII sequence has been recently reported by another 
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Figure 3A.13 DNase I footprinting analysis of the HSV-1 gD promoter region. The 
DNase I footprinting assay was performed with the end-labelled gD promoter target (details given in Fig. 
3A.11). The coding strand was the radiolabelled strand. The numbers on the scale correspond to 
nucleotide positions in the gD promoter relative to the mRNA start site at +1; the position and sequence of 
the gDII consensus binding site are given (Faber and Wilcox, 1986b). Track 1 contained a G+A Maxam 
and Gilbert sequencing reaction. Track 2 included lpl partially purified bacterial extract carrying the 
p585T7a vector. Tracks 3-5 included 0.2, 0.5 and lpl partially purified bacterial VT2 extract.
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3A.9 The VZV 140k DNA binding domain is less sequence-specific than 
the corresponding domain of HSV-1 Vmwl75
The finding that several VT2 binding sites within the VZV gene 62 promoter region 
showed similarity to the HSV-1 Vmwl75 consensus binding sequence (Fig. 3A.9), and 
also that the VZV 140k DNA binding domain recognises the HSV-1 gD and IE3 
consensus sites (Section 3A.8), suggested that 140k may have a similar DNA binding 
specificity to that of HSV-1 Vmwl75. This was investigated by comparing the binding 
specificities of the Vmwl75 and 140k DNA binding domains by use of a mutagenised 
IE3 consensus binding site. The aim was to identify differences in the binding 
specificities of these two homologous domains that might account for their opposing 
functional effects on the IE3 promoter, as seen in transfection assays (Disney et al.,
1990). An extensive mutagenesis of the IE3 consensus binding site had been performed 
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Figure 3A.14 Comparison of the effects of point mutations in the HSV-1 IE3 
consensus binding site on the binding efficiencies of the 140k and Vmwl75 DNA 
binding domains. The sequence spanning the Vmwl75 consensus binding site in the HSV-1 IE3 
promoter is shown in bold type below the graph The vertical bars above each base represent the 
percentage efficiency of peptide binding, when that base was mutated to the one shown in smaller type 
below (compared to the efficiency of binding to the wild type probe). The particular base substitution at 
each position was the one that was previously found to be most deleterious to the DNA binding efficiency 
of Vmwl75 (Everett et al., 1991a). Values were derived by quantitation of free and complexed probe 
bands resolved by gel retardation analysis (see Section 2D.2); the arrow indicates a value above 120%. 
Data used to produce the I9X binding profile was abstracted from Everett et al., (1991a). Although the 
experiments using the VT2 and I9X peptides were performed independently, the reaction conditions and 
other parameters were identical. Analysis of VT2 binding efficiency was carried out with sets of 
mutagenised probe fragments isolated from the M13IE3MB series of plasmids, and probes prepared on 
two separate occasions gave highly reproducible results. Values used to produce the VT2 profile represent 
averages of the results provided by the two analyses.
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The mutagenised progeny M13 phage resulting from this earlier study were utilised to 
isolate 'prime cut' Aval-BaniHl IE3S fragment probes, containing single point mutations 
at positions throughout the IE3 consensus binding site. Single stranded M13 templates 
were re-sequenced to ensure the presence of the expected mutation, then the probes were 
isolated by the 'prime cut' method to yield DNA targets with equivalent specific 
activities suitable for comparative analyses (Section 2D. 1.2). The mutant probes were 
used in gel retardation experiments with the partially purified VT2 bacterial extract, in 
order to determine the VT2 binding specificity for the HSV-1 IE3 binding site. The 
results are summarised in histogram form in Figure 3A.14, combined with the 
previously determined binding profile for the equivalent HSV-1 Vmwl75 domain, 
peptide I9X (Everett et al, 1991a). It is apparent that the 140k DNA binding domain has 
an overall reduced binding specificity for this IE3 consensus binding site compared to 
the Vmwl75 domain, and it appears to be virtually insensitive to point mutations in the 
3' portion of the bipartite sequence. Additionally, a point deletion of the first T (in 
brackets) of the A(T)CGTC motif reduced the I9X binding efficiency to 5% the level of 
binding to the wild type IE3 sequence (Everett et al., 1991a). This same deletion has a 
much reduced effect on the 140k domain, which bound with 20-45% wild type 
efficiency (data not shown). These data suggest that the VZV 140k DNA binding 
domain has a lower DNA sequence specificity than the HSV-1 Vmwl75 domain. This 
was previously indicated by the low sequence selectivity of the VT2 peptide seen in the 
DNase I footprinting analyses (Sections 3A.6 and 3A.8 ).
3A.10 Both intact HSV-1 Vmwl75 and its isolated DNA binding domain 
have very low affinities for the VZV gene 62 promoter binding sites
HSV- 1  Vmwl75 down-regulates the VZV gene 62 promoter in transient assays (Disney 
et al., 1990). Therefore it was of interest to determine whether the Vmwl75 DNA 
binding domain interacts with the VT2 binding sites identified in the VZV gene 62 
promoter, to further analyse whether the mechanistic basis of gene 62 repression was 
similar to autoregulation of the HSV-1 IE3 promoter by Vmwl75. Approximately 
equivalent amounts of VT2X and the corresponding Vmwl75 DNA binding domain 
peptide, I9X, were incubated with HSV-1 IE3 and VZV gene 62 promoter probes and 
the resultant complexes analysed by gel retardation assays. The 140k DNA binding 
domain, peptide VT2X, gave discrete complexes with the gene 62 and IE3 promoter 
probes (Fig. 3A.15, tracks 2, 7 and 12), and as expected, I9X specifically recognised the 
IE3 promoter probe (track 3). However, no obvious complexes specific to I9X were 
detected with either the UP6 oligo or the BT probes that were derived from the gene 62 
promoter (Fig. 3A.15, tracks 8  and 13 respectively).
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probe: IE3L UP6oIigo BT
Figure 3A.15 Gel retardation analysis of HSV-1 IE3 and VZV gene 62 promoter 
regions. The IE3L DNA probe, derived from the HSV-1 IE3 promoter is described in Fig. 3A.11. The 
UP6oligo (including the U site) and BT (including sites P1-P5) probes were derived from the VZV gene 
62 promoter and are described in Fig. 3A.6. Target DNA was incubated with approximately equivalent 
amounts of partially purified VZV VT2X or HSV-119X bacterial extracts, or equivalent amounts of HeLa 
nuclear extracts with or without intact Vmwl75 as indicated above the tracks. The Vmwl75 protein was 
expressed from plasmid pI8 that has an insertion mutation in a region not involved in DNA binding 
(Paterson and Everett, 1988a; b). HeLa extracts were produced by T. Paterson. Two different 
autoradiographic exposures of the same gel are shown here, since prolonged exposure was necessary to 
visualise the complex between the HSV-1 IE3L fragment and intact Vmwl75 (track 5), marked by the 
arrow.
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On repetition of this analysis with greater amounts of I9X extract, faint protein-DNA 
complexes were detected with the BT probe. DNase I footprinting analyses have also 
failed to detect interactions between I9X and the VZV gene 62 promoter probes BT and 
UP6  (not shown).
To verify that the binding results obtained for I9X reflect the situation with intact 
Vmwl75, nuclear extracts from HeLa cells, transfected either with or without a plasmid 
expressing Vmwl75, were incubated with the same probes as above. The only 
protein-DNA complex specific to intact Vmwl75 produced in this gel retardation 
analysis was with the HSV-1 IE3L probe (marked by the arrow in the longer exposure 
of Fig. 3A.15, track 5). Therefore, both intact HSV-1 Vmwl75 and its isolated DNA 
binding domain have greatly reduced affinities for the VT2 binding sites in the gene 62 
promoter, compared to the binding observed with the VZV 140k DNA binding domain. 
It appears that despite the sequence similarity of several of the VT2 binding sites in the 
gene 62 promoter to the Vmwl75 binding consensus, the degree of homology is 
insufficient to allow recognition of these sites by the comparatively specific Vmwl75 
peptide. These results are in agreement with those obtained from the specificity 
comparison between the VZV VT2 and HSV-1 I9X DNA binding domain peptides, 
which found VT2 to be have a reduced stringency for the IE3 consensus site compared 
to the Vmwl75 DNA binding domain (Section 3A.9).
3A.11 Binding of the VZV 140k DNA binding domain does not induce 
DNA bending at its gene 62 promoter binding sites
HSV-1 Vmwl75 and its isolated DNA binding domain both induce a significant DNA 
bend in the immediate vicinity of the HSV-1 IE3 and gDII consensus binding sites 
(Everett et al., 1992) which may be of functional relevance. Since the VZV 140k DNA 
binding domain recognised sites bearing similarity to the Vmwl75 consensus binding 
sequence in one of its target VZV promoters, and it specifically recognised the HSV-1 
IE3 and gD consensus binding sites, it was of interest to determine whether VT2 binding 
would induce similar DNA conformational alterations. VT2 induced DNA bending was 
undetectable at the HSV-1 gD and IE3 consensus sites using the probes described by 
Everett et al (1992) (data not shown). It could be argued that these heterologous 
binding sites are not directly functionally relevant to VZV 140k. Therefore the binding 
sites in the vicinities of both proposed VZV gene 62 mRNA start sites were tested for 
VT2 induced DNA bending. The method used to detect DNA bending depends on the 
principle that a bend near the end of a restriction fragment causes a less pronounced 
reduction in electrophoretic mobility as compared to a bend in the middle, as assayed by
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gel retardation analysis. Regions of the gene 62 promoter, spanning the U site and also 
the P4/P5 140k binding sites (Fig. 3A.9) were cloned into the pBend2 plasmid (Zweib et 
al., 1989) to yield plasmids pBendU and pBendP respectively. From these plasmids, 
probe DNA fragments were prepared by cutting with either Bglll, Xhol or BamHI.
VT2
I I
1 2 3 4 5 6 7 8
p ro b e : A A B C A B C C  
pBendU pBendP £ 
co a
pBend probes:
Bglll Xhol BamHI Bglll Xhol BamHI
I I lr—|i i i
A Bgl------------- 1 h
B Xhol  1 I-------
C BamHI H I------------------
Figure 3A.16 Circular permutation gel retardation assay with V Z V  gene 62 promoter 
binding sites. Track 1 contained free probe while track 8 contained probe derived from plasmid 
pBend2 by BamHI digestion. Probes in tracks 1, 2, 3 and 4 (which include site U; see Fig. 3A.9) were 
derived from the plasmid pBendU by cutting with the enzyme indicated by the letter below each track 
(A = Bglll, B = Xhol, C = BamHI) to yield 184bp DNA fragments. Similarly, probes in tracks 5, 6 and 7 
(which include sites P4 and P5) were derived from plasmid pBendP to give 218bp DNA fragments. 
Incubation mixes for tracks 2-8 contained sufficient VT2 extract to produce only primary complexes and 
the amount of non-specific inhibitor (polydI:polydC) was increased to 4(ng per reaction to reduce the 
extent of non-specific VT2 binding to the non-gene 62 promoter-derived probe regions. Non-specific 
DNA binding still occurred as indicated by the faint complex seen in track 8 containing the pBend2 probe 
with no introduced VT2 binding site, but this non-specific complex is a minor species compared to the 
specific primary complexes apparent in tracks 2-7. Beneath the gel is shown a schematic of a binding 
site-containing fragment (depicted by the box) inserted between the pBend2 derived tandemly repeated 
sequence. Bglll, Xhol and BamHI restriction sites are at equivalent positions in each of the repeats as 
shown. Single enzyme digestions gave fragments of identical lengths but with the position of the binding 
site circularly permuted with respect to the ends of the probes. Plasmid pBendU contained the blunt ended 
UP6oligo (Fig. 3A.6) inserted into the Sail site located between the tandem repeats of plasmid pBend2 
and included VZV gene 62 sequences -311 to -283. Plasmid pBendP contained an Rsal-Rsal fragment 
inserted into the pBend2 Sail site and included VZV gene 62 promoter sequences -23 to +50.
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The DNA fragments contained VT2 binding sites at circularly permuted positions within 
each set of three probes for use in gel retardation assays. An example of a typical DNA 
bending analysis is shown in Figure 3A. 16. There was no significant difference in the 
mobility of the primary protein-DNA complex within each set of three probes (A, B, C). 
Therefore, in contrast to the HSV-1 Vmwl75 DNA binding domain, the VZV 140k 
peptide does not induce detectable DNA bending in the vicinity of its binding sites.
3A.12 Discussion
The results presented in this Section (3A) demonstrate that a fragment of the VZV 140k 
protein, including the C-terminal portion of region 1 and the whole of the highly 
conserved region 2 , can be stably expressed in isolation from other viral sequences in 
E. coli. This non-fusion peptide, referred to as VT2 (VT2X), contains 140k residues 417 
to 647 and constitutes a sequence-specific DNA binding domain.
The 140k protein is known to negatively autoregulate its own VZV gene 62 promoter in 
transient transfection assays in selected cell types (Disney et al., 1990). This presumably 
reflects a homeostatic mechanism whereby levels of 140k are stabilised and high level 
expression is prevented as infection proceeds. Consistent with the mechanism of HSV-1 
Vmwl75 autoregulation (Section IB.2.3), the partially purified bacterially expressed 
VT2 peptide recognised specific sequences in the gene 62 promoter region. Wu and 
Wilcox (1991) had previously reported similar interactions between gene 62 sequences 
and a large fusion protein including these same 140k protein sequences. The analyses 
described in these Sections, utilising the non-fusion VT2 (VT2X) 140k DNA binding 
domain polypeptide, confirm and greatly extend the initial observations of Wu and 
Wilcox.
The 140k DNA binding domain peptide, VT2, specifically interacted with multiple 
sequences within the VZV gene 62 promoter region; at least six individual VT2 
recognition sites were identified in the stretches of the promoter analysed. Preferential 
binding to any single site was not apparent, and preliminary data suggested that DNA 
binding of additional 140k DNA binding domain peptides proceeded in a cooperative 
manner (given sufficient peptide amounts). No obvious 140k binding consensus 
sequence could be derived from the VT2 binding sites identified in this analysis. 
However, several of the sequences recognised by VT2  in the gene 62 promoter 
contained homologies to the 5 ' portion of a consensus sequence that was originally 
derived by Faber and Wilcox (1986b) for some of the HSV-1 Vmwl75 binding sites 
(Section 1C. 1.3). Interestingly, two such Vmwl75 consensus-like sites are located in the
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immediate vicinities of the VZV gene 62 transcriptional initiation site at +1 (McKee et 
al., 1990) and the previously proposed gene 62 mRNA start site further upstream at -287 
(Felser etal., 1988) (see Fig. 1B.4).
There is indirect evidence to suggest that the regulatory functions of HSV-1 Vmwl75 
and its PRV IE 180 homologue are mediated by simultaneous interactions with DNA and 
TFIID (see Sections IB.3.3 and 1C.3.1). Autoregulation of the HSV-1 IE3 promoter 
requires the strong interaction of Vmwl75 with a specific Vmwl75 consensus sequence 
spanning the IE3 mRNA start site, and appears to be a consequence of inhibition of Spl 
induced activation, rather than inhibition of basal transcription (see Section IB.2.3). As 
such, Vmwl75 occupation of the IE3 consensus binding site is unlikely to prohibit 
assembly of the transcriptional preinitiation complex, but may preclude further assembly 
of the active transcription complex or interfere with the activity of the TBP-associated 
factors (TAFs) for upstream activating factors. By analogy, the interactions of the VZV 
140k DNA binding domain with the sequences in close proximity to the possible VZV 
gene 62 mRNA start sites are implicated in the autoregulation function of 140k. It has 
been proposed that the VZV 140k alphaherpesvirus homologues may all share a 
common autoregulatory mechanism as sequences similar to the HSV-1 Vmwl75 
consensus are also found overlapping the transcription start sites of the PRV IE and 
EHV IE genes (Wu and Wilcox, 1991; Smith et al., 1992a). Furthermore, a fusion 
peptide containing the PRV IE 180 residues corresponding to those in peptide VT2, 
specifically recognised the site spanning its own mRNA start site (Wu and Wilcox,
1991). In the case of the VZV gene 62 promoter, a thorough mutational analysis would 
be necessary to determine whether the sequences near the mRNA start sites, or any of 
the numerous other specific VT2 binding sites identified in this study, are required for 
down-regulation of the gene 62 promoter by the 140k protein.
The similarity of several VT2 binding sites to the Vmwl75 consensus sequence 
suggests that VZV 140k may have a related sequence selectivity to that of HSV-1 
Vmwl75. This is further supported by the observation that the 140k DNA binding 
domain specifically recognised Vmwl75 consensus binding sites in the HSV-1 
promoters analysed. Recent experiments have implied that VZV 140k binding to the 
gDII consensus site contributes to the 140k-mediated transactivation of the HSV-1 gD 
promoter (Betz and Wydoski, 1993). VT2 interacts specifically with the consensus 
binding site spanning the mRNA start site of the HSV-1 IE3 gene, having an apparent 
binding affinity comparable to that of the corresponding domain of Vmwl75. Yet 
evidence from transfection assays (Disney etal., 1990) and also from analyses of the 
recombinant HSV-140 virus (Disney and Everett, 1990), suggested that intact 140k fails
t
to repress the HSV-1 IE3 promoter, although the later observation appears to depend
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upon the cell type used (J. Smiley, personal communication). Similarly, the EHV IE1 
protein down-regulates its own promoter, presumably through interaction with the 
Vmwl75 consensus-like site over its mRNA start site, yet fails to repress the HSV-1 IE3 
promoter in transient assays (Smith et al., 1992a). Slight sequence differences between 
the binding sites found at the mRNA start sites of the VZV gene 62, HSV-1 IE3 and 
EHV-1 IE genes may account for these findings, as each protein is likely to have its own 
particular sequence requirements for optimal recognition. The apparent differences 
between the details of the interactions of the 140k and Vmwl75 DNA binding domains 
with the HSV-1 IE3 consensus binding site support this idea. Therefore the interaction 
with the heterologous binding site may not be appropriate to enable promoter repression 
by the models suggested above. Additionally, there is evidence to suggest that binding 
of Vmwl75 alone to the IE3 consensus site is not sufficient for autoregulation, as a 
mutant Vmwl75 protein containing a temperature sensitive lesion (due to the 
substitution A966T in the highly conserved region 4) was indistinguishable from the 
wild type in its ability to bind to the IE3 consensus binding site, yet failed to 
autoregulate at the NPT (Paterson et al., 1990). According to the autoregulation 
mechanism suggested above, the lesion in region 4 may affect the interactions between 
Vmwl75 and other factors (perhaps TFIID) such as to allow transciptional initiation 
even in the presence of tightly bound Vmwl75. Perhaps the precise positioning of the 
HSV-1 IE3 site with respect to the TATA box may not be correct for the optimal 
interaction between the VZV 140k protein and TFIID that is required for transcriptional 
repression. A close correlation has been observed between Vmwl75-mediated negative 
autoregulation and the stereo-specific or distance-dependent placement of the IE3 
binding site and the TATA box (Didonato and Muller, 1989).
HSV-1 Vmwl75 is equally as effective as VZV 140k in the down-regulation of the 
VZV gene 62 promoter in transfection assays (Disney et al., 1990), yet intact Vmwl75 
and also its isolated DNA binding domain displayed greatly reduced affinities for the 
binding sites therein, compared to that of the 140k DNA binding domain. It is possible 
that the results of the in vitro DNA binding analyses do not fully reflect the situation in 
infected or transfected cells. Down-regulation of the gene 62 promoter, by Vmwl75 at 
least, may be more complicated than DNA binding alone and may involve interactions 
with other viral proteins or host transcription factors. It has recently been shown that the 
DNA binding activity of Vmwl75 is facilitated by TFIID and TFIIB in vitro (Smith et 
al, 1993). Perhaps the very low levels of Vmwl75 binding to the VZV gene 62 
promoter is sufficient to mediate transcriptional repression in the presence of these basal 
transcription factors in vivo.
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It is of interest to note that although negative autoregulation of the VZV gene 62 
promoter in Vero and BHK cells is well documented (Felser et al, 1988; Disney et al., 
1990; this Thesis, Section 3F.4), the opposite effect has been demonstrated in 
T lymphocytes and neural cells (PC-12). In these particular cell lines VZV 140k, and 
also HSV-1 Vmwl75, activated the VZV gene 62 promoter (Perera et a l, 1992b). T 
lymphocytes and neural cells are important sites for productive VZV growth during 
infection and therefore these cell lines were considered to be physiologically relevant. 
Tissue specific differences in the abundance or the complement of transcription factors 
may determine whether VZV 140k activates or represses its cognate gene 62 promoter.
An examination of the specificity of the VZV 140k DNA binding domain peptide for a 
Vmwl75 consensus binding site found that sequences in the 3' portion of the consensus 
site were unimportant for VT2 binding. It is possible that the VT2 binding sites may 
have their own distinct 3' motif, but none is apparent for the sites identified in this study. 
The VT2 sites may transpire to fit a broad consensus that may be a more degenerate 
form of the consensus statistically determined for a wide range of Vmwl75 sites 
(DiDonato et al, 1991). However, it should be noted that the sites of DNase I protection 
by VT2 were of highly variable sizes. The results of a specificity analysis using the 
mutagenised HSV-1 IE3 consensus site found that the VZV 140k DNA binding domain 
has a lower DNA binding specificity than the equivalent domain of HSV-1 Vmwl75. 
This reduced DNA binding specificity was reflected in the high number and also the 
variety of sequences recognised by VT2 in the VZV gene 62 and HSV-1 gD promoters. 
The low binding specificity of the VT2 peptide could explain the promiscuous 
transactivating phenotype of 140k in transfection assays (Section 1C.2.3), as the 140k 
protein would be predicted to have a low promoter selectivity. During infection, 140k 
may function by activating suboptimally utilised RNA polymerase II promoters in a 
similar manner to that previously suggested for the homologous PRV IE 180 protein 
(Thali et a l, 1990). In this scenario, the sequence of the binding site is not the primary 
determinant of a target promoter. Instead, the low specificity of the 140k protein would 
make all physically accessible, TATA-containing promoters, that are not already fully 
activated (by the presence of an enhancer or multiple ds-acting elements) targets for 
activation by 140k; the most abundant class of target would therefore be the viral 
promoters.
VT2 binding to multiple sites as seen on the VZV gene 62 promoter is unlikely to be a 
feature specific to the autoregulatory function of 140k, since DNase I footprinting 
analysis of the HSV-1 glycoprotein gD promoter, which is strongly activated by 140k in 
transfection assays (Disney, 1990), identified multiple sites of VT2 protection from 
DNase I digestion and extensive DNase I hypersensitivity. In addition, the homologous
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PRV IE 180 protein binds multiple sequences with limited homology in the AdML and 
hsp70 promoters, and DNA binding is necessary for the activation of these promoters by 
PRV IE 180 (Cromlish et al., 1989). Even though multiple VT2-DNA interactions were 
apparent in the DNA binding analyses, it is possible that multiple binding of 140k 
proteins is not functionally relevant and may just be a consequence of the low 
specificity of the protein combined with the high amounts of peptide used in the 
analyses. During infection, the low specificity of the 140k protein may provide a 
mechanism to increase the probability of target promoter recognition. By analogy to a 
current functional model for HSV-1 Vmwl75 (Section 1C.1.7), the position and 
orientation of the particular DNA binding site occupied by 140k would not greatly affect 
the efficiency of transactivation of the promoter.
The VZV 140k protein is a more potent transactivator of gene expression than HSV-1 
Vmwl75 in transfection assays (Cabirac et al., 1990; Disney, 1990). This strong 
transactivation phenotype of 140k is not merely a function of the relative strengths of 
the HSV-1 IE3 and VZV gene 62 promoters (Disney, 1990), but could be attributable to 
the relative strengths of their activating domains. This remains to be quantified, 
although an isolated 140k potential activation domain activates transcription to a level 
comparable to that of the potent HSV VP 16 activation domain (Cohen et al., 1993). An 
alternative explanation suggested by this study is that multiple interactions of 140k 
proteins within the same promoter may have an additive or perhaps even a synergistic 
effect, enhancing the efficiency of activation. This could be facilitated by interactions 
with other viral or cellular proteins or via conformational effects on the promoter (see 
below).
Of possible functional significance are the alterations of DNA conformation induced by 
binding of the 140k DNA binding domain peptide, made apparent by the sites of 
DNase I hypersensitivity flanking the VT2 binding sites on all three promoters analysed. 
The intact Vmwl75 protein and its isolated DNA binding domain significantly bend the 
DNA at its binding sites (Everett et al., 1992), whereas detectable DNA bending was not 
induced by the 140k DNA binding domain peptide in the corresponding analysis. This 
lack of DNA bending at individual VT2 binding sites, and also the extensive nature of 
the DNase I hypersensitivity pattern, suggest that the conformational effects may extend 
along the length of the 140k target promoters, induced by multiple VT2 peptides 
binding to numerous sites. If this transpires to be the case for binding of the intact 140k 
protein during VZV infection, numerous possible functional implications of such a 
broad-ranging conformational effect can be envisaged, including modification of the 
interactions of transcription factors with DNA or with other proteins, or clearing the 
promoter of non-specific or inhibitory DNA binding proteins. Thus the low speciticity
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of binding of the 140k DNA binding domain, which could alternatively be termed 
'sequence selectivity', may facilitate an unusual mechanism of transcriptional regulation.
The VZV 140k DNA binding interaction appears to be essential for the regulatory 
functions of 140k, as an insertion mutation into region 2 prevented 140k from 
transactivating or repressing gene expression (Disney et al, 1990). Therefore future 
investigations into the mechanistic details of the 140k DNA binding interaction will be 
crucial to gain an understanding of the role of 140k in infection. The molecular basis of 
whether the outcome of 140k binding to its target promoters is transactivation or 
repression remains to be determined.
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3B Determination of the VZV 140k protein sequence 
requirements for DNA binding
3B.1 Strategy
The DNA binding domain of HSV-1 Vmwl75 has been closely defined by insertion, 
deletion and truncation analyses (Sections 1C. 1.9 and 1C. 1.10). However, no 
comparable studies on the VZV 140k protein have been undertaken. The position of 
sequences important for the 140k DNA binding activity was indirectly implied from a 
single 4 amino acid insertion into 140k residue 472 that disrupted the regulatory 
functions of the intact 140k protein (Disney et al, 1990). Therefore, the protein 
sequences included in the 140k DNA binding domain peptide VT2 (amino acid residues 
417 to 647) (Fig. 3A.1) and also in the FP617 fusion protein (Wu and Wilcox, 1991), 
had been selected mainly on the basis of homology to the HSV-1 Vmwl75 DNA 
binding domain.
There are clear functional and sequence similarities between the VZV 140k and HSV-1 
Vmwl75 proteins, but there are also distinct differences in the details of their regulatory 
and DNA binding activities (Sections 1C.2.1, 1C.2.3 and 3A). The studies described in 
the following Sections aimed to discern whether the variations between these 
homologous IE proteins extend to their protein sequence requirements for DNA binding. 
It was of particular interest to investigate the requirement for the C-terminal portion of 
region 1 for 140k DNA binding activity, because this region is very poorly conserved 
between HSV-1 Vmwl75 and VZV 140k (Figs. 1C.1 and 1C.3), but is essential for the 
DNA binding activity of Vmwl75 (Section 1C. 1.9 and 1 C. 1.10; Fig 1C.2).
In order to refine the minimum region of the VZV 140k protein that is sufficient for 
sequence-specific DNA binding, a series of plasmids expressing progressively smaller 
versions of the VT2 peptide were constructed, having truncations at either one or both 
ends. The gene 62 sequences selected for bacterial expression were based on the 
availability of convenient restriction enzyme sites. Care was taken when designing 
deletion constructs to have a 'favourable' codon following the ATG initiation codon, 
because the identity of the second codon can have a dramatic effect on the level of 
Peptide expression in E. coli (Looman et a l, 1987). The experiments described in the 
following Sections analysed the DNA binding abilities of the truncated 140k peptides.
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3B.2 Construction of plasmids expressing truncated versions of the VZV 
140k DNA binding domain
Portions of the VZV gene 62 coding sequences were inserted into the MCR of the 
appropriate T7 expression vector of the p585T7 series (described in Section 3A.2), to 
maintain the correct reading frame. A summary of the gene 62 sequences inserted into 
the T7 expression vectors are given in Table 3B and the expression products are 
illustrated in Figure 3B.1. Plasmids pV17 and pV18 have an EcoRl site inserted on a 
12bp linker into gene 62 codons 418 and 472 respectively (Disney, 1990) and were 
utilised for isolation of gene 62 sequences (nucleotides are given in brackets relative to 
the gene 62 mRNA start site at +1):
p585T7aVTl - includes an EcoRl-Smal fragment of plasmid pV17 (1322-2312bp) 
inserted into an EcoRl-Smal digested p585T7a vector. 
p585T7aVT2 and p585T7aVT2X - have been fully described in Section 3A.3. 
p585T7aVT3 - an EcoRl-Aval fragment of plasmid pV17 (1322-2071bp) with the Aval 
5' overhang filled-in, was inserted into the EcoRl- blunt BamHI sites of vector p585T7a. 
p585T7aVT4 - includes a BspHl-BamHl fragment of plasmid p585T7aVT2 
(1556-2114bp) inserted into the Ncol-BamHl digested p585T7a vector (Ncol and BspHl 
digests produce complementary sticky ends).
p585T7aVT4X - derived from plasmid p585T7aVT4 by insertion of an Xbal stop linker 
into the BamHI site, as previously described for the construction of plasmid 
p585T7aVT2X (Section 3A.3).
pT7VT4toK - includes a BspHl-Aval fragment of plasmid pVZVteK (1556-207 lbp) 
inserted into the Ncol-Aval digested plasmid p585T7aVT2 (retaining 2072-2144bp). 
p585T7aVT5 - an EcoRl-Aval fragment of plasmid pV18 (1585-2071bp) was inserted 
into the EcoRl-Aval digested plasmid p585T7aVT2 (retaining 2072-2114bp). 
p585T7aVT6 - an EcoRl-Bgll fragment of plasmid p585T7aVT2 (1322-1953bp) with 
the 3' Bgll overhang removed, was inserted into the EcoRl-Smal digested p585T7a 
vector.
p585T7aVT7 - an EcoRl-Bgll fragment of plasmid pV18 (1585-1953bp) with the 3' 
Bgll overhang removed, was inserted into the EcoRl-Smal digested p585T7a vector. 
p585T7aVT8 - an EcoRl-Ncol fragment of plasmid pV18 (1585-1937bp) with the 5’ 
Ncol overhang filled-in, was inserted into the EcoRl-Smal digested p585T7a vector. 
p585T7aVT9 - an EcoRl-Kpnl fragment of plasmid pV18 (1585-1881bp) with the 3’ 
Kpnl overhang removed, was inserted into the EcoRl-Smal digested p585T7a vector. 
p585T7aVT10 - includes an EcoRl-Rsal fragment of plasmid p585T7VT5 
(1585- 1749bp) inserted into the EcoRl-Smal digested p585T7a vector.
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p585T7aVTll - a Banll-BamHl fragment of plasmid p585T7aVT2 (1683-2114bp) with 
the 3' Banll overhang removed, was inserted into the blunt Vcol-sticky BamHI sites of 
vector p585T7a.
p585T7cVT12 - includes the R s al-Kpnl fragment of plasmid p585T7aVT5 
(1750-188lbp) and the Kpnl-BamHl fragment of plasmid p585T7aVT2 (1882-2114bp) 
co-ligated into the blunt £a?RI-sticky BamHI sites of vector p585T7c.
a. Plasmid b.Peptide c.Nucleotides d.Codons e.N-term f.C-term g.Size(aa) h.Size(kD)
p585T7aVTl VT1 1322-2312 417-708 MAEF 21 317 35.2
p585T7aVT2 VT2 1322-2114 417-647 MAEF 21 256 28.4
p585T7aVT2X VT2X 1322-2114 417-647 MAEF GDQLI 240 26.7
p585T7aVT3 VT3 1322-2071 417-633 MAEF 21 242 26.9
p585T7aVT4 VT4 1556-2114 462-647 - 21 207 23.0
p585T7aVT4X VT4X 1556-2114 462-647 - GDQLI 191 21.2
pT7VT4ttK VT4ttK 1556-2114 462-647 - 21 207 23.0
p585T7aVT5 VT5 1585-2114 472-647 MAEF 21 201 22.3
p585T7aVT6 VT6 1322-1953 417-594 MAEF 21 202 22.4
p585T7aVT7 VT7 1585-1953 472-594 MAEF 36 163 18.1
p585T7aVT8 VT8 1585-1937 472-588 MAEF 18 139 15.4
p585T7aVT9 VT9 1585-1881 472-570 MAEF 34 137 15.2
p585T7aVT10 VT10 1585-1749 472-525 MAEF 36 94 10.4
p585T7aVTll VT11 1683-2114 504-647 M 21 166 18.4
p585T7cVT12 VT12 1750-2114 526-647 MN 21 145 16.1
Table 3B Specifications of the VZV 140k DNA binding domain truncation plasmids 
and their peptide products. Columns a. and b. give the nomenclature for the T7 plasmid constructs 
expressing the gene 62 sequences and their expression products respectively. Column c. gives the gene 62 
nucleotides (numbered from the mRNA start site at +1) inserted into the expression vectors (inclusively), 
column d. indicates the 140k amino acid positions corresponding to residues included in the peptides. 
Columns e. and f. give the identity or number of vector derived amino acid residues at the N- and 
C-terminus of the peptide respectively. The variation in the number of vector-encoded residues to the 
C-terminal end of the peptides is in part due to the wide spacing between translational stop codons in the 
different reading frames in the T7 termination region (see Section 3A.2). Columns g. and h. give the total 
number of amino acid residues in the peptide and the predicted peptide molecular weight respectively. 'X' 
versions of peptides contain fewer C-terminal vector-encoded amino acids than the non-X counterparts, 
hut are otherwise identical. The plasmid pT7VT4ttK contains a base change that results in the substitution 
A628V, equivalent to HSV-1 Vmwl75 tsK substitution A475V.
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3B.3 Bacterial expression of the VZV 140k DNA binding domain deletion 
peptides
The truncated VZV 140k DNA binding domain peptides were expressed in E. coli from 
the above T7 expression plasmids and partially purified extracts were prepared as 
described previously for the VT2 peptide (Section 3A.4). The majority of the truncated 
DNA binding domain peptides were expressed very efficiently, being the predominant 
species in the bacterial lysates, and were highly soluble in the partially purified extracts 
(see Fig. 3B.2, summarised in Fig. 3B.1). However, peptides with deletions encroaching 
into the C-terminal end of region 2 were expressed very poorly. These peptides, 
VT7-VT10, were not apparent in the Coomassie-stained gels of bacterial lysates and 
were barely visible in the Coomassie-stained partially purified extracts; their presence 
was verified by western blot analysis (not shown). Peptides VT6  and VT12 were both 
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Figure 3B.1 Schematic representations of the VZV 140k DNA binding domain deletion 
peptides. The expressed regions of the 140k protein (VT1-VT12) are indicated by horizontal lines. The 
numbers of the 140k amino acid residues at die N- and C-terminal ends of the peptides are given and the 
corresponding restriction sites used for the isolation and cloning of gene 62 sequences into the T7 
expression vectors are shown above. The EcoRl sites were introduced into the gene 62 sequences by 
insertion mutagenesis (Disney, 1990). The position of the highly conserved protein region 2, and the tsK 
mutation at VZV 140k amino acid 628 are also indicated. All constructs are drawn to scale. For each 
Peptide, the efficiency of bacterial expression is indicated on the right; all peptides were highly soluble 
with the exception of peptide VT6.
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The VT1 peptide included additional region 3 sequences, similar to the I9X and II OX 
DNA binding peptides of HSV-1 Vmwl75 (Fig. 3B.7). This longer VT1 peptide was 
less stable than VT2 and tended to degrade, as demonstrated by the breakdown product 
approximately 7kD below the VT1 band in the bottom panel of Figure 3B.2, track 1. 
The VT2 peptide, and to a lesser extent the VT4 peptide, were also prone to slight 
proteolytic degradation and this was particularly apparent by western blot analyses of 
extracts (not shown). Construction of the 'X' versions of these peptides largely overcame 
this degradation problem (see Section 3A.3).
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Figure 3B.2 Expression of the VZV 140k deletion peptides in E. coli and their 
subsequent partial purification. Plasmids expressing the 140k deletion peptides (described in 
Section 3B.2), were transformed into bacterial cells and expression induced (detailed in Sections 2C.1 and 
2C.2). After pelleting the bacterial cells, resuspending and lysis, 2pl aliquots were analysed by 12.5% 
SDS PAGE as shown in the top panel; the positions of the induced peptides are indicated. Below is shown 
a 12.5% SDS PAGE analysis of the corresponding partially purified peptide extracts, prepared from the 
lysed bacteria above; the amount of extract loaded in each track corresponds to that from 4ml of bacterial 
culture, the extract in track 12 was produced from bacterial cells transformed with plasmid p585T7a. 
Details of the molecular weight standards in track 13 are as given previously (Fig. 3A.4). The sizes of the 
expressed polypeptides correspond well with the predicted sizes given in Table 3B. All extracts of peptide 
VT4taK showed a prominent degradation product approximately 2kD smaller than the expected peptide, 
the particular VT4tsK extract shown here almost completely comprises the breakdown product. The 
version of the VT4ttK extract used for DNA binding analyses was approximately 50% degraded. Novel 
peptide bands in the appropriate positions for peptides VT7-10 were detectable upon close inspection of 
the stained gel shown in the bottom panel, but are lost upon photography.
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3B.4 The DNA binding activity of VZV 140k resides within residues 472 
to 633, as determined by gel retardation analysis
The DNA binding ability of each partially purified 140k deletion peptide was 
determined by gel retardation assay, an example of which is shown in Figure 3B.3. 
Peptides VT1 to VT5 gave well defined protein-DNA complexes, while equivalent 
amounts of VT7 and VT11 failed to bind to the DNA probe (Fig. 3B.3, tracks 7 and 8  
respectively), even at greatly increased protein concentrations (data not shown). As 
expected, the VT12 peptide and peptides VT8-VT10, which contained further 
truncations into the N- and C-terminal ends of the DNA binding domain respectively, 
also failed to bind DNA, even when high amounts were included (data not shown). The 
VT2X and VT4X peptides bound to DNA with a slightly higher affinity than the VT2 
and VT4 peptides (not shown), presumably due to the more stable nature of the 'X' 
peptides (Section 3B.3).
1 2 3 4 5 6  7 8
Figure 3B.3 Gel retardation assay with the VZV 140k DNA binding domain deletion 
peptides. Partially purified bacterial extracts of each deletion peptide were incubated with the HSV-1 
IE3 promoter IES fragment probe (described previously in Fig. 3A.11) and resultant complexes resolved 
by native gel electrophoresis. Similar results were obtained with VZV gene 62 promoter fragment probes. 
The particular deletion polypeptide extract present in each incubation is indicated for tracks 2-8; track 1 
contains an extract from bacteria carrying plasmid p585T7a. Primary protein-DNA complexes are 
apparent with peptides VT1-5, the VT3 and VT4 tracks also contain secondary protein DNA complexes of 
lower mobility.
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The DNA binding ability of each deletion construct is summarised in Figure 3B.7. From 
this analysis it can be concluded that the minimal DNA binding domain of the 140k 
protein lies within residues 472 to 633. These sequences are contained entirely within 
the highly conserved region 2 (residues 468 to 641) of the 140k protein. Therefore the 
equivalent sequences from region 1 that are required in the minimal Vmwl75 DNA 
binding domain, are not necessary for the DNA binding activity of 140k, as determined 
by gel retardation analysis.
VT1 VT2X VT3 VT4X VT5
BSA dimer 112kD
Albumin 45kD
1 2 3 4 5 6 7 8 9  10
Figure 3B.4 Pore exclusion gel retardation electrophoresis analysis of the 140k V Z V  
deletion peptide-DNA complexes. Partially purified 140k DNA binding domain deletion peptides 
were incubated with the VZV gene 62 promoter UP6oligo DNA probe (Fig. 3A.6) and resolved on a 4 to 
24% gradient gel as described in Section 2D.3. Equivalent amounts of the indicated 140k deletion 
peptides were included in the analysis to obtain formation of the primary (PC) and secondary (SC) 
protein-DNA complexes, the free probe is not seen as it is run far off the gel in this type of analysis. The 
second track in each pair contained double the amount of extract included in the first. The gel was run for 
40hr to allow complexes to reach their equilibrium positions. The relative migration positions of 
Coomassie-stained protein standards run on the same gel are indicated to the left.
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It was consistently noticed during these studies that the 140k peptides lacking region 1 
sequences (VT4 and VT5), readily produced secondary protein-DNA complexes; 
furthermore, it was unusual to obtain the primary complex in absence of the secondary 
complex, suggesting that the secondary complexes formed by these particular peptides 
have greater stability than their primary complexes. In addition, the mobilities of the 
VT3 peptide-DNA complexes were consistently observed to be greater than expected 
from the size of VT3 (Fig. 3B.3, track 4), as compared to the other deletion peptides. 
Pore exclusion electrophoresis (Section 2D.3) was employed to investigate whether the 
unusual mobility of the VT3-DNA complex was an artefact of the native gel retardation 
analysis, or whether there was a more structural explanation. The migration of 
macromolecules through pore exclusion gels is less dependent upon their charge, than 
with single concentration native gels that are used in gel retardation analysis (Andersson 
et al., 1972). Complexes are allowed to migrate until they are trapped in the matrix sieve 
of the gradient gel and are therefore separated on the basis of size and shape. Figure 
3B.4 shows a typical pore exclusion gel after electrophoresis of the 140k deletion 
peptide-DNA complexes to their equilibrium positions. The VT3 peptide tended to yield 
relatively smeary protein-DNA complexes, implying that the truncation to residue 633 
at the C-terminal end of region 2, destabilises the DNA binding interaction. 
Additionally, the VT3-DNA primary complex had a higher mobility than predicted and 
perhaps indicates that the VT3-DNA complex has a more ellipsoid shape than the other 
peptide-DNA complexes, enabling it to move further through the matrix before reaching 
its exclusion position. It should be noted that it is not possible to predict accurately the 
stoichiometry of the peptide-DNA interaction from comparisons of the migration 
positions of protein-DNA complexes to the protein standards in Fig. 3B.4, as the shape 
of macromolecules strongly influences their equilibrium position reached on the 
gradient. This question of stoichiometry of binding is addressed in Section 3D.4.
The tsK temperature-sensitive (ts) lesion in region 2 of HSV-1 Vmwl75 precludes 
activation of early and late viral gene expression and prevents DNA binding at the non- 
permissive temperature (Section 1C. 1.5). Furthermore, the bacterially expressed 
Vmwl75 DNA binding domain containing the tsK single amino acid substitution also 
has a temperature-sensitive DNA binding phenotype (Allen and Everett, 1994). The 
equivalent mutation had previously been introduced into the VZV gene 62 sequence on 
plasmid pVZVttK. A version of the 140k DNA binding domain containing the A628V 
substitution, peptide VT4ttK, was tested to see if it displayed a temperature-sensitive 
phenotype (Fig. 3B.5). Compared to DNA binding at 4°C, all the peptides had greatly 
reduced binding efficiencies at 38.5°C, presumably due to peptide or complex instability 
at the higher temperature.
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Consistent with this was the finding that the stability of HSV-1 Vmwl75-DNA 
complexes was increased over 100-fold by shifting the temperature from 23 to 4°C 
(Kattar-Cooley and Wilcox, 1989). As mentioned above, the 'X' peptides had slightly 
higher binding efficiencies, presumably due to their reduced tendency to degrade. 
Comparison of the relative intensities of the different complexes at each temperature 
indicates that the tsK mutation does not produce a 140k DNA binding domain with a 
temperature-sensitive DNA binding phenotype (Fig. 3B.5). The very low levels of VT5 
and VT3 binding at 38.5°C is probably not a temperature-sensitive phenotype, but is 
more likely due to enhanced instability of the peptide-DNA complexes, because even at 
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Figure 3B.5 Gel retardation analysis o f the temperature-sensitivity o f  the V ZV  140k  
deletion peptide-DNA interactions. The UP6oligo DNA target (Fig. 3A.6) used in this analysis 
contains a VT2 binding site identified by DNase I footprinting analysis (Section 3A.6). Equivalent 
amounts of partially purified bacterially expressed peptides were included in each track as indicated. 
Reactions in tracks 1-6 were incubated on ice, whereas those in tracks 7-12 were incubated in a 38.5 C 
water-bath. Samples were loaded directly onto a running gel and electrophoresed at RT. The positions of 
the free probe (P), the primary (PC) and secondary (SC) protein-DNA complexes are indicated. As seen 
here, it has been consistently observed that the relative mobilities of complexes including the UP6oligo 
probe are not as expected from the size of the peptides. The relative lack of sensitivity to temperature seen 
here for the DNA binding activity of the VT4ttK peptide was highly reproducible with several different 
preparations of the peptide and on all target DNA fragments tested.
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3B.5 Region 1 sequences are required for DNase I footprinting by the VZV 
140k DNA binding domain
Having determined by gel retardation analysis that truncated versions of peptide VT2 
were able to bind DNA, DNase I footprinting was used to determine whether these 
shorter peptides had the same specificity of binding. The DNA binding interactions of 
peptides VT1, VT2, VT3, VT4 and VT5 (Fig. 3B.1) were compared on various VZV 
gene 62 and HSV-1 IE3 promoter fragments, as determined by DNase I footprinting. 
Peptides VT1 and VT3 produced identical footprinting patterns to VT2 on each DNA 
probe tested, while peptides VT4 and VT5 consistently failed to recognise any specific 
sequences. Therefore, even though region 1 sequences are dispensable for the DNA 
interaction as assayed by gel retardation, they are essential for recognition of specific 
sequences as measured by DNase I footprinting analysis. Examples of the two binding 
phenotypes are shown in Figure 3B.6 on the VZV gene 62 UP6  promoter fragment, and 
the findings of this DNase I footprinting analysis are summarised in Figure 3B.7.
Various attempts were made to identify features in the DNA binding characteristics of 
the 140k peptides lacking region 1 sequences, that might explain why these particular 
peptides bind to DNA in gel retardation analysis with apparent similar affinities to VT2, 
yet fail to give interactions detectable by DNase I footprinting. The binding efficiencies 
of the VT4 and VT5 peptides for the mutagenised HSV-1 IE3 consensus binding site 
were assayed, as described previously for the VT2 peptide in Section 3A.9. The binding 
profiles obtained for these peptides lacking region 1 sequences were not significantly 
different to that of the VT2 peptide shown in Figure 3A.14 (data not shown). The 
relative stabilities and specificities of the VT2X-DNA and VT4X-DNA complexes were 
compared as described in Section 2D.2. No obvious differences in the relative 
dissociation rates of the VT2X and VT4X peptides were noticed, although the VT4X 
peptide had a slightly lower DNA binding specificity than VT2X (data not shown). 
Whether this reduced specificity can explain the lack of protection from DNase I 
digestion provided by the 140k peptides lacking region 1 sequences is far from certain. 
However, a similar situation was discovered with the II OX version of the HSV-1 
Vmwl75 DNA binding domain peptides, which has a reduced amount of region 1 
sequences and fails to give a DNase I footprint (see below).
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Figure 3B.6 DNase I footprinting analysis with the VZV 140k deletion peptides. The 
UP6 fragment probe was derived from the VZV gene 62 promoter, the details of which are given in 
Figure 3A.6. The position of the mRNA start site at +1 is indicated by the bent arrow and the gene 62 
nucleotide coordinates at either end of the probe fragment are given relative to the mRNA start site (+1). 
Tracks 2, 4, 6, 7 and 8 contain equivalent amounts of extracts containing the indicated partially purified 
bacterially expressed peptides; tracks 3 and 5 contain 2/5 the amount of extract included in tracks 4 and 6 
respectively. The 'con' extract was prepared from bacteria transformed with plasmid p585T7a. The 
position of the U binding site is indicated on the right (Fig. 3A.9). The amount of VT2 included in track 8 
was such that produced a generalised broadening of the region of protection.
3B.6 Discussion
The results in this Section (3B) demonstrate that residues contained within the highly 
conserved region 2 of VZV 140k are sufficient for DNA binding, although flanking 
sequences may be additionally required for the full interaction with DNA, as discussed 
below.
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VT3 417 633 yes yes
VT4 462 647 yes no
VT5 472 647 yes no
VT7 472 594 no N/D
VT8 472 588 no N/D
VT9 472 570 no N/D
VT1 0 472 525 no N/D
VT11 504 647 no N/D
VT1 2 526 647 no N/D
Figure 3B.7 The HSV-1 Vmwl75 and VZV 140k DNA binding domain peptides and 
their DNA binding activities. The portion of each protein encompassing the DNA binding domain 
is shown diagrammatically. For each protein, the numbers of the first and last residues are given for the 
highly conserved region 2 (represented by a shaded box); protein regions 1 and 3 lie to the left and right 
respectively. Below these are shown horizontal lines that correspond to the protein sequences included in 
each of the deletion peptides. The residue at the N- and C-terminus of each peptide are indicated. All 
constructs are shown to scale and region 2 of the HSV-1 Vmwl75 and VZV 140k constructs are 
accurately aligned beneath one another. The DNA binding abilities of the peptides are indicated, as 
determined by gel retardation (Section 3B.4) and DNase I footprinting assays (Section 3B.5); yes 
indicates an ability to bind to DNA, 'no' indicates that DNA binding was not detected and 'N/D' indicates 
experiments not carried out. The HSV-1 Vmwl75 peptides I9X, IIOX and IIIX are described by Pizer et 
Ql. (1991). The experiments to determine the I9X and I10X DNA binding activities were performed in 
parallel to the analyses described in this Section and are in agreement with those obtained previously 
(Pizer et al., 1991; R. D. Everett, personal communication), the IIIX result was taken from Pizer et al. 
(1991). [A loose copy of a figure showing these constructs is found at the back of this Thesis].
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Gel retardation analysis of the bacterially expressed VZV 140k peptide fragments has 
mapped the N-terminal limit of the 140k DNA binding domain to between residues 472 
and 504, and the C-terminal limit to between residues 594 and 633 (see Fig. 3B.7). This 
suggests that the maximum size of the VZV 140k DNA binding domain is 162 amino 
acids, although the precise domain may be slightly smaller. This region of the 140k 
protein does not contain any sequences strictly conforming to the known types of DNA 
binding motif such as the zinc finger, helix-turn-helix (HTH) etc. (see Section IE), 
although see Section 3E. Additionally, the mapped size of the VZV 140k domain is 
considerably larger than any of the established classes of DNA binding structures and 
may well represent a novel DNA binding structure.
The poorly conserved region 1 and 3 sequences included in the HSV-1 Vmwl75 DNA 
binding domain are not necessary for the DNA binding activity of the 140k domain, as 
determined by gel retardation assay. However VZV 140k peptides essentially 
comprising region 2 sequences (VT4, VT5), gave efficient DNA binding in gel 
retardation assays but for reasons unknown, failed to yield DNase I footprints at any of 
the sites tested. A similar situation was subsequently found with the II OX peptide of 
HSV-1 Vmwl75, as it also failed to produce DNase I footprints (Fig. 3B.7). Despite the 
lack of footprinting activity, the specificity of binding of the VT4 and VT5 peptides was 
very similar to that shown by the longer VT2 peptide; the same was true of the 
specificity of the IIOX and I9X peptides (Everett et al, 1991a). Therefore, the region 1 
sequences lacking from the VT4X and IIOX peptides of VZV 140k and HSV-1 
Vmwl7 5  respectively, appeared to be required for the full structural interaction with 
DNA, rather than being involved in forming direct contacts with the DNA.
The highly basic nature of these region 1 sequences (overall charge of +9 in VZV 140k) 
may be important for the DNA interaction. It has previously been suggested that 
Vmwl75 sequences between residues 262-274 are not directly involved in DNA binding 
and that the structure adopted by this region influences the DNA binding properties of 
Vmwl75 (Wu and Wilcox, 1990). It is noteworthy that the ability to bind to specific 
DNA targets in gel retardation assay but not in DNase I footprinting has been previously 
observed with the intact HSV-1 Vmwl75 protein (Papavassiliou and Silverstein, 1990). 
A recent one-step growth curve analysis of HSV-1 viruses with insertions at the 19,110, 
or 1 1 1  positions of the HSV-1 IE3 gene, found HSV-I9 to grow as wild type whereas 
HSV-I1 1  was severely impaired (Allen and Everett, 1994). Interestingly, the HSV-I10 
virus had intermediate growth characteristics which correlates with the findings of the 
DNA binding analyses, and indicates that the integrity of sequences around the 110 
position of HSV-1 Vmwl75 is required for normal function.
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It was interesting to find that the VT5 peptide (140k residues 472-647) possessed DNA 
binding activity because a four amino acid insertion into residue 472 destroyed the 
regulatory functions of the intact 140k protein in transient transfection assays (Disney et 
al., 1990). It has been observed previously that small insertions can have a more 
profound effect on the functions of the HSV-1 Vmwl75 protein compared to deletions 
of extensive stretches of amino acids in the same region (Section 1C. 1.9) and this may 
also be the case here. Alternatively the isolated DNA binding domain may have an 
enhanced DNA binding activity due to removal of masking protein sequences in the 
intact 140k protein. This could in part explain why it has been so difficult to detect 
sequence-specific DNA binding by the intact 140k protein (Disney, 1990). However, the 
effect of the insertion at reside 472 may indicate that the full DNA binding interaction, 
as measured by DNase I footprinting, is required for the regulatory functions of VZV 
140k. The 140k peptides that were further truncated at the N-terminal end of region 2 
(VT11, VT12) were efficiently expressed and soluble, but tended to aggregate (Section 
3D.2), suggesting that the N-terminal portion of region 2 plays a role in the formation of 
the stable physical domain.
The 140k deletion peptide VT3 was capable of the full interaction with DNA, as 
demonstrated by the DNA binding analyses. However, the mobility of the VT3-DNA 
complex was greater than expected from its predicted molecular weight in gel 
retardation and pore exclusion gel electrophoresis analyses. It is possible that the 
deletion into the C-terminal end of region 2 is encroaching upon an important part of the 
protein and altering the conformation of the complex. Further truncations into the 
C-terminal end of region 2 (as with peptides VT6-VT10) resulted in very inefficient 
peptide expression in bacteria (or insolubility in the case of VT6 ) and suggests that the 
deleted sequences constitute a structurally essential part of the stable domain. The role 
played by sequences in the central portion of 140k region 2 has not been addressed in 
this study.
By combining all the available truncation analysis data for the HSV-1 Vmwl75 DNA 
binding domain (see Section 1C. 1.10), it would appear that Vmwl75 sequences between 
residues 275 to 490 are sufficient for its DNA binding activity. Therefore, the 162 
residue region of VZV 140k that mediates its DNA binding activity is significantly 
shorter than this equivalent 216 residue minimal DNA binding region of Vmwl75. This 
indicates that the 140k protein has a lower protein sequence requirement for DNA 
binding compared to its HSV-1 counterpart.
The HSV- 1  Vmwl75 tsK mutation is found in a long stretch of residues that is 80% 
conserved between the 140k and Vmwl75 DNA binding domains (Fig. 1C.3). In
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contrast to the situation with Vmwl75 tsK, the equivalent base substitution in the VZV 
gene 62 sequence does not produce a 140k DNA binding domain with a 
temperature-sensitive phenotype. Therefore, either the 140k protein is more tolerant to 
this mutation due to lower structural requirements for DNA binding, or the exact 
sequences that are important for DNA binding are not identical in these two homologous 
IE proteins.
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3C Purification of the VZV 140k DNA binding domain as a 
dimer
3C.1 Strategy
It was desirable to have available purified preparations of the VZV 140k DNA binding 
domain peptides for physical and possible structural analyses. Once purified, the 140k 
DNA binding domain could also be used as an antigen for raising polyclonal antisera in 
rabbits. Therefore, a purification procedure was developed using the FPLC apparatus, 
based roughly on the previous purification of the HSV-1 Vmwl75 DNA binding 
domain peptides (Everett et al., 1991a). Like many protein domains that interact with 
DNA, the 140k DNA binding domain is highly basic, for example the VT2X peptide has 
a net charge of +16. This made it possible to separate the bacterially expressed 140k 
peptides from the majority of other components in the partially purified extracts by ion 
exchange chromatography. Further purification was achieved by a gel filtration 
chromatography step.
The gel filtration technique would also allow derivation of the oligomeric state of the 
140k DNA binding domain peptides. As is the case for many DNA binding proteins, the 
native form of the HSV-1 Vmwl75 protein is homodimeric (Metzler and Wilcox, 1985). 
Additionally, the isolated Vmwl75 DNA binding domain exists as a stable dimer in 
solution (Everett et al., 1991a), suggesting that sequences included within the DNA 
binding domain are involved in the dimerisation of the intact Vmwl75 protein. It was of 
interest to see whether the counterpart VZV 140k domain was also dimeric by using gel 
filtration chromatography. Glycerol gradient and protein cross-linking analyses were 
also employed to investigate the native state of the 140k DNA binding domain.
3C.2 FPLC purification of the VZV 140k DNA binding domain to 
apparent homogeneity
The VT2  peptide (codons 417-647) was selected for purification, as this version of the 
VZV 140k DNA binding domain appeared to be capable of the full interaction with 
DNA (Section 3A). The optimal conditions for the purification were determined 
empirically and are detailed in Section 2C.5.
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3C.2.1 Anion exchange chromatography o f VT2 (Mono Q column)
Initially, the partially purified extract of the bacterially expressed VT2 peptide was 
loaded onto an anion exchange column (Mono Q) and a linear salt gradient applied 
(Section 2C.5.1). The basic VT2 peptide failed to interact with the positively charged 
matrix and flowed straight through this column. Thus the VT2 peptide was purified 
away from a significant proportion of the bacterial proteins which were retained on the 
column, as seen in Figure 3C.1.
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Figure 3C.1 Anion exchange chromatography of the VT2 extract on the Mono Q 
column, lml of a partially purified VT2 bacterial extract was fractionated on a Mono Q column as 
described in Section 2C.5.1. The left hand panel shows a Coomassie-stained 12.5% SDS PAGE analysis 
of selected column fractions (lml) from the separation; track 1 contained 5jxl of the input extract, tracks 
2-12 contained 10pl of either flow-through (FT) fractions or fractions from the peaks eluting on the 
gradient, as indicated above each track. Track 13 contained molecular weight markers as detailed 
previously in the legend of Fig. 3A.4. The arrow marks the position of peptide VT2 in the flow-through 
fractions. The right hand panel shows the corresponding chart recorder uv trace for the Mono Q run (OD 
setting 0.5). The scale at die bottom indicates the elution volume, where each grid division on die 
horizontal axis represents 2ml (chart speed = 0.5cm/ml). The NaCl concentration of die elution buffer is 
indicated by the straight line where divisions on the vertical axis are as follows: 0 = 0.1M, 100 = 1.0M. A 
0.1 to 1.0M NaCl gradient was run between 13ml to 33ml, as indicated by the diagonal line. After a slight 
delay due to the dead space of the column, the VT2 peptide eluted in the flow-through, which has an OD 
off the scale. The remaining peptides eluted on the gradient as seen from the uv trace.
3C.2.2 Cation exchange chromatography ofVT2 (Mono S column)
The pooled Mono Q flow-through fractions were loaded directly onto a cation exchange 
column (Mono S, Section 2C.5.2). The VT2 peptide interacted with this column and was 
eluted on a 0.25 to 0.45M NaCl gradient (Fig. 3C.2); this narrow gradient was used to 
maximise the separation of VT2 from its proteolytic degradation fragments which eluted 
at similar salt concentrations to VT2. This Mono S column step succeeded in separating
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the VT2 peptide away from the majority of bacterial peptides, although a major 
contaminant (apparent in Fig. 3C.2, track 4; approximate Mr of 24kD) co-eluted with 
VT2 in the lower salt concentration part of the VT2 peak and was probably a 
degradation product of VT2. The major peak eluting around 0.32M NaCl contained 
substantially purified VT2 peptide, although slight degradation products co-eluted with 
VT2, as seen in Figure 3C.2, tracks 5-8.
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Figure 3C.2 Cation exchange chromatography of the VT2 peptide on the Mono S 
column. Flow through fractions 2-7 from the Mono Q column run shown in Figure 3C.1, were loaded 
directly onto a Mono S column and eluted as described in Section 2C.5.2. The left hand panel shows a 
Coomassie-stained 12.5% SDS PAGE analysis of selected column fractions (lml) from the Mono S run; 
track 1 contained 5pl of the column input, while tracks 2-12 contained 10pl of the flow-through (FT) or 
peak fractions (peak I or II) indicated above the tracks. Track 13 contains molecular weight standards as 
detailed previously in the legend of Fig. 3 A.4. The arrow marks the position of the VT2 peptide eluted in 
the peak fractions. The right hand panel gives the corresponding chart recorder uv trace for the Mono S 
run (OD setting 0.5). The scale at the bottom indicates the elution volume, each division on the horizontal 
axis represents 2ml (chart speed = 0.5cm/ml). The NaCl concentration of the elution buffer is indicated by 
the straight line, where divisions on the vertical axis are as follows; 0 = 0.25M, 100 = 0.45M. A 0.25 to 
0.45M NaCl gradient was ran between 13.5ml to 43ml as indicated by the diagonal line. The gradient was 
stalled between approximately 18 and 21ml (at 0.29M NaCl), to ensure elution of all the 26kD 
contaminant peptide. The gradient was again stalled between approximately 24 and 31ml (at 0.32M NaCl) 
to obtain maximum yield of the purified VT2 peptide. The protein peaks are identified below die trace as 
flow-through (FT), peak I (co-elution of VT2 and 24kD degradation product) and peak II (VT2).
3C.2.3 Gel filtration chromatography o f VT2 (Superose 12 column)
Lower molecular weight contaminants (around 16kD) were apparent after concentration 
of the Mono S peak fractions, as seen in track 1 of Figure 3C.3. These contaminants 
were separated from the VT2 peptide by gel filtration chromatography using a size 
exclusion column (Superose 12, Section 2C.5.3). VT2 eluted from the column as a sharp 
single peak, as seen on the chart recorder trace and appeared to be homogeneous by SDS
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PAGE analysis, although slight degradation is apparent beneath the main VT2 band 
(Fig. 3C.3, track 8 ). DNA binding activity was maintained throughout the purification 
procedure (data not shown). In all the following analyses, the peptide in the Superose 12 
peak fractions is referred to as the 'purified peptide'.
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Figure 3C.3 Gel filtration chromatography of the VT2 peptide on the Superose 12 
column. Peak fractions 25-28, containing the majority of the VT2 peptide from the Mono S column run 
shown in Figure 3C.2, were concentrated and loaded onto a Superose 12 column. The column had been 
equilibrated in 0.32M NaCl FPLC buffer and peptides were eluted in this same buffer, as described in 
Section 2C.5.3. The left hand panel shows a Coomassie-stained 12.5% SDS PAGE analysis of selected 
column fractions (lml) from the Superose 12 run. Track 1 contained 2pl of the column input, while tracks 
2-12 contained 10pl of the elution fractions indicated above the tracks. Track 13 contains molecular 
weight standards as detailed previously in the legend of Fig. 3A.4. The arrow marks the position of the 
VT2 peptide eluted in the peak fractions. The marks below the level of the VT2 band, particularly 
apparent in tracks 4-6, are a consequence of uneven destaining exaggerated by drying down of the gel. 
The right hand panel gives the corresponding chart recorder uv trace for the Superose 12 run (OD setting 
0.5) and the scale below indicates the elution volume. The VT2 peptide eluted in fractions 13 and 14 with 
an elution peak at 12.62ml, the VT2 peptide gave the only detectable peak. Slight variations in the exact 
elution volume (+/- < 0.1ml) were obtained with different VT2 extracts.
3C.2.4 Purification o f the VT4X version o f the 140k DNA binding domain 
Although the purification procedure described above yielded large amounts of highly 
purified 140k DNA binding domain, degradation products consistently co-purified with 
the VT2 peptide. This did not present a major problem for most analyses of the purified 
140k domain, but these degradation products would prohibit any attempts to obtain 
crystals for structural studies in the future. The VT4 version of the 140k DNA binding 
domain had previously been found to be less prone to degradation during bacterial 
expression and partial purification. In addition, the 'X' version of the VT4 peptide 
appeared to be particularly highly stable (Section 3B.3); compare the relative lack of 
degradation of the VT4X peptide in Figure 3C.4, track 2 to an equivalent VT2 extract in
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Figure 3C.1, track 1. For this reason, the VT4X peptide (140k codons 462 to 647) was 
purified with the following modifications of the above procedure: the Mono Q step was 
performed exactly as above, but the flow-through fractions were diluted to 0.05M NaCl 
and eluted from the Mono S column by a 0.05M to 0.45M NaCl gradient. Typically, 
VT4X eluted from the Mono S column at around 0.2M NaCl, slightly lower than that 
previously observed for the VT2 peptide (Fig. 3C.2), presumably due to the removal of 
the basic region 1 protein sequences (net charge of +9). The Superose 12 column was 
therefore equilibrated and eluted in 0.2M NaCl buffer. The gel filtration 
chromatography yielded a major peak eluting around 13.9ml and a lesser peak at 
12.9ml; both peaks contained the VT4X peptide as determined by SDS PAGE analysis 
(not shown). Figure 3C.4 shows samples taken throughout the VT4X purification from 
lysed bacterial cells (track 1), through to the purified VT4X peptide from the gel 
filtration peak (track 5). Even though the VT4X peptide tended to be less degraded than 
the VT2 peptide, a slight shadow beneath the VT4X band did develop during the later 
stages of the purification (Fig. 3C.4, tracks 4 and 5), presumably due to limited 
degradation.
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Figure 3C.4 Purification of the VZV 140k DNA binding domain peptide VT4X. 
Samples taken throughout the purification of the bacterially expressed VT4X peptide were analysed by 
12.5% SDS PAGE and visualised by Coomassie-staining as follows: track 1 contained a sample of the 
soluble proteins after bacterial lysis and track 2 contained a sample of the partially purified VT4X peptide 
after a 35% ammonium sulphate cut, as described in Section 2C.2. Track 3 contained a sample of the 
combined flow-through (FT) fractions eluted from the Mono Q column, and this was the input onto the 
Mono S column. Track 4 contained a sample of the combined VT4X peak fractions eluted from the Mono 
S column, this was the input onto the Superose 12 column. Track 5 contained a sample of the final 
purified VT4X peptide from the combined Superose 12 peak fractions. Track 6 contained molecular 
weight markers as detailed previously (Fig. 3A.4). The arrow marks the position of peptide VT4X in 
tracks 1-5. The amount of each extract loaded was adjusted to contain roughly equivalent amounts of the 
VT4X peptide to highlight the relative purification at each stage of the procedure.
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The purification of the HSV-1 Vmwl75 DNA binding domain peptides also suffered 
from proteolytic degradation problems (R. D. Everett, personal communication). DNA 
binding activity was retained throughout the VT4X purification (not shown).
Protein standards of known molecular weight were also eluted through the Superose 12 
gel filtration column: cytochrome C (13kD) eluted at 15.25ml and carbonic anhydrase 
(29kD) eluted at 14.11ml. From the elution volumes stated above for VT2 (28.4kD) at 
12.62ml and for VT4X (21.1kD) at 13.9ml (and also at 12.9ml), it is apparent that these 
140k DNA binding domain peptides are not monomeric. Comparison of the elution 
volumes for the 140k peptides with those of the protein standards suggests that the VZV 
140k DNA binding domain may be dimeric; this was further analysed below.
3C.3 Glutaraldehyde cross-linking of VZV 140k DNA binding domain 
peptides
To investigate whether the 140k DNA binding domain has the ability to oligomerise, the 
purified VT2 and VT4X peptides were incubated with the cross-linking agent 
glutaraldehyde (see Section 2E.1). Figure 3C.5 shows an SDS PAGE analysis of the 
cross-linked products. A striking novel band, with a size consistent with being a VT2 
dimer, is produced on incubation with glutaraldehyde (compare track 4 with track 1). 
Faint higher molecular weight bands were also formed and presumably reflect either 
non-specific cross-linking or a low level of higher order oligomers in the VT2 sample. 
The situation with the VT4X peptide was slightly different, in that a ladder of bands 
with decreasing intensities was produced upon incubation with glutaraldehyde. Each 
band in the ladder had a size consistent with the addition of a single VT4X monomer i.e. 
dimer, trimer, tetramer etc. (Fig. 3C.5, track 5); they may be representative of the VT4X 
oligomers (other than dimers) detected by the gel filtration analyses (Sections 3C.2.4 
and 3C.4). The negative control used in these experiments was a protein standard 
(carbonic anhydrase) which is known to be monomeric in solution. Clearly, the 140k 
DNA binding domain has the intrinsic ability to oligomerise and at least a proportion of 
the 140k peptides in solution are likely to exist as dimers or higher order oligomers at 
any given time.
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Figure 3C.5 Glutaraldehyde cross-linking analysis of the purified 140k DNA binding 
domain peptides. Approximately 4pg of peptides were incubated in the absence or presence of 0.01% 
glutaraldehyde, as described in Section 2E.1. The products were analysed by 12.5% SDS PAGE and 
visualised by Coomassie-staining. The identity of the peptide included in the incubations is indicated 
above each track. Incubations loaded in tracks 3 and 6 included a monomeric protein standard (carbonic 
anhydrase; Mr 29kD). Track 7 contains molecular weight standards, as described previously in the legend 
of Fig. 3A.4. The positions of VT2 and VT4X monomer and dimer bands are indicated on the left hand 
side, higher molecular weight bands in tracks 4 and 5 are apparent but remain unlabelled. Slight 
degradation of the VT2 peptide occurred on incubation with glutaraldehyde, apparent beneath the VT2 
bands in track 4. Cross-linking by 0.01% glutaraldehyde is rarely more efficient than that seen in track 4; 
higher concentrations of glutaraldehyde lead to increased non-specific cross-linking.
3 C . 4  T h e  n a t i v e  s t a t e  o f  t h e  V Z V  1 4 0 k  D N A  b i n d i n g  d o m a i n  i s  d i m e r i c
The multiplicity of 140k DNA binding domain peptides in the oligomers could not be 
accurately determined from the glutaraldehyde cross-linking analysis described above. 
The question also remains as to whether the oligomers are stable in solution, or whether 
an equilibrium exists between the monomeric and oligomeric units. The purified VT2 
and VT4X peptides were analysed by analytical gel filtration and glycerol gradient 
centrifugation to address these questions.
A high resolution Superdex 75 gel filtration column was used to estimate the native 
sizes of the purified VT2 and VT4X peptides, as described in Section 2E.2. A range of 
protein standards of known molecular weights were analysed on the Superdex 75 
column and their elution volumes were used to produce a calibration curve (left hand 
panel, Fig. 3C.6). The apparent size of the 140k DNA binding domain peptides were 
estimated from this curve; the purified VT2 peptide (monomeric size of 28.4kD) yielded 
a sharp peak having an elution volume consistent with it being a dimer in solution
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(approximately 65kD) (middle panel, Fig. 3C.6). A very minor VT2 peak eluted faster 
from the column and corresponded to a tetrameric form of VT2 (approximately 1 lOkD). 
The VT4X peptide (monomeric size of 21.1kD) yielded a major peak with an elution 
volume that suggested it contained VT4X dimers (approximately 43kD) (right hand 
panel, Fig. 3C.6). The presence of a faster eluting second VT4X peak corresponding to 
either the trimeric or tetrameric (approximately 72kD) form of the VT4X peptide is 
consistent with the glutaraldehyde cross-linking result (Fig. 3C.5, track 5). In addition, 
the purified VT4X peptide gave apparently trimeric protein-DNA complexes upon gel 
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Figure 3C.6 Analytical gel filtration analysis of the purified VZV 140k DNA binding 
domain peptides. The left hand panel shows a calibration curve for the Superdex 75 column produced 
by plotting log molecular weight against elution volume for various protein standards. The accurate 
elution volumes were derived from integration of the peak data by the FPLC software and are as follows: 
a = BSA dimer (112kD) at 7.83ml; b = pgalactosidase (116.2kD) at 7.95ml; c = phosphorylase b (97.4kD) 
at 8.55ml; d = BSA monomer (66kD) at 9.2ml; e = albumin (45kD) at 10.56ml; f = carbonic anhydrase 
(29kD) at 11.59ml; g = alactalbumin (14.2kD) at 12.77ml; h = cytochrome C (13kD) at 13.28ml. The 
dotted line joins all data points, the solid line is an exponential curve fitted by the graphics program; 
apparent molecular weights of the 140k peptides were estimated from the solid line. The middle panel 
shows the chart recorder uv trace obtained when approximately 50(ig of purified VT2 was analysed on the 
Superdex 75 column (as described in Section 2E.2), at chart speed 0.5cm/ml and OD setting 0.05. The 
right hand panel shows the chart recorder uv trace obtained when approximately 50pg of purified VT4X 
peptide was analysed on the Superdex 75 column, at chart speed 0.25cm/ml and OD setting 0.2. The scale 
indicates column elution volumes corresponding to the uv trace. The identity of the peptides in die peaks 
were verified by SDS PAGE analysis of 0.25ml fractions collected throughout the column runs (not 
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From the gel filtration analysis, it was apparent that the 140k DNA binding domain 
predominantly exists in the dimeric state in solution. The failure to observe any 
detectable peaks eluting at the VT2 or VT4X monomer positions indicated that dimers 
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Figure 3C.7 Glycerol gradient centrifugation analysis of the VZV 140k DNA binding 
domain. Purified peptide samples and standards were spun on 10-30% glycerol gradients as described 
in Section 2E.3, and fractions analysed by SDS PAGE. At the top is shown a calibration curve for 
estimation of the native size of sample peptides. Protein standards: cytochrome C (CytC-13kD), carbonic 
anhydrase (CA-29kD) and bovine serum albumin (BSA-66kD), were analysed on a single gradient and 
the fractions containing the majority of each peptide plotted against their log molecular weights to yield 
the calibration curve shown here. Molecular weights of samples were estimated from this curve by 
comparing the fraction numbers containing the sample after centrifugation, asterisks denote the centre of 
the position of VT2 and VT4X peptides on the glycerol gradients. Samples were centrifuged with a single 
standard (usually CA) to allow comparison of gradients with the calibration curve. Below is shown a 
Coomassie-stained 13.75% SDS PAGE gel loaded with 20pl of selected fractions from a glycerol gradient 
analysis of purified VT4X peptide and CA. The identity of the fraction samples loaded in tracks 1-14 are 
given above the tracks, track 15 contained molecular weight standards (as detailed in the legend of Fig. 
3A.4). A total of 25 fractions were obtained from the gradient (from the top downwards), the relative 
positions of fraction 6 and 19 are indicated on the diagram of the gradient on the right. The shading gives 
4n approximate representation of the peptide sedimentation positions determined from the gel on the left, 
the lighter shading in each case represents lower concentrations of the relevant peptide (striped shading = 
VT4X, solid shading = CA).
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The dimeric nature of the VZV 140k DNA binding domain was verified using glycerol 
gradient centrifugation analysis, as described in Section 2E.3. The sedimentation rates 
of the purified VT2 and VT4X peptides were compared with those of protein standards 
of known molecular weights analysed on parallel gradients. Even though the peptides 
were spread over a fairly wide range of gradient fractions, it was apparent that both VT2 
and VT4X sedimented with molecular sizes consistent with their being dimeric, from 
comparison of the sample and standard fractions containing the highest peptide amounts 
(see Fig. 3C.7). Consistently, a population of the VT4X peptides also sedimented at a 
yet faster rate, as seen in Figure 3C.7, again suggesting the existence of additional 
higher order VT4X oligomers (see above).
3C.5 Production of rabbit polyclonal antisera against the VZV 140k DNA 
binding domain
The VZV 140k DNA binding domain deletion peptides were generally expressed very 
efficiently in bacteria and were therefore easily detectable by Coomassie-staining, 
although immuno-detection was also possible using a Monoclonal antibody (Mab 
10,084) that had recently been found to cross-react with the VT2 peptide. Mab 10,084 
was originally raised against the HSV-1 Vmwl75 I9X peptide and epitope mapping 
using the 140k deletion peptides found the epitope to lie between residues 462 and 472 
of the VZV 140k protein; these experiments are described elsewhere (Everett et al., 
1993c). Therefore, MAb 10,084 failed to recognise the 140k peptides with N-terminal 
truncations up to or beyond residue 472 (see Fig. 3B.1), ironically these were the 
peptides which also tended to be poorly expressed and not always apparent by 
Coomassie-staining. In order to obtain an antiserA that could detect the VT5-VT12 
peptides, the purified VT2 peptide was emulsified in complete Freund's adjuvant and 
injected into two rabbits; subsequent injections used incomplete Freund's. The author 
acknowledges Miss Gillian McVey for raising the polyclonal antisera. Antiserum 108 
was raised by 2 injections of VT2 and diluted out to 1:920 by western blot analysis; 
antiserum 109 was produced by a course of 4 injections and diluted out to 1:512,000 by 
western blot analysis. Antiserum 109 strongly recognised the complete series of 
truncated versions of the VZV 140k DNA binding domain by western blot analysis (not 
shown).
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3C.6 Discussion
This Section (3C) describes an efficient 3 column step FPLC procedure for purification 
of the bacterially expressed VZV 140k DNA binding domain peptides, as outlined in 
Figure 3C.8. Due to the high levels of expression of the VT2 peptide obtained in the 
bacterial system (Section 3A.4), yields of purified peptide of around lOmg/litre culture 
could be obtained using this procedure. Unfortunately it has not been possible to purify 
completely the VT2 version of the 140k DNA binding domain away from all its 
degradation products, although this degradation problem was greatly reduced with the 
VT4X peptide.
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Figure 3C.8 Schematic outlining the complete purification procedure for the VZV 
140k DNA binding domain peptides. The partial purification is described in Section 3A4 and the 
FPLC purification is described in Section 3C.2. The numbers 1 and 2 denote ion exchange column steps, 
and number 3 indicates the gel filtration step.
In the past, various experimental approaches have found that the HSV-1 Vmwl75 and 
PRV IE 180 homologue proteins bind directly to their DNA target sequences (Michael et 
al., 1988; Kattar-Cooley and Wilcox, 1989; Cromlish, 1989). Similarly, the purified 
140k DNA binding domain peptides retained their DNA binding activity, indicating that 
the interaction of VZV 140k with DNA is also likely to be direct.
The physical analyses described in these Sections, using the purified VT2 and VT4X 
peptides, demonstrate that the VZV 140k DNA binding domain is predominantly 
dimeric in solution. The dimers appeared to be highly stable units, as they did not
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detectably dissociate into monomers under the buffer conditions and the preparation 
procedures used for the purification, gel filtration and glycerol gradient analyses. The 
apparent high affinity of the monomer units for each other suggests that dimerisation of 
the 140k DNA binding domain is likely to occur very rapidly after translation, perhaps 
even concurrently with the polypeptide folding process, as previously proposed for the 
intact HSV-1 Vmwl75 protein (Shepard et al., 1991a).
Additionally, higher order oligomers (trimers or tetramers) of the 140k DNA binding 
domain were detected by these analyses, and this was particularly pronounced with the 
VT4X peptide. This again suggests that the region 1 sequences lacking from VT4X 
affect the structure of the 140k DNA binding domain (as discussed in Section 3B.6). 
Higher order oligomeric forms of the affinity purified HSV-1 Vmwl75 protein have 
also been reported; the majority of Vmwl75 was dimeric, but a significant proportion 
was in the tetrameric form (Kattar-Cooley and Wilcox, 1989). Whether the tetrameric 
forms of these proteins are functionally relevant or merely a consequence of the 
purification process is not certain. It should be noted here that the VT4X peptide was 
not capable of the complete structural interaction with DNA, as indicated by its failure 
to protect specific DNA binding sites from DNase I digestion (Section 3B.5). Therefore 
the properties of the VT2 peptide are considered to be more likely to reflect the situation 
with the intact 140k polypeptide.
From these data, it was apparent that the VZV 140k DNA binding domain contains a 
dimerisation surface and it is likely that the intact 140k protein is also dimeric. The sizes 
of the mapped DNA binding domains of VZV 140k and HSV-1 Vmwl75 are very large 
compared to the established classes of DNA binding domains, and it is likely that they 
contain distinct sequences mediating their dimerisation and DNA recognition activities. 
In several of the defined classes of DNA binding domain, the amino acid sequences 
involved in dimerisation are adjacent to the DNA recognition motif. Both the 
helix-loop-helix class of proteins (for example MyoD\ Murre et al, 1989), and the 
leucine zipper family of DNA binding proteins (for example GCN4; Landschulz et al, 
1988), have a basic DNA recognition motif followed by an a-helical region that 
provides a dimerisation interface (see Section IE.3). Sequences strictly conforming to 
these or other established types of DNA recognition and multimerisation motifs are not 
apparent within the DNA binding domains of the VZV 140k family of alphaherpesvirus 
proteins. Whether sequences within the DNA binding domain alone are sulficient for 
dimerisation of the intact 140k protein, or whether other protein sequences are 
additionally involved, remains to be determined.
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140k DNA binding domain
3D.1 Strategy
The finding that the VZV 140k DNA binding domain existed as a stable dimer (Section 
3C) presented various questions: which protein sequences are involved in dimerisation? 
Is it the dimeric form of the 140k DNA binding domain that interacts with DNA? If so, 
do both monomers specifically contact the DNA binding site? Various approaches were 
used to narrow down the location of sequences mediating dimerisation. Attempts were 
made to determine whether each of the truncated versions of the VZV 140k DNA 
binding domain (Fig. 3B.1) was dimeric using the physical analyses described in 
Section 3C (protein cross-linking, gel filtration chromatography, glycerol gradient 
centrifugation). Also, pairs of differently sized 140k DNA binding domain deletion 
peptides were co-translated, and heterodimer formation assayed by gel retardation 
analysis.
Due to the sequence similarity and dimeric nature of the VZV 140k and HSV-1 
Vmwl75 DNA binding domains, it was of interest to see whether these two homologous 
domains would heterodimerise. Having found that this was the case, a whole variety of 
experiments became possible: a series of insertion mutation versions of the HSV-1 
Vmwl75 DNA binding domain were co-translated with the VZV 140k DNA binding 
domain and heterodimer formation assayed as above; the aim was to identify insertions 
that might disrupt the subunit interaction. Additionally, heterodimer formation between 
an epitope-tagged HSV-1 Vmwl75 DNA binding domain peptide and the whole 
spectrum of Vmwl75 insertion and VZV 140k deletion peptides was assayed by 
co-immunoprecipitation analyses. This last approach yielded additional information, as 
it enabled detection of all heterodimers, not just those that bind to DNA.
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3D.2 Physical analyses of the native state of the VZV 140k DNA binding 
domain deletion peptides
Various methods were used to try to establish whether each of the truncated versions of 
the VZV 140k DNA binding domain (Fig. 3B.1) existed as a dimer in solution. These 
analyses are briefly outlined here (data is not shown for negative results). The aim 
behind these experiments, and most of the following studies in these Sections, was to 
separate the sequences mediating the dimerisation and DNA binding activities of the 
VZV 140k and also the HSV-1 Vmwl75 DNA binding domain.
3D.2.1 Glutaraldehyde cross-linking o f the VZV 140k DNA binding domain deletion 
peptides
The intrinsic dimerisation activity of partially purified bacterial extracts of the truncated 
VZV 140k peptides was analysed by glutaraldehyde cross-linking (as in Section 3C.3). 
Peptides VT1-VT5 all produced cross-linked dimer bands, indicating that the sequences 
mediating dimerisation lie within region 2 of 140k. Interestingly, the peptides that 
yielded cross-linked dimers were also the versions of the DNA binding domain that 
were able to bind DNA (summarised in Fig. 3D. 14). This suggested that dimerisation is 
a prerequisite for DNA binding. It was more difficult to determine whether the peptides 
with further N- or C-terminal deletions (VT7-VT12) had intrinsic dimerisation activities 
due to their general instability, and the low level expression of peptides VT7-VT10. 
When the sensitive ECL detection technique (see Section 2C.4.2) was used, additional 
cross-linked dimer bands were produced only by the VT11 peptide. The VT7-VT10 
peptides were almost completely degraded upon cross-linking, while VT11 and VT12 
were also significantly degraded, implicating sequences at both the N- and C-termini of 
region 2 as being necessary for the overall stability of the domain. Further analyses were 
required to support the cross-linking results as the instability of the VT7-VT12 peptides 
complicated their interpretation.
3D.2.2 Analysis o f the native state o f VZV 140k peptides with N-terminal deletions o f 
region 2 sequences
The low level bacterial expression of the VT7-VT10 peptides made their analysis by gel 
filtration chromatography and glycerol gradient centrifugation impossible. However, 
peptides VT11 and VT12 were both expressed to high levels (see Section 3B.3). The 
majority of the VT11 peptide and all the VT12 peptide sedimented to the bottom of the 
glycerol gradients as aggregated complexes (in gradient fraction 25; see Fig. 3C.7 for an 
explanation of the technique). However, a population of the VT11 peptides reproducibly 
sedimented to a position on the gradient that was between the positions predicted tor
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VT11 monomers and dimers, as determined by comparison with protein standards (not 
shown). Although it is not possible for a protein to sediment at a faster rate than 
determined by its molecular weight, a protein with an open conformation will be more 
retarded on the gradient than might otherwise be expected. Therefore, it is likely that 
these VT11 peptides were partially unfolded, yet still dimeric. Additionally, the VT11 
and VT12 peptides were not amenable to further purification by ion exchange 
chromatography (as in Section 3C.2), even though the deleted sequences were not 
particularly highly charged. Gel filtration chromatography (Superose 12 and Superdex 
75 columns) found peptides VT11 and VT12 to elute in every column fraction, 
presumably due to peptide aggregation or precipitation on the column, despite elution in 
0.5M NaCl buffers. Purification and analytical gel filtration chromatography in the 
presence of 1 0 % glycerol at all stages was more successful; although the majority of 
peptide VT11 and VT12 eluted from the Superdex 75 column as very high molecular 
weight complexes, an additional VT11 peak was detected in the dimer position. 
However it remained possible that this was also a consequence of aggregation. These gel 
filtration results are consistent with the glycerol gradient centrifugation analysis (above). 
Although it appeared that a minority of the VT11 peptides were dimeric, it was difficult 
to determine unequivocally the native state of peptides VT11 and VT12 from these 
analyses (but see Section 3D.9). Clearly the deletion of sequences from the N-terminal 
part of region 2 had drastic conformational effects on the 140k DNA binding domain.
3D.2.3 Analysis o f the native state o f VZV 140k peptides with C-terminal deletions of 
region 2 sequences, by use o f the GST fusion system
The poorly expressed C-terminal deletion versions of the 140k DNA binding domain 
were expressed in bacteria as glutathione-S-transferase (GST) fusion proteins (Ausubel 
et al., 1993b). The VT7, VT9 and VT10 regions of 140k were stably expressed to high 
levels as GST fusion peptides; addition of N-terminal sequences presumably stabilised 
these 140k peptides, which were otherwise very poorly expressed. GST itself is a 
dimeric protein. Therefore the 140k portions of the fusion polypeptides had to be 
separated from GST to enable analysis of the native state of the 140k peptides. Specific 
sequences between the GST coding region and the MCR of the vector pGEX2TN3, 
resulted in fusion proteins with a protease (thrombin) recognition site immediately 
following the GST sequences (see Fig. 3D.1). Thrombin treatment of the purified 
peptides GSTVT7, GSTVT9 and GSTVT10 each yielded a cleavage product of the 
expected size (Section 2C.6; for VT10, see Fig. 3D.2, track 3). However, only the VT10 
cleavage peptide gave a discrete peak upon gel filtration analysis and clearly eluted as a 
monomer (Fig. 3D.2). Additionally, the VT10 cleavage product failed to yield dimer 
bands by glutaraldehyde cross-linking analysis (not shown).
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Figure 3D.1 Construction of the pGEXVTIO plasmid and its expression product, 
GSTVT10. At the top are shown the plasmids pGEX2TN3 and p585T7aVT10 that were used to 
construct plasmid pGEXVTIO, only selected restriction enzyme sites are shown. Plasmid pGEX2TN3 
was derived from the commercial pGEX2TN vector (Pharmacia), by altering the restriction sites 
downstream of the glutathione-S-transferase (GST) sequences (black box), as shown (R. D. Everett, 
personal communication). Shaded triangles represent expression signals. The Nco\-Hindlll fragment of 
plasmid p585T7aVT10 (described in Section 3B.2) was inserted into the Ncol-Hindlll digested 
PGEX2TN3 vector to yield plasmid pGEXVTIO. Below are shown representations of peptides GSTVT10 
and VT10 (cleavage product). The GSTVT10 expression product of plasmid pGEXVTIO comprises 234 
GST residues (black box) fused to the VT10 region of 140k (residues 472-525) (white box). Between the 
GST and VT10 sequences are 11 vector-encoded amino acids which include a thrombin cleavage site 
[LVPR/GS]. To the C-terminus of the 140k sequences are 16 vector-encoded residues (shaded boxes 
represent vector-encoded residues). Thrombin cleavage yields the VT10 peptide with 3 N-terminal 
vector-encoded residues fused to 140k residues 472-525, followed by 16 C-terminal vector-encoded 
residues. The 315 residue GSTVT10 peptide has a predicted size of 35kD, the 73 residue VT10 cleavage 
product has a predicted size of 8.1kD.
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Although attempts to obtain a cleaved VT2X peptide to serve as a positive control failed 
due to the poor expression of the GSTVT2X peptide, it appears that 140k sequences 
between codons 472 and 525 at the N-terminal end of region 2  are not sufficient for 
dimerisation.
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Figure 3D.2 Purification of the VT10 cleavage peptide and its analysis by gel filtration. 
11 of bacteria transformed with plasmid pGEXVTIO was grown, expression induced and the GSTVT10 
fusion peptide purified as described in Section 2C.6. The VT10 peptide was released from GSTVT10 by 
thrombin cleavage and samples taken before and after cleavage were analysed by 20% SDS PAGE 
(tricine buffer system) as shown on the left. Track 1 contained lfil of purified GSTVT 10-agarose beads, 
track 2 contained lpl of the beads post thrombin cleavage (after the washes), tracks 3-6 contained 20gl of 
sequential washes of the beads after thrombin cleavage. Track 7 contained 5pl of a bacterial GST extract 
and molecular weight markers were loaded in track 8 (as described in legend to Figs. 3A.4). Wash 1 was 
concentrated and loaded in 200pl onto a Superdex 75 gel filtration column and eluted in 0.3M NaCl 
buffer, as described in Section 2E.2. Shown on the right is the chart recorder uv trace from one such 
column run (OD setting 0.05). The peptides eluting in each peak were identified by SDS PAGE analysis 
of 0.5ml fractions collected throughout the run, and are indicated above the trace with their respective 
elution volumes. A small amount of un-cleaved GSTVT10 and GST cleavage product remained in the 
preparation analysed here as seen in track 3 of the left hand panel, the minor unlabelled peak was thought 
to contain proteolytic fragments of VT10 peptide. The peak eluting at 14.95ml contained the VT10 
cleavage product (8.1kD) as determined by SDS PAGE, this peak contained peptides of approximately 
7kD by comparison with the calibration curve shown in Fig. 3C.6. An independent repeat of the full 
procedure described here gave a VT10 elution peak at 14.85ml.
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3D.3 Co-translation of pairs of differently sized VZV 140k DNA binding 
domain deletion peptides
Another method for discerning whether each truncated 140k DNA binding domain 
peptide included the sequences required for dimerisation, was to determine whether they 
had the ability to heterodimerise with a larger dimerisation competent peptide i.e. 
VT2X. Heterodimers would be apparent in gel retardation analysis as novel complexes 
of intermediate mobility between the two homodimer positions, using the method first 
described by Hope and Struhl (1987). Previous analyses (discussed in Section 3C.6) 
suggested that dimers of the 140k DNA binding domain are highly stable. Therefore it 
seemed unlikely that heterodimers would form merely by mixing together preparations 
of separately-translated bacterially expressed peptides. Instead pairs of peptides were 
co-translated in vivo or in vitro.
3D.3.1 Co-translation in vivo
The in vivo approach required the two differently sized 140k deletion peptides to be 
expressed in bacteria from compatible plasmids. Therefore the VT2X peptide was 
expressed from a pACYC184 based plasmid under the T7 expression signals. This 
VT2X expressing plasmid was co-transformed with each of the p585T7 plasmids 
expressing the truncated 140k peptides (Section 3B.2), into the appropriate E. coli strain 
(Section 2A.5) and both plasmids were maintained by antibiotic selection as described 
in Section 2A.6. Peptide expression was induced (Section 2C.2) and the presence of 
heterodimers in the resulting partially purified co-translation extracts was assayed by gel 
retardation analysis. Heterodimer complexes were not detected between VT2X and any 
of the range of deletion peptides (data not shown). Even co-translation of the dimeric 
VT2X and VT4X peptides failed to produce any additional bands, although it should be 
said that the resolution of this analysis was low. A logical explanation for the lack of 
heterodimer formation is that the pBR322 and pACYC184 based plasmids localise to 
different replication compartments within the bacterial cell, so that their expression 
products are liable to be translated at different spatial cellular locations. The results of 
this analysis support the idea that dimerisation occurs very rapidly after translation. In 
view of the success of the co-immunoprecipitation procedure (Section 3D.9), it should 
be possible to co-express an epitope-tagged DNA binding domain with each 140k 
deletion peptide in the manner described above, followed by co-immunoprecipitation, to 
assay more stringently for in vivo heterodimer production.
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3D.3.2 Co-translation in vitro
An in vitro approach would facilitate formation of heterodimers by overcoming the 
possible problems of spatial separation of translation of peptides encoded by different 
plasmids (above). Transcription and translation of pairs of 140k DNA binding domain 
peptides were performed within a single reaction using the TnT T7 Coupled 
Reticulocyte Lysate System (Promega), as described in Section 2C.7. Each 140k DNA 
binding domain deletion peptide was co-translated with the larger DNA 
binding-competent, dimeric VT2X peptide, in the presence of a radiolabelled amino 
acid. All peptides were expressed from the p585T7 series of expression vectors (Section 
3B.2), previously used for the bacterial expression (Section 3B.3). The efficiency of 
translation of the radiolabelled peptides was determined by SDS PAGE, before using the 
in vitro translated peptides in further analyses. Figure 3D.3 shows typical in vitro 
translation extracts of several of the 140k DNA binding domain deletion peptides.
VT2X ►
VT4X ►  
VT11 ►  
VT12 ►
1 2 3 4 5 6  7
Figure 3D.3 In vitro translation extracts of VZV 140k DNA binding domain deletion 
peptides. Peptides VT2X, VT4X, VT11 and VT12 were translated individually (tracks 1-4) 
co-translated with peptide VT2X (tracks 5-7) using the TNT T7 Coupled Rabbit Reticulocyte Lysate 
System, as described in Section 2C.7. The gel above shows an autoradiograph of a 13.5% SDS PAGE 
analysis of 5pl aliquots from in vitro translation reactions. The identity of peptides expressed in each 
reaction are given above the tracks. Tracks labelled 'co.' indicate pairs of peptides co-translated within a 
single reaction. The position of each peptide is indicated on the left hand side. Comparative western blot 
analysis found lpl of an in vitro translated extract to contain the same amount of VT2X peptide as 0.02pl 
of partially purified bacterial extract (approximately 5ng VT2X per |il in vitro translation extract) (not 
shown).
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3D.4 The VZV 140k DNA binding domain binds to DNA as a dimer
For each 140k DNA binding domain deletion peptide, single translation and VT2X 
co-translation extracts (of the type shown in Fig. 3D.3), were incubated with the 
radiolabelled BT gene 62 promoter fragment (Fig. 3A.6) under the specific conditions 
detailed in Section 2D.2. Protein-DNA complexes were resolved by gel retardation 
analysis and Figure 3D.4 shows one such analysis.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Figure 3D.4 Gel retardation analysis of the in vitro  translated VZV 140k DNA binding 
domain deletion peptides. Aliquots of in vitro translation extracts were incubated with the BT gene 
62 promoter fragment probe (see Fig. 3A.6 for details) and complexes resolved by gel retardation 
analysis. Peptides included in the analysis in the left hand panel were radiolabelled with 35S-met, peptides 
in the right hand panel were labelled with 3H-leu due to the low number of methionine residues in 
peptides VT5-VT10. The autoradiographs shown here are second films and therefore only detected the 
32P-labelled DNA. All in vitro translation reactions contained equivalent amounts of plasmid DNA 
(lpg/50|il reaction); lfil of single translation extracts were included in the relevant incubations, 2jil of co­
translation extracts were included in the incubations in the 'co.' tracks (to provide amounts of each peptide 
equivalent to those present in the singly translated incubations). The 'mixed' incubations contained lpl of 
each of the two singly translated extracts. The identity of the in vitro translated peptides included in each 
incubation are indicated above the tracks. Track 10 contains the free probe, tracks 1 and 11 contained lpl 
of an unprogrammed translation reaction. Optimal incubation conditions were determined empirically (see 
Section 2D.2) and included no specific competitor, as the plasmid DNA present in the in vitro translation 
extracts resulted in titration of the DNA binding domains away from the radiolabelled target. The 
positions of the free probe (P) and the primary protein-DNA complexes (PC) are indicated. The probe 
used in tracks 1 to 9 contains a minor contaminant, seen above the position of the free BT probe.
The singly in vitro translated peptides VT8  (track 16), VT9 (track 19), VT10 (track 22), 
VT11 and VT12 (not shown) did not bind to DNA, while peptides VT2X (tracks 2, 5 
and 12), VT4X (track 3) and VT5 (track 13) interacted with the DNA probe. Therefore 
the behaviour of the in vitro translated peptides is in agreement with the previous DNA 
binding analysis of the bacterially expressed 140k DNA binding domain deletion 
peptides (Section 3B.4). Due to the similar sizes of the VT2X, VT4X and VT5 peptides, 
it was not possible to be certain whether heterodimer complexes were formed in the
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co-translation extracts in tracks 4 and 14 of Figure 3D.4. Therefore, gel retardation 
analysis on 35cm gels was used to increase the resolution between the VT2X and VT4X 
protein-DNA complexes (Fig. 3D.5). When the two separately-translated proteins were 
incubated together, only two bands corresponding to the separate VT2X and VT4X 




1 2 3 4 5 6
Figure 3D.5 Gel retardation analysis showing VT2X/VT4X heterodimers formed by in 
vitro  CO-translation. In vitro translation extracts were incubated with the radiolabelled gene 62 
promoter BT fragment (details in Fig. 3A.6) and complexes resolved by gel retardation analysis on 35cm 
gels. The gel shown here is a second film autoradiograph of one such analysis. In vitro translations 
included 0.02pg total plasmid DNA per 50pl reaction. Incubations loaded in tracks 3 and 4 contained 2pl 
of single peptide translation extracts, track 5 contained 4|il of the co-translation extract and track 6 
contained 2jil of each single translation extract. Track 1 contains the free probe and the incubation in track 
2 contained 2jxl of the unprogrammed translation extract. The positions and identity of peptide 
dimer-DNA complexes are indicated on the right. In the particular co-translation extract used in track 5, 
the VT2X peptide was more efficiently translated than VT4X, explaining why the VT4X homodimer 
complex is relatively faint here. The faster mobility faint bands are due to minor contaminants of the 
radiolabelled DNA.
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However, when the two peptides were co-translated, a third intermediate band was 
observed (Fig. 3D.5, track 5), which must be due to heterodimer formation between the 
VT2X peptide and the smaller VT4X peptide. This result proves unequivocally that it is 
the dimer of the 140k DNA binding domain that recognises the target binding sites. 
Therefore all primary protein-DNA complexes mentioned so far in this Thesis 
comprised one dimer bound to DNA, and the secondary complexes comprised two 
dimers bound to DNA. The finding that the intermediate heterodimeric VT2X/VT4X 
band was not formed by mixing of the two separately-translated peptides confirms that 
the dimers are highly stable, as no detectable exchange of monomer subunits occurs 
within the 2 0  minute incubation period of the binding reaction.
Heterodimers with the relatively small VT8-VT12 peptides would have migrated faster 
than the VT2X homodimer complex in Figure 3D.4. The absence of heterodimer 
complexes between the VT2X and the VT8-VT12 peptides indicates that deletions 
encroaching on either end of region 2 prevented formation of DNA binding-competent 
heterodimers. Although it is possible that sequences at both ends of region 2 are 
required for dimerisation, these results are inconclusive since (a) truncated 140k 
peptides lacking either the N- or C-terminal end of region 2 failed to bind to DNA 
(Section 3B.4), so it is possible that non-DNA binding heterodimers were produced that 
remain undetected by this method of analysis, and (b) truncations into either end of 
region 2 previously destabilised the resultant 140k deletion peptide (Sections 3B.3 and 
3D.2). Therefore failure to dimerise with VT2X may be an indirect consequence of 
general disruptions of the conformation of the truncated domains, rather than due to 
deletion of specific sequences directly involved in the dimerisation of the 140k DNA 
binding domain. These possibilities are addressed by the co-immunoprecipitation 
experiments described later (Section 3D.9).
Although not particularly apparent in the analysis shown in Figure 3D.4, it was noticed 
on several occasions that co-translation with the VT11 and VT12 peptides resulted in 
reduced formation of the VT2X homodimer complex, as compared to that seen when the 
separately-translated peptides were mixed. It was possible that non-DNA binding 
heterodimers form between these peptides and VT2X, resulting in a reduction of the 
VT2X homodimer band. This was further analysed by setting up a series of 
co-translation reactions, so as to yield increasing amounts of peptide VT11 and a 
constant amount of peptide VT2X (left hand panel of Fig. 3D.6 ). Volumes of each 
extract containing equal amounts of the VT2X peptide were analysed by gel retardation 
analysis. As suspected, co-translation in the presence of VT11 resulted in reduction ol 
the VT2X homodimer complex; see the right hand panel of Figure 3D.6, tracks 4-9. 
However, this was not considered to be solely a consequence of formation of non-DNA
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binding VT11/VT2X heterodimers because mixing the separately-translated VT11 and 
VT2X peptides also resulted in a significant reduction of the VT2X homodimer 
complex (compare track 10 to track 3 in right hand panel, Fig. 3D.6), albeit to a lesser 
degree than that occurring when VT2X and VT11 were co-translated in the same 
proportions (track 9). Previously, the bacterially expressed VT11 and VT12 peptides 
tended to aggregate either with themselves and / or with other proteins in general 
(Section 3D.2.2). The reduction of the VT2X homodimer complex in Figure 3D.6 is 
likely to reflect, at least in part, non-specific interactions between peptides VT2X and 
VT11; co-translation presumably increases the probability of these interactions. 
Identical findings were provided by the VT12 peptide (not shown).
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Figure 3D.6 Gel retardation analysis showing non-specific reduction of the V T2X  
homodimer complex by the VT11 peptide. The left hand panel shows an autoradiograph of a 
12.5% SDS PAGE analysis of 2|il aliquots of in vitro translated extracts of the VT2X and VT11 peptides. 
A constant amount of plasmid p585T7aVT2X and increasing amounts of plasmid p585T7aVTll were 
included in the reactions analysed in tracks 2-7. Track 1 and 8 included plasmids p585T7aVT2X and 
p585T7aVTl 1 alone respectively, track 9 is an unprogrammed lysate. The total amount of plasmid DNA 
in each translation reaction was equalised to 0.25|ig/50pl reaction with plasmid p585T7a. The positions of 
the VT11 and VT2X peptides are indicated on the left, the relative amounts of VT2X and VT11 peptides 
in each track were quantitated by Phosphorlmaging. The right hand panel shows the second film 
autoradiograph of the corresponding gel retardation analysis, produced when the in vitro translated 
extracts shown on the left were incubated with the radiolabelled gene 62 promoter BT fragment (details in 
Fig. 3A.6). Volumes of each translation extract containing equal amounts of the VT2X peptide were used 
in each incubation. The peptide concentration ratio of VT11/VT2X in the co-translated extracts is 
indicated above tracks 4-9. The incubations in tracks 10 and 11 contained an amount of VT11 peptide 
equivalent to the amount of VT11 included in track 9. The extra band above the position of the BT probe 
is a non-specific lysate complex (P = free probe, PC = primary protein-DNA complex).
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3D.5 The VZV 140k DNA binding domain heterodimerises with the 
corresponding domain of HSV-1 Vmwl75
Given that the DNA binding domains of the VZV 140k and the HSV-1 Vmwl75 
proteins are both dimeric and that they share a fairly high level of amino acid homology 
(Fig. 1C.3), it seemed possible that these homologous domains may dimerise in a 
similar manner. To test this, the HSV-1 Vmwl75 and VZV 140k DNA binding domains 
were co-translated in vitro, followed by gel retardation analysis of the co-translation 
extracts.
I9X / I9X 
VT4X/I9X
VT4X / VT4X
Figure 3D.7 Gel retardation analysis of heterodimer formation between the DNA 
binding domains of HSV-1 Vmwl75 and VZV 140k. In vitro translation extracts were 
incubated with the radiolabelled HSV-1 IE3 promoter fragment IE3S (details in Fig. 3A.11) and 
complexes resolved by gel retardation analysis. Shown here is a second film autoradiograph of one such 
analysis. The VT4X peptide basically comprises region 2 of VZV 140k. Peptide I9X (expressed from 
plasmid pT7I9X; Pizer et al., 1991) spans region 2 of HSV-1 Vmwl75, but also includes some region 1 
and region 3 sequences. Incubations loaded in tracks 3 and 4 contained 2|l i 1 of single peptide translation 
extracts, track 5 contained 4pl of the VT2X-I9X co-translation extract, track 6 contains 2pl of each single 
translation extract. Track 1 contains the free probe and the incubation in track 2 contained 2pl of an 
tmprogrammed translation extract. The positions and identity of peptide dimer-DNA complexes are 
indicated on the right.
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The Vmwl75 peptide I9X and the 140k peptide VT4X were utilised due to their large 
size difference (see Fig. 3B.7), and a DNA probe containing the HSV-1 IE3 consensus 
binding site was used for the gel retardation analysis. Figure 3D.7, track 5 clearly shows 
the formation of VT4X/I9X heterodimers of intermediate mobility between the two 
homodimer bands; the relative amounts of the three complexes were in the expected 
1:2:1 proportions. The VT4X/I9X heterodimer was absent when the separately- 
translated peptides were mixed after translation (Fig. 3D.7, track 6 ). The ease of 
formation of the heterodimers between the 140k and Vmwl75 DNA binding domain 
peptides suggests that the VZV 140k and HSV-1 Vmwl75 proteins have very similar 
structural requirements, and also perhaps similar sequence requirements for 
dimerisation.
3D.6 Selected heterodimers with only one fully wild type subunit can bind 
to DNA
It was previously noticed that the HSV-1 Vmwl75 protein, and also its isolated DNA 
binding domain, had very low affinities for the VT2 binding sites in the VZV gene 62 
promoter, compared to their affinities for the HSV-1 IE3 consensus binding site (see 
Fig. 3A.15). The VZV 140k domain however, recognised sites both in the VZV gene 62 
promoter and the HSV-1 IE3 promoter. Heterodimers of the Vmw 175/140k DNA 
binding domains produced in vitro (as above) were tested for their ability to bind to the 
VZV gene 62 promoter probe in gel retardation analysis. The aim was to see whether 
both subunits of the dimer contribute to the sequence-specificity of DNA binding. Track 
5 in the top panel of Figure 3D.8 , clearly shows that an in vitro co-translation extract of 
the I9X and VT4X peptides yielded I9X homodimer, I9X/VT4X heterodimer and VT4X 
homodimer complexes with the HSV-1 IE3 promoter fragment, as seen previously in 
Figure 3D.7. In a parallel experiment, aliquots of the same in vitro translation extracts 
were tested for their DNA binding activities on the VZV gene 62 promoter fragment 
probe. The low affinity of the Vmw 175 DNA binding domain for this particular probe 
fragment was apparent from the lack of any specific bands in track 4 in the lower panel 
of Figure 3D.8. However the I9X/VT4X heterodimer clearly still recognised the gene 62 
promoter binding sites, as a band in a position consistent with the production of a 
heterodimer-DNA complex was formed upon co-translation of the two homologous 
DNA binding domains (lower panel of Fig. 3D.8 , track 5). This result suggests that the 
specific interaction of the single VT4X monomer with its DNA recognition site was 
sufficient to mediate the DNA binding activity of the I9X/VT4X heterodimer. Other 
possible explanations are discussed in Section 3D. 10.
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Figure 3D.8 Gel retardation analysis of Vmwl75/140k DNA binding domain 
heterodimers on the HSV-1 IE3 and VZV gene 62 promoter fragments, in vitro translation 
extracts, as indicated above the tracks, were incubated with the radiolabelled DNA fragments and 
complexes resolved by gel retardation analysis. Shown here are second film autoradiographs. The top 
panel shows an analysis of the HSV-1 IE3 promoter fragment IE3S probe (details in Fig. 3A.11), the 
lower panel shows an analysis of aliquots of the identical in vitro translation extracts on the VZV gene 62 
promoter BT fragment (details in Fig. 3A.6). The VT4X peptide spans the VZV 140k DNA binding 
domain, and peptide I9X spans the HSV-1 Vmwl75 DNA binding domain. The I10il2X peptide spans 
the Vmwl75 DNA binding domain and includes an insertion at amino acid 310 (see Section 3D.7). The 
amounts of extract included in each incubation were comparable to those used in the analysis in Figure 
3D.4. In both panels: track 1 contained the free probe and track 2 contained 2pl ol an unprogrammed 
translation extract. The positions and identity of peptide dimer-DNA complexes are indicated on the right 
hand side.
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3D.7 Insertion mutations throughout region 2 of HSV-1 Vmwl75 disrupt 
formation of DNA binding-competent heterodimers of the VZV 140k and 
HSV-1 Vmw 175 DNA binding domains
The attempts at mapping the location of dimerisation sequences described so far, using 
the VZV 140k DNA binding domain deletion peptides, were complicated by the 
consequences of deleting large stretches of sequences which appeared to be necessary 
for the overall stability of the domain. Therefore the more subtle approach of looking at 
the effects of small insertion mutations on heterodimer formation was adopted.
Numerous insertion mutations had previously been introduced at positions throughout 
the HSV-1 Vmwl75 protein, for the mapping of functional domains (Paterson and 
Everett, 1988a; b). Many of the insertions within the mapped DNA binding domain 
prevented DNA binding of the intact Vmw 175 protein, and it was possible that some of 
these mutations affected DNA binding indirectly by interfering with dimerisation. The 
VT4X/I9X heterodimer experiment (described in Section 3D.6 ) suggested that in certain 
circumstances, the specific DNA binding property of the heterodimer can be provided 
by the VT4X monomer alone. Therefore it was possible that similar heterodimers with 
altered forms of the Vmw 175 DNA binding domain subunit might also bind to DNA. 
Such DNA binding-competent mutant heterodimers would identify positions within 
region 2 which are involved in DNA binding rather than dimerisation. Sequences 
encoding the DNA binding domains of the Vmw 175 insertion mutation proteins had 
previously been transferred to T7 expression plasmids (R. D. Everett, unpublished). 
Insertion mutation versions of the isolated HSV-1 Vmw 175 DNA binding domain 
(peptide I10X, see Fig. 3D.9) were in v itro  co-translated with the VZV 140k DNA 
binding domain peptide (VT4X) and heterodimer formation assayed by gel retardation 
analysis, as in Section 3D.4. The DNA binding activities of the individually translated 
insertion mutation versions of the IIOX domain closely corresponded to those 
previously observed with the intact Vmwl75 protein (Paterson and Everett, 1988b), as 
summarised in Figure 3D.9. This verifies the validity of the in vitro  approach using the 
isolated DNA binding domain peptides.
The i 12 insertion at the C-terminal end of region 1 of HSV-1 Vmwl75 greatly reduced 
the DNA binding activity of the intact Vmw 175 protein (Paterson and Everett, 1988b; 
see Fig. 3D.9). In accordance, the in v itro  translated Vmw 175 DNA binding domain 
including the i 12 insertion (peptide IlOi 12X), produced no apparent complex with either 
of the DNA probe fragments used in Figure 3D.8, track 7. Although the results in Figure 
3D.8 are quite faint, it can be seen that the I10il2X/VT4X heterodimers recognised both
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the HSV-1 IE3 and the VZV gene 62 promoter probes with apparent affinities 
comparable to the VT4X homodimers (Fig. 3D.8 , track 8 ). This result is consistent with 
the idea that in certain circumstances only one fully wild type monomer of the dimer is 
required for the interaction with DNA in a specific manner. Furthermore, it appears that 
sequences within the C-terminal end of region 1 of Vmw 175 are involved in DNA 
binding rather than dimerisation of the DNA binding domain.
I10X i!4
il2 i l3  I il5






275 315 489 523aa
DNA binding activity 
Insertion mutation Intact Vmwl75 Isolated Vmwl75 DNA binding domain
homodimer heterodimer
i l 2 (310) +/- - +++
il3 (324) +++ +++ ++
114(329) - - -
115 (337) - - -
i l 6  (373) - - -
117 (398) + - -
i l 8  (438) + - -
i l 9 (494) +++ +++ +++
i20 (518) ++ ++ +
Figure 3D.9 DNA binding activities of the in vitro translated insertion mutation 
versions of the HSV-1 Vmwl75 DNA binding domain. At the top is shown a representation 
of the I10X DNA binding domain peptide of HSV-1 Vmwl75 (Pizer et al., 1991). Region 2 is highly 
conserved with the VZV 140k protein and is shown shaded. The first and last amino acid residues of the 
I10X peptide and Vmw 175 region 2 are given. The position of the 4 ammo acid insertion mutations, i 12 
to i20, are given in the first column of the table and also indicated on the diagram of the I10X peptide. 
The second column of the table gives the previously published DNA binding activities of HeLa nuclear 
extracts containing insertion mutation versions of the intact Vmw 175 protein (Paterson and Everett, 
1988b). The DNA binding activities of the insertion mutation versions of the HSV-1 Vmw 175 DNA 
binding domain, expressed in vitro from the pT7I10il2X-pT7I10i20X series of plasmid^ are also given: 
the third column gives the DNA binding activity of singly translated I10X derived peptides, as determined 
by gel retardation analysis of the IE3S probe. The final column gives the ability to form heterodimer- 
DNA complexes following in vitro  co-translation with the VZV 140k DNA binding domain peptide 
VT4X. The symbols - to +++ provide an arbitrary scale to indicate the relative intensities of protein-DNA 
complexes obtained in gel retardation analyses.
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However, IIOX peptides containing single insertion mutations at positions throughout 
region 2 (i 14 to i l 8 ), failed to bind to DNA as either I10X homodimers or as 
I10X/VT4X heterodimers (Fig. 3D.9). Therefore either sequences throughout region 2 
are required for dimerisation, or the insertion mutations induce conformational 
alterations which inhibit dimerisation indirectly. Alternatively heterodimers may form, 
but fail to bind DNA (see below and Section 3D. 10).
3 D . 8  I n s e r t i o n s  t h r o u g h o u t  t h e  H S V - 1  V m w l 7 5  D N A  b i n d i n g  d o m a i n  t h a t  
d i s r u p t  D N A  b i n d i n g ,  d o  n o t  p r e v e n t  d i m e r i s a t i o n
A major problem with assaying heterodimer formation by gel retardation analysis was 
that only DNA binding-competent heterodimers were detected. The DNA binding 
activity of the HSV-1 Vmw 175 protein appears to be highly sensitive to conformational 
changes (Section 1C. 1.9). Therefore it is likely that some heterodimers which include a 
truncated or mutated monomer fail to bind to DNA. Therefore the approach of 
co-immunoprecipitation of heterodimers from solution was adopted. A panel of 
monoclonal antibodies raised against the DNA binding domain of Vmw 175 (Everett et 
al., 1993c) was tested in immunoprecipitation experiments. Unfortunately, all those 
tested were very inefficient (not shown). Therefore an epitope-tagged Vmw 175 DNA 
binding domain was constructed. MAb 11,060 (Everett et al., 1993b) had recently been 
found to recognise strongly the HSV-1 VmwllO protein in immunoprecipitations 
(Meredith et al., 1994). Sequences spanning the MAb 11,060 epitope were fused to the 
N-terminus of the Vmw 175 DNA binding domain, as described in Figure 3D. 10. The 
author is very grateful to Maggie Elliott for assistance with cloning of the epitope.
Having established that the HSV-1 Vmw 175 DNA binding domain (I10X peptide) could 
heterodimerise with the epitope-tagged NXI10X domain (not shown), NXI10X was 
co-translated in vitro with each of the insertion mutation versions of IIOX (see Fig. 
3D.9), followed by co-immunoprecipitation analysis, as described in Section 2E.4. The 
insertions had no apparent effect on peptide solubility, as all remained in the soluble 
fraction after pre-clearing of the in vitro translation extracts (upper panel, Fig. 3D. 11).
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(residues 1-105 of (residues 275-523 of
HS V-1 Vmw 110) HSV-1 Vmw 175)
Figure 3D.10 The epitope-tagged HSV-1 Vmw 175 DNA binding domain. At the top is 
shown T7 expression plasmid pNXIlOX, only selected restriction enzyme sites are indicated. An 
EcoRl-Pstl fragment of plasmid pJHOX (including Vmwl75 codons 275-523; striped box) was fused to a 
Pstl-Xhol fragment of plasmid pT7110 (including VmwllO codons 1-105; white box) with the aid of an 
Xhol-EcoRl adaptor (black box) which also restores the reading frame. Below is shown a representation 
of the NXI10X expression product of plasmid pT7NXI10X. Shading of portions of the HSV-1 Vmwl75 
and Vmw 110 coding sequences are as above. Translation of peptide NXI10X begins on the first ATG of 
the HSV-1 VmwllO ORF and a single vector-encoded residue is at the C-terminal end of the peptide, 
which has a total predicted size of 40kD. The authenticity of the expressed peptide was verified by 
western blot analysis of bacterially expressed NXI10X peptide, using MAbs recognising the VmwllO 
epitope and a Vmw 175 epitope respectively.
It was apparent that none of the insertions in the Vmw 175 DNA binding domain 
prevented dimerisation with the epitope-tagged domain, as all were specifically 
co-immunoprecipitated by MAb 11,060 (tracks 11-18 in the lower panel of Figure 
3D. 1 1 ). Additionally, the interaction was a consequence of specific heterodimerisation 
as none of the I10X insertion mutation peptides were co-immunoprecipitated when the 
separately-translated peptides were mixed together (lower panel of Fig. 3D. 11, tracks 
3-10).
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Figure 3D.11 Co-immunoprecipitation analysis of the insertion mutation versions of 
the HSV-1 Vmw 175 DNA binding domain by an epitope-tagged domain. Insertion 
mutation versions of the HSV-1 Vmwl75 DNA binding domain were in vitro translated individually, or 
co-translated in pairs with the epitope-tagged NXIIOX peptide (Fig.3D.10). The reaction products were 
pre-cleared' to reduce background, as described in Section 2E.4. The top panels show autoradiographs of 
12.5% SDS PAGE analyses of 20pl aliquots of pre-cleared extracts of die in vitro translated peptides, as 
indicated above each track. The lower panels show autoradiographs of 12.5% SDS PAGE analyses of a 
co-immunoprecipitation assay of the pre-cleared in vitro translated extracts shown above. MAb 11,060 
recognises the N-terminal VmwllO epitope of peptide NXIIOX and was used for all 
immunoprecipitations, * with the exception of track 2 which included MAb 10,503 which is specific lor a 
C-terminal epitope of VmwllO. The peptides included in the immunoprecipitation reactions were either 
co-translated or mixed after translation, as indicated above the tracks in the lower panel, 'con' indicates an 
unprogrammed translation reaction. 'MW' indicates 14C radiolabelled molecular weight markers: 
phosphorylase b, 97kD; bovine serum albumin, 69kD; ovalbumin, 46kD; carbonic anhydrase, 30kD. The 
positions of peptides NXIIOX (40kD) and I10X (28.2kD) are indicated on the left, die Vmwl 10 portion 
of the NXIIOX fusion peptide was very highly acidic and caused die peptide to have a lower mobility than 
expected on SDS PAGE analysis. MAb 11,060 was highly efficient at immunoprecipitating the NXIIOX 
peptide; the amount of peptides included in the immunoprecipitation reactions was equivalent to the 
amount of pre-cleared extracts analysed in the top panel (both sets of gels were exposed to film for three 
days). The split nature of the NXIIOX peptide in the lower panels was probably due to immunoglobulin 
Polypeptides migrating at the same position as NXIIOX.
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Insertion mutation DNA binding activity . D*mer*c by #co'
J im m u n o p recip ita tio n
homodimer heterodimer
i 12 (310) - +++ yes
i 13 (324) +++ ++ yes
114 (329) - - yes
115 (337) - - yes
116 (373) - - yes
117 (398) - - yes
118 (438) - - yes
119 (494) +++ +++ yes
120 (518) ++ + N/D
Figure 3D. 12 Summary of the activities of the in vitro translated insertion mutation 
versions of the HSV-1 Vmwl75 DNA binding domain. At the top is shown a representation 
of the I10X DNA binding domain peptide of HSV-1 Vmwl75. The first and last amino acid residues of 
the I10X peptide and Vmwl75 region 2 are given. The position of 4 amino acid insertions il2  to i20, 
described in the first column of the table, are indicated on the diagram. The DNA binding activities of the 
in vitro translated insertion mutation versions of the HSV-1 Vmwl75 DNA binding domain as 
homodimers and as VT4X heterodimers are given in columns two and three, as given previously in Figure 
3D.9. The third column gives the ability of each peptide to dimerise with the epitope-tagged NXIIOX 
peptide, as determined in Fig. 3D. 11. N/D indicates an experiment not performed.
From these studies it is apparent that the DNA binding interaction was more mutation 
sensitive than the monomer interaction, as many of the insertions within region 2  of 
HSV-1 Vmw 175 disrupted DNA binding yet none affected dimerisation (summarised in 
Fig. 3D. 12).
3D.9 Deletion of either the N- or C-terminus of VZV 140k region 2 
disrupts dimerisation
Taking advantage of the previous finding that the VZV 140k and HSV-1 Vmw 175 DNA 
binding domains can heterodimerise (Section 3D.5), the epitope-tagged HSV-1 
Vmw 175 DNA binding domain peptide was in vitro co-translated with each of the VZV
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140k DNA binding domain deletion peptides. Co-immunoprecipitations were performed 
as above on the resulting pre-cleared in v itro  translation extracts shown in the upper left 
hand panel of Figure 3D. 13. The 140k DNA binding domain peptides VT2X, VT4X and 
VT5 specifically and strongly heterodimerised with the epitope-tagged domain (right 
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Figure 3D. 13 Co-immunoprecipitation of the VZV 140k DNA binding domain deletion 
peptides following in  v itro  co-translation with the epitope-tagged HSV-1 Vmw 175 
DNA binding domain. VZV 140k DNA binding domain deletion peptides were in vitro translated 
individually, or co-translated in pairs with the epitope-tagged NXIIOX peptide (Fig. 3D. 10). The top left 
hand panel shows an autoradiograph of a 12.5% SDS PAGE analysis of 20pl aliquots of the pre-cleared 
extracts (see Section 2E.4) of the in vitro translated 35S labelled peptides, as indicated above each track. 
The right hand panel shows two different autoradiographic exposures of a 12.5% SDS PAGE analysis of 
co-immunoprecipitation assays of the pre-cleared extracts shown on the left. MAb 11,060 was used for all 
immunoprecipitations, * with the exception of track 2 which included MAb 10,503 as a negative control. 
The peptides included in the immunoprecipitation reactions were either co-translated or mixed after 
separate translation, as indicated above the tracks in the right hand panels, 'con' indicates an 
unprogrammed translation reaction. The relative positions of in vitro translated peptides in all panels are 
indicated on the far left. The amount of NXIIOX peptide in tracks 1 and 3-8 in the right hand panels, is 
approximately 10 times the amount present in tracks 9-14. This reflects the higher amount of NXIIOX 
peptide in the pre-cleared extract used in these particular immunoprecipitations (track 1, left hand panel) 
which is approximately 10 times greater than that in the co-translation extracts (tracks 8-13 on the left). 
Instability of the NXIIOX fusion peptide is apparent following the longer exposure. ’MW’ indicates 14C 
radiolabelled molecular weight markers: myosin, 200kD; phosphorylase b, 97kD; bovine serum albumin, 
69kD; ovalbumin, 46kD; carbonic anhydrase, 30kD; trypsin inhibitor, 21.5kD; lysozyme, 14.3kD. The 
bottom left hand panel gives the corresponding quantitated co-immunoprecipitation elticiencies tor the 
140k DNA binding domain deletion peptides, as determined by Phosphorlmaging. The values are 
calculated as ratio of VT peptide/NXHOX for tracks 9-14 (right hand panel), minus the corresponding 
background value (ratio of VT peptide/NXIlOX for tracks 3-8, right hand panel) expressed as a 
percentage of maximum co-immunoprecipitation obtained with the VT2X peptide (100%).
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Figure 3D. 14 Summary of the activities of the VZV 140k DNA binding domain 
deletion peptides. The portion of the 140k protein encompassing the DNA binding domain is shown 
diagrammatically at the top, the numbers of the first and last residues are given for the highly conserved 
region 2 (represented by a shaded box). Below, horizontal lines correspond to the protein sequences 
included in each of the deletion peptides VTl-VTl2. The residues at the N- and C-termini of each peptide 
are indicated. The DNA binding abilities of the peptides are indicated as determined by gel retardation 
analysis of the bacterially expressed peptides (Section 3B.4) and the in vitro translated peptides (Section 
3D.4). The ability of each peptide to dimerise is also indicated, as determined by a combination of the 
native state analyses on the bacterially expressed peptides (Section 3D.2), and heterodimerisation analyses 
of the in vitro translated peptides (Sections 3D.4 and 3D.9).
Co-immunoprecipitation of VT2X also occurred in the presence of 1M NaCl (not 
shown), indicating that the interaction is not mediated by DNA and is highly stable. The 
N-terminal deletion peptides VT11 and VTl2 also heterodimerised, albeit to a lesser 
extent (right hand panels of Fig 3D. 13, tracks 13 and 14). The VTl 1 result supports the 
findings of the previous analyses of the native state of the bacterially expressed VTl 1 
peptide, which found VT11 to be partly dimeric in solution (Section 3D.2). Since 
co-immunoprecipitation of the C-terminal deletion peptide VT8  was undetected after 
prolonged exposure of the gel shown in the right hand panels of Figure 3D. 13 (track 12), 
the quantitated value is considered to be negligible. The summary of this and all the 
other dimerisation analyses of the VZV 140k DNA binding domain deletion peptides is 
found in Figure 3D. 14.
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3D. 10 Discussion
The main aim of the work presented in these Sections (3D) was to separate sequences 
specifying the dimerisation and DNA recognition activities within the VZV 140k DNA 
binding domain. Several interesting observations were made in the course of these 
analyses.
Heterodimer formation between the VZV 140k and HSV-1 Vmw 175 DNA binding 
domain peptides occurred readily in vitro. Therefore it is likely that equivalent 
protein-protein interactions are involved in the formation of homodimers of the intact 
140k and Vmwl75 proteins during their respective viral infections. The protein interface 
mediating dimerisation must be structurally similar in 140k and Vmw 175 to allow 
heterodimerisation, and it is possible that the actual sequences involved in the 
interaction between monomers are conserved or semi-conserved between these two 
regulatory proteins. Therefore mapping of the dimerisation sequences was approached 
from two directions, utilising (i) the VZV 140k DNA binding domain deletion peptides 
and (ii) a series of insertion mutation versions of the HSV-1 Vmw 175 DNA binding 
domain.
Both approaches found that dimerisation had lower protein sequence requirements than 
DNA binding. In particular, the HSV-1 Vmwl75 insertion mutation peptides il4-il8 
failed to bind to DNA as either homodimers or heterodimers with a wild type subunit, 
yet all readily dimerised. Similarly, in a previous study insertions at Vmw 175 residue 
320 or 338 prevented DNA binding but did not disrupt dimerisation of the intact protein 
produced during viral infection (Shepard and DeLuca, 1991a). The DNA binding 
domain may be able to accommodate or compensate for the effects of insertions upon 
the individual facets of the dimerisation interface. Alternatively a short discrete 
sequence that has not been affected by the insertions may mediate dimerisation. It is 
improbable that all the insertions into Vmwl75 region 2 are directly disrupting DNA 
binding, and it is more likely that the specific structure of the domain required for DNA 
recognition is highly sensitive to minor conformational alterations.
From the studies with the VZV 140k DNA binding domain deletion peptides, it was 
apparent that sequences towards the C-terminus of 140k region 2 (between residues 588 
and 633) are essential either directly or indirectly for dimerisation. A long tract of 
residues within these region 2 C-terminal sequences is highly conserved (approximately 
80% identity; see Section 1C.1.8) between VZV 140k and HSV-1 Vmwl75 and 
secondary structure prediction programmes suggest a highly a-helical nature to this
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tract. The well studied helix-loop-helix and leucine zipper dimerisation motifs are 
almost totally a-helical (see Section 1E.3), making the C-terminal portion of region 2 of 
these alphaherpesvirus proteins a particularly favourable candidate for mediating 
dimerisation. A single amino acid mutational analysis of these conserved sequences in 
the Vmw 175 domain failed to identify any substitutions that disrupted dimerisation 
(Allen and Everett, 1994); although some of the mutations were not amenable to 
biochemical characterisation, they might re-pay analysis using the powerful in vitro 
translation and co-immunoprecipitation methods described here. It is also possible that, 
as suggested for the 4 amino acid insertions (see above), the dimerisation activity of the 
domain may tolerate minor changes of this type.
The N-terminal portion of VZV 140k region 2 (between residues 472 and 526) also 
contributes to normal dimerisation of the DNA binding domain. 140k sequences within 
amino acids 504 to 647 (peptide VT11) are sufficient for dimerisation, although at a 
lower efficiency than the full DNA binding domain (i.e. peptide VT2X). Further 
truncation of the domain to residues 526-647 (peptide VTl2) reduced dimerisation 
activity yet further. The fact that dimers containing the VT11 and VTl2 peptides were 
detected, albeit at a very low level, suggests that deletion of the N-terminus of region 2 
has indirect effects on the subunit interaction. Also, the unusual behaviour of these 
particular peptides (Section 3D.2) supports the argument that deletion of N-terminal 
sequences causes general disruption of the conformation of the domain, rather than 
directly destroying the subunit interaction. In agreement, sequences between 140k 
residues 472 and 525 were not sufficient for dimerisation, as seen from the gel filtration 
analysis of the VT10 GST cleavage peptide (Section 3D.2.3).
Heterodimers comprising the wild type VZV 140k domain (VT4X) and a severely DNA 
binding compromised mutant HSV-1 Vmw 175 peptide (I10il2X) recognised DNA with 
an apparent affinity equivalent to that of the wild type VT4X homodimers. Also a 
heterodimer comprising 140k/Vmwl75 DNA binding domain peptides, interacted with 
VZV gene 62 promoter sites for which the Vmwl75 peptide homodimer had an 
extremely low affinity. These data suggest that in certain circumstances, only one fully 
wild type subunit of the dimer is sufficient for the specific interaction with the 
recognition site. This raises the possibility that both subunits of the dimer are able to 
bind DNA independently, however there is no evidence for this occurring; gel 
retardation experiments using probes of different sizes in separate and mixed 
incubations gave no evidence of complexes containing both probe molecules (data not 
shown). The observation that in certain circumstances only one wild type subunit is 
sufficient for DNA binding could be explained by several models:
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(A) Only one subunit normally contacts the DNA binding site (Fig. 3D. 15, panel A). The 
second monomer does not directly contribute to the specificity or affinity of the DNA 
binding interaction but stabilises the overall protein-DNA complex. Evidence from 
substitution and deletion mutational analyses of the HSV-1 Vmw 175 consensus binding 
sequence (Pizer et al., 1991; Everett et al., 1991a) and also footprinting data (Didonato 
and Muller, 1989) suggested that both half-sites of the consensus are specifically 
recognised by the wild type homodimers. The lack of a direct repeat or any obvious 
dyad symmetry in the bipartite Vmw 175 consensus presents some difficulties for the 
simple model in which each monomer makes equivalent sequence-specific interactions 
with each half of the binding site. In B form DNA the two half-sites (underlined) of the 
ATCGTCnnnnYCGRC consensus are predicted to lie on the same face of the helix and 
could in theory be specifically contacted by a single monomer. In a similar scenario, the 
trimeric Drosophila heat shock factor (HSF) can form stable protein-DNA complexes in 
which only two of the three identical monomers contact the DNA (Perisic et al., 1989).
(B) Binding o f the first monomer facilitates binding of the second monomer (Fig. 3D. 15, 
panel B). The high affinity binding of the wild type monomer allows cooperative 
binding of the second monomer, by reducing its energy requirement for DNA binding. 
In this case, the low affinity of the mutant monomer would not significantly reduce the 
DNA binding affinity of the heterodimer while the mutant homodimer would fail to bind 
DNA. The recognition site for the yeast GCN4 transactivator protein has non-equivalent 
half-sites; the GCN4 interaction with the left half-site is strong compared to the 
relatively weak right half-site (Oliphant et al., 1989). The nature of this binding site 
facilitates cooperative binding of the second monomer of the GCN4 dimer to the weak 
half-site and a similar situation may hold for the Vmwl75 and 140k binding sites.
(C) Dimerisation with a wild type monomer induces a conformational change in the 
mutant monomer (Fig. 3D. 15, panel C). Binding to the wild type monomer induces the 
mutant monomer to adopt a DNA binding-competent conformation either before or after 
binding to DNA. In the presence of DNA, many DNA binding proteins adopt stabilised 
structures, for example the X Cro protein undergoes a large quaternary change when the 
dimer binds to its operator sequence (Brennan et al, 1990). Structural changes in the 
wild type Vmw 175 monomer upon DNA binding may induce analogous conformational 
changes in the mutant Vmwl75 subunit, restoring its ability to recognise target 
sequences specifically.
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ATCGTCnnnnYCGRC
ATCGTCnnnn Y CGRC ATCGTCnnnnYCGRC ATCGTCnnnnYCGRC
Wild type monomer 
DNA binding compromised monomer 
Specific interaction
Figure 3D. 15 Models for the DNA binding interaction of the dimeric DNA binding 
domain. Each oval represents a DNA binding domain monomer. The binding sequence shown in each 
section represents the HSV-1 Vmwl75 consensus binding site of Faber and Wilcox (1986b) (see Section 
1C. 1.3). Panels A, B and C illustrate possible modes of binding site recognition, as discussed in the text. 
The dimer represented comprises a wild type monomer and a DNA binding compromised monomer (i.e. a 
monomer that has a low binding affinity for the site shown, or containing a mutation (i.e. il2) that is 
deleterious for DNA binding). A. Only one subunit of the dimer specifically recognises both half-sites of 
the Vmwl75 consensus binding site. B. Binding of one monomer facilitates binding of the second 
monomer by a two step process, one monomer interacting with each half-site. C. Heterodimerisation 
induces a conformational change in the DNA binding compromised monomer, such that it adopts a wild 
type conformation that enables recognition of the binding site.
These three models for explaining the DNA binding interaction are not mutually 
exclusive. However, heterodimers including a version of the Vmwl75 DNA binding 
domain containing insertion mutation il4, il5, i l 6 , il7 or i l 8 , failed to bind to DNA. If 
these particular insertion mutations induce profound conformational changes in the 
domain, then it can be envisaged how the altered domain structure could prevent or 
destabilise heterodimer-DNA interactions occurring by any of the three models 
presented above.
Besides facilitating cooperative DNA binding of the second subunit of a dimer 
molecule, dimerisation could confer several other possible advantages upon the VZV 
140k and HSV-1 Vmwl75 proteins. The dimeric nature of these proteins may allow a 
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dimer (as opposed to a monomer) might ensure higher affinity binding. Dimerisation 
would also increase the available exposed protein surface for interactions with the host 
transcriptional machinery, such as the TATA binding protein (TBP) (Smith et al., 1993) 
or with upstream activator or co-activator proteins (see Sections ID. 1.4 and ID.2.3).
All the evidence so far has suggested that dimerisation of the VZV 140k DNA binding 
domain is a pre-requisite for DNA binding, which in turn is likely to be a requirement 
for the regulatory functions of VZV 140k during infection. In theory therefore, the 
identification of sequences specifying dimerisation would provide a favourable anti­
viral target for peptide inhibition of the 140k subunit interaction. Initial experiments 
have found that the bacterially expressed DNA binding domain peptides can be 
unfolded by dialysis into buffer containing 8 M urea, and refolded by a second dialysis to 
remove the urea (as assayed by their restored DNA binding activity) (Section 2E.5) 
(data not shown). This could provide the basis for a highly effective assay for locating 
precisely sequences mediating the dimerisation of VZV 140k, and also the HSV-1 
Vmw 175 protein. Such an assay could include peptides during the refolding process, 
and any inhibitory effects on dimerisation monitored by measurement of DNA binding 
efficiency.
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3E Mutagenesis of a short VZV 140k sequence that shows 
homology to the homeodomain DNA recognition helix
3E.1 Strategy
Structural studies and sequence comparisons have found that many DNA binding 
proteins can be grouped into classes that use related structural motifs for DNA 
recognition (see Section IE). Like several other important transactivator proteins, for 
instance SV40 large T antigen (Arthur et al, 1988) and NF-kB (Kieran et al, 1990), the 
VZV 140k DNA binding domain does not contain sequences that fit neatly into any of 
the recognised classes of DNA binding motif. However, a short stretch of residues 
within the HSV-1 Vmwl75 DNA binding domain, showing significant homology to the 
DNA recognition helix (helix 3) of the homeodomain, has been identified by sequence 
analysis (Allen, 1993). As described in Section 1E.2.2, the homeodomain is a eukaryotic 
DNA binding motif that is structurally related to the prokaryotic helix-turn-helix (HTH) 
motif found in proteins such as the X repressor. The homeodomain typically comprises 
60 residues arranged in three a-helical segments. Helices 2 and 3 comprise the HTH, 
and the third helix is the principal determinant for DNA recognition.
The region of HSV-1 Vmw 175 that shows homology to the homeodomain DNA 
recognition helix, is highly conserved within VZV 140k and the other alphaherpesvirus 
transactivator homologues. The possible functional implications of the conservation of 
this region was investigated by mutagenesis of the 140k sequence. Three single amino 
acid substitutions were introduced at positions predicted to be important for forming 
DNA contacts, by analogy to the known homeodomain-DNA structures. The DNA 
binding activities of the mutant 140k DNA binding domain peptides were investigated 
in order to determine if the homology region is directly involved in DNA recognition. In 
addition, the effects of the mutations on the regulatory functions of the intact 140k 
protein were analysed by transient transfection assays.
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3E.2 The WLQN region of VZV 140k that shows homology to the 
homeodomain DNA recognition helix
To date, dozens of homeodomains have been described, falling into at least 25 distinct 
families (Scott et al., 1989; Laughon, 1991). Residues at several positions are 
significantly conserved throughout all the homeodomain families, but the remaining 
residues show considerable divergence. The homeodomain homology region was first 
identified by sequence alignment of a weight matrix compiled for a variety of 
homeodomains to the HSV-1 Vmwl75 DNA binding domain (Allen, 1993). 
Subsequently, similar homeodomain consensus sequence alignments with VZV 140k 
and the other alphaherpesvirus homologue proteins identified the same region (data not 
shown). The variation within the homeodomain sequences creates significant divergence 
in any consensus derived for homeodomain sequences. However, individual 
homeodomain sequences also aligned convincingly to the same alphaherpesvirus 
sequences. Figure 3E.1 shows the DNA recognition helix (helix 3) of the prototype 
Drosophila Antennapedia (Antp) homeodomain aligned with the homology region 
identified within the VZV 140k alphaherpesvirus homologues. The level of sequence 
homology between the first two homeodomain helices and the alphaherpesvirus proteins 
was not considered significant and is therefore not shown in the alignment in Figure 
3E.1.
■recognition helix
H BHHBB PBP P
* ** * *
45 50 55
Antp ERQIKIWFQN RRMKWKK
VZV 140k 537 DRDPIAWLQN PKLTGVN
HSV-1 V m w l75 384 DAEAMGWLQN PRW PG D
PRV IE180 554 AGEAMSWLQN PRMQAPD
EHV-1 IE1 487 SREAMSWLQN SKLSGQD
Figure 3E.1 Alignment of the DNA recognition helix of the Drosophila Antp 
homeodomain to the alphaherpesvirus homologues of VZV 140k. The top sequence shows 
the Antp DNA recognition helix (homeodomain helix 3). Antp amino acids are numbered according to 
convention to indicate their position in the 60-residue homeodomain (Laughon, 1991). Positions 
corresponding to the hydrophobic core (H), base contact (B) and phosphate contact (P) amino acids of the 
Antp (Otting et al., 1990), MATa2 (Wolberger et al., 1991) and en  (Kissinger et al., 1990) 
homeodomain-DNA structures are indicated above the Antp sequence. Positions that are invariant or 
nearly invariant within all known homeodomains are indicated by asterisks. Aligned beneath are the 
sequences identified within region 2 of the alphaherpesvirus proteins (VZV 140k, HSV-1 Vmw 175, 
pseudorabies virus IE 180 and equine herpesvirus 1 IE1) that show homology to the homeodomain DNA 
recognition helix. The position of the first amino acid in each sequence is given. The VZV 140k residues 
that were subject to mutation are shown in bold. The alignment between the Antp homeodomain and the 
full length alphaherpesvirus proteins was produced using the GCG PileUp and Pretty programmes 
(Section 2G).
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It should be noted that helices 1 and 2 are also highly variable between the 
homeodomains; in essence, the homeodomain is a structural fold carrying the DNA 
recognition helix that lies across the major groove of DNA. The sequences shown in 
Figure 3E. 1 are approximately in the centre of region 2 of each alphaherpesvirus protein 
(as indicated for VZV 140k in the lower panel of Fig. 3E.3). The asterisks in Figure 
3E.1 indicate positions that are invariant or almost invariant within the DNA recognition 
helix of all homeodomains. These residues are also conserved or semi-conserved within 
the alphaherpesvirus proteins. Especially highly conserved is the quartet of residues 
WLQN, hence this short region of homology to the homeodomain is referred to as the 
WLQN region. The structures determined for three homeodomain-DNA complexes 
(Kissinger et al., 1990; Otting etal., 1990; Wolberger et al., 1991), demonstrate that the 
invariant homeodomain residues either mediate specific DNA contacts or maintain the 
hydrophobic core that stabilises the homeodomain protein fold (as indicated in Fig. 
3E.1).
To investigate further the relevance of the sequence homology between the 
homeodomain and the WLQN region of the alphaherpesvirus proteins, a weight matrix 
was created for the 60 residues of the VZV 140k, HSV-1 Vmwl75, PRV IE180 and 
EHV-1 IE1 proteins that corresponded to their hypothetical homeodomains 
(encompassing the WLQN region). When this weight matrix was used to search the 
Swissprot protein sequence database, six of the ten highest scoring alignments were to 
homeodomains of recognised homeobox proteins (discounting the first four alignments 
to the viral IE proteins). The scores for these ten alignments were between 4.51-5.83; 
they represent the differences in standard deviation units between each normalised 
comparison score and the mean normalised comparison score for sequences unrelated to 
the weight matrix profile.
A site directed mutagenic approach was adopted to investigate whether this potentially 
interesting WLQN region of sequence conservation is involved in the DNA recognition 
function of the VZV 140k protein.
3E.3 Mutagenesis, expression and purification of the VZV 140k DNA 
binding domain
In vitro mutagenesis was used to alter charges on single specific VZV 140k residues, 
while maintaining the size of amino acid side chains to minimise alterations of the 
protein conformation. Two single conserved residues within the WLQN motif itself 
were mutated: 140k residue Gin 545 was replaced with Leu (Q545L), and residue Asn
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546 was replaced with Leu (N546L). In the known homeodomain-DNA structures 
(Kissinger et a l, 1990; Otting et al, 1990; Wolberger et al, 1991), the corresponding 
residues of the homeodomain, residues 50 and invariant Asn 51 (Fig. 3E. 1), both point 
into the major groove of DNA and hydrogen bond with DNA bases. In addition, genetic 
and biochemical analyses have shown that the residue at homeodomain position 50 
determines the differential binding specificity of the homeodomain-DNA interaction 
(Hanes and Brent, 1989; Treisman etal., 1989; Hanes and Brent, 1991).
Thirdly, VZV 140k residue Lys 548 was replaced with Glu (K548E), due to the 
conservation of a basic residue at this position in the alphaherpesvirus proteins and all 
homeodomains. The corresponding homeodomain residue Arg 53 is known to form 
critical hydrogen bonds with two phosphate groups of the DNA backbone, thus 
stabilising the protein-DNA interaction.
Synthetic oligonucleotides including the relevant base changes (Fig. 3E.2) were used to 
direct the mutagenesis, using the single stranded bacteriophage M13mpl8EK template 
(see Fig 3E.3), as described in Section 2B.10. The resultant bacteriophage M13Q545L, 
M13N546L and M13K548E were utilised to derive plasmids pVT2XQ545L, 
pVT2XN546L and pVT2XK548E (collectively referred to as pVT2X[substitution]) 
(Fig. 3E.3).
5 4 2  5 5 2
A W L Q N P K L T G V  
Wild type 5 -  GCATGGCTCCAGAACCCCAAGCTGACCGGTGTC - 3
140k 3 -  CGTACCGAGGTCTTGGGGTTCGACTGGCCACAG - 5
W L L N P K L T G  
O ligol 3 -  TACCGAGGACTTGGGGTTCGMTGGCCACA - 5
H indlll
W L Q L P K L 
OligO 2 3 -  ACCGAGGTCGACGGGTTCGAC - 5
P vu ll
N P E L T G 
OligO 3 3 -  TGTTGGGGCTCGAGTGGCCACA - 5
S acl
Figure 3E.2 Oligonucleotides used for mutagenesis of the WLQN region of VZV 140k. 
At the top is shown the wild type VZV 140k protein sequence (residues 542-552) and the corresponding 
sequences of both VZV gene 62 DNA strands which encompass the region of mutagenesis. Below are 
given the sequences of the three oligonucleotides (corresponding to the gene 62 non-coding strand) used 
for the oligonucleotide-directed mutagenesis, and the relevant coding potentials. The nucleotides that 
differ from the wild type sequence and the resultant amino acid alterations are shown in bold. Restriction 
enzyme sites introduced by taking advantage of the degenerate nature of the genetic code are also 
indicated and were used in screening for the mutated gene 62 sequences. Oligo 1 facilitated the Q545L 
substitution; oligo 2, the N546L substitution; oligo 3, the K548E substitution.
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Figure 3E.3 Vectors used for mutagenesis of the VZV 140k DNA binding domain and 
its subsequent expression. Only selected restriction enzyme sites are shown. Mutagenesis template 
bacteriophage M13mpl8EK was constructed by insertion of an EcoRI-Kpnl fragment spanning codons 
417 to 570 of VZV gene 62 (isolated from plasmid p585T7aVT2X), between the £coRI and Kpnl sites of 
the MCR of vector M13mpl8. Oligonucleotide-directed mutagenesis of the gene 62 sequences in vector 
M13mpl8EK was performed as described in Section 2B.10. Mutagenesis yielded bacteriophage 
M13Q545L, M13N546L and M13K548E (collectively referred to as M13mpl8EK[substitution]). The 
restriction sites introduced by the mutagenesis facilitated identification of the appropriate mutagenised 
progeny bacteriophage, and the presence of the correct mutations was confirmed by direct plasmid 
sequencing. The arrow head on both vectors indicates the approximate site of the introduced base 
changes. EcoRl-Kpnl fragments were re-isolated from replicative forms of the M13mpl8EK[substitution] 
bacteriophage. Each mutated EcoRI-Kpnl fragment was swapped for the wild type EcoRl-Kpnl fragment, 
by insertion between the EcoRI and Kpnl sites of plasmid p585T7aVT2X. This cloning procedure 
produced plasmids pVT2XQ545L, pVT2XN546L and pVT2XK548E which encode the mutated 140k 
DNA binding domain under the control of T7 expression signals (collectively referred to as 
pVT2X[substitution]). In the bottom panel are shown diagrammatic representations of VZV 140k and its 
DNA binding domain peptide, VT2X (Section 3A.3). The region 2 and 4 sequences that are highly 
conserved between VZV 140k and HSV-1 Vmw 175 are shown shaded, amino acid coordinates of the 
boundaries of the conserved regions are given (inclusively). The VT2X peptide contains VZV 140k 
residues 417 to 647, encompassing the highly conserved region 2. The arrow indicates the approximate 
positions of the three residues, whose substitution is discussed in the text.
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The pVT2X[substitution] T7 expression plasmids encoded versions of the 140k DNA 
binding domain peptide, VT2X (bottom panel, Fig. 3E.3), containing single amino acid 
substitutions. Partially purified bacterial extracts of the mutant 140k DNA binding 
domains, expressed from the pVT2X[substitution] plasmids, were produced as described 
previously in Section 3A.4. Figure 3E.4 shows for each mutant and wild type peptide, 
samples of initial soluble (tracks 2-5) and partially purified (tracks 7-10) bacterial 
extracts, following SDS PAGE analysis. The mutations did not affect the efficiency of 
expression in bacteria, as all the peptides were induced to high levels (Fig. 3E.4, tracks 
2-5). In addition, all the peptides were highly soluble, indicating that the mutations did 
not induce conformational disruptions leading to protein precipitation.
1 2 3 4 5 6 7 8 9  10 11
Figure 3E.4 Bacterial expression and partial purification of the mutated VZV 140k 
DNA binding domain. Shown here is a Coomassie-stained 12.5% SDS PAGE analysis of the partial 
purification of bacterially expressed wild type and mutant VT2X peptides. Expression of the 140k DNA 
binding domain peptides was induced in E. coli from the appropriate T7 expression plasmids (as 
described in Sections 2C.1 and 2C.2). Tracks 1-5 contained 2pl of the total soluble proteins from 100ml 
of each induced bacterial culture after resuspension in 1ml buffer, bacterial lysis and centrifugation 
(Section 2C.2). Tracks 6-10 contained 2pl of partially purified extracts after 35% ammonium sulphate 
precipitates were resuspended in 300pl buffer, ’con' indicates an extract prepared from induced bacteria 
carrying the p585T7a plasmid. The arrow indicates the position of the 26.7kD VT2X peptide; a smaller 
proteolytic degradation product is apparent beneath. Track 11 contains molecular weight standards: BSA, 
66kD; albumin, 45kD; glyceraldehyde-3-phosphate dehydrogenase, 36kD; carbonic anhydrase, 29kD; 
trypsinogen, 24kD; trypsin inhibitor, 20.1kD.
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3E.4 Mutation of a single lysine residue within the WLQN region severely 
impairs the DNA binding activity of the VZV 140k DNA binding domain
Initially, the mutant 140k DNA binding domain peptides were analyzed for their 
abilities to recognise their own VZV gene 62 promoter in gel retardation analyses. 
Incubation of an equivalent range of amounts of each peptide with the gene 62 promoter 
BT fragment yielded primary protein-DNA complexes for wild type VT2X, 
VT2XQ545L and VT2XN546L peptides (Fig. 3E.5, tracks 3-5, 6 -8 , 9-11 respectively) 
and secondary complexes were produced with higher amounts of these peptides. The 
VT2X, VT2XQ545L and VT2XN546L peptides had comparable DNA binding 
affinities, as determined by competition experiments (data not shown). The 
VT2XK548E peptide produced a very faint, smeary protein-DNA complex with the 
gene 62 promoter fragment when included at an amount which yielded secondary 
complexes with the other three peptides (Fig. 3E.5, track 14). The greatly reduced DNA 
binding activity of VT2XK548E could be accounted for by a lower DNA binding 




Figure 3E.5 Gel retardation analysis of the VZV gene 62 promoter with the mutant 
VZV 140k DNA binding domain peptides. The radiolabelled BT DNA fragment was derived 
from the VZV gene 62 promoter (details given in Fig. 3A.6). The probe was incubated with 
approximately 25ng, 50ng or lOOng of the partially purified bacterial extracts of wild type or mutant 
VT2X peptide indicated above tracks 3-14. Protein amounts were determined by densitometry of 
Coomassie-stained SDS PAGE gels. The incubation reaction for track 1 contained no extract and for track 
2 contained a control extract prepared from bacteria carrying the p585T7a vector. Complexes were 
resolved by gel retardation analysis as described in Section 2D.2, followed by autoradiography. The 
positions of the free DNA probe, primary (PC) and secondary (SC) protein-DNA complexes are indicated 
on the right hand side. A contaminating probe band is seen in all tracks, migrating above the free BT 
probe.
VT2X VT2X VT2X
VT2X Q545L N546L K548E
1 2 3 4 5 6 7 8 9 10 11 12 13 14
VZV gene 62 promoter BT fragment
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Additionally, gel retardation assays were performed with DNA fragments derived from 
the HSV-1 IE3 and glycoprotein D (gD) promoters, to analyse whether the effects of 
mutations in the WLQN region on DNA binding were specific to sites within the VZV 
gene 62 promoter. Both of the HSV-1 fragment probes that were employed included a 
Vmwl75 consensus binding site recognised by the wild type 140k DNA binding domain 
(Section 3A.8). As seen with the gene 62 promoter fragment, mutations Q545L and 
N546L had little effect on the apparent DNA binding affinity of VT2X for either the 
IE3S or the gD probe (Fig. 3E.6).
PC
probe■
®  *» to*
PC
probe





Figure 3E.6 Gel retardation analysis of HSV-1 promoter fragments with the mutant 
VZV 140k DNA binding domain peptides. Radiolabelled DNA fragments were derived from die 
HSV-1 EE3 gene promoter (probe IE3S) (tracks 1-6) and the HSV-1 gD early gene promoter (tracks 7-12) 
(details given in Fig. 3A.11). The IE3S and gD probes were incubated widi approximately 40ng and 30ng 
(respectively) of the partially purified bacterial extracts of the VT2X derived peptides, as indicated above 
the tracks. The incubation reactions for tracks 1 and 7 contained no extract, and for tracks 2 and 8 
contained a control extract prepared from bacteria carrying the p585T7a vector. The components of the 
reactions were resolved by electrophoresis, as in the previous analysis (Fig. 3E.5). This experiment used 
an equivalent amount of each peptide diat gave only die primary protein-DNA complex, at the positions 
indicated at each side.
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No detectable binding of peptide VT2XK548E to the HSV-1 IE3 promoter fragment 
was observed (Fig. 3E.6, track 6 ) and a barely detectable complex was seen on the gD 
promoter fragment (Fig. 3E.6, track 12). The greatly reduced DNA binding activity of 
VT2XK548E on all three probes analysed, indicated that the effects of this substitution 
reflect a generalised disruption of the VZV 140k DNA binding interaction.
The VZV 140k DNA binding domain is a stable dimer and dimerisation appears to be a 
prerequisite for DNA binding (Section 3C). Therefore, it was necessary to eliminate the 
possibility that mutation K548E might have disrupted dimerisation rather than affected 
DNA binding directly. Aliquots of each mutant VT2X peptide were analyzed by 
analytical gel filtration chromatography as described previously (Section 3C.4) and were 
all found to elute as single discrete species, with elution volumes identical to that of the 
VT2X homodimer (data not shown). Therefore, mutation of residue K548 in the 140k 
WLQN region did not affect the subunit interaction, and was likely to interfere with 
DNA binding directly.
3E.5 Mutations in the WLQN region alter DNA recognition by the VZV 
140k DNA binding domain
DNase I footprinting analysis was used to provide further information about the effects 
of the mutations in the 140k WLQN region on the specificity of DNA binding. 
Particular care was taken to ensure equal input of the different DNA binding domain 
peptides within each experiment. Footprinting on the VZV gene 62 promoter probe 
showed that VT2X provided characteristic protection of multiple sequences from DNase 
I digestion, flanked by marked sites of DNase I hypersensitivity (as in Section 3A.6); 
the most apparent sequences protected by VT2X from DNase I digestion were centred 
over the gene 62 mRNA start site, and around nucleotides -30, -50 and -80 (left hand 
panel, Fig. 3E.7). Peptides VT2XQ545L and VT2XN546L both provided protection for 
sequences similar to those recognised by VT2X, albeit more faintly. This weaker DNase 
I protection was not merely a consequence of reduced DNA binding affinity (see above). 
These two mutant peptides also induced sites of DNase I hypersensitivity in similar 
positions to those produced with VT2X, although closer examination of the VT2X, 
VT2XQ545L and VT2XN546L tracks reveals slight differences in the details of these 
hypersensitivity sites. The VT2XK548E peptide failed to produce any footprinting 
pattern. However, on comparison with the control track, it is apparent that a degree of 
DNase I hypersensitivity was induced by the VT2XK548E peptide at similar positions 
to those produced by the other three peptides.
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Figure 3E.7 DNase I footprinting analyses of the mutant VZV 140k DNA binding domain 
peptides. DNase I footprinting assays were performed with end-labelled promoter DNA fragments and 
partially purified bacterial extracts (as described in Section 2D.4). The radiolabelled promoter DNA fragment 
used in each experiment is indicated at the bottom left of each panel (details given in Fig. 3A.6 for the VZV 
gene 62 BT probe, in Fig. 3A.11 for the HSV-1 probes). Radiolabelling of the BT fragment was on the bottom 
DNA strand, the IE3S and gD fragments were labelled on the top strand. The wild type and mutant VT2X 
tracks contained approximately 1.6pg of the DNA binding domain peptide indicated. Tracks labelled G+A',
'___1 and 'con' contain Maxam and Gilbert sequencing reactions, no extract and induced an extract from
bacteria carrying the p585T7a vector respectively. The numbered scale on the left of each panel identifies the 
Positions of nucleotides included within each DNA fragment, numbered with respect to the mRNA start site 
(+1). The bent arrows indicate the position and orientation of the proposed mRNA start sites. The positions 
and sequences of the HSV-1 Vmwl75 consensus binding sites in the IE3 and gD promoters are indicated.
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Perhaps peptide VT2XK548E interacts transiently with DNA, but not so as to provide 
sequence-specific protection or yield stable protein-DNA complexes in gel retardation 
assays.
Further DNase I footprinting experiments were performed upon the same HSV-1 IE3 
and gD promoter probes used in the gel retardation analyses above (Fig. 3E.6). On the 
HSV-1 IE3S probe, VT2X protected both halves of the bipartite Vmwl75 consensus site 
(Muller, 1987) (as seen previously in Fig. 3A.12) and faint protection extended beyond 
the 3' end of the consensus site to nucleotide +25 (middle panel, Fig. 3E.7). 
VT2XQ545L weakly protected some similar sequences to those recognised by VT2X, 
although on close comparison with the VT2X track, slight differences in 
hypersensitivity and also in the DNase I protection pattern are apparent. Interactions 
between the VT2XN546L and VT2XK548E peptides and DNA was illustrated by the 
DNase I hypersensitivity induced to the 5' of the consensus binding site, but there was 
little specific protection from DNase I digestion.
As previously (Fig. 3A.13), the HSV-1 gD promoter fragment contained multiple 
sequences weakly recognised by VT2X, flanked by sites of DNase I hypersensitivity 
(right hand panel, Fig. 3E.7). The sequences protected by VT2X were centred over 
nucleotides -130, -100 (the Vmwl75 consensus binding site; Faber and Wilcox, 1986b), 
-45 and also to a lesser degree around nucleotide -85. The gD Vmwl75 consensus 
sequence was also weakly recognised by VT2XQ545L and VT2XN546L, but not by 
VT2XK548E. Examination of the sites of DNase I hypersensitivity induced by VT2X 
and its mutant derivatives demonstrates that the three mutant peptides had differing 
effects on the details of the DNase I footprint on the HSV-1 gD promoter fragment, 
indicating the involvement of the WLQN region of VZV 140k in the interaction with 
DNA.
3E.6 The lysine mutation that disrupts sequence-specific DNA recognition, 
also destroys the transactivation function of VZV 140k
Having established that amino acid substitutions within the WLQN region affected, to 
varying degrees, the interaction of the isolated VZV 140k DNA binding domain with 
DNA, it was of interest to determine the effects of these mutations, if any, on the 
transactivation function of the 140k protein. Each mutation was incorporated into the 
intact 140k protein as described in Figure 3E.8.
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Figure 3E.8 Introduction of the WLQN region mutations into the intact VZV 140k 
protein. Nucleotide changes introduced by oligonucleotide-directed mutagenesis (Section 3E.3) were 
incorporated into the intact VZV gene 62 open reading frame in plasmid pl40 as follows: Narl-Kpnl 
fragments (A) isolated from plasmids pVT2XQ545L, pVT2XN546L and pVT2XK548E were each 
co-ligated with three fragments (Kpnl-Pstl fragment (B), 2414bp; PstI-SphI fragment (C), 4572bp; 
Sphl-Narl fragment (D), 632bp) isolated from plasmid pl40. The resultant plasmids pl40Q545L, 
pl40N546L and pl40K548E (collectively referred to as pl40[substitution]) were identified by extensive 
restriction enzyme digestion analyses using the restriction sites introduced by the mutagenesis procedure. 
The pl40[substitution] plasmids encode the entire VZV 140k coding region including the specific base 
substitutions, under the control of its own VZV gene 62 promoter.
The abilities of each mutant 140k protein to transactivate the heterologous HSV-1 gD 
promoter was determined by transient transfection assay (CAT assay), to allow direct 
comparisons with the DNA binding results obtained on the gD promoter (above). The 
transactivation efficiency of each mutant 140k protein was compared to that obtained for 
wild type 140k, which is known to be a potent transactivator of the HSV-1 gD promoter 
(Disney, 1990). Figure 3E.9 shows the results of two such experiments where a range of 
concentrations of each effector plasmid and a fixed amount of the gD promoter-CAT 
reporter construct were transiently co-transfected into HeLa cells. Due to the variable 
nature of this type of assay, titration of the effector plasmids allowed a more accurate 
interpretation of the effects of each protein on promoter activity, as compared to using a 
single plasmid amount. As anticipated, wild type VZV 140k very strongly transactivated 
the HSV-1 gD promoter in a dose dependent manner (Fig. 3E.9). 140Q545L and 
140N546L had reduced transactivation strengths, and this was more pronounced with 
protein 140N546L. The 140K548E protein consistently failed to activate gene 
expression from the gD promoter. The lack of function of the 140K548E protein was not 
specific to the HSV-1 gD promoter but represented a general phenomenon: 140K548E 
failed to transactivate the HSV-1 IE1 and tk promoters, and also the SV40 early 
promoter-enhancer regions (data not shown).
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Figure 3E.9 Transactivation efficiencies of the mutant V Z V  140k proteins. At the top are 
shown autoradiographs of CAT assay TLC plates from an experiment measuring transactivation of the 
HSV-1 gD promoter-leader sequences, by the VZV 140k protein and its mutant derivatives. Increasing 
amounts of each effector plasmid (as indicated) were co-transfected with 4pg of the reporter construct 
pgDCAT into HeLa cells by the calcium phosphate precipitation method (Section 2F.2). The CAT activity 
of the resultant HeLa cell extracts were determined by CAT assay as described in Section 2F.3. The 
identity of the 14C-labelled spots are indicated on the left as follows: a - chloramphenicol, b and 
c - tautomers of monoacetyl chloramphenicol, d - diacetyl chloramphenicol; a is the substrate and b, c and 
d are products of the acetyl transferase reaction catalysed by the chloramphenicol acetyl transferase 
enzyme (CAT). Fold induction promoter activity induced by each effector plasmid over the level 
produced with gDCAT alone is indicated below each track. Fold induction was calculated by dividing the 
proportion conversion from substrate to product per microgram protein obtained at a particular plasmid 
amount (Section 2F.4), by the control value obtained when no effector plasmid was present (the control 
value typically represented an average of three individual transfections). Below are plotted the results of 
the CAT assay shown above (right hand graph), and also the results of another independent repeat of the 
experiment (left hand graph). The fold induction gD promoter activity for each transfection is expressed 
as a percentage of the maximum induction by lOpg of plasmid pl40 (100%) and plotted against the 
amount of effector plasmid; the maximum fold induction was 117 for the graph on the left, and 191 for 
the graph on the right. The symbols corresponding to the effector plasmids expressing the VZV gene 62 
sequences are as explained below the graphs.






Figure 3E.10 Immunofluorescent staining of VZV 140k wild type and mutant proteins 
in BHK cells. Plasmids expressing protein 140k (pl40), 140Q545L (pl40Q545L), 140N546L 
(pl40N546L), 140K548E (pl40K548E) and no plasmid were transfected into BHK cells by lipofection 
(Section 2F.5). The 140k derived proteins were stained with polyclonal rabbit antiserum 109 to the VZV 
140k DNA binding domain (Section 2F.6) and visualised by immunofluorescence microscopy. Granular 
and diffuse nuclear staining characteristic of the VZV 140k protein is provided by all the 140k derived 
peptides, as seen in the top four panels.
Even though the isolated VZV 140k DNA binding domain peptides containing 
mutations within the WLQN region were stable, soluble dimers (see Sections 3E.3 and 
3E.4), it is conceivable that these mutations may have altered the expression or stability 
of the intact 140k protein. In this case, the reduced transactivation activities of the 
mutant 140k proteins seen in the transient transfection assays may have been due to 
protein instability. To clarify this issue, the immunofluorescence profiles of the mutant 
140k proteins were compared to that of wild type 140k. The separation ot the 140k 
DNA binding domain and the putative nuclear localisation signal in the primary
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sequence means that any instability is likely to alter the cellular distribution of the DNA 
binding domain region of the 140k polypeptides. All four proteins localised to the 
nucleus and the characteristic distribution of nuclear staining was seen with each mutant 
140k protein (Fig. 3E.10). For each set of transfections, similar intensity fluorescence 
was observed in comparable numbers of cells for the wild type and mutant proteins. 
Additionally, the mutant peptides gave bands of similar size and stability as wild type 
140k in western blot analysis of extracts from transfected BHK cells (not shown). It 
appeared that the mutations in the WLQN region were not deleterious to the expression 
or stability of the 140k protein. Therefore, the differential efficiencies of transactivation 
induced by the mutant 140k proteins were likely to be a consequence of their altered 
DNA binding activities, as identified in the DNA binding analyses described in Sections 
3E.4 and 3E.5.
3E.7 Discussion
A conserved sequence within the VZV 140k DNA binding domain, including the 
residues WLQN, showed significant similarity to the DNA recognition helix of the 
homeodomain. In order to determine whether the WLQN region is implicated in DNA 
recognition, three single 140k residues were mutated within this conserved sequence. 
The findings and implications of this mutagenesis for the DNA recognition and 
regulatory functions of VZV 140k are discussed here.
Strong homology between VZV 140k and the homeodomain was only apparent in the 
vicinity of the DNA recognition helix (homeodomain helix 3), but this does not 
automatically rule out the possibility of the 140k DNA binding domain including a 
homeodomain-like structure. The homeodomain protein fold is highly conserved 
between homeodomains that show very low sequence homology, as illustrated by a 
structural comparison of the yeast MATa2 (a 2) and Drosophila engrailed (e n) 
homeodomain-DNA complexes (Wolberger et al., 1991). Recently, structural studies 
have identified numerous highly divergent homeodomains or eukaryotic HTH proteins 
(see Section 1E.2.3). The structures of non-classical homeodomains, such as the dimeric 
hepatocyte transcription factor HNF1/LFB1, have revealed their almost identical spatial 
arrangement of helices to those found in the corresponding HTH motifs of the en and oc2 
homeodomains, despite their very low level of sequence identity outside of the DNA 
recognition helix (reviewed by Brennan, 1993).
Unlike the homeodomain recognition helix, the WLQN region of VZV 140k is unlikely 
to be folded into a single uninterrupted linear a-helix, due to the presence of proline
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residues at amino acids 540 and 547, but it could quite possibly adopt two helical turns 
between residues 540 and 547 and resume a helical conformation after residue 547 (see 
Fig. 3E.1). Typically, a-helices are kinked by 26° around a proline residue (Barlow and 
Thornton, 1988); examples of proline-induced a-helix kinking are seen in the EcoRV 
endonuclease structure (Winkler et al., 1993), in the fourth helix of the divergent 
homeodomain (POU-specific domain) of Oct- 1  (Assa-Munt et al., 1993; Dekker et al., 
1993), and very recently the crystal structure of a heat shock factor (HSF) DNA binding 
domain identified a 29° proline-induced kink in helix 2 of a variant HTH motif 
(Harrison et al., 1994). Applying the secondary structure prediction rules of Garnier et 
al. (1978) and Chou and Fasman (1974), only VZV 140k sequences corresponding to 
the hypothetical homeodomain helix 1 were predicted to fold into an a-helix (not 
shown). However, it should be noted that these types of prediction are only 62% 
accurate on average (Garnier et al, 1978).
The bacterially expressed VZV 140k DNA binding domain provided a well 
characterised (Section 3A) and convenient tool for analysing the consequences of 
mutations in the WLQN region on DNA binding. By analogy to the findings of a 
comparative analysis of the HSV-1 Vmwl75 protein and its isolated DNA binding 
domain (Everett et al., 1991a), the effects of point mutations in the WLQN region on the 
DNA binding activity of the 140k DNA binding domain peptide are likely to reflect 
their probable consequences on the intact 140k protein.
Replacement of VZV 140k residue lysine 548 with glutamic acid (K548E) drastically 
reduced the sequence-specific DNA binding activity of the mutant 140k DNA binding 
domain, and resulted in a non-functional intact 140k protein, as determined by transient 
transfection assays. This residue occupies a position in the WLQN homology region 
equivalent to an invariant basic homeodomain residue (arginine 53) which forms two 
important contacts with the DNA phosphate backbone in the known structures. Given 
that no gross changes in dimerisation state, nuclear localisation, stability, solubility or 
efficiency of expression were detected as a result of the K548E mutation, these findings 
suggest that DNA binding is essential for the transactivation function of the VZV 140k 
protein. The relationship between the DNA binding and regulatory functions of the 
equivalent protein of HSV-1, Vmwl75, is slightly controversial (see Section 1C.1.7). 
Detailed mutational and functional analyses have shown that mutations within the DNA 
binding domain that abrogated the DNA binding activity of Vmwl75 also disrupted its 
regulatory functions (Paterson and Everett, 1988b; Shepard et al., 1989), with one 
exception. This solitary case comprised a pseudorevertant of an inactive Vmwl75 
protein which had restored regulatory activities (in the context of viral infection) and 
impaired DNA binding properties (Shepard and DeLuca, 1991b). However, the isolated
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DNA binding domain of the Vmwl75 pseudorevertant protein was able to bind to DNA, 
at least at room temperature (K. E. Allen, N. DeLuca, R. Everett, unpublished data).
Although substitution K548E had pronounced effects on the DNA binding and 
regulatory functions of VZV 140k, the consequences of two further single mutations in 
the WLQN region were more subtle. Replacement of 140k residue glutamine 545 with 
leucine (Q545L) and asparagine 546 with leucine (N546L) had no apparent effect on 
DNA binding affinity as measured by gel retardation analysis. However, the specific 
details of their DNA binding interactions, as determined by DNase I footprinting 
analysis, significantly differed from those of either wild type VT2X or VT2XK548E. 
Mutations Q545L and N546L each reduced the transactivation efficiency of the 140k 
protein, the N546L mutation resulting in a more pronounced reduction in activation. The 
effects of these two mutations on the transactivation function are most easily explained 
as a consequence of their slightly altered interactions with DNA, although they may be 
caused by other factors not addressed in this study, such as subtle conformational 
changes within the domain resulting in defects in other macromolecular interactions. 
The corresponding homeodomain residues 50 and 51 are involved in determining the 
specificity of the homeodomain-DNA binding interaction. However, no change in 
specificity as a result of altering VZV 140k residue 545 or 546 was apparent, but would 
not necessarily be expected since the VT2X peptide has a fairly low sequence specificity 
(Section 3A.9) and may be tolerant to alteration of these hypothetical 'specificity- 
determining' residues. The effects of these three 140k mutations on DNA binding 
support the idea that this WLQN homology region is directly involved in the DNA 
binding interaction. Verification of the importance of the WLQN region will be 
provided by the analysis of the effects of these, and further amino acid substitutions, on 
the life cycle of the alphaherpesviruses.
The homeodomain contains a HTH motif. However, unlike the isolated HTH unit, the 
homeodomain forms a stable folded structure that is capable of binding to DNA by itself 
(Sauer et al., 1988; Qian et al., 1989; Affolter et al., 1990). This 60 residue domain is 
much smaller than the minimum defined 140k DNA binding domain (162 residues) 
(Section 3B.4), although the structures of larger variant homeodomains have recently 
been determined. For example, the 'winged-helix' DNA binding motif of proteins such 
as HNF-y3 (Clark et al, 1993, reviewed by Brennan, 1993) is well over 100 amino acids
in size.
The DNA binding activity of the HSV-1 Vmwl75 protein is highly sensitive to insertion 
mutations throughout its entire DNA binding domain (see Section 1C. 1.9 and this 
Thesis, Section 3D.7), and it is possible that other additional sequences within these
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large domains are directly involved in DNA binding. Indeed, a HTH motif has been 
proposed on the basis of secondary structure predictions further C-terminal to the 
WLQN region of the HSV-1 Vmwl75 protein (Shepard et al., 1989) (Section 1C.1.9). 
Several substitutions within this helical region resulted in a temperature-sensitive DNA 
binding phenotype, while two other single mutations in the proposed 'turn' disrupted 
DNA binding (Allen and Everett, 1994). Although it is a possibility that this predicted 
HTH sequence may encode a structural scaffold which holds the WLQN region in such 
a way that it can be stably presented to DNA, it is not uncommon for proteins containing 
a homeodomain to couple additional DNA binding motifs or domains to increase their 
affinity or specificity of DNA binding. For example, prokaryotic HTH proteins such as 
X repressor, use an extended region of peptide chain to wrap around the DNA (Clarke et 
al., 1991). Similarly, the POU proteins have a conserved 65-75 residue segment, the 
POU-specific domain, on the N-terminal side of the homeodomain (Herr et al., 1988) 
which contacts the DNA sequence ATGC, adjacent to the homeodomain target sequence 
(Ruvkun and Finney, 1991). Thus each of the two DNA binding motifs of the POU 
protein contacts one half of a non-palindromic bipartite target sequence; the bipartite 
nature of the non-palindromic HSV-1 Vmwl75 consensus binding site is suggestive of 
an analogous DNA binding mechanism for the alphaherpesvirus proteins. Other DNA 
binding domains found in association with homeodomains include the paired domain 
(Treisman et al., 1991), C2 H2 zinc fingers and even additional homeodomains. The 
Drosophila zfh-2 protein, containing three homeodomains and 16 zinc fingers, is an 
extreme example of this domain coupling (Fortini et al., 1991). The involvement of 
several independent structural elements in the interaction with DNA would be consistent 
with the large size of the mapped DNA binding domains of the VZV 140k and HSV-1 
Vmwl75 proteins.
An interesting difference between the DNA recognition helix of the homeodomain and 
the corresponding sequences of the alphaherpesvirus proteins is that the latter lack basic 
C-termini. In this way the alphaherpesvirus WLQN region resembles the shorter DNA 
recognition helix of the prokaryotic HTH motif, which is equivalent to the N-terminal 
half of the homeodomain DNA recognition helix. The homeodomain-DNA interaction is 
stabilised by phosphate contacts by the basic residues in the C-terminal part of the 
recognition helix. Homeodomains are invariably monomeric, whereas the HTH proteins 
bind to DNA as dimers, perhaps to compensate for their lower DNA binding affinities 
resulting from the absence of the stabilising C-terminal basic residues. Comparisons can 
therefore be drawn between the prokaryotic HTH motif and the WLQN region of the 
VZV 140k protein, which has a single C-terminal basic residue (instead of the 
homeodomains1 four) and binds DNA as a dimer.
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Lastly, it may transpire that many DNA recognition motifs are variations on the same 
theme (Suzuki, 1993) and DNA binding proteins have evolved different structural 
scaffolds to present their DNA recognition motif to probe the DNA. The DNA 
recognition region of the VZV 140k family of alphaherpesvirus proteins may be an 
example of a divergent motif that has retained a minimum set of residues necessary for 
the interaction with DNA. The differences between the potential WLQN recognition 
sequence of the 140k protein and the known types of recognition motifs may facilitate 
its particular DNA binding characteristics, such as its low DNA binding specificity 
which allows it to bind multiple recognition sequences within a presumably very wide 
range of VZV promoters. The details of the involvement of the WLQN region in the 
DNA binding interaction awaits future structural analyses.
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3F Activities of a hybrid HSV-1 Vmwl75 protein containing 
the VZV 140k DNA binding domain in place of its own
3 F . 1  S t r a t e g y
There is evidence to suggest that VZV 140k and HSV-1 Vmwl75 are functional 
counterparts in their respective alphaherpesviruses (Section 1C.2.1), although 
differences in detail between the two proteins have been identified in transient 
transfection assays. For example, 140k and Vmwl75 were not entirely interchangeable 
in IE promoter repression assays; whereas HSV-1 Vmwl75 down-regulated the VZV 
gene 62 promoter, VZV 140k actually slightly activated the HSV-1 IE3 promoter (in our 
assay system at least) (Disney et al., 1990). In addition, 140k was a more potent and a 
more promiscuous transactivator of gene expression than Vmwl75 in transient 
transfection experiments (see Section 1C.2.3).
Numerous differences between the DNA binding characteristics of the isolated VZV 
140k and HSV-1 Vmwl75 DNA binding domains have been identified (see Section 3A) 
which might account for the functional variations seen between the two intact proteins 
in the transient transfection experiments. To test this idea, a hybrid HSV-1 Vmwl75 
protein was constructed with the VZV 140k DNA binding domain in place of its own 
(protein 175R2DS). Transient transfection assays were used to compare the regulatory 
activities of the 175R2DS domain swap protein with those of the intact 140k and 
Vmwl75 proteins. Additionally, the hybrid coding sequences were recombined into the 
HSV-1 genome and the effect of the domain swap on the efficiency of viral growth in 
tissue culture was determined.
3 F . 2  C o n s t r u c t i o n  o f  a  h y b r i d  H S V - 1  V m w l 7 5  p r o t e i n  c o n t a i n i n g  t h e  
V Z V  1 4 0 k  D N A  b i n d i n g  d o m a i n  ( 1 7 5 R 2 D S )
Due to the lack of structural information on the HSV-1 Vmwl75 and VZV 140k 
proteins, the details of the exchange of sequences encoding the DNA binding domains 
were designed using the information available from mutational analyses and sequence 
comparisons. The I9X and VT2X DNA binding domain peptides of Vmwl75 and 140k 
respectively, appeared to be equivalent in that both were stable domains capable ol the
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full interaction with DNA, as determined by gel retardation and DNase I footprinting 
analyses (see Fig. 3B.7). Therefore the VT2X region of VZV 140k was inserted in place 
of the I9X region of HSV-1 Vmwl75. Additionally, the relevant 140k region 3 
sequences were included in the domain swap due to the presence of such sequences in 
the I9X peptide (for details, see Fig. 3F.1). VZV gene 62 codons 417-673 (spanning the 
140k DNA binding domain) were amplified by PCR, due to the lack of convenient 
restriction enzyme sites for isolation of the required VZV gene 62 sequences.
175R2DS
| region 1 1 2 | 3 |__________________ - ________________  5
HSV-1 Vmwl75 sequences VZV 140k sequences
5 f junction 3 ’ junction
2 5 1 2 5 3 5 2 2
V m w P P R I R G A A A G Y G A A G I L A
175i9 CCC CCC CGA ATT CGG GGG GCG GCG GCG A cc GGG TAC GGC GCC GCG GGG ATC CTC GCC G
417 673
Q P G Y R S I S G L S V C P P D D R
140k CAA CCG GGA TAT CGA TCC ATC AGC GGT C CT CTT TCT GTG TGT CCA CCG GAT GAT CGT T
primer GCA TCG AQA ATT CGA TCC ATC AGC GGT C CT CTT TCT GTG TGT CCA GGG ATC CTC ATG C
2 5 1 417 673 5 2 2
175 P P R I R s I S G L S V C P G I L A
R2I)S CCC CCC CGA ATT CGA TCC ATC AGC GGT c CT CTT TCT GTG TGT CCA GGG ATC CTC GCC G
Figure 3F.1 Details of the 175R2DS domain swap protein. At the top is shown a schematic 
representation of the 175R2DS protein, which contains the DNA binding domain of VZV 140k (residues 
417 to 673) replacing the corresponding region of HSV-1 Vmwl75 (residues 252 to 521). Protein regions 
1 to 5 are indicated on the scale above (Section 1C. 1.8). Given beneath are details of the junctions 
between the Vm wl75 and 140k coding sequences. The DNA sequence (top strand) and corresponding 
coding potential are shown for the Vmwl75i9, 140k and 175R2DS proteins in the regions spanning the 5’ 
and 3 ’ fusion junctions. Vmwl75i9 is a version of the Vmwl75 protein including a 4 amino acid insertion 
as described below, and is encoded by gene IE3i9. Selected 140k and Vmwl75 amino acids are numbered 
as appropriate. The sequences o f the PCR primers used for amplification of the gene 62 sequences 
encoding the 140k DNA binding domain are also shown; the 3’ junction PCR primer had the 
complementary sequence to that given here. All Vmwl75i9 derived sequences are shown in bold, the 
140k derived sequences are shown in normal text, and random sequences at the end of the primers are 
shown in italics. Underlining indicates restriction enzyme sites: the 5' primer was designed to include an 
E coR l site which allows cloning of the PCR amplified fragment into the EcoRl site of the IE3i9 gene; the 
E coR l site had been previously introduced on a 12bp linker (indicated by the dashed line) into codon 252 
of die IE3 gene (Paterson and Everett, 1988a); this accounts for the discontinuity in the numbering of the 
Vm wl75 amino acid residues. The 3' primer included a BamYW site to allow cloning of die PCR product 
into the B am U l site at codon 523 of the HSV-1 IE3 sequence. The 5' junction created an exact fusion 
between proteins Vmwl75i9 and 140k, according to the alignment of the 140k and Vmwl75 sequences of 
McGeoch et al. (1986). The 3'junction maintained the exact number of region 3 residues diat are present 
in protein Vmwl75i9.
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Figure 3F.2 Construction of plasmids expressing the R2DS VZV 140k DNA binding 
domain peptide and the 175R2DS hybrid protein. The top part shows schematic diagrams of the 
VZV 140k protein and the PCR product encompassing VZV gene 62 codons 417 to 673; the PCR 
product was synthesised on the pl40 plasmid template using the primers given in Figure 3F.1. After 
amplification and purification of the PCR product as described in Section 2B.8, it was cleaved with 
restriction enzymes EcoRl and BamHI to yield sticky ends. The P585T7bR2DS plasmid was produced by 
insertion of the digested PCR product between the EcoRl and BamHI sites of the MCR of T7 expression 
plasmid p585T7b2 (Section 3A.2). The pl75R2DS plasmid was produced by co-ligation of the digested 
PCR product with the Pstl-EcoRl fragment (1925bp) of plasmid pI9' (including the remaining 5 
sequences of the Vmwl75 coding region) and the BamHl-Pstl fragment (7084bp) of plasmid pLI10/l 1 
(including the remaining 3’ sequences of the Vmwl75 coding region). Only selected restriction enzyme 
sites are shown. The corresponding expression products are shown schematically beneadi each plasmid, 
the olasmid p585T7bR2DS expressed the 140k DNA binding domain peptide (R2DS), and plasmid 
pl75R2DS expressed the hybrid Vmwl75 protein containing the 140k DNA binding domain (protein 
175R2DS). The total number of viral amino acid residues in each protein are indicated. The shading 
scheme for portions of protein sequences are consistent with that used in Fig. 3F.1.
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The PCR primers were designed to yield 5' EcoRl and 3' BamHI restriction enzyme sites 
flanking the VZV gene 62 sequences, in order to facilitate cloning of the resultant PCR 
product (Figs. 3F.1 and 3F.2). Before proceeding any further with the construction of 
the 175R2DS domain swap protein, the integrity of the VZV 140k DNA binding domain 
peptide encoded by the PCR product was verified. The PCR product was cloned into the 
appropriate T7 expression vector (see Fig. 3F.2) and expression of the VZV gene 62 
sequences was induced in bacteria (as previously in Section 3A.4). The resultant 140k 
DNA binding domain peptide (R2DS) was partially purified (as in Section 3A.4) and 
found to be soluble. Having determined that the R2DS peptide was DNA binding 
competent by gel retardation analysis, it was assumed that no deleterious mutations had 
been introduced by the PCR procedure (data not shown).
A plasmid expressing the HSV-1 Vmwl75 protein that contained the VZV 140k DNA 
binding domain in place of its own, was constructed by insertion of the PCR amplified 
VZV gene 62 sequences between the EcoRl and BamHI sites (at codons 252 and 523 
respectively) of the HSV-1 IE3i9 gene, as described in Figures 3F.1 and 3F.2. The i9 
insertion sequences, including the EcoRl site, had no deleterious consequences on the 
regulatory functions of the intact Vmwl75 protein (Paterson and Everett, 1988a) or 
growth of the HSV-1 virus (Allen and Everett, 1994). The resultant plasmid pl75R2DS 
expressed the domain swap protein, 175R2DS, under the control of the SV40 early 
promoter-enhancer sequences (Fig. 3F.2). A BamHl-Pstl fragment from the plasmid 
pLI10/ll (which had the second BamHI site of the IE3 ORF removed) was used in the 
construction of pl75R2DS, in order to circumvent the complications that the presence of 
the extra BamHI site would have presented for the cloning procedure (Fig. 3F.2). 
Substitution of the VZV 140k DNA binding domain for that of HSV-1 Vmwl75 caused 
no apparent reduction in the stability of the protein, as determined by western blot 
analysis of extracts from transiently transfected BHK cells (data not shown).
3F.3 Transactivation properties of the hybrid 175R2DS protein
The phenotype of the hybrid 175R2DS protein, was compared with those of intact VZV 
140k and HSV-1 Vmwl75 in transient transfection assays. It was of interest to 
determine the transactivation strength of the hybrid 175R2DS protein, as the 140k 
protein is known to be a much more potent transactivator than Vmwl75 (Cabirac et al., 
1990; Disney, 1990). The strong transactivation phenotype of VZV 140k may be due to 
a specific feature of the binding activity of the 140k DNA binding domain, such as its 
lower sequence specificity (Section 3A.9) which presumably accounts for its ability to 
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- pl75
— * — - pl40SV
----- B — - P175R2DS
----- M----- pSVEB
Figure 3F.3 Transactivation of the HSV-1 gD promoter in HeLa cells. The reporter 
construct pgDCAT (4pg) (carrying the CAT gene under control of the gD promoter of HSV-1) was 
transfected with increasing amounts of effector plasmids expressing Vmwl75, 140k, 175R2DS or no 
coding region (plasmid pl75, pl40SV, pl75R2DS or pSVEB respectively) and the resulting CAT activity 
was assayed as described in the legend to Figure 3E.9. The relative CAT activities (expressed as 
percentage of the maximum gD promoter induction by plasmid pl40SV) from three independent repeats 
of such an experiment are shown above, plotted against amount of effector plasmid. The symbols 
representing effector plasmids are explained in the key beneath. The maximum fold gD promoter 
induction over the level resulting from transfection of plasmid pgDCAT alone was 69, 1093 and 15, for 
each experiment (from left to right).
The Vmwl75, 140k and 175R2DS proteins were expressed from identical SV40 early 
promoter-enhancer sequences, to allow direct comparison of their relative 
transactivation strengths. Additionally, a plasmid which had the identical SV40 
expression signals, but lacking a coding region (plasmid pSVEB), was included in these 
experiments to indicate the effects of promoter competition alone on the efficiency of 
gene expression from the reporter construct. As previously (Section 3E.6), 
transactivation of the HSV-1 glycoprotein D (gD) early promoter was determined from 
the reporter construct pgDCAT, following co-transfection into HeLa cells with 
increasing amounts of each effector plasmid. The results of three such experiments 
measuring transactivation of the HSV-1 gD promoter are shown in Figure 3F.3. 
Although variation in transfection efficiencies between the three experiments prevented 
statistical analysis of the data, it is clear that the relative transactivation strengths of the
pg plasmid pg plasmid pg plasmid
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Vmwl75 and 140k and 175R2DS proteins were highly reproducible (Fig. 3F.3). 
Expression from the gD promoter was most strongly activated by VZV 140k, consistent 
with an earlier analysis of this promoter (Disney, 1990). Whereas the HSV-1 Vmwl75 
protein was a much weaker transactivator, activating up to 1 .9 , 3 . 2  and 1 0 .1 % of the 
maximum level of activation by 140k, for each experiment shown in Figure 3F.3 
respectively. The 175R2DS hybrid protein had a transactivation strength intermediate 
between those of Vmwl75 and 140k, activating the gD promoter up to 16, 13 and 26% 
of the maximum 140k level, as seen in Figure 3F.3 (for each graph respectively). These 
experiments clearly demonstrated the requirement for analysing a range of effector 
plasmid amounts, as efficient transactivation was only induced at the lower amounts of 
plasmid. This was likely to be a consequence of promoter competition by the strong 
SV40 expression sequences, which presumably sequestered transcription factors 
otherwise required for activation of the gD promoter.
This analysis demonstrated that the HSV-1 Vmwl75 binding domain could be replaced 
with that of VZV 140k DNA to make a functional hybrid protein. Additionally, these 
data imply that the particular DNA binding characteristics of the 140k DNA binding 
domain are responsible, at least in part, for the strong activation phenotype of the VZV 
140k protein. Other sequences outside the DNA binding domain may also contribute to 
the transactivation strength of 140k. Alternatively, unfavourable conformational effects 
caused by the domain swap could explain the lower transactivation efficiency of the 
175R2DS hybrid, as compared to the 140k protein (see Section 3F.6).
Individually, HSV-1 immediate-early proteins Vmwl75 and VmwllO (see Section 
1C. 1.6) are very weak transactivators, only activating the gD promoter to 1-3 fold basal 
activity, following transfection into HeLa cells (Everett, 1986; this study, data not 
shown). However, co-transfection of Vmwl75 and VmwllO resulted in synergistic 
activation of gene expression, as a greater than additive increase in transcription resulted 
when the activators were present simultaneously (Everett, 1984b) (Section 1C. 1.6). This 
synergistic activation of gene expression had not been observed between VZV 140k and 
HSV-1 VmwllO in our assay system (Disney, 1990; this study, data not shown). 
However, the 175R2DS hybrid protein was able to activate the gD promoter in synergy 
with VmwllO. Synergistic activation resulted from co-transfection of the pl75R2DS 
plasmid with increasing amounts of a plasmid expressing Vmwl 10 (plasmid p i l l )  into 
HeLa cells, and also in the reciprocal experiment (Fig. 3F.4). Again, as with the 
transactivation experiments (Fig. 3F.3), large increases in activation were induced by 
addition of low amounts of (in this case) the second effector plasmid, resulting in further 
activation of the gD promoter over the combined etfects of each separate eflector 
plasmid. For example, co-transfection of O.lftg ol plasmid p i l l  with pl75R2DS
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resulted in an increase in transactivation of approximately 7  fold over the combined 
activation by the two separately transfected plasmids, (compare tracks 3 and 4, Fig. 
3F.4), even though transactivation due to plasmid p i l l  alone was negligible (track 11). 
The finding that Vmwl75 and 175R2DS, but apparently not 140k, acted in synergy with 
HSV-1 VmwllO, suggested that the DNA binding domains of 140k and Vmwl75 are 
not sufficient for determining whether the protein can activate gene expression in 
synergy with VmwllO. However, synergistic activation may not occur when one of the 
transactivators works at very high efficiency, such as VZV 140k (see Section 3F.6).
__________4[ig p!75R2DS______________________  4pg p i l l
1  2111________________________  p!75R2DS_1
pg plasmid i
— — — 0.1 0.2 1.0 5.0 10.0 — — — 0.1 0.2 1.0 5.0 10.0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16




Figure 3F.4 Synergistic activation of the gD promoter by the 175R2DS hybrid protein 
with HSV-1 VmwllO in HeLa cells. Increasing amounts of a plasmid expressing HSV-1 
Vmwl 10 (pi 11) were co-transfected with 4pg of plasmid pl75R2DS (left half of the Fig.). The reciprocal 
titration of increasing amounts of plasmid pl75R2DS co-transfected with 4pg of plasmid pi 11 was also 
performed (right half of the Fig.), all transfections included 4pg of the target construct pgDCAT. Shown 
here are autoradiographs of TLC plates from CAT assays of the HeLa extracts resulting from such 
experiments. Fold induction of the gD promoter over the basal level of gD promoter activity for each 
extract (as indicated below each track) was calculated as described in the legend to Figure 3E.9. The 
letters on the right hand side indicate the positions of the radiolabelled substrate (a) and products (b and 
c), as described previously (legend to Fig. 3E.9).
3F.4 Analysis of the phenotype of the hybrid 175R2DS protein in 
autoregulation assays
As mentioned above (Section 3F.1), VZV 140k and HSV-1 Vmwl75 affect differently 
the activities of their cognate promoters, as determined by transient transfection 
autoregulation assays (also see Section 1C.2.3). To investigate whether the DNA 
binding domain alone determines the specificity of transcriptional repression or whether 
other sequences modify this function, the phenotype ol the 175R2DS hybrid protein in 
autoregulation assays was analysed. The cell lines and conditions used for these 
transient transfection assays were in keeping with those of the previous analysis of the 
140k and Vmwl75 proteins (Disney et al., 1990).
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Figure 3F.5 Autoregulation assay of the VZV gene 62 promoter in BHK cells. The 
reporter construct pl40CAT (4pg) (carrying the CAT gene under the control of the VZV gene 62 
promoter), was co-transfected into BHK cells with 2pg of plasmid pMCl (expressing HSV-1 Vmw65) 
and increasing amounts of an effector plasmid: pl75, pl40SV, pl75R2DS or pSVEB (see legend to Fig. 
3F.3.). CAT activities were quantitated and corrected for the protein concentration of BHK extracts as 
described previously (Fig. 3E.9). Gene 62 promoter induction is expressed as percentage of the gene 62 
promoter activity when only plasmids pMCl and pl40CAT were transfected (100%). The data obtained 
from two repeats of such an experiment are shown graphically here, plotted against amount of transfected 
effector plasmid (as identified in the key below). The pSVEB plots indicate the level of repression due to 
promoter competition alone.
Consistent with the previous report (Disney et al., 1990), both HSV- 1  Vmwl75 and 
VZV 140k repressed gene expression from the VZV gene 62 promoter in BHK cells 
(Fig. 3F.5). Inclusion of a plasmid (pMCl) which expresses the HSV-1 Vmw65 
transactivator of immediate-early promoters (see Section IB.2.2) was necessary to 
increase the initial level of gene 62 promoter activity in order to allow down-regulation 
to be detected. The control titration of plasmid pSVEB (carrying the SV40 expression 
signals but no coding region) was particularly important in these autoregulation assays, 
in order to differentiate between true repression due to the effector protein and 
repression caused by promoter competition effects which resulted from increasing the 
concentration of the SV40 promoter-enhancer sequences. The 175R2DS hybrid 
repressed the gene 62 promoter to the same degree as both Vmwl75 and 140k (Fig. 
3F.5). Although the analysis of the gene 62 promoter could not yield further information 
about the differential functional specificities of the 140k and Vmwl75 DNA binding
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domains (as they have the same phenotype on this promoter), it is apparent that the 
hybrid protein is fully functional for repression in this transient transfection system. This 
suggests that the integrity of the R2DS 140k DNA binding domain was fully maintained 
in the context of the 175R2DS protein, at least for the repression function.
A similar analysis was carried out to compare the effects of the Vmwl75, 140k and 
175R2DS proteins on the HSV-1 IE3 promoter in Vero cells. However, the experience 
of a number of attempts at this experiment indicated that for reasons unknown the 
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Figure 3F.6 Autoregulation assay of the HSV-1 IE3 promoter in Vero cells. The graphs 
represent the results of two repeats of an experiment measuring the effects of Vmwl75, 140k and 
175R2DS on the activity of the HSV-1 IE3 promoter. Experiments were performed exactly as for the 
VZV gene 62 promoter analysis (Fig. 3F.5) except that no pMCl plasmid was included in transfections 
and the target construct was pIE3CAT (having the CAT gene under the control of the HSV-1 IE3 
promoter sequences). For each transfection extract, the relative CAT activity was determined (as 
described in Figure 3E.9), expressed as a of the percentage of the basal level of gene expression (100%) 
and plotted against effector plasmid amount included in the transfection (using a log scale on die x-axis). 
The key below the graphs identifies the effector plasmid represented by each symbol, plasmid pSVEB 
included no coding region. In order to determine whether a particular amount of effector plasmid 
represses or activates gene expression, die IE3 promoter activity is compared to the value obtained using 
the equivalent amount of plasmid pSVEB.
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Consistent with the previous findings using this system (Disney et al., 1990), HSV-1 
Vmwl75 weakly repressed gene expression from its own IE3 promoter, while VZV 
140k strongly activated this promoter (particularly apparent at around 2\ig transfected 
plasmid) (Fig. 3F.6). Transactivation of the IE3 promoter by the 175R2DS hybrid 
protein was also observed at low amounts of effector plasmid, although activation was 
to a lesser extent than that seen with 140k. The Vmwl75, 140k and 175R2DS proteins 
also had similar relative effects on the IE3 promoter activity in BHK cells (data not 
shown). These data suggested that the 140k DNA binding domain is important for 
determining the specificity of repression of the 175R2DS hybrid protein.
3F.5 Construction of a viable recombinant HSV-1 virus expressing the 
175R2DS DNA binding domain swap protein (HSV-175R2DS)
A recombinant HSV-1 virus with both copies of the Vmwl75 coding sequences 
replaced by the homologous VZV gene 62 open reading frame (virus HSV-140) was 
viable in tissue culture, yet had certain growth defects including the inability to form 
distinct plaques on BHK monolayers (Disney and Everett, 1990). These growth defects 
were presumably a result of an altered pattern of HSV-1 gene expression which in turn 
may have been due to the variations between the DNA binding properties of Vmwl75 
and 140k. To test this idea, a recombinant virus (HSV-175R2DS) was constructed with 
the hybrid 175R2DS coding sequences replacing those of Vmwl75. The HSV-175R2DS 
virus was constructed by transfecting plasmid pl75R2DS into BHK cells, followed by 
infection with the virus D30EBA which includes large deletions in the IE3 reading 
frames (see Figure 3F.7). A stock of the resulting HSV-175R2DS recombinant virus 
was titrated on BHK monolayers (Section 2F.8) and the plaquing efficiency compared to 
that of a recombinant HSV-1 virus stock made in parallel by infecting BHK cells 
previously transfected with plasmid pl75, with the D30EBA deletion virus. These 
plaque counts give a preliminary indication of the effects of the domain swap on virus 
viability and hence the functional importance of the DNA binding characteristics 
specific to the 140k DNA binding domain (identified in Section 3A).
The results showed that the initial isolate of the HSV-175R2DS virus gave plaques on 
BHK monolayers with a titre of approximately 102 pfu/ml, compared to 104 pfu/ml of a 
virus stock obtained from a parallel recombination experiment using plasmid p i75, 
which carries the wild type HSV-1 IE3 gene (see Fig. 3F.7).
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Figure 3F.7 Construction of the recombinant HSV-175R2DS virus. The HSV-175R2DS 
virus was produced by recombination between the D30EBA virus and the pl75R2DS plasmid, as 
described in Section 2F.7. Virus D30EBA has a large deletion in both copies of die IE3 gene in die short 
repeats of the genome (Paterson and Everett, 1990). The pl75R2DS plasmid encoding the domain swap 
protein is described in Section 3F.2. The recombinant HSV-1 virus was constructed in this same manner 
by inserting the wild type EE3 sequences, carried on plasmid pl75, into virus D30EBA. Care was taken to 
include identical amounts of plasmid DNA in each transfection experiment and to infect widi equal 
amounts of D30EBA.
A negative control stock produced in parallel from cells transfected with the pUC9 
plasmid and infected with D30EBA contained no virus. Therefore a virus which 
expresses the hybrid Vmwl75 protein with the VZV 140k DNA binding domain is 
viable in tissue culture, although it appeared to grow less efficiently than HSV-1. At this 
stage in the project the constraints of time prevented further characterisation of the 
HSV-175R2DS virus, but this has been undertaken by others during the writing of this 
Thesis. This further work showed that, of a sample of 12 plaques grown from the above 
HSV-175R2DS virus stock, all 12 had the recombinant gene at both IE3 loci of the 
genome. Further characterisation of the HSV-175R2DS virus will be presented 
elsewhere (Tyler et al., 1994).
3F.6 Discussion
The DNA binding domains of the VZV 140k and HSV-1 Vmwl75 proteins have been 
mapped to protein sequences that are highly conserved between the two proteins (see
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Section 3B). The results presented in this Section demonstrate that the Vmwl75 DNA 
binding domain can be replaced with that of VZV 140k to make a hybrid protein that is 
functional for both transactivation and transrepression in transient transfection assays 
and which supports viral growth in tissue culture. This data further establishes the 
similarity between the DNA binding domains of the VZV 140k and HSV-1 Vmwl75 
proteins.
Insertion of the VZV 140k DNA binding domain into the HSV-1 Vmwl75 protein, in 
place of its own domain, produced a hybrid protein (175R2DS) that was a more efficient 
transactivator of the HSV-1 glycoprotein D (gD) promoter than Vmwl75. This could be 
accounted for by the specific DNA binding properties of the 140k DNA binding 
domain, not shared with the Vmwl75 domain, as discussed in Section 3A.12. For 
example, the ability of multiple 140k DNA binding domains to associate with the gD 
promoter region (Fig. 3A.13), may reflect additive or perhaps synergistic activation of 
this promoter due to the tethering of multiple 140k transcriptional activation domains to 
the promoter. This situation might be analogous to the synergistic activation mediated 
by other activator proteins such as Spl, HSV-1 VP16 and EBV ZEBRA, that occurs as a 
consequence of multiple promoter occupancy or multimerisation of activation domains 
within the protein (Courey et al, 1989; Emami and Carey, 1992; Chi and Carey, 1993).
However, the DNA binding properties of the VZV 140k DNA binding domain alone 
may not explain the strong transactivation phenotype of the 140k protein, as the hybrid 
175R2DS protein was a less efficient transactivator than the intact 140k protein. There 
are several possible explanations for the transactivation strength of the hybrid protein 
being intermediate between that of Vmwl75 and 140k. One of the more obvious 
explanations is that the VZV 140k protein may have a stronger transcriptional activation 
domain. This cannot be determined until the HSV-1 Vmwl75 activation domain has 
been characterised. A potent activation domain has recently been identified within the 
first 90 amino acids of VZV 140k (Perera et a l, 1993; Cohen et a l, 1993) with a 
potency comparable to that of the activation domain of HSV-1 VP 16 (Cohen et a l, 
1993); the VP 16 activation sequences are commonly held to be among the most potent. 
The activation domain of HSV-1 Vmwl75 is not conserved with 140k, at least as far as 
location within the protein is concerned, as the first 90 amino acids of Vmwl75 are 
dispensable for HSV-1 growth in tissue culture (DeLuca and Schaffer, 1987).
Alternatively, it is possible that the domain swap was not completely without 
consequence to the overall structure of the protein, leading to a reduction in the 
transactivation efficiency of the 175R2DS hybrid protein. Although the isolated R2DS 
domain was DNA binding competent, it is possible that in the background ot Vmwl75
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sequences, the 140k DNA binding domain (R2DS) does not adopt the optimal 
conformation required for the efficient transactivation function. Region 2 of the 140k 
and Vmwl75 proteins have very similar sizes and predicted primary sequences, whereas 
the requirement for the amount of region 1 and 3  sequences is very different between the 
two proteins (Section 1C. 1.8). Mutational analyses have found that the regulatory 
functions of the Vmwl75 protein are unaffected by insertions into region 1 and 3 
sequences in the vicinities of the domain swap fusion junctions (Paterson and Everett, 
1988a; Shepard et al., 1989); so it is unlikely that the junctions themselves are 
deleterious to the functions of 175R2DS. Region 1 and 3 sequences are poorly 
conserved between 140k and Vmwl75, and will probably fold differently in the two 
proteins. The tertiary conformations adopted by the 140k region 1 and 3 sequences 
included in the 175R2DS protein, may not be fully compatible with the conformations 
of the remaining Vmwl75 protein regions, so reducing the transactivation efficiency of 
175R2DS. It would be useful to construct the complementary domain swap (a VZV 
140k protein including the HSV-1 Vmwl75 DNA binding domain), in order to 
determine whether the intermediate transactivation strength of 175R2DS was due to 
conformational disruptions, or due to the absence of other specific 140k sequences 
required in addition to the DNA binding domain.
Like HSV-1 Vmwl75, the 175R2DS hybrid protein activated gene expression in 
synergy with the HSV-1 immediate-early protein VmwllO. Little is known about the 
precise function of the VmwllO protein (Section IB.3.4); there is no evidence for 
Vmwl 10 binding directly to DNA although there is weak evidence for indirect binding 
(Hay and Hay, 1980). It is possible that Vmwl 10 and Vmwl75 increase the efficiency 
of distinct rate-limiting steps in the transcription process, resulting in a greatly enhanced 
transactivation efficiency overall. There appeared to be a correlation between the extent 
of synergy with VmwllO and the transactivation strength of the other effector protein, 
suggesting that addition of the second activator protein allows target promoter induction 
to reach maximum capacity. For example, the degree of synergy between the 175R2DS 
protein and VmwllO (additional activation of 7 fold the combined individual effects) 
was not as marked as that seen previously with the weaker Vmwl75 transactivator 
(around 11 fold the combined individual effects; Everett, 1986). Consistent with this 
idea, synergistic activation has not been detectable between the Vmw 110 and VZV 140k 
proteins in our assay system. It is likely that the 140k protein is such a strong 
transactivator that the gD promoter was already fully activated by the 140k protein, in 
which case addition of further activators (i.e. VmwllO) would have little effect. This 
would be consistent with a findings of Thali et al, (1990); they demonstrated that the 
pseudorabies virus homologue of VZV 140k only stimulates promoter activity when the 
promoter is not already fully activated by other r/^/rs-inducing factors. Synergistic
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activation of the VZV and HSV-1 tk promoters has been reported by VZV 140k with 
VmwllO in HeLa and CV- 1  cells (Cabirac et al., 1990). This could be due to 
differences between the systems or alternatively the lower basal activity of the tk 
promoters might allow further activation beyond the level achieved by 140k alone.
As discussed previously (Section IB.2.3), HSV-1 Vmwl75 negatively autoregulates its 
own HSV-1 IE3 promoter. The fact that, like VZV 140k, the hybrid 175R2DS protein 
transactivated the HSV-1 IE3 promoter suggested that the DNA binding domain is 
important for determining the specificity of repression of these proteins. Presumably, the 
specific DNA binding characteristics of each DNA binding domain determined the 
outcome of the 140k and Vmwl75 proteins binding to the HSV-1 IE3 promoter. The 
previously identified differences between the interactions of the Vmwl75 and 140k 
DNA binding domains with the IE3 consensus site (Fig. 3A. 12) may be relevant to the 
different effects that the two proteins have on the activity of the IE3 promoter.
The HSV-1 virus including the VZV 140k DNA binding domain (virus HSV-175R2DS) 
was viable, further demonstrating the functional similarity of the 140k and Vmwl75 
DNA binding domains. Any alterations in growth properties of the HSV-175R2DS virus 
are being explored and any differences found may be accounted for by the differences in 
the specific DNA binding activities of the 140k and Vmwl75 DNA binding domains 
(Section 3A).
It is important to realise that the results obtained from transient transfection assays are 
notoriously variable (Everett, 1988b). For example, different consequences of the 
Vmwl75 and 140k proteins on their cognate promoters have been reported in cell lines 
other than those used here (Perera et al, 1992b). Therefore great caution is required 
when attempting to extrapolate the results of transient transfection assays to the situation 
during viral infection. However for the purposes of the analyses described here, transient 
transfection assays were utilised solely as a tool to compare the relative regulatory 
activities of the Vmwl75, 140k and 175R2DS proteins. This allowed analysis of 
whether DNA binding characteristics unique to the 140k DNA binding domain were of 
functional relevance. Reliable information regarding the situation during infection 
would only be obtained from characterisation of the HSV-175R2DS virus.
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The experiments described in this Thesis were designed to investigate the properties and 
functions of the DNA binding domain of the VZV 140k protein. Interpretations of the 
individual results can be found at the end of Sections 3A-3F. Section 4A integrates these 
findings and discusses their implications for the functions of VZV 140k. A model for 
the regulatory mechanism of VZV 140k is presented in Section 4B, taking into account 
the data presented in this Thesis and the previously published research on the other 
alphaherpesvirus homologue proteins (Section 1C). Finally, Section 4C discusses some 
possible avenues for future research leading on from these studies.
4A Overview and implications of the presented research
4A.1 The DNA binding characteristics of the VZV 140k DNA binding 
domain and their possible functional significance
The initial part of this project sought to characterise the DNA binding activity of the 
VZV 140k protein and to examine whether the functional differences between VZV 
140k and its HSV-1 counterpart, Vmwl75, that are apparent in transient transfection 
assays (Section 1C.2.3), are a consequence of possible variations in the DNA binding 
activities of the two proteins. As the full length VZV 140k protein had proved difficult 
to characterise (Disney, 1990), the approach chosen was to define the DNA binding 
properties of a bacterially expressed peptide fragment encompassing the 140k DNA 
binding domain. It is highly likely that the DNA binding activity of the isolated VZV 
140k DNA binding domain reflects that of the intact 140k protein, by analogy to the 
very close correlation between the DNA binding characteristics of HSV-1 Vmwl75 and 
its isolated DNA binding domain (Everett etal., 1991a).
In common with the equivalent domain of HSV-1 Vmwl75, the isolated VZV 140k 
DNA binding domain interacted with DNA in a direct and sequence-specific manner. 
Furthermore, it appears that DNA binding is an essential component of the regulatory
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function of VZV 140k because a mutation (K548E) that disrupted DNA binding activity 
destroyed 140k transactivation (Section 3E). Importantly, mutation K548E had no 
apparent effect on other physical properties of the isolated domain or the full length 
protein (i.e. solubility, efficiency of expression, dimerisation, nuclear localisation). The 
involvement of DNA binding in the regulatory functions of VZV 140k has also been 
implied by the increased 140k-mediated transactivation that resulted from 
multimerisation of a 140k target binding site in the promoter of a reporter construct used 
in transient transfection experiments (Betz and Wydoski, 1993).
The VZV 140k DNA binding domain was found to interact specifically with a wide 
variety of sequences in all the target promoter fragments analysed and several of the 
140k binding sites showed similarity to the HSV-1 Vmwl75 consensus binding 
sequence (Section 3A). This indication that the VZV 140k and HSV-1 Vmwl75 
proteins may have similar DNA binding specificities was supported by the ability of the 
VZV 140k domain to interact specifically with Vmwl75 consensus binding sites within 
HSV-1 promoters. This similar sequence specificity was not completely unexpected 
since the 140k and Vmwl75 DNA binding domains share a high degree of predicted 
amino acid sequence identity (see Figs. 1C.1 and 1C.3).
The DNA binding characteristics of the 140k DNA binding domain, not shared with the 
Vmwl75 domain, may account for the differences in the regulatory functions of VZV 
140k and HSV-1 Vmwl75 (Section 1C.2.3). The ability to bind multiple, fairly closely 
positioned binding sites within its target promoters was particular to the 140k DNA 
binding domain, and was a reflection of its lower DNA binding specificity, as compared 
to that of HSV-1 Vmwl75 (Section 3A.9). This low specificity of DNA binding could 
account for both the wide range of 140k target promoters and also its powerful 
activation phenotype (see Sections 3A.12 and 4B). Furthermore, the distinct alterations 
to the DNA conformation induced by binding of the 140k and Vmwl75 domains may 
have relevance to the different transactivation potencies of the two proteins; whereas the 
Vmwl75 domain induced a significant DNA bend in the vicinity of its binding sites 
(Everett et al., 1992), binding of the 140k domain induced marked DNase I 
hypersensitivity along the length of its target promoters.
The differences between the details of the interactions of the 140k and Vmwl75 DNA 
binding domains with the HSV-1 IE3 consensus binding site (Section 3A.8 ) might 
explain the observation that VZV 140k activates the IE3 promoter, whereas HSV-1 
Vmwl75 down-regulates it (Section 1C.2.3). However, the fact that the Vmwl75 DNA 
binding domain failed to recognise any sequences within the VZV gene 62 promoter, 
yet down-regulates this promoter in transient assays (Disney et al., 1990) indicates that
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there is no direct correlation between the ability to bind DNA in vitro and repression as 
measured by transient transfection experiments. It is likely that interactions with 
additional cellular factors, that do not occur in the in vitro binding analyses, are 
involved in repression by Vmwl75; this would be consistent with the findings of Gu et 
al (1993).
Characterisation of the activities of the hybrid 175R2DS protein, which contained the 
140k DNA binding domain in the background of the HSV-1 Vmwl75 protein, allowed 
the functional relevance of the differences between the DNA binding characteristics of 
the 140k and Vmwl75 DNA binding domains to be assessed (Section 3F). The 
comparative analysis of the regulatory properties of the Vmwl75 and 175R2DS proteins 
in transient transfection experiments indicated that the specific DNA binding properties 
of the VZV 140k DNA binding domain were responsible, at least in part, for the potent 
transactivation phenotype of VZV 140k and also for its specificity of repression. 
However, the intermediate nature of the regulatory activities of the hybrid protein 
between those of 140k and Vmwl75 suggested that VZV 140k sequences, other than 
those within the DNA binding domain, may also play a part in determining the specific 
functional properties of the 140k protein. The possibility also remains that the domain 
swap between Vmwl75 and 140k resulted in unfavourable conformational alterations; 
analysis of the complementary domain swap protein would differentiate between these 
two alternative explanations.
The viability of the HSV-175R2DS virus in tissue culture demonstrates clearly the 
homologous nature of the DNA binding domains of the VZV 140k and HSV-1 Vmwl75 
proteins. However, the reduced growth efficiency of HSV-175R2DS further supports the 
functional relevance of the differences between the DNA binding activities of the 
Vmwl75 and 140k DNA binding domains detected in vitro. Thus, the specific DNA 
binding characteristics of the VZV 140k and HSV-1 Vmwl75 transcriptional regulatory 
proteins are likely to contribute to the different characteristics of these two viral 
infections.
4A.2 The structure of the VZV 140k DNA binding domain
The VZV 140k and HSV-1 Vmwl75 DNA binding domains occupy similar positions 
within each protein; both span protein region 2 (approximately 175 amino acids) that 
was originally defined on the basis of its high degree of sequence homology between 
140k and Vmwl75 (McGeoch et a l, 1986). Interestingly, the relatively poorly 
conserved sequences from the C-terminal end of region 1 were additionally required for
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the full DNA binding interactions of the 140k and Vmwl75 DNA binding domains, 
although this is to varying degrees in the two proteins (Section 3B). For instance, a VZV 
140k DNA binding domain peptide lacking virtually all of region 1 (peptide VT4) 
bound to DNA with the same efficiency and specificity as the full domain (i.e. peptide 
VT2) in gel retardation analyses, whereas at least 30 amino acids of region 1 were 
additionally required for the HSV-1 Vmwl75 DNA binding domain to exhibit the 
equivalent DNA binding activity. However, only those 140k and Vmwl75 DNA 
binding domain peptides which included approximately 50-60 amino acids from region 
1 were able to protect specific DNA sequences from DNase I digestion. These data 
demonstrate that the poorly conserved region 1 sequences are indirectly involved in the 
DNA binding interaction. This was previously implied by the findings of an insertion 
mutational analysis of the intact HSV-1 Vmwl75 protein (Shepard et al., 1989; Section 
1C. 1.9) and truncation analysis of the Vmwl75 DNA binding domain (Wu and Wilcox, 
1990; Section 1C. 1.10).
The smaller size of the minimal 140k DNA binding domain indicates that the VZV 140k 
and HSV-1 Vmwl75 proteins have different structural requirements for DNA binding, 
and this was further evidenced by the lack of a temperature-sensitive DNA binding 
phenotype of a 140k domain including the mutation equivalent to HSV-1 tsK. 
Interestingly, at 162 residues, the minimal VZV 140k DNA binding domain is larger 
than any of the documented DNA binding domains, with the exception of the C-terminal 
domain of the TATA binding protein (180 residues) (see Section IE). No obvious 
extended homologies to the consensus sequences of the established types of DNA 
binding motifs are apparent within the VZV 140k or HSV-1 Vmwl75 DNA binding 
domains, although this does not exclude the possibility that sequences within these 
alphaherpesvirus domains may adopt a similar fold to one of the previously recognised 
DNA binding motifs, as occurs with variant HTH proteins (Section 1E.2.3).
Of interest was a short conserved sequence (the WLQN region), located approximately 
in the centre of region 2  of the major alphaherpesvirus regulatory proteins, that shows 
homology to the DNA recognition helix of the homeodomain (Section 3E). The effect of 
mutations within the WLQN region of VZV 140k have demonstrated a possible direct 
role for these sequences in DNA recognition. The fact that the K548E mutation greatly 
reduced DNA binding activity of the 140k DNA binding domain indicates the 
importance of this region; however, more suggestive of a role for the WLQN region in 
DNA recognition is the fact that two further mutations (Q545L and N546L) altered the 
details of the specific DNA binding interaction. Verification of the role of the WLQN 




The intriguing question remains as to the requirement for the very highly conserved tract 
of sequences towards the C-terminus of region 2  of all the alphaherpesvirus homologue 
proteins (see Fig. 1C.3). The strong helical secondary structure predictions for this 
region make it a favourable candidate for either a dimerisation interface or a DNA 
recognition element; a substitution analysis confirmed the importance of this region but 
no dimerisation defective derivatives were isolated (Sections 1C. 1.4 and 1C. 1.9).
4A.3 The dimeric nature of the VZV 140k DNA binding domain
Like many sequence-specific DNA binding domains, the VZV 140k domain was found 
to be a stable dimer in solution, and to bind to DNA as a dimer (Sections 3C and 3D). It 
shares these properties with the HSV-1 Vmwl75 protein and its isolated DNA binding 
domain, and functional studies have indicated that the dimerisation property of Vmwl75 
is significant in vivo (see Section 1C. 1.4). Dimerisation itself is unlikely to play a 
regulatory role in the activities of 140k in the manner seen with the bHLH and bZIP 
proteins (Section 1E.3), as the dimers of the 140k DNA binding domain were extremely 
stable in solution. It is more likely that the dimeric nature of the 140k protein serves to 
increase the efficiency of the interaction with DNA, or its transactivation efficiency, by 
bringing additional 140k transcriptional activation domains to the promoter. The lack of 
any apparent palindromic nature of the VZV 140k and HSV-1 Vmwl75 DNA target 
sequences is interesting because it indicates that, in contrast to the situation with other 
dimeric DNA binding proteins, the 140k monomers may not interact symmetrically 
with each half-site of the target DNA binding sequence. Furthermore, it appears that 
only one subunit of the dimer is sufficient for initial recognition of the binding site, even 
though both half-sites of the HSV-1 IE3 consensus binding site were protected by the 
140k DNA binding domain from DNase I digestion. The alternative models for the 
dimer-DNA interaction accommodating these data are discussed in Section 3D. 10. In 
the case of the 140k DNA binding domain, it is tempting to interpret the specificity data 
on the IE3 binding site (Section 3A.9) as indicating that the second monomer of the 
dimer binds non-specifically to the 3' half-site.
Although the entire minimal VZV 140k DNA binding domain (162 residues) was 
required for fully efficient dimerisation, the data indicate that the protein sequence and 
structural requirements for dimerisation are lower than those for DNA binding. 
Sequential deletions into the N-terminal end of 140k region 2 prevented DNA binding, 
yet only reduced the efficiency of dimerisation (see Fig. 3D. 14). This suggests that 
sequences at the N-terminus of region 2 play an indirect role in the subunit interaction, 
perhaps stabilising the conformation of the domain. The fact that the VZV 140k and
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HSV-1 Vmwl75 DNA binding domains readily heterodimerised clearly demonstrates 
that the two proteins employ very similar modes of subunit interaction, and therefore the 
finding that insertions throughout the Vmwl75 DNA binding domain had no apparent 
effect on the monomer interaction is applicable to the situation with the VZV 140k 
protein. It appears that dimerisation of these DNA binding domains is mediated by 
either a short stretch of amino acids that was missed by the insertion mutations or by a 
large interface that can accommodate the individual mutations.
Since the integrity of the entire domain was required either directly or indirectly for the 
DNA binding activity, it has not been possible using the current approaches to define 
completely individual sequences within the DNA binding domain of either 140k or 
Vmwl75 that mediate the DNA binding and dimerisation interactions. Furthermore the 
results indicated that the majority of the DNA binding domain was also necessary for 
dimerisation, but this may reflect the requirement of sequences for the overall stability 
of the domain. It is probably that a large proportion of the sequences included in the 
DNA binding domain are required to form a scaffold for presentation of the DNA 
binding and dimerisation interfaces, rather than being directly involved in the 
macromolecular interactions. The localisation of the dimerisation interface will therefore 
require the identification of a subtle mutation that disrupts dimerisation of the domain 
without destroying its conformation. However it might be inferred from the fact that 
monomers of the DNA binding domains were never detected in solution, that such a 
monomeric mutant domain would be highly unstable and not amenable to analysis. As 
with the DNA recognition function of 140k, the details of the monomer interaction are 
only likely to be provided by structural analysis of the DNA binding domain.
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4B A Model for transcriptional regulation by VZV 140k
Information concerning the mechanisms of transcriptional regulation by VZV 140k is 
scarce, but it is likely that parallels can be drawn with the other alphaherpesvirus 
homologue proteins. Possible mechanisms for VZV 140k function will be discussed on 
this basis.
The weight of evidence suggests that DNA binding is required for the regulatory 
functions of HSV-1 Vmwl75 (see Sections 1B.2.3 and 1C.1.7), PRV IE 180 (Cromlish 
et a l, 1989) and VZV 140k (this Thesis, Section 3E). However, unlike the majority of 
cellular transcription factors, these alphaherpesvirus proteins have degenerate DNA 
binding specificities (less pronounced with HSV-1 Vmwl75), that could be more 
accurately termed as sequence-selectivity. Therefore it is unlikely that the DNA binding 
specificity of VZV 140k is itself responsible for selecting its target promoters. It is more 
probable that VZV 140k will bind to and transactivate any accessible class II promoter 
that is not already fully activated, according to the mechanism suggested for the PRV 
IE180 protein by Thali et a l (1990) (Section 1C.3). The viral promoters are the most 
abundant class of targets according to this model, and would account for the ability of 
VZV 140k to transactivate all the VZV IE, E and L promoters that have been analysed 
(Section 1C.2.3). The exception to this is the VZV gene 62 promoter, which is down- 
regulated by VZV 140k in certain cell types (see below) (Section 1C.2.3).
The HSV-1 Vmwl75 protein appears to be able to activate gene expression from a 
variety of different positions within the vicinity of a promoter (Section 1C. 1.7). The 
requirement for this property is not clear, but may solely be a consequence of its 
degenerate DNA binding specificity. As the 140k DNA binding domain is even less 
sequence-specific than Vmwl75, and does not show any clear preference for particular 
sites within its target promoters, it is likely that 140k also functions in a position 
independent manner. If sufficient 140k is present, multiple 140k proteins may bind 
within the same promoter region in a possibly cooperative manner (Section 3A.7). 
Synergistic activation would result from multiple 140k occupancy in the promoter 
region and may even account for the potent transactivation phenotype of the VZV 140k 
protein seen in transient transfection assays. The 140k protein is highly abundant in 
these transiently transfected tissue culture cells, but it is not known whether this is also 
the case within VZV infected cells.
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By analogy to the apparent situation with the HSV-1 Vmwl75 and PRV IE 180 proteins 
(Section IB.3.3), VZV 140k-mediated transactivation probably involves contacts with 
the TFIID transcription factor complex and as such might enhance transcription by a 
mechanism similar to cellular transactivators (Section 1D.2.3). Deletion of the Spl 
binding sites of the HSV-1 tk promoter have indicated that Vmwl75 can operationally 
substitute for Spl (Imbalzano et al., 1991). This could occur if the transactivation 
mechanisms of Spl and Vmwl75 are through a common pathway, perhaps involving 
contacts with a common protein. As Spl has recently been shown to contact a specific 
TAF co-activator component of TFIID (Section ID. 1.4), it is tempting to speculate that 
transactivation by Vmwl75 (and perhaps the other alphaherpesvirus homologues) may 
also be mediated by contacting the Spl TAF. In agreement, the TAFs have also been 
implicated in the negative autoregulatory mechanism of HSV-1 Vmwl75 (see Section
IB.2.3).
The autoregulatory mechanism of VZV 140k is liable to involve binding to the site(s) 
that has been identified adjacent to the gene 62 mRNA start site(s). When so positioned, 
140k could interfere with the activity of cellular regulatory factors in a manner similar to 
that proposed for HSV-1 Vmwl75 (Gu et al., 1993; Section 1B.2.3). As the 140k DNA 
binding domain appeared to have a similar affinity for its different target sites, the 
inhibitory influence of 140k bound at the mRNA start site would have to be dominant 
over the stimulatory effect of 140k bound elsewhere within the gene 62 promoter 
region.
As with the apparent situation with the HSV-1 Vmwl75 DNA binding activity (Section
IC. 1.3), it is possible that the DNA binding activity (and hence the transactivation and 
repression functions of VZV 140k) might be regulated by post-translational 
modifications such as phosphorylation. Differential interactions with other cellular or 




The work presented in this thesis has provided important insight into the activities of the 
VZV 140k protein, and in particular the properties of its DNA binding domain. 
However, numerous areas for potential investigation remain and several of these are 
outlined here.
It will be important to investigate further the relevance of the WLQN region for DNA 
recognition by analysing the consequences of other carefully selected mutations within 
this region of the VZV 140k DNA binding domain. Introduction of the WLQN 
mutations into the DNA binding domains of the other alphaherpesvirus homologue 
proteins could be used to indicate whether the conservation of these sequences reflects 
an evolutionary conserved DNA recognition interface. Mutant forms of the HSV-1 
Vmwl75 DNA binding domain would be of particular value; the higher sequence- 
specificity of the Vmwl75 DNA binding interaction would allow directional changes in 
binding specificity to be detected, using the random binding site selection method. By 
this approach it should be possible to identify the specific bases of the recognition site 
that are contacted by particular amino acids of the DNA recognition interface of 
Vmwl75. Another question that could easily be answered, and would provide a better 
understanding of the mode of DNA recognition of these alphaherpesvirus proteins, is 
whether these DNA binding domains contact bases in the major or minor groove of 
DNA.
A fundamental objective should be to obtain X-ray crystallographic data for the VZV 
140k DNA binding domain. This would provide answers to many questions, including 
the locations and structure of the DNA recognition and dimerisation interfaces, and 
would also elucidate the manner in which the dimer binds to an apparently asymmetrical 
target DNA sequence. The efficiency of the bacterial expression system and the 
purification procedure outlined in this Thesis will hopefully enable the structure of the 
DNA binding domain to be determined in the not too distant future.
The amino acid sequence of the poorly characterised region 4 of the alphaherpesvirus 
major regulatory proteins is even more highly conserved than their DNA binding 
domains, and as such is likely to be functionally important. During the course of this 
study an attempt to express the VZV 140k region 4 sequences as a GST fusion protein, 
and also as a non-fusion protein in E. coli, met with solubility problems. It would be
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worthwhile to select a larger fragment of the protein for expression, perhaps including 
portions of region 3 and 5 sequences. Various approaches could be employed to 
investigate possible protein-protein interactions mediated by the 'tagged' sequences 
encompassing region 4, such as affinity chromatography or the co-immunoprecipitation 
technique that proved to be highly successful in Section 3D.
The approach of studying individual protein domains has many merits, but it is always 
important to relate their findings back to the situation with the intact protein, preferably 
in a physiological environment. Detailed characterisation of the properties of the HSV- 
175R2DS virus, in comparison with wild type HSV-1, might shed light on the functional 
relevance of the differences in the DNA binding characteristics of the Vmwl75 and 
140k DNA binding domains. In the near future, important mechanistic information 
regarding the transactivation activities of the alphaherpesvirus major regulatory proteins 
will no doubt be provided by reconstituted transcription systems, in the manner that the 
autoregulatory function of Vmwl75 has been addressed (Gu et al, 1993). It would be 
interesting to analyse further the role of DNA binding by studying the activities of the 
hybrid 175R2DS protein and also the WLQN mutant 140k proteins in this type of in 
vitro transcription system. The interplay between the alphaherpesvirus major regulatory 
proteins and the basal transcription machinery, the TAFs and also cellular cis-acting 
factors (such as Spl) could all be addressed by such an in vitro approach. Such studies 
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